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Based on the concept of covalent capture of supramolecular assemblies, the idea of 
mechanical encapsulation is exploited for the protection and delivery of peptide-
based molecules. This thesis aims to establish a general method for the encapsulation 
of peptides within a rotaxane structure, as well as studying their mode of release 
under specific stimuli. The synthesis of such structures, relying on the elongation of 
short peptido[2]rotaxanes, is applied to the design of rotaxane peptide carriers whose 
function is to protect against biological degradation and release peptides under a 
biological stimulus. These molecules are composed of a rotaxane-encapsulated 
peptide bearing a biodegradable stopper, the enzyme-specific cleavage of which 
triggers peptide release, via ‘dethreading’.  
The synthesis and in vitro assessment of rotaxane carriers as agents for anti-cancer 
therapy will be described in detail. The future challenges and potential applications 
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The	  Layout	  of	  this	  Thesis	  
 
This thesis is divided into two distinct and non-related parts.   
 
Part 1 expounds the results from a side project developed besides the main project. 
Chapter one introduces the synthesis of interlocked architectures chronologically. 
Chapter two is presented in the form of an article that has already been published in a 
peer-reviewed journal. No attempt has been made to re-write this work out of 
context, other than to insert references where appropriate and to ensure consistency 
of presentation throughout this Thesis. This Chapter is reproduced in the Appendix, 
in its published format. 
 
Part 2 represents the main core of this thesis, composed of three closely related 
chapters. The first chapter of this second part, Chapter three, outlines some pertinent 
examples of natural interlocked molecules and the synthesis of synthetic analogues 
with emphasis on peptide containing structures. Some examples where mechanical 
interlocking is used to encapsulate substrates are expounded, along with a detailed 
discussion of the design of future synthetic rotaxane-encapsulated peptide carriers. 
Chapter four focuses on the optimisation of a methodology developed in the group 
for the synthesis of peptido-rotaxanes of long peptides. This methodology is then 
used to synthesize an anticancer therapy-compatible anticancer peptide rotaxane 
carrier in Chapter five. Chapter six is dedicated to the study of self-immolative 
stoppers and the functionalization of the macrocycle constituent of peptide carrier 
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“Whoever undertakes to set himself up as a judge of Truth and Knowledge is 





During the latter half of the 20th century a more comprehensive understanding of the 
weak forces that govern intermolecular interactions evolved into the 
interdisciplinary field now known as supramolecular chemistry. One particular 
application of supramolecular chemistry has been the exploitation of non-covalent 
forces for the synthesis of mechanically interlocked molecules. The study of such 
compounds, which was once the domain of a handful of pioneering chemists, has 
rapidly evolved into an important field in its own right. 
A wealth of different supramolecular interactions has been exploited to direct the 
formation of interlocked architectures. Although Template-directed syntheses are the 
only methods that produce interlocked molecules in respectable yields, new 
methodologies for the assembly of such molecules are still being developed. Indeed, 
the main challenges are to improve the efficiency of the assembly step and to widen 
the selection of substrates that these reactions can be applied to. This work is of 
capital importance for the development of  (currently highly synthetically 
demanding) interlocked-architecture-based molecular machines.  
This chapter will cover briefly the history of catenane, rotaxane and knot synthesis 
through the last four decades and summarize the most common templating methods 
that have been used to date. Finally, a recently developed ‘Active Template’ 













Chapter one  Introduction 
 
 3 
1.1  Definition and nomenclature 
 
  
Figure 1.1. Cartoon representations of a) a [2]catenane, b) a [2]rotaxane, c) a trefoil knot 
 
Unambiguous scientific definitions have been assigned to the different classes of 
mechanically interlocked molecular architectures. A catenane (Figure 1.1.a) consists 
of two or more interlocked macrocycles connected like links in a chain. In a rotaxane 
(Figure 1.1.b) one or more macrocycle circumscribe a ‘thread’ comprised of a linear 
component terminated by two bulky end groups. Normally, a numerical prefix is 
added to the descriptor to denote the number of species that are associated, e.g. a 
[3]catenane is made up of three linked macrocycles. A trefoil knot (Figure 1.1.c) is 
the simplest non-trivial entangled molecule and, as its name suggests, contains three 
crossing points within its structure. Critically, all three species depicted in Figure 1.1 
are molecules not supramolecular complexes, as covalent bonds must be broken in 
order to separate the mechanically bound fragments.1 
Three distinct strategies have historically been employed for the synthesis of 
mechanically interlocked architectures: the ‘statistical’ method, the covalent bond 













1.2 Early synthetic methodologies to interlocked architectures 
1.2.1 Statistical method 
 
The first mechanically interlocked architectures to be realized synthetically were 
assembled in the absence of any favourable intercomponent interactions using a 
technique commonly referred to as the ‘statistical’ method. This concept relies on the 
statistical threading of one ring by a linear molecule, which is to be formed into the 
second ring. Although the existence of interlocked molecular rings was discussed, 
according to Schill,2 as early as 1912 by Willstätter, it was only at the beginning of 






Figure 1.2. Early examples of interlocked molecules reported by a) Wasserman, b) Harrison. 
 
They demonstrated that acycloin condensation of a diester in the presence of a partly 
deuteriated cyclic hydrocarbon yielded a small amount of catenane. The latter could 
not be isolated but they provided strong evidence of its formation.  Even if this 
example has no synthetic value, historically it is of great importance because it 
proved that scientists’ early thoughts on interlocked architectures were not only 
speculation.  
From a preparative point of view, statistical threading became significant by the 
work of Zilkha.4 Statistical threading of a crown polyether by poly(ethylene 
glycol)400 led to catenane in 14% yield after cyclization in high-dilution conditions.  
Randomness, which is a highly limiting factor in the statistical syntheses of the 
catenanes discussed above, may become less determining if the threading process is 
favoured by an even weaker interaction between the linear thread and the ring. As 
early as 1958, Lüttringhaus et al. discussed the formation of a rotaxane-like inclusion 
between α or β-cyclodextrin and an aromatic long chain dithiol. Unfortunately they 
could not achieve the expected ring closure that would have led to a catenane 
Chapter one  Introduction 
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1.2.2 Covalent bond directed synthesis 
 
Four years after Wasserman reported the first [2]catenane synthesis, Schill and 
Lüttringhaus described the use of covalent bonds as templates in the first ‘directed’ 
synthesis of a mechanically interlocked molecule.2,5  Their elegant synthetic pathway 
is shown in scheme 1.1.  In this multistep synthesis, the carefully planned geometry 
of intermediate 3  (bond angles, bond lenghts, tetrahedral structure of the ketal 
carbon atom, size of the polymethylene macrocycle, lengths of the alkyl chloride 
chains) directs intramolecular macrocyclization in a unique and predetermined way 
(Schme 1.1).  
 
Scheme 1.1. Schill’s covalent bond-directed synthesis of a [2]catenane. 
 
Alkylation of the amino group occurs only with the two alkyl chloride chains located 
one above and one below the plane of the central benzene ring to give 4. Selective 
cleavage of the aryl-nitrogen bond and hydrolysis of the ketal group leads to 
[2]catenane 5.  
The feasibility of constructing mechanically interlocked architectures using a 
covalent bond template is well illustrated by Schill’s ingenious synthetic routes. 
However, such routes require many synthetic steps and a high level of technical 
expertise, thus limiting the study of these novel compounds. 
 
1.1. Template directed synthesis of interlocked architectures 
1.2.3 Transition metal directed synthesis of catenanes and rotaxanes 
 
Schill’s directed synthesis of catenanes may be considered as relying on a central 
core, the benzo-ketal group, around which the different rings are built up. Another 
central core around which interlocked architectures could be build, in the way Frisch 
and Wasserman defined it,6 could be a transition metal. Interestingly such an 
 6 
approach was evoked (the term template effect was not used in 1961 or 1972), twice 
in the past. In 1961 by Frisch and Wasserman6 and in 1972 by Sokolov.7 
It was later, in 1983,8 that Sauvage and co-workers achieved the first metal templated 
synthesis of a [2]catenane and turned interlocked architectures from chemical 
curiosities into accessible molecules.  
The Strasbourg group took advantage of the ability of transition metals to organize 
ligands in a predictable spatial orientation creating a crossover point that directs 
subsequent macrocyclization reactions in an intertwined manner. The preferred 
tetrahedral geometry of Cu(I) was employed to organize the two bidentate 
phenentroline ligands 6 in an mutually orthogonal manner (Scheme 1.2, Route A). 
Alkylation of 7 with a bisalkyl-iodide led to the metallocatenane 8 or catenate in 
27% yield. 
 
Scheme 1.2. Sauvage’s original Cu(I) directed [2]catenate synthesis. 
 
This catenate was de-metallated to give the catenand 9 using KCN. The yield was 
subsequently improved by synthesizing macrocycle 10 and complexing it with an 
appropriately derivatized phenanthroline unit to give pre-catenane 11, followed by 
macrocyclization to furnish the corresponding [2]catenane in 40% yield (Scheme 
1.2., Route B). 




The first synthesis of a rotaxane based on a metal template was reported by Gibson 
and co-workers, elaborating on the Sauvage phenanthroline/Cu(I) core (Scheme 
1.3).9 The pseudo-rotaxane 12 was treated with a trityl-terminated alkyl halide and 
subsequently de-metallated to give rotaxane 13 in 42% yield. 
 
Scheme 1.3. Gibson’s Cu(I)-phen based rotaxane synthesis. 
 
1.2.4 Copper mediated synthesis of molecular knots 
 
Schill and co-workers conceived and attempted direct synthesis of a trefoil knot 
before the 1980s.10 This strategy, which relied on a benzoacetal central core, is 
closely related to the one used to prepare catenanes. Unfortunately no desired 
product could be identified in their case. Following these attempts and building on 
the copper (I) core, Sauvage reported the first molecular trefoil knot in 1989 (Scheme 












































14a X = (CH2)4
14b X = 1,3 phenylene
15a/b
16a 3%
16b 29%   
Scheme 1.4. Synthesis of a trefoil knot. 
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In this strategy, the disposition of two bisphenantroline ligands in a helical 
arrangement is exploited for the formation of the knot. Two molecules of bis-
chelating threads 14 are bound in a tetrahedral manner on two copper (I) centres, 
leading to double helix 15. After double macrocyclization to form 16 followed by de-
metallation, a knotted system was obtained. 
The initial ligand, 14a, was composed of a (CH2)4 linker between the two 
phenantroline units to prevent the complexation of one ligand around a single Cu(I) 
ion. However it was observed that the desired helical complex, 15a, was relatively 
labile and thus able to interconvert with its co-planar analogue. This facile exchange 
led to a modest 3% yield of 16a following Williamson reaction. Replacing the 
(CH2)4 linker with the more rigid 1,3-phenylene group (14a→14b) increased the 
yield to an excellent 29% of 16b.13  
 
1.3 The assembly of mechanically interlocked molecules using non-
transition metal template-based methodologies 
 
Following Sauvage’s success, template-directed synthesis has become the only way 
of synthesizing interlocked architectures. To date, most of these routes depend on the 
use of neutral or cationic species to achieve the desired template effect, utilizing a 
variety of noncovalent forces such as metal-ligand coordination, hydrogen bonding, 
π-π stacking, or hydrophobic interactions.  
The template-directed synthesis of rotaxanes and catenanes can be classified in two14 
main strategies: the ‘clipping’ strategy proceeds via a preformed thread (or 
macrocycle) coordinated to a ‘u-shape’ which is closed, or ‘clipped’ around the 
thread (or macrocycle). The macrocycle may also be assembled around the thread 
from multiple fragments in this strategy. In the ‘stoppering’ approach, the axle is 
threaded through the macrocycle, followed by attachment of the stoppers (Figure 
1.3).  




Figure 1.3. Schematic representations of clipping approaches to catenanes and stoppering and 
clipping approach to rotaxanes. 
 
1.3.1 Hydrophobic effect  
 
The most extensively studied type of rotaxanes formed by the use of the hydrophobic 
effect is those with a cyclodextrin (CD)-based structure. The CDs posses a 
hydrophilic exterior, due to the hydroxyl groups on the outer surface, and a 
hydrophobic core due to the carbon-containing carbohydrate backbone. Such 
structural properties make them both water-soluble and convenient hosts for 
complexing lipophilic molecular guests in water.  
The group of Ogino first exploited these properties for the synthesis of rotaxanes in 
1981.15  Rotaxane, made from a β-CD and a diaminoalkyl thread was synthesized via 
two slightly different routes (scheme 1.5). Both routes rely on a similar threading 





Scheme 1.5. Ogino’s cyclodextrin-based [2]rotaxane. 
  
Several other groups have successfully employed the hydrophobic effect to 
synthesize interlocked molecules based on cyclodextrins. In particular, Harada16 and 
Anderson17 have intensively investigated CD-based rotaxane and polyrotaxane 
formation. It has proved more difficult to assemble catenanes using cyclodextrins, 
but such molecules were realized for the first time by Stoddart in 1993. 18  
1.3.2 Aromatic interactions 
 
The discussion of synthetic molecular architectures assembled using aromatic 
interactions must be centred on the extensive research of Stoddart and co-workers. In 
the late 1980s they began developing a self-assembly approach to interlocked 
architectures, based on previous observations of paraquat and a crown forming a 
host-guest complex.19 The ability of the π-electron deficient paraquat derivative 17 
and π-electron donating macrocycles such as 18 (bis-p-phenylene-34-crown-10) to 
form host-guest complexes was thus used to direct the synthesis of interlocked 
architectures. The first catenane based on this system was synthesized in 1989 
(Scheme 1.6).20 Treatment of an acetonitrile solution of 17 and 18 with 1,4 dibenzyl 
bromide resulted in the formation of catenane 19 in an impressive 70% yield.  
 












































Scheme 1.6. Synthesis of Stoddart’s original paraquat-crown ether [2]catenane. 
 
Stoddart and co-workers have mastered the art of building interlocked architectures 
using the paraquat-crown ether association and have described a wide variety of 
different structures based on this motif.21 Almost a decade after the synthesis of their 
first catenane the group applied the same methodology the synthesis of molecular 
knots.22 
 
1.3.3 Hydrogen bonding interactions 
 
Typically, hydrogen bonds are much weaker than covalent bonds or those in metal 
complexes. As a consequence, effective H-bonding templates  generally contain 
multiple recognition sites. The most effective H-bonding templates are those with a 
high level of preorganization.  
 
1.3.3.1 Ammonium-Crown Ether-Based Rotaxanes 
 
Concurrently, Stoddart and Busch demonstrated that dibenzo-24-crown-8 (DB24C8) 
could form strong inclusion complexes with secondary dialkylammonium cations. 
[2]Rotaxane 20, assembled using this system was published by Busch and co-



























Figure 1.4. Original ammonium-crown ether rotaxanes reported by a) Busch, b) Stoddart. 
 
Stoddart and co-workers showed that the same crown ether and a dibenzyl 
ammonium ion formed a 1:1 complex. They then went on to describe the synthesis of 
rotaxanes such as 21, synthesized by ‘capping’ the thread component with bulky 
terminating groups (Figure 1.4.b).24 
 
1.3.3.2 Anion-Based Catenanes and Rotaxanes  
 
 
Vögtle reported the first example of a rotaxane assembled around an anionic 
phenolate template in 1999.25 Using a tetra-lactam macrocycle 22, they took 
advantage of its hydrogen bonding ability towards anionic species to template the 
formation of a [2]rotaxane in an impressive yield of 95% (Scheme 1.7). The authors 
rationalized this yield by the reaction of dibromide 24 with the phenoxide-
macrocycle complex [22+23] to form mono-stoppered thread 25. The latter then 
dissociates from the macrocycle and reacts with another phenoxide-macrocycle 
complex to form the [2]rotaxane 26 (Scheme 1.7).  
 
















































 Scheme 1.7. Synthesis of Vögtle [2]rotaxane assembled using a phenoxyde template. 
 
 More recently, Beer and co-workers have elegantly shown how chloride ion 
recognition can be utilized to assemble rotaxanes26 and catenanes.27   
 
1.4 Active template strategies to interlocked architectures 
1.4.1 Basic principle of active-metal template  
 
Most template-directed approaches to rotaxanes developed to date require at least 
stoichiometric quantities of a template, which often involves pre-established strongly 
binding recognition motifs that ‘live on’ in the mechanically interlocked molecule 
that is formed. Besides holding the reactive fragments in an orientation that directs 
interlocking, the template is generally otherwise passive during the reaction. 
Building on the principles of transition metal catalysis, the group of Leigh28 
developed a strategy in which template ions could also play an active role in 
promoting the crucial final covalent bond forming reaction that captures the 
interlocked structure (i.e. the metal has a dual function; acting as a template for 
entwining the precursors and catalyzing covalent bond formation between the 
reactants). This ‘active-metal’29 template process is shown schematically in Figure 
 14 
1.5 in both stoichiometric (one equivalent of the active template is required) and 
catalytic (the active template turns over during the reaction) versions.  
 
Figure 1.5. The ‘active template’ strategy to rotaxane architectures. The formation of a covalent bond 
between the green and orange stoppered units to generate the thread is promoted by the catalyst 
(shown in grey) and directed through the cavity of the macrocycle (shown in blue) by the catalyst’s 
coordination requirements. (a) (I) Stoichiometric active-metal template synthesis of a [2]rotaxane, (II) 
subsequent de-metallation; (b) Catalytic active-metal template synthesis of a [2]rotaxane. 
 
There are several potentially attractive features of such a synthetic approach to 
mechanically interlocked architectures, including:  
 
i) The inherent efficiency of a reaction in which the metal-macrocyclic species 
performs multiple functions. 
ii) The strategy should prove applicable to many different types of well-known 
transition metal catalyzed (and even organocatalytic) reactions. 
iii) The lack of requirement for permanent recognition elements in each 
component of the interlocked product increases the structural diversity 
possible in catenanes and rotaxanes and enables their formation to be 
‘traceless’.  
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iv) In some cases only substoichiometric quantities of the active template may be 
required (i.e. the catalytic active-metal template variant, Figure 1.5.b). 
v) Reactions that only proceed through a threaded intermediate would allow 
access to several currently inaccessible mechanically linked macromolecular 
architectures; and, finally.   
vi) The coordination requirements during key stages of the catalytic cycle of 
active-template reactions could provide insight into the mechanisms of metal-
catalyzed reactions.  
 
1.4.2 CuAAC active template formation of rotaxanes 
 
In their first report,28 they utilized the so called “click” Cu(I)-catalyzed Alkyne-
Azide cycloaddition (CuAAC) popularized by Meldal and Fokin a few years before 
(Scheme 1.8). The macrocycle bearing an endotopic pyridine motif is bound to the 
copper atom in such a way that the metal-mediated bond formation is directed toward 






















Scheme 1.8. Active-metal template synthesis of triazole containing rotaxanes via CuAAC reaction 
 
Simple stirring of a mixture containing the endo-pyridine macrocycle, 
Cu(MeCN)4PF6, and azide and alkyne functionalized half-stoppered threads in 
CH2Cl2 overnight, followed by KCN treatment, gave an impressive 57% yield of 
[2]rotaxane which was increased to 94% using 5 equivalents of half-stoppered in 
respect to macrocycle (Scheme 1.8). Addition of pyridine to the reaction mixture 
avoided Cu(I) to be sequestered in the reaction product and thus allowed the metal to 
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be reused in a further transformation step. Yields were as high as 82 % with only 20 
mol% mol of copper catalyst and 3 equivalent of pyridine.  
 
1.4.3 Active-metal templated sythesis of rotaxanes and catenanes via 
Glaser alkyne homo-coupling and C-S bond formation reaction 
 
This methodology proved to be attractive and was adopted soon afterwards by the 
group of Saito. The Japanese group made use of a Sauvage-type phenantroline-based 
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Scheme 1.9. Saito’s synthesis of rotaxanes and catenanes via active-metal template copper (I) 
catalyzed reactions 
 
Their procedure was slightly different to the CuAAC example: a Cu(I) iodide 
macrocycle complex, 27, was reacted with suitably functionalized half-stoppered 
threads (Route A) and bis-functionalized U-shaped molecule (Route B) to form [2] 
rotaxanes and [2]catenanes, respectively. Glaser alkyne homo-couplings and C-S 
bond formation proved efficient and gave, under optimized conditions, rotaxane in 
72% and 27% (28) respectively and 64% of [2]catenane 29 (Scheme 1.9). Both these 
yields were obtained under large excess of substrates and of the majority of the side 
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1.4.4 Active-metal templated synthesis of molecular machines 
 
Several other examples of active-metal templated synthesis of rotaxanes have been 
described over the past three years,32 and the active-metal template has also been 
applied to the synthesis of more complex architectures.33,34 The Cadiot-Chodkiewicz 
reaction could be well adapted to the method using a bipyridine-based macrocycle. 
Homo and hetero-coupled adducts were obtained in very good yields and with very 
good selectivity. A switchable molecular shuttle, which would be difficult or 
impossible to access via traditional methods, was synthesized via this Cadiot-
Chodkiewicz active template method, demonstrating the usefulness of the reaction 
































Scheme 1.10. Cadiot-Chodkiewicz active template synthesis of molecular shuttles. 
 
The single H-bond contact that exists between the aniline group of the thread and the 
bipyridine of the macrocycle is too weak to template rotaxane formation through 
‘stoppering’ or ‘clipping’ strategies and the bipyridine-pyridine combination would 
not easily accommodate a metal for passive templated synthesis. Molecular shuttle 
30 was obtained in 61% yield, with no homo-coupled rotaxane products being 
detected.   
 
 18 
1.5 References and notes 
 
[1] J. S. Hannam, S. M. Lacy, D. A. Leigh, C. G. Saiz, A. M. Z. Slawin,  S. G. 
Stitchell, Angew. Chem., Int. Ed., 2004, 43, 3260-3264. 
[2] G. Schill, Catenanes, Rotaxanes and Knots; Academic Press: New York, 
1971. 
[3] E. Wasserman, J. Am. Chem. Soc., 1960, 82, 4433-4. 
[4] G. Agam, D. Graiver,  A. Zilkha, J. Am. Chem. Soc., 1976, 98, 5206-5214. 
[5] G. Schill,  A. Luttringhaus, Angew. Chem. Int. Ed., 1964, 3, 546-547. 
[6] H. L. Frisch,  E. Wasserman, J. Am. Chem. Soc, 1961, 83, 3789. 
[7] V. I. Sokolov, Russ. chem. rev., 1973, 42, 452-463. 
[8] C. O. Dietrichbuchecker, J. P. Sauvage,  J. P. Kintzinger, Tetrahedron Lett., 
1983, 24, 5095-5098. 
[9] C. Wu, P. R. Lecavalier, Y. X. Shen,  H. W. Gibson, Chem. Mater., 1991, 3, 
569-72. 
[10] G. Schill, G. Doerjer, E. Logemann,  H. Fritz, Chem. Ber., 1979, 112, 3603-
3615; Boeckman.J,  G. Schill, Tetrahedron, 1974, 30, 1945-1957. 
[11] C. O. Dietrichbuchecker,  J. P. Sauvage, Angew. Chem. Int. Ed., 1989, 28, 
189-192. 
[12] C. O. Dietrichbuchecker, J. Guilhem, C. Pascard,  J. P. Sauvage, Angew. 
Chem. Int. Ed., 1990, 29, 1154-1156. 
[13] C. O. Dietrich-Buchecker, J. F. Nierengarten, J. P. Sauvage, N. Armaroli, V. 
Balzani,  L. De Cola, J. Am. Chem. Soc., 1993, 115, 11237-44. 
[14] It should be noted that a third approach to pseudorotaxane assembly, 
‘slippage’, also exists, whereby a system is heated so that the ring may slip over the 
stoppers, where it is kinetically trapped upon cooling. However this is not template-
directed and the molecules produced are not, according to the IUPAC definition, 
rotaxanes, see: IUPAC Compendium of Chemical Terminology - the Gold Book 
(http://goldbook.iupac.org/index.html). Date of access 26/01/09. 
[15] H. Ogino, J. Am. Chem. Soc., 1981, 103, 1303-1304. 
[16] A. Harada, Acc. Chem. Res., 2001, 34, 456-464. 
[17] M. R. Craig, T. D. W. Claridge, M. G. Hutchings,  H. L. Anderson, Chem. 
Commun., 1999, 1537-1538; S. Anderson, T. D. W. Claridge,  H. L. Anderson, 
Angew. Chem., Int. Ed., 1997, 36, 1310-1313; C. A. Stanier, M. J. O'Connell, W. 
Clegg,  H. L. Anderson, Chem. Commun., 2001, 493-494; M. R. Craig, M. G. 
Chapter one  Introduction 
 
 19 
Hutchings, T. D. W. Claridge,  H. L. Anderson, Angew. Chem., Int. Ed., 2001, 40, 
1071-1074; C. A. Stanier, M. J. O'Connell, W. Clegg,  H. L. Anderson, Chem. 
Commun., 2001, 787-787; E. J. F. Klotz, T. D. W. Claridge,  H. L. Anderson, J. Am. 
Chem. Soc., 2006, 128, 15374-15375. 
[18] D. Armspach, P. Ashton, C. P. Moore, N. Spencer, J. F. Stoddart, T. J. Wear,  
D. J. Williams, Angew. Chem. Int. Ed., 1993, 32, 854-858. 
[19] B. L. Allwood, N. Spencer, H. Shahriarizavareh, J. F. Stoddart,  D. J. 
Williams, J. Chem. Soc. Chem. Commun., 1987, 1064-1066; B. Odell, M. V. 
Reddington, A. M. Z. Slawin, N. Spencer, J. F. Stoddart,  D. J. Williams, Angew. 
Chem. Int. Ed., 1988, 27, 1547-1550; J. Y. Ortholand, A. M. Z. Slawin, N. Spencer, 
J. F. Stoddart,  D. J. Williams, Angew. Chem. Int. Ed., 1989, 28, 1394-1395. 
[20] P. R. Ashton, T. T. Goodnow, A. E. Kaifer, M. V. Reddington, A. M. Z. 
Slawin, N. Spencer, J. F. Stoddart, C. Vicent,  D. J. Williams, Angew. Chem. Int. Ed., 
1989, 28, 1396-1399. 
[21] D. B. Amabilino,  J. F. Stoddart, Chem. Rev., 1995, 95, 2725-2828; D. Philp,  
J. F. Stoddart, Angew. Chem., Int. Ed., 1996, 35, 1154-1196; D. B. Amabilino, F. M. 
Raymo,  J. F. Stoddart, Comprehensive Supramolecular Chemistry, (M. W. Hosseini, 
J.-P. Sauvage Eds.), Pergamon Press: Cambridge, 1996, Vol. 9, p 85-130; F. M. 
Raymo,  J. F. Stoddart, Chem. Rev., 1999, 99, 1643-1663. 
[22] P. R. Ashton, O. A. Matthews, S. Menzer, F. M. Raymo, N. Spencer, J. F. 
Stoddart,  D. J. Williams, Liebigs Ann., 1997, 1997, 2485-2494. 
[23] A. G. Kolchinski, D. H. Busch,  N. W. Alcock, J. Chem. Soc. Chem. 
Commun, 1995, 1289-91. 
[24] P. R. Ashton, P. T. Glink, J. F. Stoddart, P. A. Tasker, A. J. P. White,  D. J. 
Williams, Chem. Eur. J., 1996, 2, 729-736. 
[25] G. M. Hubner, J. Glaser, C. Seel,  F. Vogtle, Angew. Chem. Int. Ed. Engl., 
1999, 38, 383-386. 
[26] J. A. Wisner, P. D. Beer, M. G. B. Drew,  M. R. Sambrook, J. Am. Chem. 
Soc., 2002, 124, 12469-12476. 
[27] M. R. Sambrook, P. D. Beer, J. A. Wisner, R. L. Paul,  A. R. Cowley, J. Am. 
Chem. Soc., 2004, 126, 15364-15365. 
[28] V. Aucagne, K. D. Hanni, D. A. Leigh, P. J. Lusby,  D. B. Walker, 2006, 128, 
2186-2187. 
[29] ‘Active template’ is used as a general term to describe a reaction in which a 
moiety both catalyzes covalent bond formation and acts as a template for the 
assembly of a particular architecture. The term ‘active-metal template’ describes a 
subset of active template reactions in which the ‘active’ moiety is a metal. A 
‘catalytic active-metal template’ reaction is one in which the metal catalyst turns 
over; a ‘stoichiometric active-metal template’ reaction is one in which it does not. 
 20 
[30] S. Saito, E. Takahashi,  K. Nakazono, Org. Lett., 2006, 8, 5133-5136. 
[31] Y. Sato, R. Yamasaki,  S. Saito, Angew. Chem., Int. Ed., 2009, 48, 504-507. 
[32] J. Berna, J. D. Crowley, S. M. Goldup, K. D. Haenni, A.-L. Lee,  D. A. 
Leigh, Angew. Chem., Int. Ed., 2007, 46, 5709-5713; J. D. Crowley, K. D. Hanni, A.-
L. Lee,  D. A. Leigh, J. Am. Chem. Soc., 2007, 129, 12092-12093. 
[33] V. Aucagne, J. Berna, J. D. Crowley, S. M. Goldup, K. D. Haenni, D. A. 
Leigh, P. J. Lusby, V. E. Ronaldson, A. M. Z. Slawin, A. Viterisi,  D. B. Walker, J. 
Am. Chem. Soc., 2007, 129, 11950-11963; S. M. Goldup, D. A. Leigh, P. J. Lusby, 
R. T. McBurney,  A. M. Z. Slawin, Angew. Chem., Int. Ed., 2008, 47, 3381-3384. 
[34] J. Bernà, S. M. Goldup, A.-L. Lee, D. A. Leigh, M. D. Symes, G. Teobaldi,  






A catalytic 'active-metal' template strategy to 
[2]rotaxanes, [3]rotaxanes and some observations on 
the mechanism of the Cu(I)-catalyzed azide-alkyne 
1,3-cycloaddition 
 
Published as “A Catalytic 'Active-Metal' Template Strategy to [2]Rotaxanes, 
[3]Rotaxanes and Molecular Shuttles and Some Observations on the Mechanism of 
the Cu(I)-Catalyzed Azide-Alkyne 1,3-Cycloaddition”, V. Aucagne, J. Berná, J. D. 
Crowley, S. M. Goldup, K. D. Hänni, D. A. Leigh, P. J. Lusby, V. E. Ronaldson, A. 
M. Z. Slawin, A. Viterisi and D. B. Walker, J. Am. Chem. Soc., 2007, 129, 11950 
 
Acknowledgments 
The following persons are greatfully acknowledged for their contribution to the work 
in this chapter. Dr. Vincent Aucagne synthesized macrocycles 1b, 1c, 1d, 1e, 1f, 1h, 
1i, 1l and Rotaxane 4a for the first time. Dr. Stephen Goldup synthesized 
macrocycles 1g and 1j. Dr. D. Barney Walker carried out the synthesis of 
macrocycle 1n for the first time. Dr. Vicki Ronaldson optimized the synthetic route 
to macrocycles 1a and 1n. Paul Lusby synthesized macrocycle 1m. Dr. James 
Crowley carried out the synthesis of rotaxane 1k and performed molecular modeling 
of macrocycles 1a to 1o. Dr. José Bernà synthesized Rotaxanes S24 and S26. Kevin 
Hänni first carried out the ‘Click’ rotaxane-forming reactions with macrocycles 1b, 
1c, 1d, 1e, 1f, 1h, 1i, 1n and carried out copper salt screenings.  
Isolation and characterization of rotaxanes 4b, 4i, 4j, 4l, 4m, 4n was done by the 
author. Rotaxanes 7a and 7l were synthesized by the author. Single crystals of 7l 
were grown by the author and X-Ray-diffraction was carried out by Dr. Alexandra 
Slawin (University of St. Andrews). All kinetic studies were carried out by the 
author.  
Patrice Staub and Dr. J.-P. Sauvage (Strasbourg) are greatly acknowledged for 
generously providing us with a sample of macrocycle 1o. 
Chapter two                                  Active-metal template synthesis of [2] and [3]rotaxanes  
 
 22 
2  Synopsis 
 
A synthetic approach to rotaxane architectures is described in which metal atoms 
catalyze covalent bond formation whilst simultaneously acting as the template for the 
assembly of a mechanically interlocked structure. This 'active-metal' template 
strategy is exemplified using the Huisgen-Meldal-Sharpless Cu(I)-catalyzed 1,3-
cycloaddition of azides with terminal alkynes (CuAAC), a so-called 'click' reaction. 
Coordination of Cu(I) to an endotopic pyridine-containing macrocycle allows the 
alkyne and azide to bind to metal atoms in such a way that the metal-mediated bond-
forming reaction occurs through the cavity of the macrocycle or macrocycles 
forming a rotaxane. A variety of mono- and bidentate macrocyclic ligands are 
demonstrated to form [2]rotaxanes in this way and, by adding pyridine, the metal 
can turn over during the reaction giving a catalytic active-metal template assembly 
process. Under conditions that feature a high macrocycle:copper ratio, [3]rotaxanes 
(two macrocycles on a thread containing a single triazole ring) are also produced in 
the active-metal template reaction. The latter observation suggests that under these 
conditions the mechanism of the Cu(I)-catalyzed terminal alkyne-azide cycloaddition 



















2.1.1 The Cu(I)-Catalyzed terminal alkyne azide cycloaddition (CuAAC 
reaction)  
 
Recently, there has been a tremendous surge of interest in so-called “click”1,2 
methodologies for functional molecule synthesis, the most popular of which is the 
Huisgen-Meldal-Sharpless Cu(I)-catalyzed 1,3-cycloaddition of organic azides with 
terminal alkynes (the CuAAC reaction).3,4,5 The most common catalyst systems for 
this reaction employ water or alcohol solvents and use a Cu(II) salt in the presence of 
a reducing agent (often sodium ascorbate) to generate the required Cu(I) catalyst in 
situ.3,6 Metallic copper3,6 copper clusters7 or Cu zeolites8,9  have also been employed 
as pre-catalysts and, in some cases, Cu(I) salts can be used directly. However, in 
apolar solvents Cu(I) salts usually require the presence of nitrogen3,6,10 or 
phosphorus11 ligands, or acetonitrile as a co-solvent, to stabilize the Cu(I) oxidation 
state and undesired alkyne-alkyne homocoupling products are often observed under 
such reaction conditions.3,6 The basic mechanism of the CuAAC reaction is believed 
to be that shown in Scheme 2.1. A [2+3]cycloaddition—the mechanism of the 
thermal (i.e. uncatalyzed) Huisgen reaction12—is ruled out13 for the Cu(I)-catalyzed 
reaction on the basis of DFT calculations which show that reaction via a Cu(III)-
metallacycle (as shown in Scheme 2.1) is a more favorable pathway by up to 11.7 
kcal/mol.3,14,15,16,17 The same calculations suggest that the rate determining step is the 
formation of the Cu(III)-metallacycle from a reactive intermediate involving copper-
coordinated alkyne and, presumably, azide (organoazido-metal complexes are likely 
intermediates in many transition metal-mediated reactions of azides and Cu(I)-N3R 
complexes have been characterized by X-ray crystallography18). However, the exact 
nature of this reactive intermediate is unclear (Scheme 2.1, A-C). 
 





Scheme 2.1. The Proposed Mechanism of the Huisgen-Meldal-Sharpless Cu(I)-Catalyzed Alkyne-



























































Possible types of reactive intermediate
 Type A 
(i) one copper atom or (ii) one copper atom + !-activation of Cu-acetylide by a second copper 
atom
Type B 
Glaser-likex bis-alkyne bridged intermediate - only differs from A (ii) by the two copper atoms being
doubly bridged. Doubly-bridged intermediates are not possible with bidentate ligands for copper 





The azide and alkyne groups that react are on different copper atoms - (i) non-!-activated alkyne, 
(ii) !-activated alkyne. If the bridging ligands are alkynes, this differs from B only in the location of 
the alkyne which reacts with the azide. Doubly-bridged intermediates are not possible with 



























































In the absence of competing ligands,19 copper(I) acetylides exist as complex multi-
metal atom aggregates20 and kinetic studies3,21 by Fokin and Finn on the generic 
ligand-free19 Cu(I)-catalyzed alkyne-azide reaction show that in DMSO-water 
mixtures the reaction mechanism is second order with respect to copper. However, 
relatively little is known about the ligand-promoted Cu(I)-catalyzed cycloaddition in 
organic solvents. Recent experimental results from Straub,22 in which mononuclear 
Cu(I) acetylides ligated by a sterically shielding N-heterocyclic carbene react 
efficiently with bulky organoazides at room temperature, support the notion that a 
single copper atom mechanism (A(i), Scheme 2.1) is viable for the reaction, at least 
when the copper is bound to bulky ligands. Recent DFT calculations15 suggest that π-
activation of the copper-acetylide unit by coordination of a second copper atom (e.g. 
A(ii) or, more likely under ligand-free conditions or with small monodentate ligands, 
the bis-alkyne bridged ‘Glaser-like’23 intermediate B, Scheme 2.1) greatly enhances 
the reactivity of the Cu-σ-acetylide, accelerating formation of the metallacycle. 
Alternatively, a pathway21 in which the reacting azide and alkyne are coordinated to 
different copper(I) atoms (intermediate C(i) or (ii)) would be consistent with the 
second order kinetics observed in DMSO/water). It may well be that several or all of 
these types of intermediate24 can provide viable pathways for the CuAAC reaction, 
with the different characteristics of the intermediates being relatively favoured or 
inhibited by factors such as the solvent, bulk and coordination number of an added 
ligand, the strength of ligand-copper binding and the amount of ligand-free Cu(I) 
present in solution. Given the tendency of Cu(I)-acetylides to aggregate, it seems 
likely that the Glaser-like intermediates B or C(ii) feature in the dominant pathways 
in most reported CuAAC reactions. 
 
2.2 Results and discussion  
2.2.1 Preliminary studies 
 
Despite the uncertainty over the precise nature of the reactive intermediate in the 
CuAAC reaction, since tertiary amines and pyridines facilitate3,10 the reaction in 
organic solvents we reasoned that a macrocycle, 1, bearing an endotopic ligating 
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nitrogen atom might be able to direct the CuAAC reaction of a stoppered alkyne, 2, 
and a stoppered azide, 3, through the macrocycle cavity to give a [2]rotaxane, 4, in 
an active-metal template synthesis (Scheme 2.2). 
 
Scheme 2.2. The Active-Metal Template CuAAC Synthesis of [2]Rotaxanes 4a-o from Alkyne 2, 
Azide 3 and Macrocycles 1a-o. Reaction conditions: (i) 1a-o (0.01 M), Cu(I) salt (generally 
[Cu(CH3CN)4](PF6), see text), poorly coordinating solvent (generally CH2Cl2, see text) and, in the 
catalytic version of the active-metal template reaction, 3 equiv. pyridine. (ii) KCN, CH2Cl2/CH3OH.25 
For the effect of reaction conditions and reagent stoichiometry on the yields of 4a and 5, see Table 
2.1. For relative yields of 4a-o using a standardized set of reaction conditions see Figure 2.3. 
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A 2,6-di(alkyloxymethyl)pyridine macrocycle (1a), previously used26,27  as both a 
mono- and bidentate ligand for various transition metals in classical ‘passive’ 
template rotaxane and catenane syntheses, seemed a suitable candidate for initial 
investigations. Pleasingly, stirring of an equimolar mixture of the pyridine 
macrocycle 1a, alkyne 2, azide 3 and [Cu(CH3CN)4](PF6) in CH2Cl2 for 24 hours 
afforded―after demetallation with KCN―a mixture of [2]rotaxane 4a (57%) and the 
non-interlocked triazole thread 5 (41%), together with some of the unconsumed 
starting macrocycle (Scheme 2.2 and Table 2.1, entry 1).25  
 
Table 2.1. The Effect of Reaction Conditions and Reagent Stoichiometry on the Active-Metal 
Template CuAAC Synthesis of [2]Rotaxane 4a (Scheme 2.2).25 a All reactions were carried out at 0.01 
M concentration with respect to 1a using the procedure shown in Scheme 2.2; b 3 equiv. pyridine; c 
Control experiment with no [Cu(CH3CN)4](PF6) present to demonstrate that the thermal reaction does 
not occur at these temperatures; d 24 h; e12 h then 24 h; f12 h then 72 h.  
 
By varying the reaction conditions and reactant stoichiometry (Table 2.1), yields of 
up to 94% of [2]rotaxane with respect to the amount of macrocycle used were 
achieved (5 equiv. 2 and 3; Table 2.1, entry 2) for this stoichiometric active-metal 
template reaction (Figure 2.1a). The use of sub-stoichiometric amounts of copper 
was investigated to determine whether the metal would turn over as both a template 
and a cycloaddition catalyst (i.e. a catalytic active-metal template synthesis, Figure 
2.1b). When using 20 mol% (with respect to 1a) of [Cu(CH3CN)4](PF6) at room 
temperature, the reaction appeared to stop after [2]rotaxane equivalent to the amount 
of copper present had been formed, suggesting that the multidentate rotaxane 
sequesters the transition metal during the reaction inhibiting further catalytic activity. 














1a 1 1 CH2Cl2 25d >95% 57% 
2a 5 1 CH2Cl2 25d 92% 94% 
3b 5 0.2 CH2Cl2 25d 44% 59% 
4b 5 0.2 (ClCH2)2 25→70e 94% 82% 
5c 1 0 (ClCH2)2 25→70f <5% 0% 
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producing a sub-stoichiometric reaction, but the reaction was extremely slow at 25 
°C (Table 2.1, entry 3). Elevating the temperature (70 °C, ClCH2CH2Cl) gave an 
improved yield (82%) of rotaxane 4a in a reasonable time period (36 h) using only 4 
mol% Cu(I) with respect to both 2 and 3 (Table 2.1, entry 4).  
 
2.2.2 Effect of the nature of the Cu-(I) source 
 
A number of different Cu(I) salts were screened for the reaction shown in Scheme 
2.2 using the conditions shown in Table 2.1, entry 1 but replacing the 
[Cu(CH3CN)4](PF6) salt with other Cu(I) complexes. The use of CuOTf·benzene 
gave a 78% conversion of 2 and 3 into triazole products after 24 h but only a 46% 
yield of [2]rotaxane 4a. By letting the reaction continue for a further two days (72 h 
in total) complete conversion of the starting azide and alkyne to triazole products 
(48% rotaxane) was achieved. Substituting CuI for [Cu(CH3CN)4](PF6) led to very 
little reaction during the first 24 hours (8% conversion to triazole) presumably due to 
the low solubility of CuI in CH2Cl2, but interestingly, what little alkyne and azide 
had reacted formed rotaxane with high selectivity (7:1 rotaxane:thread). The reaction 
proceeded slowly to completion (>98% conversion) over three weeks. However, at 
the end point of the reaction the product ratio (56:44 rotaxane:thread) was identical 
to that of the analogous [Cu(CH3CN)4](PF6)-mediated experiment.   
We also synthesized and isolated various discrete Cu(I)-1a complexes and tested 
their efficacy in the active-metal template reaction. The macrocycle, 1a, and the 
different Cu(I) salts were mixed in CH3CN solution and the resulting Cu(I)-1a 
complexes obtained as solids by vapour diffusion with diethyl ether. The preformed 
Cu(I)-1a complexes were then submitted to the standard rotaxane-forming reaction 
conditions (Table 2.1, entry 1). The preformed [Cu(CH3CN)4](PF6)-1a complex gave 
76% conversion to triazole and a 53% yield of [2]rotaxane; the preformed CuOTf-1a 
complex gave 53% conversion triazole but only a 5% yield of [2]rotaxane; the 
preformed CuI-1a complex gave identical results to the Cu(I)-1a complex formed in 
situ (i.e. >98% triazole conversion over 3 weeks; 56% rotaxane).   
Although there is some variation in the efficacy of the various Cu(I) salts on the 
rotaxane-forming reaction, and some unexplained variation in the rotaxane:thread 
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ratio during the course of the reaction with some sources of Cu(I), simple addition of 
[Cu(CH3CN)4](PF6) is the most convenient way of maximizing the CuAAC yield of 
rotaxane.28 
2.2.3 Kinetic studies 
 
Some simple kinetic measurements were made to determine whether, under these 
reaction conditions, the Cu(I)-catalyzed alkyne-azide cycloaddition is actually 
accelerated by pyridine-based ligands. The rate of formation of triazole products (i.e. 
thread, plus rotaxane where relevant) was compared for the ligand-free reaction and 
reactions containing pyridine, 2,6-dimethylpyridine (lutidine), 2,6-
di(alkyloxymethyl)pyridine macrocycle 1a, and 6, a close but acyclic analogue of 1a.  
The results (Figure 2.1) show that both lutidine and 6, the acyclic analogue of 1a, 
significantly accelerate the CuAAC reaction rate (essentially complete conversion to 
triazole after 3 h) compared to the Cu(I)-catalyzed reaction when no pyridine-based 
ligand is added (complete conversion after 6 h). 
The presence of pyridine also initially accelerates the reaction, but the conversion 
tails off after 2 h suggesting that using unsubstituted pyridine as a ligand facilitates 
the oxidation of Cu(I) to non-catalytic Cu(II) under the reaction conditions. The role 
of the pyridine ligands in this rate acceleration is probably to break up extended 
Cu(I)-acetylide aggregates to form smaller reactive intermediates of the type shown 
in Scheme 2.1, although we cannot rule out an electronic effect of the ligand on the 
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Figure 2.1. Conversion to triazole (i.e. thread + rotaxane if applicable) vs. time for different pyridine-
based ligands for the CuAAC reaction. Conditions:  i) ligand (1 equiv.), alkyne 2 (1 equiv.), azide 3 (1 
equiv.), [Cu(CH3CN)4](PF6) (1 equiv.; 1 or 2 equiv. with 1a), CD2Cl2, RT, 0.01 M. The conversion of 
2 and 3 into the triazole products (thread 5, + rotaxane 4a where relevant) was monitored by 1H NMR.  
 
Interestingly, the Cu(I)-catalyzed formation of triazole products (both rotaxane and 
thread) in the presence of macrocycle 1a (with 1 equiv. of Cu)―which also 
presumably breaks up the Cu-acetylide aggregates―is actually slower (24 h cf 6 h) 
than the ligand-free Cu(I)-catalyzed reaction. Whilst it might seem surprising that the 
active-metal template reaction is slower than the ligand-free reaction given that 
excellent yields of rotaxane are obtained under both stoichiometric and catalytic 
active-metal template conditions (Table 2.1), the rationale for this is quite 
straightforward. First, the reaction might be expected to be slower with the 
macrocyclic ligand since the alkyne-azide cycloaddition must take place through the 
macrocycle cavity, a sterically restricted environment compared to the ligandless 




















































(1 equiv. Cu) 
(2 equiv. Cu) 
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hindering any motion required to achieve bond formation or changes of geometry at 
the copper centre. Second, the macrocyclic ligand might disfavour certain types of 
reactive intermediate (e.g. B) on steric grounds and so the reaction may proceed 
through another, type of slower reacting, but still viable, intermediate (e.g. A or C 
rather than B). The reason that the ligandless formation of triazole thread does not 
dominate given the slow rate of rotaxane formation is that the macrocycle is an 
excellent ligand for the Cu(I) and sequesters it, preventing the inherently faster 
ligand-free reaction (probably via B or A(ii)) from occurring. Accordingly, addition 
of a second equivalent of Cu(I) to the reaction containing 1a should increase the rate 
of triazole formation to close to that of the ligand-free rate. Indeed, this was found to 
be the case (Figure 2.1 and 2.2). However, whilst one might expect this increase to 
be totally due to thread formation, analysis shows that the rate of rotaxane formation 
is also slightly increased by adding an extra equivalent of Cu(I) to this reaction 
(Figure 2.2). In fact, the final yield of [2]rotaxane only falls from 57% to 22% even 
though the triazole-forming reaction is complete in 6 h instead of 24 h. The 
acceleration of the rotaxane-forming reaction by excess Cu(I) strongly suggests that 
π-activation of the copper-acetylide unit (i.e. reactive intermediate A(ii), B or C(ii)) 
is the dominant process in the CuAAC reaction mechanism of 1a. 
 
Figure 2.2. Formation of triazole products (rotaxane 4a ■, thread 5 ●) vs time for the CuAAC reaction 
in the presence of macrocycle 1a. Conditions: i) 1a (1 equiv.), 2 (1 equiv.), 3 (1 equiv.), 
[Cu(CH3CN)4](PF6) (1 or 2 equiv.), CD2Cl2, RT, 0.01 M. The conversion of 2 and 3 into thread 5 and 




















1 equiv. Cu 1 equiv. Cu 
2 equiv. Cu 2 equiv. Cu 
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2.2.4 Effect of the macrocycle structure on [2]rotaxane formation 
 
To further investigate both the scope and the mechanism of the active template 
rotaxane-forming reaction shown in Scheme 2.1 the structure of the pyridine-based 
macrocycle was varied. The macrocycles used in the study are shown in Figure 2.3 
and their syntheses are detailed in the experimental part. In order to compare the 
relative yields of rotaxane and thread within the ligand series, the macrocyclic 
ligands were screened using a standard, rather than optimized,29 set of stoichiometric 
active-metal template reaction conditions in which the original macrocycle (1a) 
generates appreciable quantities of both rotaxane and thread. The conditions used 
were 1 equiv. macrocycle (1a-o), 1 equiv. alkyne 2, 1 equiv. azide 3 and 1 equiv. 
[Cu(CH3CN)4](PF6), at a concentration of 0.01 M in CH2Cl2 at room temperature for 
24 h. In most cases the starting alkyne (2) and azide (3) were completely consumed 
during the course of the reaction. After 24 h (72 h for 1n and 1o) each reaction was 
treated with KCN to remove the Cu(I), analyzed by 1H NMR to determine the yield 
(shown in Figure 2.4) under the standard set of conditions, and then purified to give 
authenticate samples of each [2]rotaxane. Molecular ions corresponding to [M+H]+, 
[M+Na]+, [M+K]+ for the intact rotaxanes were detected by ESI-MS mass 
spectroscopy of the KCN-treated reaction mixtures as the major or sole peaks in the 
1.2-2 kDa range. The yield (the percentage shown in red in Figure 2.3) of each 
rotaxane is the conversion of the macrocycle (1a-o) to the corresponding [2]rotaxane 
(4a-o). The conversion to triazole (the percentage shown in parentheses in Figure 
2.3) is the overall conversion of the alkyne (2) and azide (3) into both thread (5) and 
rotaxane (4a-o). 





Figure 2.3. Influence of macrocycle structure on the active-metal template CuAAC rotaxane-forming 
reaction in Scheme 2.2 using a standardized set of reaction conditions. Conditions for Scheme 2.2: (i) 
1a-o, 2, 3, [Cu(CH3CN)4](PF6), CH2Cl2, RT, 24 h (72 h for 4n and 4o); 0.01 M concentration with 
respect to each of 1a-o, alkyne 2, azide 3 and [Cu(CH3CN)4](PF6). The reactions were not run under 
an inert atmosphere, nor using distilled or dried solvents. (ii) KCN, CH2Cl2/CH3OH. The conversion 
of each macrocycle to [2]rotaxane is given as a percentage yield in red and the overall conversion of 2 
and 3 into triazole products (rotaxane 4a-o and thread 5) is shown for each macrocycle in parentheses. 
‘Trace’ means that the rotaxane was observed by ESI-MS but could not be detected by 1H NMR. 72 h 
reaction time. The colours and lettering correspond to the signals and assignments of the 1H NMR 
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2.2.4.1 Mono- and tridentate macrocycles 
 
In addition to the strongly coordinating pyridine nitrogen, macrocycle 1a has two 
ether oxygen atoms that could potentially be involved in (albeit presumably weak) 
coordination to the metal atom during the active template reaction, making 1a a 
monodentate or possibly weakly bidentate or very weakly tridentate ligand.30,27 
Macrocycle 1b is not only missing the ether oxygen atoms, but the pyridine nitrogen 
atom lone pair is tied up in strong intramolecular bifurcated hydrogen bonds to the 
adjacent amide groups31 and so it was rather surprising to find that [2]rotaxane 4b 
was successfully produced in the active-metal template reaction, albeit in only 6% 
yield. Presumably coordination of 1b to the copper is able to occur at the expense of 
the intramolecular hydrogen bonds32,33 and 1b is then able to act as a monodentate 
ligand. In contrast the use of 1c, a tridentate macrocyclic ligand with three hard 
donor atoms, gave a similar overall conversion to triazole but with no rotaxane 
formed. Upon addition of 1c to the copper catalyst and other reagents the solution 
changed colour immediately from colourless to blue-green. This suggests that some 
of the Cu(I) is rapidly oxidized to Cu(II) upon coordination to 1c.34 The resulting 
Cu(II)-1c complex is not catalytically active for the alkyne-azide cycloaddition and 
any tridentate Cu(I)-1c complex lacks the free coordination sites necessary to bind 
azide and alkyne in the same aggregate.35,36 However, enough of the copper in the 
reaction is not tied up as the 1c complex for the ligandless thread-forming triazole 
reaction to proceed to completion within 24 h. 
Macrocycle 1d has a similar structure to 1a except that the pyridine nitrogen is 
oxidized. The result, >98% conversion to triazole but only a trace of rotaxane when 
using 1d as the macrocycle in the active template reaction, show that the N-oxygen 
atom greatly affects the ligands ability to coordinate to Cu(I). Macrocycle 1e also has 
a similar constitution to 1b, but the secondary amides are methylated, eliminating 
their ability to form hydrogen bonds. AM1 calculations37,38using Spartan (see 
Experimental Section) show that the methyl groups distort and partially fill the 
macrocycle cavity. The result is that, like 1d, little of the CuAAC reaction is directed 
through the macrocycle cavity to form rotaxane. The same effect is seen for 
macrocycle 1f, the bis-N-acetylated analogue of 1c.  
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Removing the pyridine nitrogen atom, macrocycle 1g, completely switches off 
rotaxane formation, confirming the need for a ligating donor atom. Replacing the 
benzylic oxygens of 1a by more strongly coordinating sulfur atoms produces another 
tridentate macrocycle, 1h. As with 1c, no rotaxane is formed―consistent with the 
premise that tridentate ligand complexes of Cu(I) lack the vacant coordination sites 
necessary to bind both azide and alkyne35―and the yield of triazole is also only 30%, 
indicating that 1h is particularly effective in sequestering the copper. Oxidation of 
the sulfide groups to sulfones, macrocycle 1i, restores the ability of the macrocycle to 
bind to the Cu(I) as a monodentate ligand and, despite the increased bulk around the 
coordinated metal ion, a significant amount (13%) of [2]rotaxane 4i is formed by the 
stoichiometric active-metal template reaction. In fact, substitution of the benzylic 
ether oxygen atoms by methylene groups confirms that only a monodentate 
macrocycle with a single strongly coordinating donor atom is required for an 
efficient active template rotaxane-forming reaction; macrocycle 1j generates just as 
much [2]rotaxane as the parent macrocycle 1a. It should be noted that the cavity of 
macrocycle 1j is probably rather more flexible than 1a, yet this is not detrimental for 
rotaxane formation. 
To test whether other macrocycle geometries would be tolerated by the active 
template reaction, we prepared 1k and 1l, in which the substituted benzylic units 
were replaced by arylalkyne and aryl groups, respectively. The 2,6-bisalkyne 
pyridine unit proved to be unstable39,40 under the reaction conditions, suppressing the 
overall yield of the CuAAC reaction with no rotaxane being produced. However, the 
active-metal template CuAAC reaction with 1l proceeded smoothly, albeit generating 
rather less rotaxane (25%) than the most effective examples of other macrocycle 
geometries (1a and 1j). AM1 calculations37 using Spartan (see Experimental Section) 
indicate that 1l has a well-defined persistent cavity suitable for the threading of a 
molecular chain.  However, the phenyl groups flanking the pyridine sterically 
encumber the nitrogen donor atom of the macrocycle, and a combination of steric 
and electronic factors probably reduces the binding strength of this macrocycle for 
Cu(I) ions. The weaker binding leads to more ligandless Cu(I) in solution, resulting 
in higher conversion of the substrates into the non-interlocked thread, 5 and the 
relatively modest yield of [2]rotaxane 4l. Increasing the steric bulk at the 4-position 
of the pyridine group, whilst simultaneously increasing the electron-donating ability 
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of the heterocyclic nitrogen atom, (macrocycle 1m) had little effect on the rotaxane 
yield. 
 
2.2.4.2 Bidentate macrocycles 
 
Having established that monodentate ligands of several different macrocycle 
geometries and donor atom orientations (1a, 1j, 1l, 1m) efficiently promote active 
template rotaxane formation, whereas tridentate macrocycles (1c and 1h) do not, the 
efficacy of bidentate macrocycles 1n and 1o was then investigated.10,41The bipyridyl 
macrocycle, 1n, directs the CuAAC reaction through its cavity to form rotaxane 
almost as efficiently as the best monodentate macrocycles (45% 1n→4n cf 57% 
1a→4a and 60% 1j→4j). However, it severely inhibits the rate of the Cu(I)-
catalyzed reaction and it took 3 days for the active-metal template reaction 1n→4n to 
go to completion, compared to 24 h for 1a→4a and 6 h for the ligand-free Cu(I)-
catalyzed control reaction (Figure 2.2). The inhibition of the Cu(I)-catalyzed 
cycloaddition is even more dramatic with the other bidentate ligand investigated, the 
2,9-diphenylphenanthroline macrocycle (1o) used extensively to assemble rotaxanes 
and catenanes by the Sauvage group.42 Macrocycle 1o completely inhibits the 
CuAAC reaction. Even after 3 days under the standard stoichiometric active-metal 
reaction conditions in the presence of 1o, no triazole products were observed. This 
latter result is particularly interesting given that phenanthroline ligands have 
previously been reported.10 to promote the CuAAC reaction. The lack of reactivity is 
presumably a result of the steric bulk about the Cu(I) centre in the complex 
preventing the complex from adopting various orientations required for reaction to 
take place (e.g. tolerating the change in geometry from Cu(I) to Cu(III), Scheme 2.1), 
together with the macrocycle being very effective in sequestering the Cu(I) in this 
unreactive form. A related Cu(I)-macrocycle complex has recently been reported to 
act as a stoichiometric active-metal template for the formation of [2]rotaxanes via a 
Glaser alkyne homocoupling.43 However, in that case, intermediates of type B 
(Scheme 2.1) are possible with a bidentate ligand for copper because no azide need 
be coordinated to the metal atom.   
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2.2.5 1H NMR spectra of the metal-free [2]rotaxanes  
 
The 1H NMR spectra (400 MHz, 298 K, CDCl3) for each of the rotaxanes formed in 
>5% yield is shown in Figure 2.4.  The 1H NMR spectra of the rotaxanes (Figure 
2.4b-g) all show upfield shifts of several signals with respect to the non-interlocked 
components (thread 5, Figure 2.4a, and the macrocycles 1a, 1b, 1i, 1j, 1m and 1n, 
see experimental section). Such shielding is typical of interlocked structures in which 
the aromatic rings of one component are positioned face-on to another component 
and is observed for all the non-stopper resonances of the axle (Hf-j) indicating that the 
macrocycle is able to access the full length of the thread in the rotaxanes. This is as 
expected; there should be no strong intercomponent non-covalent interactions 
between the thread and the macrocycle in the metal-free rotaxanes. The one 
exception is the amide containing rotaxane 4b (Figure 2.4c), which exhibits a 
significant downfield shift of the amide resonance with respect to free macrocycle 
(see Experimental Section). This is presumably due to the formation of hydrogen 
bonds between the amides of the macrocycle and the triazole unit of the thread in an 
interaction similar to that previously observed between interlocked amide and 
pyridine components in rotaxanes and catenanes.26,27,44 
 
 




Figure 2.4. 1H NMR spectra (400 MHz, CDCl3, 300 K) of a) triazole thread 5, b) [2]rotaxane 4a, c) 
[2]rotaxane 4b, d) [2]rotaxane, 4i, e) [2]rotaxane, 4j, f) [2]rotaxane, 4m, g) [2]rotaxane, 4n. The 
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2.2.6 The active-metal template CuAAC reaction at high 
macrocycle:Cu(I) ratios: the unexpected formation of 
[3]rotaxanes 
 
The picture of the active-metal template CuAAC reaction that we can build up that is 
consistent with the experimental observations so far is that the ligand-free 
[Cu(CH3CN)4](PF6) salt and macrocycles 1a-o are in equilibrium with the 
corresponding copper(I)-macrocycle complex in which, in most cases, the metal 
atom directs the cycloaddition of the azide and alkyne through the macrocycle cavity. 
Although the ligand-free reaction is inherently faster than the active-metal template 
one, the coordinating ability of the macrocycle means that the rotaxane-forming 
reaction can become competitive with, or even dominate, the thread-forming 
reaction. In general, a stronger binding macrocyclic ligand (e.g. 1a cf 1b) should 
move this equilibrium in favour of rotaxane formation. However, some changes in 
coordination geometry about the metal are required for the CuAAC mechanism to 
operate (Scheme 2.1) and so the most strongly binding macrocycle (1o), which 
apparently does not tolerate such changes, actually inhibits the rotaxane-forming 
reaction. In view of this, we decided to investigate other conditions in which the 
rotaxane-forming reaction might be increased at the expense of the formation of 
thread.   
In an attempt to minimize the amount of ligandless Cu(I) present in the reaction, we 
carried out the active metal template CuAAC protocol under the standard conditions 
(1 equiv. 2, 1 equiv. 3, 1 equiv. [Cu(CH3CN)4](PF6), CH2Cl2, RT) used previously 
but in the presence of 10 equivalents of macrocycle (Scheme 2.3). Our initial 
experiments were carried out with monodentate macrocycle 1l, because it is a rather 
poor ligand (we were unable to generate several other metal complexes with it) due 
to the steric crowding around the pyridine nitrogen and the π-electron density 
presented to the low oxidation state copper from the adjacent aromatic rings. The 
rather weak Cu(I) binding affinity―meaning there is more ligandless Cu(I) present 
in solution than many of the other macrocycles shown in Figure 2.3―would account 
for the modest yield of rotaxane using 1 equiv. of this macrocycle. This, we 
reasoned, should be improved by increasing the macrocycle:copper ratio. 
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We were immediately intrigued to find that the reaction was much slower with 10 
equivalents of the macrocycle than it had been with 1 equivalent (Figure 2.2), the 
higher macrocycle:Cu(I) reaction taking more than one week to go to completion. 
Upon reaching this endpoint, the mixture of triazole products was found to consist of 
30% thread 5, 37% [2]rotaxane 4l and, to our surprise, 33% [3]rotaxane, 7l (yields 
quoted with respect to the alkyne and azide reactants). A reaction using macrocycle 
1a under the same experimental conditions (1 equiv. 2, 1 equiv. 3, 1 equiv. 
[Cu(CH3CN)4](PF6) and 10 equiv. 1a, CH2Cl2, RT) was again slower than the same 
reaction with 1 equivalent of macrocycle (3 days to reach completion cf. 24 h) 
generating a product mixture of 5% thread 5, 90% [2]rotaxane 4a and 5% 
[3]rotaxane 7a (yields quoted with respect to the alkyne and azide reactants). A 
similar but less dramatic trend was seen with bidentate macrocycle 1n; with 10 
equivalents of 1n the reaction took 10 days to complete (cf. 7 days with 1 equivalent) 
producing 3% thread 5 and 97% [2]rotaxane 4n (in this case no traces of [3]rotaxane, 
4n, could be detected by 1H NMR spectroscopy or mass spectrometry). 
The remarkable features of these high macrocycle:Cu(I) ratio active-metal template 
reactions are:  
i) The exceptional combined rotaxane yields: 95% ([2]rotaxane 4a + 
[3]rotaxane 7a) cf 57% 4a with 1 equiv. 1a; 70% ([2]rotaxane 4l + 
[3]rotaxane 7l) cf 25% 4l with 1 equiv. 1l; 97% ([2]rotaxane 4n) cf 45% 
4n with 1 equiv. 1n.  
ii) The significant decrease in the reaction rates compared to the low 
macrocycle:Cu(I) ratio reactions. The largest effect on rates is with the 
weakly copper-binding macrocycle 1l; the smallest effect on rates is with 
the strongly copper-binding macrocycle 1n. Again, this is strongly 
suggestive that the dominant mechanism of the CuAAC reaction under 
these conditions involves π-activation of the copper-σ-acetylide unit by a 
second, preferably ligandless for steric reasons, copper atom (i.e. I or II, 
Scheme 2.3, which correspond to reactive intermediates for the CuAAC 
reaction of type A(ii), II, or B or C(ii), I, in Scheme 2.1). 
iii) The formation of [3]rotaxane (in 33% yield using macrocycle 1l)—i.e. 
TWO macrocycles being threaded during the formation of ONE triazole 
ring. Molecular models show that this can most reasonably occur through 
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Scheme 2.3. The Effect of the Macrocycle:Cu(I) Ratio on the Active-Metal Template CuAAC 
Reaction. Reagents and conditions: (i) 1a, 1l or 1n (10 equiv.), 2 (1 equiv.) and 3 (1 equiv.), 
[Cu(CH3CN)4](PF6) (1 equiv.), CH2Cl2, RT, 24 h (1a); 7 days (1l); 10 days (1n). (ii) KCN, 
CH2Cl2/CH3OH. Product yields starting from macrocycle 1a: thread 5 (5%), [2]rotaxane 4a (90%), 
[3]rotaxane 7a (5%). Product yields starting from macrocycle 1a: thread 5 (5%), [2]rotaxane 4i (33%), 
[3]rotaxane 7l (37%). Product yields starting from macrocycle 1n: thread 5 (3%), [2]rotaxane 4n 
(97%), [3]rotaxane 7n (0%). In the reactive intermediates shown, the Cu-azide (orange) reacts with 
any of the Cu-alkyne units shown in green. L can be any non-reacting ligand, including other alkyne 
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The 1H NMR spectra of [2]rotaxane 4l and [3]rotaxane 7l are shown in Figure 2.5b 
and 2.5c, respectively. The resonances for the axle (Hf-j) of the rotaxanes are shifted 
upfield compared to the free non-interlocked thread 5 (Figure 2.5a), and 
unsurprisingly, this effect is more pronounced in the [3]rotaxane (Figure 2.5c) than 
in the [2]rotaxane (Figure 2.5b).  Also, due to the asymmetry of the thread the 1H 
NMR spectrum of [3]rotaxane 7l (Figure 2.5c) displays inequivalent but overlapping 
peaks for the two macrocycle components, which are double the intensity of the 
corresponding macrocycle signals in the [2]rotaxane.  Single crystals of 7l suitable 
for X-ray crystallography were grown by slow cooling of a hot, saturated solution of 
7l in acetonitrile. The solid state structure (Figure 2.6) confirmed the structure of 7l 
as a [3]rotaxane. Although it may appear at first glance that face to face π-stacking 
interactions might help to orient the two macrocycles on the thread, in the solid state 
structure the aromatic rings of adjacent macrocycles are not co-planar and their 
interplanar separation is somewhat large (> 3.8 Å) to be considered π-stacking.  
 
Figure 2.5. 1H NMR spectra (400 MHz, CDCl3, 300 K) of a) triazole thread 5, b) [2]rotaxane 4l, c) 


































J, J’, K, 
K’, L, L’
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Figure 2.6. X-Ray structure of [3]rotaxane 7l, from a single crystal obtained from a saturated 
acetonitrile solution: (a) viewed side-on; (b) viewed along axis of the thread. For clarity, different 




The Cu(I)-catalyzed 1,3-cycloaddition of azides with terminal alkynes is a highly 
effective reaction for the active-metal template synthesis of rotaxanes, with this new 
synthetic approach being illustrated through both stoichiometric (up to 97% yield) 
and catalytic (up to 82% yield) versions of the strategy. The reaction tolerates a wide 
variety of both monodentate and bidentate macrocyclic ligands which, although 
inherently slower than the ligand-free Cu(I)-catalyzed reaction, all work by 
sequestering the majority of the Cu(I) present so that the rotaxane-forming CuAAC 
reaction becomes competitive with―and, under many conditions, dominates―the 
ligand-free CuAAC reaction. The addition of pyridine enables the Cu(I) active-metal 
template to turnover without significantly compromising the yield of rotaxane. 
Amongst several potentially attractive features of this type of synthetic strategy is 
that it offers an unusual probe of reaction mechanism. The increase in rates of 
rotaxane formation by excess ligand-free Cu(I) support the suggestion that in CH2Cl2 
the copper-σ-acetylide is activated by π-coordination to a second ligand-less19 copper 
atom, and the remarkable formation of [3]rotaxanes at high macrocycle:Cu(I) ratios 
suggest that, under these conditions, the CuAAC reaction proceeds via a multi-
copper atom complex in which the reacting azide and alkyne are almost certainly 
located on different copper atoms. 
The template-directed assembly of otherwise difficult-to-access molecules and the 
catalysis of covalent bond formation are two of the most useful tasks that transition 
metals can perform in organic chemistry. The present work demonstrates that the 
combination of these apparently disparate functions can produce high yielding, mild 
a) b) 
Chapter two                                  Active-metal template synthesis of [2] and [3]rotaxanes  
 
 44 
and effective synthetic routes to complex molecular architectures that require only 
substoichiometric amounts of metal. The already great amount of work published so 
far regarding ‘active-metal’ templated reactions seems to be in accordance with this 
statement. 
 
2.4 Experimental section 
2.4.1 Experimental procedures for the formation of “click” rotaxanes  
 
General method for the formation of “click” rotaxanes 
CAUTION: copper acetylides, which are potential by-products of this reaction, are 
shock-sensitive when dry. Care should be taken if performing these reactions on a 
large scale that these are not isolated in other than trace amounts by washing with 
basic ammonium citrate or dilute HCl. 
A solution of macrocycle, (1 equiv.), azide, (1 equiv.), alkyne, (1 equiv.) and 
[Cu(CH3CN)4](PF6) (1.1 eq) in dry CH2Cl2 (5 mL) and under N2 was stirred at room 
temperature for 24 h. The resulting mixture was diluted with CH2Cl2 (5 mL) and 
methanol (15 mL). Then a solution of KCN (10 equiv.) in methanol (2 mL) was 
added and the resulting suspension stirred vigorously for 1 h. Solvents were 
evaporated (80 ºC) and the residue was partitioned between water (15 mL) and 
CH2Cl2 (20 mL). The layers were separated and the aqueous layer was extracted with 
CH2Cl2 (3 × 10 mL). The combined organic fractions were washed with water (10 
mL) and brine (10 mL), then dried (MgSO4) and concentrated under reduced 
pressure. The resulting solid was purified by flash column chromatography and/or 











Spectroscopic data of the non-interlocked thread 5 generated during click reactions: 
1H NMR (400 MHz, CDCl3): δ = 7.61 (s, 1H, Hi), 7.21 (d, 12H, J = 8.52 Hz, Hb, 
Hn), 7.03-7.11 (m, 16H, Hc, Hd, Hm, Hl), 6.82 (d, 2H, J = 8.92 Hz, Hk), 6.72 (d, 2H, J 
= 8.89 Hz, He), 5.17 (s, 2H, Hj), 4.59 (t, 2H, J = 6.92 Hz, Hh), 3.94 (t, 2H, J = 5.53 
Hz, Hf), 1.23-1.43 (m, 2H, J = 6.26 Hz, Hg), 1.29 (s, 54H, tBu). 13C NMR (100 
MHz, CDCl3): δ = 156.1, 156.0, 148.3 (×2), 144.3, 144.0 (×2), 140.1 (×2), 132.3 
(×2), 130.6 (×2), 124.0 (×2), 123.1, 113.2, 112.9, 63.7, 63.0 (×2), 61.9, 47.2, 34.2 





Following the general procedure, macrocycle 1a (100 mg, 0.2 mmol) was reacted 
with alkyne 2 and azide 3 to give a crude yellow solid. Purification by column 
chromatography (CH2Cl2 then a gradient from 5 to 20 % CH3CN in CH2Cl2) gave 
pure rotaxane 4 as a colourless solid (180 mg, 54%).  1H NMR (400 MHz, CDCl3): 
δ = 7.50 (t, 1H, J = 7.7 Hz, HA), 7.31 (s, 1H, Hi), 7.22-7.30 (m, 14H, HB, Hb and Hn), 
7.09-7.17 (m, 12H, Hm and Hc), 7.08 (d, 2H, J = 8.6 Hz, Hl), 7.04 (d, 2H, J = 8.6 Hz, 
Hd), 6.97 (d, 4H, J = 8.3 Hz, HE), 6.77 (d, 2H, J = 8.6 Hz, Hk), 6.56 (d, 4H, J = 8.3 
Hz, HF), 6.48 (d, 2H, J = 8.6 Hz, He), 4.91 (br s, 2H, Hj), 4.49 (br s, 4H, HD), 4.31 (br 
s, 4H, HC), 3.76-3.87 (m, 4H, HG), 3.71 (t, 2H, J = 7.1 Hz, Hh), 3.34 (t, 2H, J = 5.4 
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Hz, Hf), 1.61-1.73 (m, 4H, HH), 1.54-1.62 (m, 2H, Hg), 1.34 (s, 27H, Ha or Ho), 1.33 
(s, 27H, Ha or Ho), 1.17-1.41 (m, 12H, HI, HJ and HK); 13C NMR (100 MHz, 
CDCl3): δ = 158.8, 157.7, 156.4 (× 2), 146.4 (×2), 144.4, 144.3, 143.5, 139.9, 139.7, 
137.3, 132.3, 132.1, 130.1, 130.0, 129.1 (× 2), 124.2, 124.1, 123.6, 120.2, 114.4, 
113.3, 113.1, 72.6, 71.4, 67.2, 64.0 (× 2), 63.2, 61.6, 46.7, 34.4, 34.3, 31.5 (× 2), 
29.7, 29.5, 28.7 (× 2), 25.8;  LRESI-MS: m/z = 1619 [M+H]+; HRFAB-MS (3-
NOBA matrix): m/z = 1621.04087 (calcd. for 13C12C110H135N4O6, 1621.04152). 
 
4b 
Using general method, macrocycle 1b (260 mg, 0.50 mmol, 1.0 equiv.), azide 3 (296 
mg, 0.50 mmol, 1.0 equiv.), alkyne 2 (300 mg, 0.55 mmol, 1.1 equiv.), 
[Cu(CH3CN)4](PF6) (206 mg, 0.55 mmol, 1.1 eq) and KCN (327 mg, 5.03 mmol, 10 
equiv.) gave the crude product as a mixture of rotaxanes 4b, thread 5 (5:95, by 1H 
NMR spectroscopy), macrocycle 4b. Purification by flash column chromatography 
(Acetone/CH2Cl2; 2:96 to 5:95) followed by preparative TLC on silica gel (2 elutions 
in Acetone/CH2Cl2; 4:96) gave the rotaxane 4b as a white solid (20 mg, 3%). M.p. 
165-168 °C; 1H NMR (400 MHz, CDCl3): δ = 9.02 (t, 2H, J = 6.3 Hz, HC), 8.37 (d, 
2H, J = 7.8 Hz, HB), 7.90 (t, 1H, J = 7.9 Hz, HA), 7.24-7.22 (m, 12H, Hb and Hn), 
7.13-7.03 (m, 16H, Hc, Hd, Hm, Hl), 6.90 (s, 1H, Hi), 6.72 (d, 4H, J = 8.5 Hz, HE), 
6.66 (d, 2H, J = 8.9 Hz, Hk), 6.61 (d, 2H, J = 8.9 Hz, He), 6.41 (d, 4H, J = 8.6 Hz, 
HF), 4.58 (s, 2H, Hj), 4.48 (dd, 2H, J = 6.6 Hz, J = 14.6 Hz, HD ), 4.29 (dd, 2H, J = 
6.5 Hz, J = 14.6 Hz, HD’), 3.77 (t, 4H, J = 6.0 Hz, HG), 3.66 (t, 2H, J = 7.5 Hz, Hh), 
3.55 (t, 2H, J = 5.8 Hz, Hf), 1.71-1.54(m, 6H, Hg, HH), 1.47-1.10 (m, 12H, HI, HJ, 
HK), 1.30 (s, 27H, Ha or Ho), 1.29 (s, 27H, Ha or Ho); 13C NMR (100 MHz, CDCl3): 
δ = 163.6, 157.7, 155.8, 155.6, 149.1, 148.3, 148.3, 143.9 (×2), 143.8, 140.4, 140.2, 
138.6, 132.2 (×2), 130.6 (×2), 130.2, 129.0, 125.2, 124.1 (×2), 122.4, 113.8, 112.8, 
112.6, 66.7, 63.8, 63.0 (×2), 60.8, 46.7, 42.5, 34.2 (×2), 31.3 (×2), 29.4, 28.6, 28.4, 
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28.3 and 25.5; LRFAB-MS (3-NOBA matrix): m/z = 1647 [M+H]+; HRFAB-MS 
(3-NOBA matrix): m/z = 1646.03336 (calcd. for 13C12C110H133N6O6, 1646.02866). 
 
4i 
Using general method, macrocycle 1i (20.0 mg, 34.1 µmol, 1.0 equiv.), azide 3 (20.0 
mg, 34.1 µmol, 1.0 equiv.), alkyne 2 (20.3 mg, 37.5 µmol, 1.1 equiv.), 
[Cu(CH3CN)4](PF6) (14.0 mg, 37.5 µmol, 1.1 eq) and KCN (22.2 mg, 0.34 mmol, 10 
equiv.) gave the crude product as a mixture of rotaxane 4i, thread 5 (13:87, by 1H 
NMR spectroscopy), macrocycle 1i. Purification by preparative TLC on silica gel (1 
elution in CH3CN/CH2Cl2/Petrol; 11:29:60) gave the rotaxane 4i as a white solid (5 
mg, 8%). M.p. 92-95°C; 1H NMR (400 MHz, CDCl3): δ = 7.67 (t, 1H, J = 7.6 Hz, 
HA), 7.48 (s, 1H, Hi) 7.46 (d, 2H, J = 8 Hz, HB), 7.26-7.15 (m, 12H, Hb, Hn), 7.15-
7.00 (m, 16H, Hc, Hd, Hm, Hl), 6.93 (d, 4H, J = 8.6 Hz, HE), 6.75 (d, 2H, J = 8.9 Hz, 
Hk), 6.59 (d, 2H, J = 8.9 Hz, He), 6.49 (d, 4H, J = 8.6 Hz, HF), 4.88 (s, 2H, Hj), 4.11 
(s, 4H, HC), 4.09 (s, 4H, HD), 3.87 (t, 2H, J = 7.3 Hz, Hh), 3.78-3.69 (m, 4H, HG), 
3.52 (t, 2H, J = 6.0 Hz, Hf), 1.73 (quint., 2H, J = 6.5 Hz, Hg), 1.67 (quint., 4H, J = 
6.6 Hz, HH), 1.47-1.09 (m, 12H, HI, HJ, HK); 1.30 and 1.29 (2s, 54H, Ha, Ho); 13C 
NMR (100 MHz, CDCl3): δ = 159.6, 156.2 (×2), 148.2, 147.7 (×2), 144.1, 144.0, 
143.3, 139.7, 139.6, 137.5, 132.1, 132.0, 131.6, 130.6 (×2), 126.3, 124.0 (×2), 123.8, 
118.4, 114.9, 113.0 (×2), 67.4, 64.2, 63.0 (×2), 60.1, 58.3 (×2), 46.6, 34.2 (×2), 31.3 
(×2), 29.6, 29.0, 28.5, 28.3, 25.4; LRFAB-MS (3-NOBA matrix): m/z = 1716 
[M+H]+; HRFAB-MS (3-NOBA matrix): m/z = 1716.97173 (calcd. for 
13C12C110H135N4O8S2, 1716.97549). 





Using general method, macrocycle 1j (12.1 mg, 25.0 µmol, 1.0 equiv.), azide 3 (14.7 
mg, 25.0 µmol, 1.0 equiv.), alkyne 2 (14.9 mg, 27.5 µmol, 1.1 equiv.), 
[Cu(CH3CN)4](PF6) (10.0 mg, 27.5 µmol, 1.1 eq) and KCN (16.0 mg, 0.25 mmol, 10 
equiv.) gave the crude product as a mixture of rotaxane 4j, thread 5 (60:40, by 1H 
NMR spectroscopy), macrocycle 1j. Purification by preparative TLC on silica gel (2 
elutions in CH3CN/CH2Cl2/Petrol; 3.5:40:56.5) gave the rotaxane 4j as a white solid 
(17 mg, 42%). M.p. 128-132 °C; 1H NMR (400 MHz, CDCl3): δ = 7.33 (t, 1H, J = 
7.6 Hz, HA), 7.24 (d, 6H, J = 8.5 Hz, Hn), 7.21-7.01 (m, 23H, Hb, Hc, Hd, Hi, Hl, Hm), 
6.83 (d, 2H, J = 7.7 Hz, HB), 7.74 (br d, 6H, J = 8.4 Hz, HF, Hk), 6.48 (d, 6H, J = 8.6 
Hz, HG, He), 4.91 (s, 2H, Hj), 3.81-3.70 (m, 6H, HH, Hh), 3.34 (t, 2H, J = 5.8 Hz, Hf), 
2.60 (2d, 4H, J = 6.8 Hz, HC), 2.51 (t, 4H, J = 7.3 Hz, HE), 1.84-1.72 (m, 4H, HD), 
1.70-1.60 (m, 6H, HI, Hg), 1.57-1.11 (m, 12H, HJ, HK HL), 1.31 and 1.30 (2s, 54H, 
Ha, Ho); 13C NMR (100 MHz, CDCl3): δ = 161.4, 156.9, 156.1 (×2), 148.2 (×2), 
144.1, 144.0, 143.5, 139.7, 139.5 (×2), 133.5, 132.1, 132.0, 130.6 (×2), 129.1, 124.0 
(×2), 123.1, 119.6, 114.2, 113.0, 112.9, 67.0, 63.8, 63.0 (×2), 61.5, 46.7, 37.9, 35.0, 
34.2 (×2), 32.4, 31.3 (×2), 29.4, 29.3, 28.6, 28.5, 25.6; LRFAB-MS (3-NOBA 
matrix): m/z = 1617 [M+H]+; HRFAB-MS (3-NOBA matrix): m/z = 1617.08218 
(calcd. for 13C12C112H139N4O4, 1617.08299). 
 
 





Using general method, macrocycle 1l (29.0 mg, 60.4 µmol, 1.0 equiv.), azide 3 (35.5 
mg, 60.4 µmol, 1.0 equiv.), alkyne 2 (36.0 mg, 66.4 µmol, 1.1 equiv.), 
[Cu(CH3CN)4](PF6) (24.8 mg, 66.4 µmol, 1.1 eq) and KCN (40 mg, 0.66 mmol, 10 
equiv.) gave the crude product as a mixture of rotaxane 4l, thread 5 (25:75, by 1H 
NMR spectroscopy), macrocycle 1l. Purification by flash column chromatography 
(CH3CN/CH2Cl2/Petrol; 2.5:20:77.5) gave the rotaxane 4l as a white solid (15 mg, 
14%). M.p. 130-132°C; 1H NMR (400 MHz, CDCl3): δ = 7.73 (d, 4H, J = 8.8 Hz, 
HC), 7.61 (t, 1H, J = 7.8 Hz, HA), 7.39 (d, 2H, J = 7.8 Hz, HB), 7.22-7.18 (m, 12H, 
Hb, Hn), 7.10-7.03 (m, 16H, Hc, Hd, Hm, Hl), 6.89 (s, 1H, Hi), 6.82 (d, 4H, J = 8.8 Hz, 
HD), 6.78 (d, 2H, J = 8.9 Hz, Hk), 6.66 (d, 2H, J = 8.9 Hz, He), 4.96 (s, 2H, Hj), 4.04 
(t, 4H, J = 7.2 Hz, HE), 4.00 (t, 2H, J = 7.1 Hz, Hh), 3.70 (t, 2H, J = 5.6 Hz, Hf), 1.97 
(quint., 2H, J = 6.4 Hz, Hg), 1.60 (quint, 4H, J = 7.0 Hz, HF), 1.33-0.98 (m, 24H, HG, 
HH, HI, HJ, HK, HL), 1.30 and 1.29 (2s, 54H, Ha, Ho); 13C NMR (100 MHz, CDCl3): 
δ = 158.9, 156.9, 156.2 (×2), 148.2 (×2), 144.0 (×2), 143.5, 139.8 (×2), 137.3, 132.5 
(×2), 132.1, 130.7, 130.6, 128.8, 124.0 (×2), 123.2, 117.2, 115.3, 113.1, 112.8, 68.0, 
63.9, 63.0 (×2), 61.7, 46.7, 34.2 (×2), 31.3 (×2), 30.1, 30.0, 29.6 (×2), 29.5 (×2), 
28.2, 25.7; LRFAB-MS (3-NOBA matrix): m/z = 1617 [M+H]+; HRFAB-MS (3-









A solution of macrocycle 1l (170 mg, 0.35 mmol, 10 equiv.), azide 3 (20.6 mg, 35.0 
µmol, 1.0 equiv.), alkyne 2 (19.0 mg, 35.0 µmol, 1.1 equiv.), [Cu(CH3CN)4](PF6) 
(14.3 mg, 38.5 µmol, 1.1 eq) in CH2Cl2 (10 mL) and under N2 was stirred at RT for 8 
days. The solution was then refluxed for further 48 h then cooled to RT. The 
resulting mixture was diluted with CH2Cl2 (5 mL) and methanol (15 mL). Then a 
solution of KCN (25 mg, 0.38 mmol, 10 equiv.) in methanol (2 mL) was added and 
the resulting suspension stirred vigorously for 1 h. Solvents were evaporated (80 ºC) 
and the residue was partitioned between water (15 mL) and CH2Cl2 (20 mL). The 
layers were separated and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL). 
The combined organic fractions were washed with water (10 mL) and brine (10 mL), 
then dried (MgSO4) and concentrated under reduced pressure to give the crude 
product as a mixture of [2]rotaxane 4l, [3]rotaxane 7l, thread 5 (33:37:30, by 1H 
NMR spectroscopy), macrocycle 1l, remaining azide 3 and alkyne 2, (75% overall 
conversion). Purification by preparative TLC on silica gel (3 elutions in 
CH3CN/CH2Cl2/Petrol; 3.5:40:56.5) gave the [3]rotaxane 7l as a white solid (15 mg, 
20%). M.p. 302-304 °C; 1H NMR (400 MHz, CDCl3): δ = 7.68 (m, 10H, HC, HC’, 
HA, HA’), 7.37 (d, 4H, J = 7.8 Hz, HB, HB’), 7.20 -7.10 (m, 12H, Hb, Hn), 7.09 (s, 1H, 
Hi), 7.05-6.91 (m, 16H, Hc, Hm, Hd, Hl), 6.82 (d, 2H, J = 8.9 Hz, Hk), 6.74-6,65 (m, 
8H, HD, HD’), 6.46 (d, 2H, J = 8.9 Hz, He), 5.04 (s, 2H, Hj), 4.03-3.89 (m, 8H, J = 7.2 
Hz, HE, HE’), 3.70 (t, 2H, J = 7.5 Hz, Hh), 3.50 (t, 2H, J = 5.7 Hz, Hf), 1.69 (br. 
quint., 2H, J = 6.7 Hz, Hg), 1.54 (br. quint, 8H, J = 7.35 Hz, HF), 1.40-0.81 (m, 48H, 
HG, HG’, HH, HH’, HI, HI’, HJ, HJ’, HK, HK’, HL, HL’), 1.27 and 1.26 (2s, 54H, Ha, Ho); 
13C NMR (100 MHz, CDCl3): δ = 158.9, 158.8, 156.8, 156.7, 156.2, 156.1, 148.1, 
148.0, 144.0 (×2), 143.1, 139.7, 139.5, 137.1, 136.9, 132.5, 132.1, 132.0, 131.8, 
130.6 (×2), 128.6 (×2), 123.9 (×2), 123.1, 116.9, 116.7, 115.2, 115.0, 113.3, 113.0, 
68.2, 68.1, 64.1, 62.9 (×2), 61.7, 46.7, 34.2 (×2), 31.3 (×2), 30.1, 29.9 (×2), 29.7 
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(×2), 29.6 (×2) , 29.5 (×2), 29.4 (×2), 28.3, 28.2 and 25.7 (×2); LRFAB-MS (3-
NOBA matrix): m/z = 2101 [M]+; HRFAB-MS (3-NOBA matrix): m/z = 




A solution of macrocycle 1a (400 mg, 0.817 mmol, 10 equiv.), alkyne 2 (48.0 mg, 
8.17 μmol, 1.0 equiv.), azide 3 (44.3 mg, 8.17 μmol, 1.0 equiv.), Cu(CH3CN)4PF6 
(30.0 mg, 38.5 μmol, 1.0 eq) in dry CH2Cl2 (10 mL) and under N2 was stirred at RT 
for 72 h. The solution was refluxed for further 48 h then cooled to RT. The resulting 
mixture was diluted with CH2Cl2 (15 mL) and methanol (25 mL). Then a solution of 
KCN (106 mg, 1.63 mmol, 20 equiv.) in methanol (2 mL) was added and the 
resulting suspension stirred vigorously for 2 h. Solvents were evaporated (80 ºC) and 
the residue was partitioned between water (15 mL) and CH2Cl2 (20 mL). The layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3 × 15 mL). The 
combined organic fractions were washed with water (10 mL) and brine (10 mL), then 
dried (MgSO4) and concentrated under reduced pressure to give the crude product as 
a mixture of [2]-rotaxane 4a, [3]-rotaxane 7a, thread 5 (90:5:5, by 1H NMR 
spectroscopy) and macrocycle 1a. Purification by column chromatography (CH3CN-
CH2Cl2-Petrol; 5:35:60) followed by preparative TLC on silica gel (5 elutions in 
CH3CN-CH2Cl2-Petrol; 7:33:60) gave pure rotaxane 7a as a white solid (3.5 mg, 
2%); M.p. 210-212  °C; 1H NMR (400 MHz, CDCl3): δ = 7.48 (m, 2H, HA, HA’), 
7.27-7.20 (m, 16H, HB, HB’, Hb, Hn), 7.19 (s, 1H, Hi), 7.10 (d, 6H, J = 8.5 Hz, Hc or 
Hm), 7.07 (d, 6H, J = 8.5 Hz, Hc or Hm), 6.98 (d, 4H, J = 8.4 Hz, HE or HE’), 6.94 (d, 
4H, J = 8.4 Hz, HE or HE’), 6.76 (t, 4H, J = 8.8 Hz, Hd, Hl), 6.52 (d, 4H, J = 8.5 Hz, 
HF or HF’), 6.49 (d, 4H, J = 8.5 Hz, HF or HF’), 6.15 (d, 2H, J = 8.8 Hz, Hk), 5.99 (d, 
2H, J = 8.8 Hz, He), 4.54-4.45 (m, 8H, HC, HC’), 4.39 (s, 2H, Hj), 4.25(s, 8H, HD, 
HD’), 3,84-3.66 (m, 8H, HG, HG’), 3.66-3.56 (m, 2H, Hh), 3.00 (t, 2H, J = 5.8 Hz, Hf), 
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1.70-1.52 (m, 10H, HH, HH’, Hg), 1.47-0.93 (m, 24H, HI, HI’, HJ, HJ’, HK, HK’), 1.31 
(2s, 54H, Ha, Ho); 13C NMR (100 MHz, CDCl3): δ = 158.6 (×2), 157.6 (×2), 155.9 
(×2), 148.0 (×2), 144.3(×2), 143.1, 139.1, 139.0, 136.9 (×2), 131.6, 131.5, 130.7 
(×2), 129.8 (×2), 129.0, 128.8, 124.0 (×2), 123.2, 119.4 (×2), 114.3 (×2), 112.8, 
112.7, 72.4, 72.3, 70.9, 70.8, 67.0 (×2), 63.8, 62.9 (×2), 61.0, 46.7, 34.2 (×2), 31.4 
(×2), 29.6 (×2), 29.6, 28.7, 28.6, 28.5 (×2), 25.6, 25.5; LRFAB-MS (3-NOBA 
matrix): m/z = 2110 [M+H]+; HRFAB-MS (3-NOBA matrix): m/z = 2110.33050 




Using general method, macrocycle 1m (12.1 mg, 25.0 µmol, 1.0 equiv.), azide 2 
(14.7 mg, 25.0 µmol, 1.0 equiv.), alkyne 3 (14.9 mg, 27.5 µmol, 1.1 equiv.), 
[Cu(CH3CN)4](PF6) (10.0 mg, 27.5 µmol, 1.1 eq) and KCN (16.0 mg, 0.25 mmol, 10 
equiv.) gave the crude product as a mixture of rotaxane 4m, thread 5 (20:80, by 1H 
NMR spectroscopy), macrocycle 1m. Purification by flash column chromatography 
(CH3CN/CH2Cl2/Petrol; 3.5:20:76.5) followed by preparative TLC on alumina (3 
elutions in CH3CN/CH2Cl2/Petrol; 2.5:15:82.5) gave the rotaxane 4m as a white 
solid (10 mg, 16 %). M.p. 99-101 °C; 1H NMR (400 MHz, CDCl3): δ = 7.71 (d, 4H, 
J = 8.6 Hz, HC), 7.21 (d, 6H, J = 8.5 Hz, Hb), 7.20 (d, 6H, J = 8.5 Hz, Hn) 7.12-7.03 
(m, 16H, Hc, Hd, Hm, Hl), 6.99 (s, 1H, Hi). 6.80 (d, 6H, J = 8.6 Hz, HD, Hk), 6.71 (s, 
2H, HB), 6.69 (d, 2H, J = 8.8 Hz, He), 4.91 (s, 2H, Hj), 4.04 (t, 4H, J = 7.1 Hz, HE), 
3.97 (t, 2H, J = 7.1 Hz, Hh), 3.72 (t, 2H, J = 5.8 Hz, Hf), 3.00 (s, 6H, HA), 1.94 (br 
quint., 2H, J = 6.5 Hz, Hg), 1.58 (br quint, 4H, J = 7.1 Hz, HF), 1.46-0.97 (m, 24H, 
HG, HH, HI, HJ, HK, HL), 1.29 (s, 54H, Ha, Ho); 13C NMR (100 MHz, CDCl3): δ = 
158.5, 157.5, 156.3 (×2), 155.8, 148.2 (×2), 144.0 (×2), 143.3, 139.7 (×2), 133.8, 
132.1 (×2), 130.7 (×2), 128.8, 124.0 (×2), 123.5, 115.1, 113.1, 112.9, 100.8, 68.0, 
64.1, 63.0 (×2), 61.6, 46.7, 39.4, 34.2 (×2), 31.3 (×2), 30.1, 30.0, 29.7, 29.6, 29.5 
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(×2), 28.2, 25.7; LRFAB-MS (3-NOBA matrix): m/z = 1660 [M+H]+; HRFAB-MS 




Using general method, macrocycle 1n (9.9 mg, 17.4 µmol, 1.0 equiv.), azide 2 (10.2 
mg, 17.4 µmol, 1.0 equiv.), alkyne 3 (10.4 mg, 19.2 µmol, 1.1 equiv.), 
[Cu(CH3CN)4](PF6) (7.1 mg, 19.2 µmol, 1.1 eq) and KCN (11.4 mg, 0.17 mmol, 10 
equiv.) gave the crude product as a mixture of rotaxanes 4n, thread 5 (45:65, by 1H 
NMR spectroscopy), macrocycle 1n. Purification by flash column chromatography 
(acetone/CH2Cl2; 4:96) followed by preparative TLC on alumina (3 elutions in 
diethyl ether/Petrol; 1:1) gave the rotaxane 4n as a white solid (10 mg, 35%). M.p. 
90-94°C; 1H NMR (400 MHz, CDCl3): δ = 7.89 (d, 2H, J = 7.7 Hz, HA), 7.43 (t, 
2H, J = 7.7 Hz, HB), 7.30-7.17 (m, 14H, Hb, Hn, HC), 7.17-7.00 (m, 16H, Hc, Hd, Hm, 
Hl), 7.00-6,92 (m, 5H, HF, Hi), 6.66 (d, 2H, J = 8.8 Hz, Hk), 6.54 (d, 4H, J = 8.5 Hz, 
HG), 6.33 (d, 2H, J = 8.8 Hz, He), 4.81 (s, 2H, Hj), 4.54 (s, 4H, HD), 4.51 (s, 4H, HE), 
3.75-3.66 (m, 6H, HH, Hh), 3.24 (t, 2H, J = 5.6 Hz, Hf), 1.65-1.50 (m., 6H, HI, Hg), 
1.40-1.03 (m, 12H, HJ, HK, HL), 1.30 and 1.29 (2s, 54H, Ha, Ho); 13C NMR (100 
MHz, CDCl3): δ = 158.5 (×2), 158.1, 156.1 (×2), 148.2 (×2), 144.1, 144.0, 143.4, 
139.8, 139.5, 137.1, 132.1, 131.9, 130.6 (×2), 129.6, 129.5, 124.0 (×2), 123.1, 121.5, 
119.9, 114.2, 113.0, 112.7, 72.4, 72.2, 67.5, 63.6, 63.0 (×2), 61.5, 46.7, 34.2 (×2), 
31.3 (×2), 29.6, 29.2, 28.7 (×2), 25.7; LRFAB-MS (3-NOBA matrix): m/z = 1698 
[M+H]+; HRFAB-MS (3-NOBA matrix): m/z = 1698.06527[M+H]+ (calc. for 
13C12C115H138N5O6 1698.06807 [M+H]+). 
 





Spectroscopic data of the non-interlocked thread S23 generated during the synthesis 
of rotaxane S24: 1H NMR (400 MHz, CDCl3): δ = 7.31 (s, 1H, Hi), 7.22 (m, 12H, 
Hb, Hp), 7.10-7.05 (m, 16H, Hc, Hd, Hn, Ho), 6.73 (d, 2H, J = 9.0 Hz, Hm/He), 6.72 (d, 
2H, J = 8.9 Hz, Hm/He), 4.53 (t, 2H, J = 6.9 Hz, Hh), 3.96 (t, 2H, J = 6.1 Hz, Hl), 3.92 
(t, 2H, J = 5.5 Hz, Hf), 2.90 (t, 2H, J = 7.5 Hz, Hj), 2.35 (quint, 2H, J = 6.4 Hz, Hg), 
2.14 (quint, 2H, J = 6.3 Hz, Hk), 1.29 (s, 54H, Ha, Hq); 13C NMR (100MHz, CDCl3): 
δ = 156.6, 156.2, 148.3, 148.2, 147.2, 144.1, 144.0, 139.9, 139.5, 132.3, 132.2, 130.7 
(x 2), 124.0, 123.9, 121.4, 112.8, 112.7, 66.6, 63.8, 63.0 (x 2), 46.9, 34.2 (x 2), 31.3, 
30.0, 29.6, 28.9, 22.1; LRESI-MS: m/z = 1158 [M+1]+; HRFAB-MS (3-NOBA 




Using general method, macrocycle 1a (24.0 mg, 50.0 μmol, 1.0 equiv.), azide 3 (29 
mg, 25.0 μmol, 1.0 equiv.), alkyne 2a (29.0 mg, 50.0 μmol, 1.0 equiv.), 
[Cu(CH3CN)4](PF6) (19.0 mg, 27.5 μmol, 1.1 eq) and KCN (33.0 mg, 0.5 mmol, 10 
equiv.) gave the crude product as a mixture of rotaxane S24, thread S23 (60:40, by 
1H NMR spectroscopy) and macrocycle 1a. Purification by preparative TLC on silica 
gel (3 elutions in CH3CN/CH2Cl2/hexane; 5:40:55) gave the rotaxane S24 as a white 
solid (44 mg, 53%); M.p. 130-131 °C; 1H NMR (400 MHz, CDCl3): δ = 7.51 (t, 
1H, J = 7.7 Hz, HA), 7.27-7.23 (m, 14H, HB, Hb, Hp), 7.13-7.09 (m, 12H, Hc, Ho), 
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7.05 (d, 2H, J = 8.8 Hz, Hn/Hd), 7.04 (d, 2H, J = 8.8 Hz, Hn/Hd), 6.99 (d, 4H, J = 8.5 
Hz, HE), 6.86 (s, 1H, Hi), 6.63 (d, 2H, J = 8.8 Hz, He/Hm), 6.60 (d, 4H, J = 8.5 Hz, 
HF), 6.49 (d, 2H, J = 8.8 Hz, He/Hm), 4.89 (s, 4H, HC), 4.27 (s, 4H, HD), 3.84-3.78 (m, 
6H, HG, Hh), 3.71 (t, 2H, J = 6.2 Hz, Hl), 3.34 (t, 2H, J = 5.8 Hz, Hf), 2.60 (t, 2H, J = 
7.7 Hz, Hj), 1.87 (quint, 2H, J = 6.4 Hz, Hk), 1.68 (quint, 2H, J = 6.0 Hz, Hg), 1.65 
(quint, 4H, J = 6.5 Hz, HH), 1.32-1.15 (m, 12H, HI, HJ, HK); 1.32 and 1.31 (2s, 54H, 
Ha, Hq); 13C NMR (100 MHz, CDCl3): δ = 158.6, 157.5, 156.6, 156.2, 148.2, 148.1, 
146.6, 144.1 (x 2), 139.5, 139.2, 137.0 (x 2), 132.0 (x 2), 130.6, 129.8, 129.0, 124.0 
(x 2), 121.1, 119.8, 114.3, 112.8, 72.4, 71.1, 67.0, 66.5, 63.8, 63.0 (x 2), 46.5, 34.2 (x 
2), 31.3 (x 2), 29.6, 29.5 (x 2), 28.7, 28.6 (x 2), 25.6, 22.0; LRESI-MS: m/z = 1648 





Spectroscopic data of the non-interlocked thread S25 (derived from 2c and 3) 
generated during the synthesis of rotaxane S26: 1H NMR (400 MHz, CDCl3): δ = 
7.82 (d, 2H, J = 8.1 Hz, Hk), 7.77 (s, 1H, Hi), 7.48 (d, 2H, J = 8.1 Hz, Hk), 7.25-7.22 
(m, 12H, Hb, Hp), 7.12-7.07 (m, 16H, Hc, Hd, Hn, Ho), 6.85 (d, 2H, J = 8.9 Hz, Hm), 
6.77 (d, 2H, J = 8.8 Hz, He), 5.05 (s, 2H, Hl), 4.64 (t, 2H, J = 6.8 Hz, Hh), 3.98 (t, 2H, 
J = 5.5 Hz, Hf), 2.43 (quint, 2H, J = 6.3 Hz, Hg), 1.30 (s, 54H, Ha, Hq); 13C NMR 
(100 MHz, CDCl3): δ = 156.5, 156.1, 148.3, 148.2, 147.3, 144.0 (x 2), 140.1, 139.8, 
137.0, 132.3, 132.2, 130.7, 130.6, 130.2, 128.0, 125.8, 124.0 (x 2), 120.2, 113.2, 
112.9, 69.6, 63.7, 63.0 (x 2), 47.1, 34.2 (x 2), 31.3 (x 2), 30.0; LRESI-MS: m/z = 
1206 [M+H]+; HRFAB-MS (3-NOBA matrix): m/z = 1206.78135 [M+H]+ (calcd. 
for C86H100N3O2, 1206.72516). 
 
 





Using general method, macrocycle 1a (24.0 mg, 50.0 μmol, 1.0 equiv.), azide 3 (29 
mg, 25.0 μmol, 1.0 equiv.), alkyne 2c (31.0 mg, 50.0 μmol, 1.0 equiv.), 
[Cu(CH3CN)4](PF6) (19.0 mg, 27.5 μmol, 1.1 equiv.) and KCN (33.0 mg, 0.5 mmol, 
10 equiv.) gave the crude product as a mixture of rotaxane S26, thread S25 (33:66, 
by 1H NMR spectroscopy) and macrocycle 1a. Purification by preparative TLC on 
silica gel (5 elutions in CH3CN/CH2Cl2/hexane; 5:40:55) gave the rotaxane S26 as a 
white solid (33 mg, 39%); M.p. 142-143 °C; 1H NMR (400 MHz, CDCl3): δ = 7.66 
(d, 2H, J = 7.8 Hz, Hk), 7.59 (s, 1H, Hi), 7.51 (d, 1H, J = 7.7 Hz, HA), 7.29-7.22 (m, 
16H, HB, Hb, Hj, Hp), 7.12-7.05 (m, 14H, Hc, Hn/Hd, Ho), 7.02 (d, 2H, J = 8.1 Hz, 
Hn/Hd), 6.94 (d, 4H, J = 7.9 Hz, HE), 6.75 (d, 2H, J = 8.9 Hz, He/Hm), 6.54-6.49 (m, 
6H, HF, He/Hm), 4.87 (s, 2H, Hl), 4.47 (d, 2H, J = 11.8 Hz, HC), 4.44 (d, 2H, J = 11.7 
Hz, HC’), 4.29 (s, 4H, HD), 3.84-3.75 (m, 6H, HG, Hh), 3.41 (br t, 2H, Hf), 1.68-1.58 
(m, 6H, HH, Hg), 1.35-1.14 (m, 12H, HI, HJ, HK); 1.30 and 1.29 (2s, 54H, Ha, Hq); 13C 
NMR (100 MHz, CDCl3): δ = 158.6, 157.5, 156.5, 156.2, 148.2 (x 2), 146.7, 144.1 
(x 2), 139.7, 139.6, 137.1, 136.5, 132.1, 132.0, 130.6 (x 2), 130.5, 129.8 (x 2), 127.7, 
125.5, 124.0 (x 2), 120.5, 120.0, 114.2, 113.2, 112.9, 72.5, 71.2, 69.5, 67.1, 63.8, 
63.0 (x 2), 46.6 (x 2), 34.2, 31.3 (x 2), 29.6, 29.5, 29.4, 28.5, 25.6; LRESI-MS: m/z 
= 1696 [M+H]+; HRFAB-MS (3-NOBA matrix): m/z = 1697.07342 [M+H]+ (calcd. 
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2.4.2 Crystal data and structure refinement for 7l . 
 
Single crystals of 7l suitable for x-ray crystallography were grown by slow cooling 
of a hot, saturated solution of 7l in acetonitrile.  
Structural data for 7l were collected at 173 K using a Rigaku Saturn diffractometer 
(MM007 high-flux RA/MoKa radiation, confocal optic). All data collections 
employed narrow frames (0.3–1.08) to obtain at least a full hemisphere of data. 
Intensities were corrected for Lorentz polarization and absorption effects (multiple 
equivalent reflections). The structure was solved by direct methods, non-hydrogen 
atoms were refined anisotropically with CH protons being refined in riding 
geometries (SHELXTL) against F2. The structure determination for 7l proved 
particularly problematic; we collected full datasets using a variety of collection 
routines on more than 10 different crystals from several different crystallization 
experiments. The data were always poor, principally because of disorder arising from 
the alkyl chain and solvent molecules and this disorder was not resolved. Atoms 
C20-C22 and C81 to C88 refined isotropically subject to DFIX constraints. 
 
 
Identification code   7l 
Empirical formula   C146 H181N5O6 
Formula weight   2101.96 
Temperature    173(2) K 
Wavelength    1.54178 Å 
Crystal system   Triclinic 
Space group    P-1 
Unit cell dimensions  a = 14.0813(12) Å α = 84.390(4)°. 
    b = 19.2182(17) Å β = 73.528(4)°. 
    c = 24.208(2) Å γ = 83.845(4)°. 
Volume   6230.5(10) Å3 
Z    2 
Density (calculated)  1.120 Mg/m3 
Absorption coefficient 0.511 mm-1 
F(000)    2280 
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Crystal size    0.200 x 0.200 x 0.100 mm3 
Theta range for data collection 2.32 to 44.72°. 
Index ranges    -12<=h<=12, -17<=k<=17, -22<=l<=22 
Reflections collected   31202 
Independent reflections  9695 [R(int) = 0.1469] 
Completeness to theta = 25.00° 99.2 %  
Absorption correction   Multiscan 
Max. and min. transmission  1.0000 and 0.0040 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  9695 / 16 / 1319 
Goodness-of-fit on F2   1.819 
Final R indices [I>2sigma(I)]  R1 = 0.1765, wR2 = 0.4507 
R indices (all data)   R1 = 0.2049, wR2 = 0.4713 
Extinction coefficient   0.0007(3) 
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2.4.3 Computational Details (Molecular Modeling) 
 
The energy minimized equilibrium geometries shown below were computed using 
the AM1 Semi-Empirical method as implemented in the SPARTAN 06 molecular 
modelling program.45 
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The interlocking of one ore more chemical entities occur in natural molecules. Most 
systems discovered so far, in which constituents are covalently bound in an 
intertwined manner, exhibit very different properties compared to their non-
interlocked analogues. Exploring these structures reveals that in most cases, 
interlocking in biological systems has a defined function. It can be used, for example, 
to hold two or more parts together in a molecular machine in order to create motion 
of one element relative to the other, or, in the simplest case to give extra stability to a 
supramolecular assembly. 
Biosynthesis of naturally occurring interlocked molecules arises from the reversible 
or non-reversible covalent capture of self-assembled elements. The first synthetic 
approaches to interlocked architectures however, relied on random pairing events 
until chemists exploited self-assembly in a similar way to nature. These synthetic 
analogues, although discovered at the very end of the synthetic chemistry era, have 
already proved to be capable of achieving similar tasks to their natural analogues 
and have often displayed similar properties. The unique nature of the mechanical 
bond has allowed synthetic chemists to create devices that could be operated at the 
nanoscopic scale.  
This chapter gives a general overview of some biological and synthetic interlocked 
architectures and their functions, with particular emphasis on structures containing 
peptidic backbones and on interlocked architectures whose function is to encapsulate 
and deliver guest molecules. The basic principles for the design and operation of 
rotaxane-based devices that encapsulate, deliver and release bioactive peptides 
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3.1 Naturally occurring interlocked molecules  
 
The synthesis of interlocked architectures and their corresponding synthetic 
machines has been greatly inspired by their naturally occurring homologues. 
Nature’s chemical building blocks (e.g. amino acids, nucleotides, nucleosides) are 
composed mainly of hydrogen-bond donors and acceptors, which are essential for 
recognition and self-assembly. It is not surprising that interlocked architectures are 
widely available in living organisms as self-assembly can potentially occur in an 
intertwined manner and direct the synthesis of the interlocked architecture. However, 
in order to form, an extra stabilization factor is required to counteract the entropy 
loss occasioned by the assembly.  
The properties of these interlocked species (e.g. strong bioactivity, high chemical 
stability) are, in most cases, very different to that of their non-interlocked analogues. 
In section 3, some of the most significant naturally-occurring interlocked 
architectures, and some ideas on how they may form in vivo, are discussed. 
 
3.1.1 DNA-based interlocked architectures  
 
 As early as 1967 the group of Vinograd described the first topologically interlocked 
double stranded circular mitochondrial DNA. Isolated by centrifugation of HeLa cell 
mitochondria and human leukaemic leucocytes, what appeared to be linked 
monomeric circular units of DNA exhibited high stability under denaturing 
conditions. Careful analysis of electron micrographs revealed these species to be 
[2]catananes and [3]catenanes of a few micrometre size (Figure 3.1).1 
 
Figure 3.1. Electron micrographs showing the interlocked nature of the mitochondrial DNA dimers. 
a) and b) × c. 18775, a’) and b’) × c. 34600. Adapted with permission form Nature publishing group. 
 
Chapter three   Introduction 
 
 68 
The formation of such architectures was postulated to occur in the course of 
replication or recombination. [2]Catenanes would results from a double 
recombination between two circular mitochondrial DNA molecules. Higher degree 
catenanes are formed by the double recombination between a monomer and a 
catenated dimer (Scheme 3.1). If this simplified theory gives an explanation of the 
interlocking process, it does not take into account the recognition pattern necessary 
to form the entangled precursor.  
Since then scientists have been able to construct several synthetic topologically 
linked molecules based on DNA strands.2 
 
Scheme 3.1. Vinograd’s explanation of catenane formation from circular mitochondrial DNA. The 
circular mitochondrial DNA strands first pair (a) and recombine in different ways (d), (h), (i) 
according to the breaking pattern of intermediates (b), (c), (e). Higher degree of catenation occurs via 
the double recombination of a monomeric circular entity and a just formed catenane. Reproduced with 
permission from Nature Publishing Group. 
 
3.1.2 The viral capsid catenane 
 
Recently, it was found that the capsid of HK 97 bacteriophage consists of a network 
of deeply catanated hexameric and pentameric proteins units (Figure 3.2). The 
structure and formation of this unique catenane assembly as been well studied by 
Duda3 and was later confirmed by an X-ray diffraction structure of the empty capsid 
obtained by Johnson et al.4 The fascinating formation of the capsid goes through 
several protein assembly and maturation sequences. Three capsid intermediates are 
subsequently modified before leading to the final covalently linked protein chainmail 
(Figure 3.2).  




Figure 3.2. a) Three-dimensional view of HK 97 capsid. The subunits cross-linked into pentamers and 
hexamers are highlighted. The coloured ring shows the catenated nature of the link. b) Three 
hexamers each with a surrounding metahexamer ring of covalently bonded subunits (magenta, green, 
and blue). c) Expanded view on one subunit, showing the residues involved in cross-linking d) 
expanded view on the interlocked cross-linked region, isopeptidic bonds are highlighted in blue. 
Adapted from ref. [4] with permission from American Association for the Advancement of Science. 
 
The first step is the assembly of head subunits into hexamers and pentamers, assisted 
by Escherichia coli GroEL/ES, and subsequent formation of the shell (prohead I) 
(Scheme 3.2). The protein subunits are then cleaved at residue 104 and 385 and the 
resulting prohead II is packed with double stranded DNA (dsDNA, the genetic 
information of the virus). Final ligation of each subunit forms covalently linked 
interpenetrated hexamers and pentamers. This links occurs between Lys 169 of one 
subunit and Asn 356 of the second one, in a process which appears to be auto-
catalyzed by a Glu 363 residue of the third subunit (Figure 
 3.2.c and 3.2d).  
 
Scheme 3.2. The biosynthesis of HK97 capsid. Adapted from ref. [3] with permission from American 
Association for the Advancement of Science. 
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The most likely function of the chainmail is to stabilize the HK 97 capsid, and it has 
indeed been proven that the capsid is more stable than its non-topologically linked 
analogue (Head I) towards denaturation. Recent studies have shown that the cross 
linking is essential for production of a viable HK 97 phage.5 
 
3.1.3 Cysteine knots 
 
The so-called cysteine knots are a class of small proteins whose backbone is arranged 
in a tangled manner. These proteins, originally thought to be rare, have in fact found 
to be common and are usually referred as covalent knots6 as they involve disulfide 
covalent bonds.7,8 Their high disulfide bond content gives them a compact shape, 
accounting for their remarkably high stability9 and specific biological properties. 
Being the constituent of several toxins, cysteine knots have attracted much interest 
due to their potential for pharmacological use.8,10 Their structure consists of a 
macrocyclic moiety, formed by two disulfide-bonded peptidic segments threaded by 
a third disulfide bond (Figure 3.3).  
 
           
Figure 3.3. a) A Schematic representation of a generic cysteine knot showing the arragement of the 
six cysteine residues involved in the knot. b) Structure of Kalata B1 the first cyclic cysteine knot to be 
isolated,11 showing the interpenetrating β-sheets. Reproduced with permission from the American 
Society for Biochemistry and Molecular Biology. 
 
Cysteine knots can be divided into three different classes: growth factor cysteine 
knots (GFCK), inhibitor cysteine knots (ICK) and cyclic cysteine knots (CCK). 
These three classes differ topologically from the order in which the cysteine residues 
are interconnected. Figure 3.4 shows the three types of knots and their connectivity. 
The three structures exhibit a remarkable similarity, featuring a set of three or four 
anti parallel beta-strands interconnected via disulfide bonds. 
a) b) 
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Extensive folding studies on toxin cysteine knots has revealed that both ICK and 
CCK can be folded artificially from mature protein sequences. Interestingly, each 
disulfide bond appears to stabilize the native protein conformation and directs the 
formation of the other two.12 
 
Figure 3.4. The three classes of cysteine knots. The β-strands are represented as arrows, the cysteine 
residues are labelled I–VI in order from the N- to C-terminus and the disulfide bonds are represented 
as green lines. The penetrating disulfide bond for the growth factor cysteine knot is Cys(I–IV) 
whereas it is Cys(III–VI) in the inhibitor cysteine knot and cyclic cysteine knot peptides 
 
3.1.4 Lasso peptides 
 
Lasso peptides (or protoknots) are a class of relatively short peptides that have one 
linear end threaded through a macrocyclic loop, formed by linkage between the N-
terminus and a side chain amino acid residue.13 
Originally believed to be circular, Microcin J25 (Mcc J25) (Figure 3.5), probably the 
most studied of the family,14 was later found to have a lasso structure.15 Made out of 
a 21 amino acid sequence, the C-terminus end is threaded through an 8 amino acid-
wide macrocycle, resulting from the condensation of the N-terminus -NH2 and the 
carboxylic acid of Asp 8 (Figure 3.5).  
 
Figure 3.5. Representations of MccJ25 a) simplified structure b and c) ribbon structure of the lowest 
energy conformation illustrating the two small antiparallel-sheet. Reproduced with permission from 
the American chemical society 
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The C-terminus end is maintained threaded in the loop by the consecutive Phe and 
Tyr residues. Structural analysis suggests the presence of two small anti-parallel 
beta-sheets, each comprising two strands. The first sheet comprises residues 6-7 and 
18-19 and is formed between part of the ring and the penetrating segment. The 
second sheet involves residues 10-11 and 15-16 (Figure 3.5b and 3.5c).  
Secreted by certain strains of E. Coli to combat competing microbes, Mcc J25 
inhibits bacterial transcription by interfering with the nucleotide uptake channel of 
bacterial RNA polymerase. As well as high level of biological activity, Mcc J25 also 
exhibits high resistance to thermal and proteolysis degradation, due to its interlocked 
nature. Its bio-synthesis has recently been achieved in vivo and has demonstrated that 
two enzymes encoded by genes belonging to the Mcc J25 gene cluster are 
responsible for converting the 58 amino acid precursor (coded by one of the four 
genes of the cluster) into the interlocked 21 amino acid lasso structure.16  
 
3.2 Synthetic Interlocked architectures based on amides, peptides 
and proteins 
3.2.1 Amide-Based Catenanes and Rotaxanes and knots 
 
Amide bond were first used to direct the assembly of interlocked architectures in 
1992. During attempts to increase the yield of a macrocyclization, Hunter 
serendipitously discovered a two step synthesis of the first amide-based catenane 
(Figure 3.6).17  
 
Figure 3.6. The first amide-based [2]catenane reported by Hunter (R = H) and Vögtle (R = OMe). 
 
This supramolecular self-assembly process, wherein multiple H-bonds direct the 
synthesis of two interlocking rings, resulted in a 34% yield of [2]catenane, the 
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remainder of the product being a tetrameric species and the free macrocycle. This 
was closely followed by the publication of a very similar molecule by Vögtle (Figure 
3.6).18 
 
A rather similar, but structurally simpler, amide-based [2]catenane was discovered  a 
few years later by Leigh and co-workers.19 The combination of isophthaloyl 
dichloride 2 and para-xylylenediamine 3 at high dilution was expected to form the [2 
+ 2] macrocyclic adduct, but [2]catenane 6 formed instead, in 20% yield  (Scheme 





























































































































Scheme 3.3. Synthesis of Leigh’s serendipitously discovered [2]catenane and [2]rotaxane and their 
supposed mechanism of formation. 
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It is assumed that, amongst other higher degree polymeric and macrocyclic adducts, 
free macrocycle 1 is formed and consequently bound by one equivalent of the 
macrocycle precursor 4 to form intermediate [1+4]. Subsequent intramolecular 
macrocyclization affords [2]catenane 6.  
Soon afterwards, it was demonstrated that, if the reaction was carried out in the 
presence of a suitably stoppered benzylic 1,3-diamide thread 5, [2]rotaxanes could 
also be formed.20 Similarly to [2]catenane, the formation of [2]rotaxane appears to 
involve the directed assembly of the preformed macrocycle precursor [1+5] around 
the two E-amide bonds of the thread.  
Importantly, in 1997 Leigh and co-workers showed that, when glycylglycine was 
incorporated into thread 8, formation of [2]rotaxane 9 occurred in yields of up to 
62% (Scheme 3.4a).21  By further preorganizing the orientation of the carbonyl 
groups using the fumaramide moiety 10, [2]rotaxane 11 was assembled in a near 
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3.2.2 H-bond directed synthesis of molecular knots 
 
Eight years after the publication of the first amide-based catenane by Hunter, the 
group of Vögtle discovered that a knotted structure was produced during the 
macrocyclization of U-shaped precursor 12 with pyridine dicarbonyl dichloride 


































































































Scheme 3.5. Hydrogen bond-templated synthesis of a molecular knot.  The assembly occurs through 
sequential, multiple self-assemby processes.   
 
Producing knot in 20% yield, this impressive one step self-assembly was later 
rationalized, in a study supported by theoretical calculations.24 The reactants were 
modified in order to evaluate the effect of structure on knot formation. One important 
feature is the presence of the pyridine unit in the backbone: replacing it with a phenyl 
group does not produce any knotted structure. The ability of the pyridine to form 
hydrogen bonds with its adjacent amide groups in a pyridine dicarboxamide moiety, 
spatially pre-organizes intermediate 13. The pseudo-cavity thus formed is able to 
accommodate U-shape 12. The entropy loss due to threading one molecule of U-
shape 12 inside this arrangement is compensated by the enthalpy gain induced by the 
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formation of four hydrogen bonds between the two molecules in a comparable way 
as in formation of amide based catenanes and rotaxanes (intermediate [12+13]).  The 
four terminal amines are now close in proximity to allow for fast reaction with 
dichloride in an intramolecular fashion.  This last step traps intermediate [12+13] 
covalently leading to knot 14.  
 
3.2.3 Synthesis of peptide-containing [2]rotaxanes 
 
The Leigh group has pioneered the field of synthetic interlocked architectures based 
on peptidic building blocks. As depicted in Scheme 3.4, the transoïd arrangement of 
the two adjacent carbonyl groups of a glycyl-glycyl sequence provides an excellent 
template for the formation of the benzylic amide macrocycle. 21 
In order to investigate the effect of the side chain substituents on the rotaxane 
forming reaction various dipeptidic threads were reacted under standard conditions, 

































16a R1= H; R2= H (Gly-Gly); 62%
16b R1= H; R2=Me (Gly-Ala); 40%
16c R1= H; R2= CH2CHMe2 (Gly-Leu); 37% 
16d R1= H; R2= CH2CH2SMe (Gly-Met); 36%
16e R1= H; R2= CH2Ph (Gly-Phe); 32%
16a-e
 
Scheme 3.6. Hydrogen bond-directed self-assembly of peptido[2]rotaxanes with various dipeptidic 
template units. 
 
 In most cases rotaxane was produced provided at least one of the two amino acids 
was a glycine. Yields varied according to the steric bulk of the side chain residues, 
but respectable yields were obtained in most cases.  
Rotaxanes could also be formed, in moderate to good yields, with tripeptidic threads. 
The best yields were obtained when the thread contained two consecutive glycine 
residues. More than three amino acid in the thread gives yields of less than 5%, 
presumably due to the formation of intramolecular hydrogen bonds within the 
backbone, which disrupts the transoïd amide arrangement necessary to template the 
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rotaxane assembly. The poor solubility of long peptides in non-hydrogen bonding 
solvents (necessary conditions for efficient rotaxane formation) is also a limiting 
factor. Thus, Leu-enkephalin analogue 17, despite containing the glycylglycyl 





















































Scheme 3.7. Synthesis of a Leu-enkephalin analogue rotaxane via hydrogen bond-directed self-
assembly. 
 
3.2.4 Synthesis of rotaxanes of cyclic peptides 
 
Using a fundamentally different approach the group of Leigh recently achieved the 
synthesis of [2] and [3]rotaxanes of cyclic peptides.28 Contrary to the previous 
examples, the peptidic component is the macrocycle in this case (Scheme 3.8). 
Consisting of an eight or a ten amino acid repeating Gly-Pro unit, these macrocycles 
exhibit a strong affinity for metal cations and diammonium salts.29 The geometry 
adopted by such rings in 1:2 host-guest ammonium complexes is cylindrical, with the 
glycine carbonyls rotated towards one face of the ring and the proline carbonyls 
toward the other face, with each set of carbonyls directed towards one ammonium 
group (Scheme 3.8). Binding occurs outwith the macrocycle. 
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Scheme 3.8. Synthesis of rotaxanes of cyclic peptides. Atom labels are only shown for one repeat unit 
of the cyclopeptide in [2]rotaxanes. 
 
This feature has been exploited to form rotaxanes by threading diammonium-based, 
linear molecules through the cavity of the macrocycle. In a typical procedure, an 
inclusion complex is prepared in situ by mixing an alkyl diamonium thread 20, 
bearing free hydroxy groups at each end, with the cyclic peptide 19. Reaction of the 
1:1 complex with an acid chloride-functionalized stopper affords rotaxanes of cyclic 
peptides 21 and 22 in good yield. Similar yields were obtained with either Cyclo-
L(Pro-Gly)4 or Cyclo-L(Pro-Gly)5, with two different diammonium threads (Scheme 
3.8).  
3.2.5 Synthesis of a p53-derived [2]catenane 
 
In this unique example of a synthetic protein based catanane, the group of Dawson 
took advantage of the ability of tumour suppressor p53 protein to form entangled 
tetramers to direct catenation between two synthetic short analogues of p53.30 The 
tetramerization domain of p53, characterized by X-ray crystallography,31 is in fact a 
“dimer of dimers” in which each dimer consists of two monomeric fragments held 
together in an intertwined manner (Scheme 3.7). 




Figure 3.7. Structure of the tetramerization domain of the tumor suppressor protein p53. The 
backbone is represented as a ribbon to highlight the interlocked structure of the dimers. Reproduced 
with permission from WILEY-VCH Verlag GmbH. 
 
A polypeptide corresponding to residues 325 to 361 (the dimerization domain of one 
monomeric unit of p53), with an additional CGG fragment at the N-terminus and a 
thioester at the C-terminus, was synthesized by solid phase peptide synthesis. The 
terminal cysteine and thioester allowed for intramolecular native chemical ligation 
after interlocked folding of two units of the polypetide had taken place (Scheme 3.9).  
 
 
Scheme 3.9. Assembly of protein catenane. A synthetic analogue of the dimerization domain, 
functionalized at both ends, is macrocyclized after folding held the two monomers in  interlocked 
manner.  Adapted with  permission from WILEY-VCH Verlag GmbH. 
 
[2]-Catenane was isolated in an excellent 47% yield, and its interlocked structure was 
confirmed by single cleavage of the cysteine residue and mass spectrometry analysis 
of the cleavage products.  
 
3.3 Mechanical encapsulation and applications 
 
Since its inception, supramolecular chemistry has paved the way towards molecular 
encapsulation. Host-guest chemistry is, in fact, one of the first forms of molecular 
encapsulation. The first two-dimensional crown ethers capable of sequestering 
anions were soon extended to cryptands, compounds having a capsular or cage 
shape.32 If these early systems were based on coordination interaction, they were 
soon complemented by more complex architectures, able to encapsulate various 
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substrates through hydrogen bond interaction, hydrophobic effect or Van der Waals 
forces.33  
However, encapsulation in an interlocked system (or mechanical encapsulation) is a 
relatively recently developed concept.34 It represents a novel and rather different 
approach to encapsulation: although the formation of the molecule is directed by a 
process relying on supramolecular interactions, the final guest is locked in the cavity 
of the host by a mechanical bond. A covalent bond has to be broken to release the 
guest, making these non-supramolecular entities very stable. This covalent bond 
breakage can be stimulus-triggered widening the scope of the systems to include the 
selective delivery of guests.  
 
3.3.1 Cyclodextrin-based rotaxane-encapsulated dyes  
 
Improving the properties of dyes by molecular encapsulation has recently attracted a 
great deal of attention from organic chemists. It has been found that rotaxanes, 
especially those based on cyclodextrins, can be very useful for dye encapsulation.34 
The group of Anderson has been one of the pioneers in demonstrating the dramatic 
change in properties that can arise from mechanical interlocking. In a recent report, 
they describe how an α-cyclodextrin (α-CD)-encapsulated azo dye had its resistance 
towards oxidation greatly improved as a results of encapsulation.35 The synthesis of 
such rotaxanes has been achieved in very high yields on a gram scale, making it very 
appealing for potential applications. The structure of these rotaxane, an example of 
which is depicted in Figure 3.8, consist of a diazo moiety, which is threaded through 











Figure 3.8. Anderson’s encapsulation of a diazo dye. TM-α-CD corresponds to an α-cyclodextrin in 
which all free hydroxyl group have been methylated. 
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Several tests have been carried out with both interlocked and non-interlocked 
versions of the dye, all of them confirming the greater resistance to oxidation of the 
rotaxane compared to that of the free dye, both in solution and on a surface. A cotton 
sample dyed with rotaxane 23 showed increased resistance against bleaching than a 
sample dyed with the non-interlocked species. 
Other examples have been published by Anderson and co-workers, in which 
mechanical encapsulation is reported to improve the properties of the molecule.36 
 
3.3.2 Rotaxane-encapsulated squaraine dyes for in vivo imaging 
                         
The group of Smith has used rotaxane encapsulated squaraine dyes in in vivo and in 
vitro near infra-red (NIR) imaging. The squaraine motif, composed of a four-
membered ring, substituted with two oxoanions, has interesting fluorescence 
properties. However, these properties can be altered by aggregation in solution (band 
broadening), and more importantly, by chemical decomposition (the highly electron 
deficient cyclobutene ring is readily attacked by nucleophiles, leading to the loss of 
the dye’s colouration). 
In a preliminary study,37 Smith and co-workers demonstrated the ability of the 
squaraine motif to template the formation of a Leigh-type benzylic amide macrocycle 
around a thread-shaped dye, ‘stoppered’ at each end by benzylic groups. An example 
is shown in Figure 3.10. 













24b X=CH   
Scheme 3.10. Chemical structure of a rotaxane of a squaraine dye and its X-ray crystal structure. 
 
Unlike the free dye, this molecule (24a) retained its absoption properties in the 
presence of strong nucleophiles. The macrocycle induces only a slight shift in the 
absorption and emission bands, but gives a slightly higher quantum yield and keeps 
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aggregation to a minimum, greatly improving the overall properties of the dye 
(Figure 3.10). 
In a second report,38 rotaxane-encapsulated squaraine dyes were applied in vitro and 
in vivo. As an example, E.Coli cells stained with a squaraine rotaxane could be 
monitored while cells underwent division. Subcutaneous injection of the stained 
bacterias in nude mice could be observed in a live mouse by irradiating the animal at 
the appropriate wavelength. 
 
3.3.3 Rotaxane-encapsulated peptides 
 
Mass spectrometry analysis of the first peptido[2]rotaxane synthesised by Leigh and 
co-workers strongly suggested that the macrocycle protects the thread from 
fragmention.21 This apparent shielding effect was later confirmed and exploited to 
protect peptides against enzymatic cleavage. It was demonstrated that in the presence 
of α-chymotripsin, a pancreatic peptidase, rotaxane 26 (Scheme 3.11) had a 
significantly longer half-life than its non-interlocked counterpart. Boc-Leu-
enkephalin 25 is cleaved within minutes, whereas rotaxane 26 shows complete 








































































Scheme 3.11. The stability of a rotaxane-encapsulated Leu-enkephalin analogue towards α-
chymotripsin compared to that of the parent peptide. 
 
In addition, the binding affinity between the Boc-Leu-kephalin rotaxane 26 and 
opioid receptors was found to be significantly decreased compared to that of its 
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parent thread.39 The additional lipophilic character given to the structure makes the 
concept of peptidorotaxanes very attractive for drug delivery, since it can provide an 
effective way to protect peptides against in vivo degradation, enhance intracellular 
transport and temporarily ‘turn off’ their activity during transport throughout the 
journey to the target. 
  
3.4 Molecular carriers based on interlocked architectures 
3.4.1 Polyrotaxane-based drug carriers 
 
The first drug delivery devices based interlocked architectures were described by Yui 
et al.40 In a series of different studies, they demonstrated the ability of multi α-CD-
containing polyrotaxanes to be involved in various biological processes.41,42 One of 
their first studies involved the design of a drug-polyrotaxane conjugate able to 
transport and deliver theophylline to a target organ. Scheme 3.12 depicts the model 
device, 27, which consist of a polyethylene glycol chain (PEG) threaded through 
multiple α-CD rings. Each α-CD is functionalized by the active drug (theophylline), 











































Scheme 3.12. Chemical structure and schematic representation for the operation of Yui’s rotaxane 
based drug carrier.  
 
The PEG thread is stoppered by a biodegradable moiety in such a way that it would 
be cleaved in the extracellular media, supposedly releasing the drug-functionalized 
rings in close proximity to the targeted cell.  Stopper cleavage-mediated release of 
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the rings was assessed in vivo in the presence of both papain and α-chymotripsin and 
in both cases cleavage occurred, albeit very slowly (320 h and 150 h respectively).43 
Using similar structures Yui et al. designed a range of drug carrier systems43,44 and 
have recently applied them to gene transfection.45 
 
3.4.2 Host-guest rotaxane as cell membrane transporters 
 
In a different approach, the group of Smithrud have shown that host-[2]rotaxanes can 
transport various compounds through the cell membrane.46,47 The transporting device 
is composed of an ammonium containing thread, stoppered at one end with either a 
cyclophane pocket or an aromatic cleft, and a diarginine derivatized crown ether 
macrocycle. The various guests bind to the lipophilic pocket and the whole complex 
travels passively through the cell membrane. Host-[2]rotaxane 28 (Figure 3.9) is an 
example of such a device, which has been subjected to rigorous experiments in order 




























Figure 3.9. Smithrud’s Host[2]rotaxane. 
 
To evaluate the influence of the ring position on the binding affinity with the guest, 
an analogue of 28, where the ring is locked away from the ammonium group (by 
acetylation of it), was synthesized and subjected to binding affinity experiments.46 
These revealed that ring motion along the thread is crucial in reaching maximal 
binding of the host-[2]rotaxane with the guest, promoting cell penetration. When 
moving from the aqueous media to the vey lipophilic cell membrane, the rotaxane 
carrier experiences a sudden change in polarity of its environment. The host-rotaxane 
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has the flexibility to alter its conformation through shuttling of the ring along the 
thread in order to maximize the binding free energy of host-guest association, and 
simultaneously minimize the environmental effects on the stability of the complex.  
In a polar medium the ring is expected to be separated in space from the polar 
ammonium group, whereas in the cell membrane the ring slides back over it to give a 
‘more lipophilic character’ to the complex (Figure 3.10). 
 
Figure 3.10. Representation of the host-[2]rotaxane-fluorescein-functionalized peptide complex 
crossing the cell membrane. The ring slides along the thread in order to maximize the binding free 
energy of the complex and minimize environmental effect. 
 
3.4.3 Rotaxane-based nanovalves 
 
In an approach combining nanofabrication and supramolecular assembly, the group 
of Stoddart and Zink first designed48 drug carriers based on nanoporous silica 
nanoparticules derivatised with rotaxane or pseudo-rotaxanes gatekeepers.49 The 
concept has attracted attention from other research groups over the last decade,50 and 
various rotaxanes and pseudo-rotaxanes have been used as gatekeepers: paraquat 
(Scheme 3.13), crown ethers,51 cyclodextrins,52 and more recently cucurbiturils.53 
Silica-based nanoparticules of a 500 nm size range were used for the fabrication of 
the device. Within these particules 2-3 nm wide containers were carved using 
templating methods. Functionalization of the outer face of the pore by rotaxane- or 
pseudo-rotaxane-based stalks enables the system to function as a valve (Scheme 
3.13). The pores can be selectively opened or closed by controlling the position of 
the macrocycle on the thread. When the macrocycle is located close to the pore 
opening, the pore is obstructed and the valve is said to be closed. Contrary, when the 
macrocycle is far away, the pore is less obstructed and the valve is opened. The 
device can then be loaded with guest molecules and subsequent closing traps them in 
until the appropriate stimuli is applied to open the valve and release them.  




                                        
Scheme 3.13. a) The chemical structure of a bistable [2]rotaxane, 29 used as a valve. b) Schematic 
representation of the operating cycle of the nanovalve. 
 
Scheme 3.13 shows the mechanism of action of a nanovalve described by Stoddart et 
al. The valve is based on the well studied bistable [2]rotaxane 29, which is composed 
of a paraquat-based macrocycle (CBPQT4+) and a combination of tetrathiafulvalene 
(TTF) and dioxynaphtalene (DNP) units on the thread. Chemical oxidation of TTF 
using Fe(ClO4)3 triggers displacement of the macrocycle from the preferred TTF 
station to the DNP station, closing the pores and trapping guest molecules inside. 
Opening of the valve is achieved by reducing the TTF2+ station with ascorbic acid, 
which releases the trapped molecules.  
Simpler stimuli such as pH51,53 or more recently enzymes,52 have subsequently been 
used. 
 
3.5 Design and outlook of the project 
 
Designing nanodevices capable of transporting active chemicals safely and release 
them under controlled stimuli is no longer hypothetical. As has been discussed, 
complex supramolecular or mechanically linked architectures, capable of 
encapsulating guest molecules, have already been built and operated with great 
29 
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success. The Leigh group has previously demonstrated that peptides (and bioactive 
peptide analogues) could be mechanically encapsulated as part of a rotaxane 
structure. However to perform a useful task, these devices should be able to deliver 
and release the encapsulated peptide to a given target. This aspect had not been 




In the transformation of these early peptidorotaxanes into real drug carriers, there are 
several factors to take in to account. As well as protecting the backbone against 
peptidase hydrolysis, the potential peptide carriers should be able to release the 
active peptide in a controlled manner (i.e. at a specific location, under a specific 
stimulus). A logical way to proceed towards achieving this goal would be to adapt 
the prodrug approach54 to the specific release of the mechanically encapsulated 
peptide. Accordingly, the function of the nanodevice is to improve the peptide’s 
administration properties, mainly low bioavailability and poor membrane transport, 
as well as significantly decreasing its activity and toxicity during transport to the 
target.   
 
In a similar way as Yui’s carriers,42 the encapsulated peptide should be ‘sandwiched’ 
between two stoppers, which are cleaved by a specific enzyme, triggering slipping of 
the macrocycle component and release of the peptide from its protective capsule. 
This means that the N-terminus amine and the C-terminus carboxylic acid are 
restored after cleavage has occurred (Scheme 3.14).  
 
Scheme 3.14. Schematic representation of a universal rotaxane peptide carrier. 
 
In order to efficiently protect the peptide against proteolysis, the macrocycle should 
be able to explore the whole backbone through random Brownian motion (i.e. its 
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cavity should be large enough to accommodate each residue). It is difficult to predict 
the maximum length that could be protected through random shuttling of the ring 
along the peptide, however as a result from a previous study by Anderson it can be 
accepted that to be the most efficient, the macrocycle has to reside over or in very 
close proximity of the residues prone to hydrolysis for as long a period of time as 
possible.55 In his study, Anderson shows that when the macrocycle constituent of a 
rotaxane is concealed in proximity to a specific peptidic bond, the latter is not 
cleaved by α-chymotrypsin. If, however, the macrocycle is free to move along the 


















































Scheme 3.15. Anderson’s enzymatic cleavage of a peptide-linked rotaxane. When the α-CD is 
concealed in proximity to the Arg-Phe residues (30b) , the rotaxane is not cleaved by α-chymotrypsin. 
If, however, the macrocycle is free to move along the whole thread (30a), the Arg-Phe linkage is 
readily hydrolyzed by the enzyme. 
 
In most common proteolytic enzymes only one or two residues are sufficient for 
substrate recognition (hydrolysis will occur after or between these residues). For 
example, α-chymotrypsin is very specific to one Leu, Phe or Tyr residue but is not 
demanding concerning the remaining amino acids of the sequence.56 This somewhat 
low specificity of peptidases explains why, even though the macrocycle constituent 
of the peptidorotaxane is proximity to the hydrolysis position, this may not be a 
sufficient condition to interfere with enzyme recognition. Hence it is important that 
for maximum protection efficiency the macrocycle is statistically located over the 
side chain of each amino acid for as long a period of time as possible (determined by 
the length of the peptide). Thus in the case of a wholly peptidic thread, to protect 
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every peptidic bond in the sequence, the ring should reside over each residue for a 
statistically equal length of time. The faster the ring shuttles from on end of the 
thread to the other the better both aforementioned conditions will be fulfilled.57 
 
As well as functioning as a protective shield the ring can be functionalized to 
perform additional tasks. For example, solubility of the device can be fine tuned, 
therapeutic targeting can be achieved by attaching ligands specific to a certain type 
of cell, active intracellular transport can also be triggered by selecting ligands that 
provoke endocytosis. One can also envisage functionalizing the macrocycle with 
bioactive molecules, which once delivered, could act complementarily to the 
bioactive peptide, or have a similar activity to enhance therapy efficiency (Scheme 
3.16). 
 
Scheme 3.16. Schematic representation of a universal rotaxane peptide carrier for targeted therapy 




The conditions mentioned above, constitute the requirements for the construction of 
a universal peptide carrier, which, by definition, could be adapted to any type of 
peptide and to any type of therapeutic target. There is no doubt that such devices will 
be accessible in the near future, but to approach this design one has to adopt a 
stepwise strategy. Thus, in the following chapters, some elements of the design (size 
of the macrocycle, type of biodegradable stoppers) are based on previous studies. In 
summary: 
i) The cavity of the benzylic amide macrocycle used in previous peptide 
rotaxanes is not sufficiently large to accommodate all proteinogenic amino 
acids. However, it constitutes the key element of peptide mechanical 
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encapsulation and as such no attempt was be made in this study to find a 
larger substitute 
ii) Biodegradable stoppers were elaborated for tumour-triggered release of 
peptides and were designed, as a first example, for the N-terminus of the 
peptide only. 
 
This thesis will describe, in the first place, the optimization of a methodology for the 
synthesis of peptido-rotaxanes of long peptides (Chapter 4). The use of this 
methodology to build an anti-cancer therapy compatible peptide rotaxane carrier will 
be described in Chapter 5. Finally, Chapter 6 will describe the development of 
biodegradable stoppers and the functionalization of the macrocycle constituent of 
peptide carrier models for anti-cancer therapy. 
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diminished in the prodrug version in order to improve drug targeting and 
administration quantities. Cleavage of the pro-moiety is usually achieved by enzymes 
specifically located at the periphery of the target organ. For a recent review see: [J. 
Rautio, H. Kumpulainen, T. Heimbach, R. Oliyai, D. Oh, T. Jarvinen,  J. Savolainen, 
Nat. Rev. Drug. Discov., 2008, 7, 255-270.] 
[55] A. G. Cheetham, M. G. Hutchings, T. D. W. Claridge,  H. L. Anderson, 
Angew. Chem., Int. Ed., 2006, 45, 1596-1599. 
[56] For an account on proteolytic enzymes specificity see: R. Beynon,  J. S. Bond 
Proteolytic Enzymes; Second ed.; Oxford university press: Oxford, 2001. 
[57] Even though it seems that fast shuttling rates will decrease the time that the 
ring spends on each residue, over a longer period of time the ring is statistically 
uniformly distributed over the whole surface of the peptide backbone. Shielding 













A new methodology for the 










Most of the practical work described in this chapter was originally carried out by 
Stéphanie Potok.  However, it was found that several final compounds contained 
considerable amounts of epimerization adducts. With the aim of submitting this work 
for publication, some key coupling reactions were optimized, and enantiomerically 
pure final rotaxanes were isolated and characterized (16 to 28). Dr. Anthony 
Fernandes and Dr. Vincent Aucagne are also greatly acknowledged for their valuable 
help in synthesizing peptide fragment 25 and peptide 28, respectively. 





Although rotaxanes of dipeptidic fragments have previously been synthesized using 
the Leigh-type direct self-assembly of benzylic amide rotaxanes, longer peptidic 
sequences have so far failed to afford rotaxanes in respectable yield under the same 
conditions. There are two main reasons for this. Firstly, long peptide threads are 
only poorly soluble under the strictly non-protic solvent conditions necessary for 
rotaxane formation. Secondly and most importantly, long peptidic backbones self-
satisfy in terms of hydrogen bonds and fold up on themselves, resulting in disruption 
of the transoïd arrangement between carbonyl groups necessary to template the 
formation of rotaxane. 
 
In the following chapter, the synthesis of wholly proteinogenic peptide rotaxanes via 
the elongation of lateral chains of short peptide rotaxane precursors is described. 
These pre-activated rotaxane building blocks consist of a Leigh-type benzylic amide 
macrocycle around a three amino acid long thread, bearing a set of N and side chain 
bulky protecting groups at the N-terminus and a sterically blocking activated para-
nitrophenol ester at the C-terminus. Reaction of theses precursors with the 
nucleophilic amine of a stoppered peptidic fragment gives C-elongated adducts in 
good to excellent yields. Subsequent deprotection at the Nα allows reaction with the 
free carboxylic acid of an N-stoppered peptidic fragment under phosphonium-type 
coupling conditions. This method is the only method to date leading to rotaxanes in 
which the thread is made out of exclusively proteinogenic amino acids. 
 
 






Since amino acids are one of the main constituents of the human body, most 
biological processes are regulated by the endogenous production of specific peptides 
or proteins. Hence peptide-based drugs offer the possibility of highly efficacious 
interaction with many biological processes. Unfortunately, however, peptide-based 
drugs suffer from several severe drawbacks, of which the most significant are their 
very low bioavailability (they are rapidly decomposed by peptidases in vivo) and 
their very low membrane-crossing ability (due to their highly polar nature). The 
metabolism of peptides and proteins has been studied extensively,1 and a number of 
proteolytic enzymes found in various part of the human body break down proteins 
and peptides into smaller peptidic fragments or single amino acids.  
Backbone chemical modification has been the major technique used in order to get 
around these issues. L to D amino acid substitution, N and C-terminus modification 
and liposome encapsulation are probably the most significant examples of methods 
used in development laboratories. These methods give variable levels of success and 
often require a high degree of optimization.2 
Mechanical encapsulation proved to be a viable alternative to the degradation of 
peptides in vivo (Chapter 3). The evidence suggests that the macrocycle constituent 
protects the backbone in a rotaxane-encapsulated peptide but the range of peptides 
that can be encapsulated is so far still limited. A new methodology needs to be 




The original synthesis of interlocked architectures using an amide-based hydrogen 
bond template as the recognition motif for their self-assembly dates back to the early 
1990’s.3 A few years later, following the serendipitous discovery of benzylic amide 
[2]catenanes by Leigh and co-workers,4 it was demonstrated that rotaxanes could 
also be easily synthesized in a similar way using a stoppered thread containing pre-
organized amide groups.5-7 Two consecutive glycines were shown to adopt the 
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prerequisite transoïd conformation between the two carbonyls of the peptidic 
backbone to template the formation of rotaxane in 62% yield (Scheme 4.1).6 
 
 
Scheme 4.1. Templated assembly of [2]Rotaxane around a glycylglycyl fragment. 
 
Since this discovery, the Leigh group has investigated the effect of mechanical 
interlocking on different peptide backbones.8 Although the macrocycle plays a 
crucial role in the stability and the solubility of the ensemble, the synthesis of peptide 
rotaxanes is however limited to threads containing five consecutive amino acids and 
practically viable only for sequences not longer than three amino acids.8 The 
predisposition of the peptide backbone to fold due to intramolecular hydrogen-
bonding is detrimental for the integrity of the transoïd arrangement between the 
carbonyl groups necessary to template the assembly. This effect is more prevalent 
with longer peptide sequences and is apparently emphasized in non-polar solvents, 
which are essential for the rotaxane-forming reaction. It appeared to us that a 
solution to circumvent this apparent conundrum was to build up longer peptide 
rotaxanes by elongation of short-sequence building blocks. 
The feasibility of such strategy was in fact demonstrated in a report from Stoddart et 
al. a few years ago, in which the Authors used phosphorus ylide rotaxane building 
blocks to synthesize rotaxane polymers and molecular shuttles via a Wittig 
elongation reaction.9 Soon afterwards, the group of Smithrud described a rather 
similar elongation strategy (Scheme 4.2),10 which, despite having the merit of 
creating a peptidic bond within an interlocked structure, has never been applied to 
the synthesis of natural peptide rotaxanes.  









































DCC-activated rotaxane  
Scheme 4.2. Smithrud elongation of DCC- activated rotaxanes 
  
Using Smithrud’s approach, the terminal carboxylic acid of an ammonium-crown 
ether pseudo-rotaxane is treated with DCC to form a bulky O-acylurea, preventing 
the structure from de-threading. The resulting activated rotaxane is isolated and 
further elongated by displacement of the reactive O-acylurea with an amine-based 
suitably stoppered half-thread (Scheme 4.2). 
However. to be adapted to the synthesis of peptide rotaxanes such method would 
require that a DCC-activated short peptidic thread is converted into a rotaxane under 
our ‘clipping’ conditions. Unfortunately, the large excess of para-xylylenediamine 
(15 equivalents compared to the thread) required during the rotaxane-forming step 
would undoubtedly quickly consume the highly reactive O-acylurea and mostly lead 
to undesired products. 
 
4.1.2 Active esters 
 
The high reactivity exhibited by O-acylureas is generally regarded as a drawback for 
the formation of an amide bond. In particular, when an amide bond is to be formed 
between peptidic fragments directly from O-acylurea, numerous side reactions 
(particularly epimerization) are likely to occur.11 The mechanisms of these unwanted 
reactions are well established and peptide chemists have spent the past four decades 
tackling this issue. Wünsch and Weygand first developed a protocol,12 which was the 
foundation of a nowadays generally-used procedure. In their original work, whilst 
attempting to synthesize glucagon and calcitonin, one equivalent of DCC and two 
equivalents of N-hydroxysuccinimide (HOSu) were applied concomitantly. During 
the course of the reaction the HOSu additive intercepts the highly reactive O-
acylurea before it undergoes side reactions, thereby forming an OSu active ester, 
which is lower in reactivity but still reactive enough to be displaced by the amino 
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acid to be coupled. Since then, extensive research has focused on the elaboration of a 
variety of active esters in order to obtain the best reactivity to side reaction ratio.  
According to a general assumption, the electrophilicity of an ester is related to the 
pKa of the parent alcohol and increases as the pKa decreases.13 The benchmark has 
been centred on 1-hydroxybenzotriazole (HOBt) (Table 4.1), which is by far the 
most frequently used activating agent in peptide syntheses. It is either used in 
combination with a DCC type carbodiimide reagent or formed in situ from 
phosphonium (e.g. BOP, PyBOP) or uronium coupling reagents (e.g. HBTU, 
TBTU). Reactions employing a combination of diimide reagent and HOBt are 
typically complete in less than an hour in solution or on solid phase, and 
epimerization and/or side reactions are generally suppressed.  
 
Table 4.1. Selected coupling additives and their pKa values. 
 
  HOAt HOBt HOSu ONp 
Structure  
   
 
pKa14 3.47 4.57 6.0 7.15 
 
The ability of such activated esters to decrease the reactivity of the O-acylurea 
intermediate could be exploited in the elongation of short peptide rotaxanes.  
Exchange of stoppers in rotaxanes involving ester groups has been described15 and 
the fact that active esters can be isolated and are stable towards hydrolysis motivated 
us to adopt this strategy (Scheme 4.3). 
 








































































Scheme 4.3. Elongation mechanism of ester-activated peptidorotaxanes. The group X should be bulky 
enough to avoid dethreading. The tetrahedral intermediate allows the rotaxane to be elongated without 
potential dethreading  
 
The challenge, in this particular case, was to find an appropriate type of active ester, 
which would be unreactive towards the excess of amine needed for the rotaxane 
forming step, but that could subsequently be activated for the coupling of the 
elongation segment.16 To fulfill these requirements, the parent alcohol should have a 
significantly higher pKa value than HOBt, given the fast rate of aminolysis exhibited 
by HOBt esters at room temperature.  HOSu (pKa = 6) is expected to be just over 25 
times less reactive than HOBt (pKa ≈ 4.6), and would not be sufficiently inactivated 
(Table 4.1). 
An initial screening of the pKa values of the some common activating agents led us 
to para-nitrophenol (ONp) (Table 4.1), a less frequently used additive but known to 
give a slower rate of reaction.17,18,19 With a pKa of 7.15, the latter can be expected to 
be over 300 times less reactive than HOBt at room temperature. Chemical 
functionalization of the phenyl ring is straightforward and appropriate ortho 
substitution could be used to tune the reactivity of the ester. Adding electron 
withdrawing groups would decrease the pKa of the phenol, rendering the 
corresponding ester a better leaving group, whereas adding bulky donating groups 
would have the opposite effect. This rather ‘unreactive’ ester could then be ‘turned 
on’ at higher temperatures to allow for reaction with terminal amines, after rotaxane 
has been formed at room temperature.  
Commercial diphenyl-para-nitrophenol seemed a perfect candidate for a first trial. 
Molecular modeling (CPK) showed that the two ortho-phenyl groups are large 
enough to avoid slippage of the ring in a Leigh-type rotaxane structure. The two 
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ortho-phenyl groups would certainly add a significant increase in pKa, ensuring that 
the ester would be robust enough for the rotaxane-forming step. Additionally, once 
formed, the macrocycle should have a shielding effect on the thread and protect the 




To assess the inertness of the para-nitrophenol unit under rotaxane-forming 
conditions and its reactivity toward aminolysis at elevated temperatures, we designed 
a dipeptidic model thread stoppered at its C-terminus by 2,6-diphenyl para-
nitrophenol ester. Rotaxane was formed in good yield and elongation by various 
peptide fragments proved the method to be very efficient.  
A universal method for the synthesis of theoretically unlimited length 
peptido[2]rotaxanes was then developed, in which the threads are made out of 
exclusively proteinogenic amino acids. The process for the construction of such 
original interlocked architectures relies on the C-elongation of rotaxane building 
blocks via nitrophenol ester stopper aminolysis and N-elongation via peptide 
coupling chemistry. Figure 4.1 gives a schematic representation of such building 
blocks, which are stoppered at the N-terminus, by a bulky protecting group (P2) 
attached to the side chain of an amino acid. Once C-elongated, the rotaxane is Nα 
deprotected and further N-elongation is achieved under standard peptide coupling 
conditions.20  
 















Figure 4.1. Structure of tripeptide precursors: The side chain at the N-terminus bears a bulky 
protecting group (P2) that acts as a stopper while the two following amino acids (Rr and R2) template 
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4.2 Results and discussion 
4.2.1 Design and synthesis of activated rotaxane building block  
 
To test whether the nitrophenol group is suitable for rotaxane elongation, a model 
thread was designed and the elongation of rotaxane was assessed under various 
conditions and using various peptide fragments. The synthesis of activated thread 
and rotaxane is depicted in scheme 4.4. For comparison reasons, the activated thread 
was made out of the same glycylglycyl fragment (4, Scheme 4.2) previously reported 










































































Scheme 4.4. Synthesis of the dipeptide activated ester thread and of rotaxane building block. 
 
The nitrophenol moiety was incorporated after basic hydrolysis of known ester 3 
using BOP as the coupling agent (Scheme 4.4). A 5-fold excess of 5 was necessary 
to obtain a satisfactory yield of coupling and unreacted 5 could be easily recoved 
during chromatography purification of the product. Formation of rotaxane 7 was 
carried out using a slightly modified procedure from the one initially reported by 
Leigh (where equimolar quantities of isophthaloyl dichloride and para-
xylylenediamine are simultaneously added to a solution of thread in CHCl3 
containing an excess of NEt3). To avoid any premature decomposition of the thread,21 
NEt3 was mixed with para-xylylenediamine prior to addition allowing it to be 
immediately consumed by the HCl produced during the course of the reaction. 
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Filtration of the crude mixture left a solution containing mainly peptido[2]rotaxane 7 
and unreacted thread 6, together with catenated and polymeric species. Purification 
by flash column chromatography led to rotaxane 7 in 48% yield, which is 
comparable to the 62% obtained with the non-activated thread in Scheme 4.1. 
Although one can suspect partial nucleophilic attack of para-xylylenediamine on the 
activated carbonyl to be responsible for this slight decrease in yield, reaction of the 
diamine with the dichloride is essentially favoured. Importantly, rotaxane 7 proved to 
be stable in air for months without any sign of decomposition. 
 
4.2.2 Elongation of activated rotaxane 
 




































































Scheme 4.5. Elongation of the activated rotaxane by different peptide fragments and the suggested 
mechanism for the formation of free macrocycle. 
 
As expected, rotaxane 7 did not react with the primary amine of stoppered amino 
acids at room temperature (Table 4.2, Entry 1). This lack of reactivity is believed 
enhanced by the shielding effect of the macrocycle. In a first attempt, rotaxane 7 was 
heated at reflux in CHCl3 with the trifluoroacetate salt of stoppered glycine 8a and an 
excess of NEt3 (Table 4.2, Entry 2). Pleasingly, after a few hours, TLC analysis 
showed the slow disappearance of 7 and the appearance of new compounds. Isolation 
of the major compound by flash chromatography afforded tripeptido[2]rotaxane 9a 
in 61% yield. Together with 9a, the eliminated nitrophenol stopper 5 and other 
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unknown by-products, we were surprised to isolate a fair amount of free macrocycle 
1. Originally thought to be produced via hydrolysis of the activated ester by residual 
water,22 this was better rationalized by the intramolecular formation of an undesired 
oxazolone ring, 10, at the C-terminus, causing de-threading. (Scheme 4.5).23  
The formation of this intermediate is often observed in peptide couplings and can 
expected to be favoured by the use of excess of base and high temperatures.11,18,24 In 
the hope of minimizing undesired side reactions, the elongation was performed 
without the addition of base. The best results were then obtained when a mixture of 
rotaxane 7 and at least two equivalents of peptide as the free amine were heated at 
reflux in CHCl3. A series of mono- to tri-peptide half-stoppered threads have been 
reacted under these optimized conditions. Peptido[2]rotaxanes were isolated in good 
to excellent yields (Table 4.2).  
 
Table 4.2. Effect of stoichiometry, reaction time, and reaction conditions on the C-elongation of 
model rotaxane 7. a The TFA salt of the substrate was used.  
 
 
Substrate   
Entry 









1 G - - 8a 2 1 RT 24 GGG  9a 0 
2 G - - 8a a 2 2 reflux 24 GGG 9a 61 
3 G - - 8a 2 0 reflux 24 GGG  9a 91 
4 A - - 8b 2 0 reflux 24 GGA 9b 88 
5 L - - 8c 2 0 reflux 24 GGL  9c 78 
6 F - - 8d 5 0 reflux 52 GGF 9d 74 
7 A G G 8e 2 0 reflux 72 GGAGG  9e 55 
 
 
Although reactivity drops according to the bulkiness of the substrate, the reaction 
could easily be forced towards completion by increasing the load of reactant or by 
extending the reaction time (Table 4.2, Entries 6 and 7). The excess of peptide 
fragments could be recovered in each case during purification of the elongated 
rotaxanes. 
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4.2.3 Synthesis of a Leu-enkephalin rotaxane 
 
Rotaxane of the biologically active pentapeptide Leu-enkephalin (YGGFL), whose 
synthesis had previously been unsuccessfully attempted in our group by direct 
formation of rotaxane using the pentapeptide (1% yield),8 has the right structural 
requirements to be synthesized via the new approach expounded above. The first 
three amino acids of the sequence (YGG) will indeed adopt the correct orientation to 
template the formation of the macrocycle as internal hydrogen bonding will be 
minimal (Scheme 4.6).  
 
 
Scheme 4.6. C-elongation strategy applied to the synthesis of a Leu-enkephalin analogue rotaxane 
 
A permanent Nα protecting group is needed to stopper the assembly as the tyrosine is 
not large enough on its own, whereas the consecutive phenyalanyl and leucyl 
residues will provide an appropriate stopper at the other end after being incorporated 
into the thread by elongation. 
The phenol of the tyrosine and the carboxylate of the terminal leucine were both 
protected by benzyl groups, which can be selectively cleaved in the last step, leaving 
the Boc group intact. The synthesis of Boc-Leu-enkephalin rotaxane is depicted in 
Scheme 4.7.  


























































































































Scheme 4.7. Synthesis of Leu-enkephalin analogue rotaxane. 
 
Starting from known25 ester 11, the tripeptide activated thread 12 was prepared in 
two steps in 60% overall yield (Scheme 4.7). Rotaxane formation was carried out 
using the procedure described earlier, producing rotaxane 13 in an isolated yield of 
19%, after purification by flash chromatography on silica gel without any sign of 
decomposition. This activated rotaxane proved to be stable in air at room temperature 
for several months. The key elongation step was achieved in very good yield (86%) 
using an excess of commercial nucleophile 14 under the optimized conditions 
described above. Finally, deprotection of the two benzyl groups – carried out with H2 
and Pd/C as catalyst – appeared to be sluggish but finally reached completion after 
48 hours. LCMS analysis of the final product showed the presence of one major 
compound (> 92%, HPLC purity), whose m/z of 1188 corresponded to the expected 
[M+H]+. 
 




Figure 4.2. 1H NMR spectra (400 MHz, CDCl3-CD3OD (1:1), 300 K) of a) Boc-Leu-enkephalin, b) 
Boc-Leu-enkephalin rotaxane 16. The assignments and colouring of signals correspond to that shown 
in Scheme 4.7. Residual solvent peaks are shown in grey. 
 
1H NMR spectra of rotaxane 16 and of Boc-Leu-enkephalin are shown in Figure 4.2. 
The spectrum of the rotaxane shows upfield shifts of several signals with respect to 
the non-interlocked counterpart. Such shielding is typical of interlocked architectures 
where the aromatic rings of one component are positioned face on with another 
component. They are most intense for the protons of the two glycines (HG) indicating 
that the macrocycle is mostly located over that portion, on the NMR timescale. The 
signals of the eight methylene protons (HE) from the macrocycle display a high 
multiplicity pattern (i.e. the eight methylene protons belong to magnetically distinct 
environments), indicating that the macrocycle experiences rather slow pirouetting on 
the NMR timescale.7 The availability of many hydrogen bond donors within the 
structure and the confinement of the macrocycle within a restricted area (i.e. over the 
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4.2.4 N and C-elongation: synthesis of a wholly proteinogenic peptide 
rotaxane  
4.2.4.1 Design and synthesis of a ready-to-elongate building block 
 
To complete this study, we extended the methodology to the synthesis of more 
challenging structures where the thread is of a wholly peptidic nature, without 
additional protecting groups and of a greater length. The key step to accessing longer 
peptide rotaxanes is the combination of the C-elongation described earlier together 
with an N-elongation procedure. To allow for extension at the N-terminus the side-
chain of the N-terminal amino acid has to bear a large enough protecting group to 
prevent the structure falling apart after deprotection of its Nα (24, Scheme 4.8). In 
addition, both elongation fragments should comprise two consecutive large amino 
acids to prevent the final assembly from dissociating.  
 
Scheme 4.8. Combined N- and C-elongation strategy in the synthesis of petido[2]rotaxanes containing 
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We initially considered extending this N-elongation approach to a slightly modified 
version of the tyrosylglycylglycyl fragment 13 (Scheme 4.7) where the tyrosyl 
residue would bear a bulky diphenylmethyl (Dpm) group instead of a benzyl group. 
While Dpm is cleaved under the same conditions as the latter, the Nα of the N-
elongation fragment would optimally require a Cbz-type protecting group to fit in 
this H2-labile protecting groups scheme. Although final hydrogenolysis should in this 
case afford the fully deprotected product, the slow reaction times upon 
hydrogenation observed in the previous example suggested that a one-pot 
deprotection of a Dpm, Bn and Cbz groups could be rather challenging. More 
importantly, Dpm groups are not resistant under classical Boc cleavage conditions 
(10% TFA in CH2Cl2),26 and as a result, the Nα-protecting group of the rotaxane 
building block would have to be substituted by an non-acid-labile protecting group.  
To circumvent such concerns, we opted for a variation of the classical Fmoc 
synthesis approach, routinely used in solid phase peptide synthesis (SPPS). This 
universally approved approach takes advantage of the base-labile Fmoc protecting 
group at the N-terminus while side-chain and C-terminus deprotections are 
accomplished under acidic conditions.11 A bulky, acid labile silyl group such as 
TBDPS on the side chain would then be appropriate, while a tert-butyl (t-Bu) 
protecting group at the C-terminus of the C-elongation fragment and a Boc at the N-
terminus of the N-elongation fragment would suit these requirements perfectly 
(Scheme 4.8). Additionally, switching from a tyrosine to a serine for the  seemed a 
wise choice to us as acid mediated deprotection of TBDPS-protected primary 
alcohols are several orders of magnitude faster than the corresponding reaction with 
phenols27 (Scheme 4.9).  
 














































ii) 5, BOP, NEt3, CHCl3























































Scheme 4.9. Synthesis of the ready-to-elongate precursor. 
 
Hence, the synthesis of the ready-to-elongate rotaxane was carried out according to 
Scheme 4.9, where it was obtained in four steps, starting from precursor 17. The 
serine was then coupled to this glycylglycyl-benzylated fragment 18 under HATU-
mediated coupling conditions. A moderate yield was obtained although examples in 
the literature report higher yields for the coupling of non-alcohol-protected amino 
acids.28 A comparable yield was obtained using EDC together with HOBt, whereas a 
significant drop in yield occurred under BOP or TBTU conditions.  
C-terminus deprotection, activation and rotaxane formation gave the ready-to-
elongate rotaxane 21 in 15% yield which, given the steric hindrance around the 
template, is very remarkable.  
The 1H NMR spectrum of building block rotaxane 21 shows the peaks of the 
macrocycle with those of the thread shifted upfield, characteristic of an interlocked 
architecture (Figure 4.3). Surprisingly, the two β protons of the serine residue in 
rotaxane 21 exhibit a significant upfield shift (~1 ppm) compared to the parent 
thread, indicating that the macrocycle is predominantly located over the bulky N-
terminus end of the peptide chain. This feature is confirmed by the chemical shift of 
the α protons of the same amino acid. It appears to us that to minimize the steric 
clash at the N-terminus, the carbamate moiety of the Fmoc group adopts a cisoïd 
conformation relative to the adjacent carbonyl of the peptidic bond (Scheme 4.9). 
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The carbonyl of the carbamate group is then accessible by the macrocycle, whose 
amides groups form a hydrogen bond with it. 
 
Figure 4.3. Partial 1H NMR spectra (400 MHz, CDCl3, 300 K) of a) thread 20, b) Ready-to-elongate 
precursor rotaxane 21. The assignments and colouring of signals correspond to that shown in Scheme 
4.9. Residual solvent peaks are shown in light grey. 
 
Furthermore, one of the -NH signals of the glycines is greatly deshielded compared 
to the non-interlocked thread suggesting that this proton is involved in hydrogen 
bonding, probably to a carbonyl of the macrocycle, which adopts a twisted 
conformation (Scheme 4.9). The high multiplicity signal of the methylene protons of 
the macrocycle (HE) is also an indication of an unusually unsymmetrical environment 
and a rather rigid conformation. The double set of protons given by HA and HB shows 
that the upper and bottom half of the macrocycle are not equivalent on the NMR 
timescale, implying that pirouetting is also fairly slow. 
 
4.2.4.2 C- and N-elongation of the building block 
 
C- and N-elongation of building block 21 were performed with three amino acid long 
peptide fragments. Both fragments contained two consecutive terminal leucyl and 
phenylalanyl residues to stopper the assembly. According to the planned strategy 
(Scheme 4.8), the C-elongation fragment was t-Bu protected at its C-terminus and 
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the N-elongation fragment was Boc protected at its N-terminus, both of which allow 



























































































































































Scheme 4.10. Synthesis of nona-peptido[2]rotaxane via C- and N-elongation. 
 
Rotaxane 21 and 5 equivalents of the amine 22 were then stirred in CHCl3 under 
reflux overnight to give 23 in very good yield (Scheme 4.10). Cleavage of the Fmoc 
protecting group with piperidine gave a quantitative yield of the free amine 24, 
which was further elongated under BOP coupling conditions. A good yield of 
rotaxane was obtained using only 2 equivalents of peptide 25, suggesting that the 
terminal amine was less shielded by the macrocycle than originally expected. This 
could be due to the fact that the thread comprises four accessible binding sites of 
equivalent affinity on which the macrocycle spends a statistically equal amount of 
time, leaving the terminal amine less shielded by the macrocycle and thus more 
prone to react. 
Final lateral and side chain deprotections were achieved with TFA/H2O (9:1), which 
(after evaporation and precipitation of the supernatant in Et2O) led to 
peptido[2]rotaxane 27 as its TFA salt. A pure sample of 27 was analyzed by LCMS. 
The chromatogram confirmed the presence of one major compound (> 95% HPLC 
purity) whose m/z of 1386 corresponded to the expected [M+H]+. 





Figure 4.4. 1H NMR spectra (400 MHz, CD3OD, 300 K, H2O suppression) of a) nona-peptide thread 
28, b) nona-peptido[2]rotaxane 27. The assignments and colouring of signals correspond to that 
shown in Scheme 4.10. Residual solvent peaks are shown in grey.  
 
The 1H NMR spectrum of rotaxane 27 is shown in Figure 4.4, together with a 
spectrum of the analogous non-interlocked thread 28 prepared by standard Fmoc/t-
Bu automated solid phase synthesis. The chemical shift differences observed in the 
spectrum of the rotaxane compared to the thread follow the usual trend (upfield shift) 
but to a lesser extent than seen previously. The signals are indeed less shifted (≤1 
ppm) and this seems consistent with the fact that the structure is much less 
constrained than in earlier examples. The peptide backbone consists of multiple 
adjacent binding sites of similar affinities (each one being two consecutive carbonyls 
in a transoid conformation): the macrocycle is then able to ‘travel’ freely from one 
end of the thread to the other, spending an approximately equal amount of time over 
each fragment of the thread. The sharp signal given by the protons HE of the 












In conclusion, an efficient and versatile methodology for assembling interlocked 
molecular architectures where the thread is made entirely out of proteinogenic amino 
acids has been described. These architectures are, to best of our knowledge, the first 
examples of synthetic rotaxanes were the thread is entirely made of fully deprotected 
proteinogenic amino acids.  
The C-elongation method described is readily accessible from commercial 2,6-
diphenyl-para-nitrophenol whereas N-elongation simply requires a protected side 
chain amino acid. The majority of proteinogenic amino acids are suitable for this 
task, since most of them contain a heteroatom of some sort on their side chain that 
can be substituted with a temporary blocking group. The synthesis of short peptide 
rotaxane building blocks requires a certain level of pre-organization in the template, 
but a combination of side chain protected amino acids and two consecutive amino 
acids of moderate bulkiness are the only prerequisites for the synthesis of such 
architectures.  
 
Scheme 4.11. A potential C-elongation strategy for improved coupling efficiency and milder reaction 
conditions.  
 
Future work could be to consider an alternative to the somewhat high temperatures 
required to ‘turn on’ the active ester for C-elongation. An intramolecular acyl-
transfer, in a similar way as Danishefsky has recently described, could be a viable 
option.29 In this ingenious system, resembling native chemical ligation, an S-
protected mercaptophenol ester substituted at the 4-position by the fragment to be 
ligated is ‘turned on’ for coupling when the thiol is deprotected. Deprotection 
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triggers S → O acyl transfer, transforming the phenol ester into a thioester, which is 
a much better leaving group than the former. Subsequent N → S acyl transfer 
terminates the coupling sequence. Using a similar idea, a bulky nitromercaptophenol 
could serve the purpose of elongating rotaxane building blocks with longer 
sequences at significantly lower temperatures (Scheme 4.11). 
 
4.4 Experimental section  
4.4.1 General methods 
 
General method A: Formation of 2-6 diphenyl-p-nitrophenol esters 
To a solution of carboxylic acid (3.2 mmol, 1.0 equiv.), NEt3 (48 mmol, 15.0 equiv.) 
and BOP (4.8 mmol, 1.5 equiv.) in CHCl3 (70 mL), was added 2-6 diphenyl-p-
nitrophenol (16 mmol, 5.0 equiv.). The reaction mixture was stirred for 4 hours at 
room temperature. An aqueous solution (1M) of HCl (50 mL) was added. The layers 
were separated and the aqueous layer was extracted with CH2Cl2 (2 × 40 mL). The 
combined organic fractions were washed with an aqueous saturated solution of 
NaHCO3 (2 × 40 mL), followed by H2O (1 × 50 mL), dried (MgSO4) and 
concentrated under reduced pressure. Purification by flash column chromatography 
on silica gel afforded pure activated ester. 
 
General method B: Benzylic amide rotaxane-forming reaction  
To a vigorously stirred solution of thread (1.91 mmol, 1.0 equiv.) in dry CHCl3 (100 
mL) under nitrogen, was simultaneously added a solution of p-xylylenediamine (15.6 
mmol, 15 equiv.) and NEt3 (39.3 mmol, 30 equiv.) in CHCl3 (50 mL) and a solution 
of isophthaloyl dichloride (15.6 mmol, 15 equiv.) in CHCl3 (50 mL) over a period of 
3 hours using motor-driven syringe pumps. The reaction mixture was stirred for 
another 2 hours, filtered over a Celite® pad and the filtrate was concentrated under 
reduced pressure. The resulting orange solid was purified by flash column 








General method C: C-elongation of 2-6 diphenyl-p-nitrophenol esters 
[2]rotaxanes  
A solution of activated [2]rotaxane (79 µmol, 1 equiv.) and the stoppered nucleophile 
(158-395 µmol, 2 to 5 equiv.) in CHCl3 (20 mL) was heated at reflux for 24-72 
hours. The solvent was removed under reduced pressure and the resulting yellow oil 
was directly purified by flash column chromatography on silica gel to give in order 
of elution 2,6-diphenyl-p-nitrophenol, and the elongated [2]rotaxane. 
 
4.4.2 Characterization of Boc-Leu-enkephalin rotaxane (16) 
 
A solution of 15 ( 17.5 mg, 12.8 mmol, 1 equiv.) and palladium (10%) on carbon (60 
mg) in AcOEt (500 mL) was purged with H2 by means of three vacuum/H2 cycles 
and the mixture was stirred at room temperature for 48 hours. The solid was filtered 
off with Celite® and AcOEt was evaporated under reduced pressure. The resulting 
yellow oil was purified by preparative TLC on silica gel with acetone-CH2Cl2 
(10:90, 3 runs) as eluent to give 16 as a light yellow solid (12 mg, 10.1 µmol, 79%); 
1H-NMR (400 MHz, CDCl3-CD3OD [1:1]): δ = 8.36 (s, 2H, HC), 8.06 (d, 4H, J = 
9.5 Hz, HB), 7.57 (t, 2H, J = 9.1 Hz, HA), 7.28-6.9 (m, 17H, HF, H4, H5, H10, H11, and 
H12), 6.80 (d, 2H, J = 8.2 Hz, H5), 6.65 (d, 2H, J = 8.4 Hz, H4), 4.54-4.03 (m, 9H, 
HE, and H2), 4.28-4.17 (m, 1H, H13), 4.09 (dd, 1H, J = 5.4 Hz, J = 8.8 Hz, H8) 3.18-
3.02 (m, 2H, H3), 3.02-2.83 (m, 4H, H6 and H7), 2.78 (dd, 1H, J = 5.4 Hz, J = 14.0 
Hz, H3’ or H9’), 2.71 (dd, 1H, J = 10.0 Hz, J = 14.0 Hz, H3’ or H9’), 2.50 (dd, 1H, J = 
8.8 Hz, J = 13.8 Hz, H9), 1.45-1.10 (m, 3H, H14 and H15),  0.94-0.70 (m, 6H, H16); 
13C-NMR (100 MHz, CD3OD): δ = 172.5, 172.4, 171.4, 169.1, 168.2, 167.3, 167.2, 
157.6, 155.8, 137.2, 136.8, 136.4, 135.2, 134.0, 133.9, 131.3, 131.22, 130.2, 129.9, 
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58.2, 57.4, 56.4, 48.8, 45.9, 43.5, 42.4, 39.9, 29.0, 23.7, 22.5, 22.3; LRESI-MS: m/z 
= 1188 [M+H]+, ESI-HRMS : m/z = 1205.5677 [M+NH4]+ (calc. for C65H77O13N10 
1205.5666 [M+NH4+). 
 
4.4.3 Experimental procedures for the synthesis of nonapeptide 
rotaxane (27)  
 
 
To a solution of Boc-Gly-Gly-OBn (126 mg, 0.39 mmol, 1 equiv.) in CH2Cl2 (10 
mL) at 0°C was added Trifluoroacetic acid (1.65 mL, 0.22 mol, 45.0 equiv.) drop-
wise. After 30 minutes at 0°C, the solution was stirred a further 1.5 hours at room 
temperature and then cooled to 0°C. After neutralization with a saturated solution of 
NaHCO3, the mixture was extracted with a CHCl3/iPrOH (3/1, v/v) mixture, dried 
and concentrated under reduced pressure to give 17 (34 mg, 0.15 mmol, 39%) as a 
light yellow wax. 1H-NMR (400 MHz, CDCl3): δ = 7.31-7.18 (m, 6H, H2, H5, H6 
and H7), 5.08 (s, 1H, H4), 4.50 (bs, 2H, NH2), 3.95 (s, 2H, H1), 3.24 (bs, 1H, H3); 
13C-NMR (100 MHz, CDCl3): δ = 173.7, 169.4, 134.7, 127.9, 127.8, 127.6, 126.6, 
126.3, 66.5, 66.5, 43.2, 40.3; LRFAB-MS: m/z = 223 [M+H]+ 
 
 
To a solution Fmoc-Ser-OH (200 mg, 0.58 mmol, 1 equiv.), NEt3 (180 µL, 1.29 
mmol, 2.2 equiv.) and HATU (331 mg, 0.87mmol, 1.5 equiv.) in CH2Cl2 (15 mL) at 
0°C, was added 17 (193 mg, 0.87 mmol, 1.5 equiv.). The reaction mixture was left to 
warm up to room temperature and stirred overnight. An aqueous solution (1M) of 
HCl (15 mL) was added, the layers were separated and the aqueous layer was 
extracted with CHCl3 (3 × 15 mL). The combined organic fractions were washed 
with an aqueous saturated solution of NaHCO3 (2 × 20 mL) followed by H2O (1 × 40 
mL), dried (MgSO4) and concentrated under reduced pressure. The resulting brown 
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MeOH (98:2 to 92:8) as eluent to afford pure 18 as a white solid (145 mg, 0.27 
mmol, 47%). M.p. 130-133°C; [α]D -4.4 (c 0.05 in CHCl3); 1H-NMR (400 MHz, 
CDCl3): δ = 7.73 (d, 2H, J = 7.6 Hz, H1), 7.57-7.24 (m, 13H, H2, H3, H4, H10, H12, 
H15, H16 and H17), 6.12 (d, 1H, J = 6.4 Hz, H7), 5.12 (s, 2H, H14), 4.38 (d, 2H, J = 7.0 
Hz, H6), 4.33-4.26 (m, 1H, H8), 4.16 (t, 1H, J = 7.0 Hz, H5), 4.05-3.91 (m, 5H, H9, 
H11 and H13), 3.70-3.63 (m, 1H, H9’), 2.04-1.93 (m, 1H,); 13C-NMR (100 MHz, 
CDCl3): δ = 170.9, 170.1, 169.5, 158.0, 143.6, 141.3, 134.8, 128.6, 128.6, 128.3, 
127.8, 127.1, 125.0, 120.0, 67.4, 67.2, 62.9, 56.3, 47.0, 43.0, 41.2; LRFAB-MS: m/z 
= 554 [M+Na]+, HRFAB-MS : m/z = 554.19050 [M+Na]+ (calc. for C29H29N3O7Na 
554.19035 [M+H]+).  
 
 
To a solution of 18 (1.89 g, 3.55 mmol, 1 equiv.) and imidazole (609 mg, 8.95 mmol, 
2.5 equiv.) in dry DMF (5 mL) under nitrogen was added TBDPSCl (4.5 mL, 17.58 
mmol, 5 equiv.) and the solution was stirred at room temperature for 24 hour. The 
solvent was evaporated under reduced pressure and the resulting yellow oil was 
purified by flash column chromatography on Silica gel with CH2Cl2-MeOH (98:2) as 
eluent to afford pure 19 as a white solid (2.06 g, 2.67 mmol, 73%); M.p. 153-156°C; 
1H-NMR (400 MHz, CDCl3): δ = 7.76 (d, 2H, J = 7.2 Hz, H1), 7.64-7.23 (m, 21H, 
H2, H3, H4, H11, H12, H13, H19, H20 and H21), 7.05 (bt, 1H, H14 or H16), 6.97 (bt, 1H, 
H14 or H16), 5.63 (d, 1H, J = 6.0 Hz, H7), 5.11 (s, 2H, H18), 4.46-4.35 (m, 2H, Fmoc 
H6), 4.31-4.25 (m, 1H, H8), 4.19 (t, 1H, J = 6.8 Hz, H5), 4.09-3.93 (m, 5H, H9, H15 or 
H17), 3.84 (dd, 1H, J = 5.2 Hz, J = 10.4 Hz, H9’), 1.05 (s, 9H, H10); 13C-NMR (100 
MHz, CDCl3): δ = 169.1, 169.0, 168.2, 157.9, 141.3, 135.5, 135.4, 134.8, 130.1, 
128.6, 128.5, 128.4, 128.0, 127.8, 127.1, 125.1, 124.9, 120.0, 80.0, 68.0, 67.41, 67.2, 
57.1, 56.1, 43.1, 41.2, 26.8; LRFAB-MS: m/z = 770 [M+H]+, HRFAB-MS : m/z = 






































A solution of 19 (2.34 g, 3.04 mmol, 1 equiv.) and palladium (10% wt) on carbon 
(345 mg) in AcOEt (80 mL) was purged with H2 by means of three vacuum/H2 
cycles and the mixture stirred at room temperature for 4 hours. The solid was filtered 
off with Celite® and AcOEt was evaporated under reduced pressure to afford S2 as a 
white solid. (2.06 g, 3.05 mmol, 100%); M.p. 80-83°C; 1H-NMR (400 MHz, 
CDCl3): δ = 7.73 (d, 2H, J = 6.8 Hz, H1), 7.58 (d, 2H, J = 6.8 Hz, H2), 7.42-7.24 (m, 
15H, H3, H4, H11, H12, H13 and H14 or H16), 7.15 (bt, 1H, H14 or H16), 5.71 (d, 1H, J = 
6.4 Hz, H7), 4.39-4.31 (m, 3H, H6 and H8), 4.19-4.11 (m, 2H, H5 and H9), 3.99 (bd, 
2H, H15 or H17), 3.93 (bd, 2H, H15 or H17), 3.82 (dd, 1H, J = 4.8 Hz, J = 9.6 Hz, H9), 
1.02 (s, 9H, H10); 13C-NMR (100 MHz, CDCl3): δ = 172.0, 170.8, 169.5, 156.6, 
143.7, 143.5, 141.2, 135.4, 134.8, 132.4, 130.0, 129.6, 127.9, 127.9, 127.8, 127.7, 
127.1, 126.9, 125.1, 125.0, 120.0, 119.8, 80.1, 67.4, 63.8, 56.6, 46.9, 42.9, 41.2, 
26.7; LRFAB-MS: m/z = 680 [M+H]+, HRFAB-MS : m/z = 680.27965 [M+H]+ 
(calc. for C38H42N3O7Si 680.27921 [M+H]+).  
 
 
Using general method A, carboxylate S2 (2.06 g, 3.04 mmol, 1.0 equiv.), DIPEA 
(530 µL, 3.04 mmol, 1.0 equiv.), 2-6 diphenyl-p-nitrophenol 5 (1.77 g, 6.08 mmol, 
2.0 equiv.) and BOP (2.02 g, 4.56 mmol 1.5 equiv.) in CHCl3 (60 mL) afforded 
crude material which was purified by flash column chromatography on silica gel 
with AcOEt/cyclohexane (1:2 to 1:1) as eluent to give 20 as a yellow solid (1.53 g, 
1.61 mmol, 53%). M.p. 103-105°C; 1H-NMR (400 MHz, CDCl3): δ = 8.24 (s, 2H, 
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H20 and H21) 6.57 (bt, 1H, H14), 6.44 (bt, 1H, H16), 5.37 (d, 1H, J = 5.2 Hz, H7), 4.38 
(dd, 1H, J = 6.4 Hz, J = 10.4 Hz, H6), 4.30 (dd, 1H, J = 6.4 Hz, J = 10.4 Hz, H6’), 
4.18-4.10 (m, 2H, H5 and H8), 4.00 (dd, 1H, J = 4.8 Hz, J = 10.8 Hz, H9), 3.88 (dd, 
1H, J = 5.2 Hz, J = 18.8 Hz, H17), 3.82-3.73 (m, 3H, H14 and H9’) , 3.69 (dd, 1H, J = 
4.8 Hz, J = 18.8 Hz, H17’), 1.03 (s, 9H, H10); 13C NMR (100 MHz, CDCl3): δ = 
171.1, 167.8, 166.9, 157.7, 149.2, 145.9, 143.6, 141.3, 137.4, 135.5, 135.4, 135.2, 
130.1, 128.8, 128.8, 128.7, 128.0, 128.0, 127.9, 127.8, 127.1, 127.0, 125.0, 124.9, 
124.8, 120.0, 80.7, 67.2, 63.3, 56.9, 47.0, 42.8, 40.8, 26.8; FAB-HRMS: m/z = 
953.35770 [M+H]+ (calc. for C56H53N4O9Si 953.35818 [M+H]+).  
 
 
Using general method B, thread 20 (495 mg, 0.52 mmol, 1.0 equiv.), p-
xylylenediamine (1.135 g, 8.35 mmol, 15 equiv.), isophthaloyl dichloride (1.69 g, 
8.35 mmol, 15 equiv.), NEt3 (2.32 mL, 16.68 mmol, 30.0 equiv.) in CHCl3 (90 mL) 
afforded crude material which was purified by flash column chromatography on 
silica gel with cyclohexane-EtOAc (1:1) and  CHCl3/MeOH (98:2) as eluent to give 
21 as a light yellow solid (108 mg, 0.073 mmol, 14%); M.p. 144°C; [α]D -29.1 (c 
0.01 in CHCl3); 1H NMR (400 MHz, CDCl3): δ = 8.23 (s, 2H, H2, H16), 8.07 (s, 2H, 
HC and HC’), 8.03 (d, 2H, J = HB), 7.96 (d, 2H, J = 7.8 Hz, HB’), 7.77-7.60 (m, 2H, 
HA and HA’), 7.60-7.17 (m, 33H, H1, H2, H9, H10, H11, H12, H17, H18, H19, HD and HD’), 
6.94 (m, 4H, HF and HF’), 6.48 (bs, 1H, H14), 5.22 (d, 1H, J =6.0 Hz,  H5), 4.65 (dd, 
2H, J = 6.0 Hz, J = 13.6 Hz, HE), 4.33 (dd, 2H, J = 4.4 Hz, J = 14.2Hz, HE), 4.24 (dd, 
2H, J = 4.8 Hz, J = 14.2 Hz, HE’), 4.12-4.02 (m, 4H, HE’ and H3), 3.93 (m, 2H, J = 
6.8 Hz, H4), 3.75 (m, 1H, H6), 3.67-3.53 (m, 4H, H13 and H15), 2.90 (bd, 1H, H7), 
2.36 (bd, 1H, H7’), 0.99 (s, 9H, H8); 13C NMR (100 MHz, CDCl3): δ = 169.20, 
168.12, 167.02, 166.86, 166.20, 158.1, 149.1, 146.1, 141.2, 137.4, 137.3, 137.1, 
133.9, 132.4, 132.2, 131.3, 131.2, 130.9, 130.2, 129.2, 128.9, 128.8, 128.7, 128.6, 
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52.4, 47.0, 44.3, 44.1, 42.7, 40.7, 26.7; FAB-HRMS: m/z = 1485.56038 [M+H]+ 
(calc. for C88H81N8O13Si 1485.56924 [M+H]+).  
 
 
Using general method C, activated rotaxane 21 (69 mg, 46.7 µmol, 1.0 equiv.) and 
H-Phe-Leu-OtBu 22 (79 mg, 233 µmol, 5.0 equiv.) in CHCl3 (5 mL) for 24 hours 
afforded crude material which was purified by flash column chromatography on 
silica gel with CH2Cl2-MeOH (98:2 to 10:90) as eluent to give 23 as a white foam 
(74 mg, 46.6 µmol, 98%); 1H NMR (400 MHz, CDCl3): δ = 8.27 (s, 1H, HC), 8.22 
(s, 1H, HC’), 8.02 (d, 2H, J = 7.8 Hz, HB), 7.98 (d, 2H, J = 7.8 Hz, HB’), 7.86 (bt, 2H, 
HD), 7.79 (bt, 2H, HD’), 7.74-7.15 (m, 29 H, H1, H2, H9, H10, H11, H21, H22, H23, H14, 
H16, H18, H24 and HA), 7.10 (s, 4H, HF), 7.09 (s, 4H, HF’), 6.56 (bs, 1H, H12), 5.58 (d, 
1H, J = 6.8 Hz, H5), 4.62-4.43 (m, 5H, HE and H19), 4.38-4.21 (m, 7H, HE‘, H4 and 
H25) , 4.19-3.97 (m, 2H, H6 and H3), 3.80 (dd, 1H, J = 5.6 Hz, J = 10.2 Hz, H7), 3.75 
(dd, 1H, J = 5.2 Hz, J = 10.2 Hz, H7’), 3.25 (dd, 1H, J = 4.8 Hz, J = 16.8 Hz, H13 or 
H15 or H17), 3.17-3.05 (m, 2H, H13 or H15 or H17), 2.99 (dd, 1H, J = 4.0 Hz, J = 16.8 
Hz, H13 or H15 or H17), 2.95-2.89 (m, 2H, H20 and H13 or H15 or H17), 2.84 (dd, 1H, J = 
7.6 Hz, J = 13.6 Hz, H20’), 2.60 (dd, 1H, J = 4.4 Hz, J = 17.2 Hz, H13 or H15 or H17), 
1.50-1.33 (m, 12H, H26, H27 and H29) , 1.00 (s, 9H, H8), 0.81 (d, 3H, J = 5.8 Hz, H28), 
0.78(d, 3H, J = 5.8 Hz, H28’); 13C NMR (100 MHz, CDCl3): δ = 171.5, 170.5, 170.3, 
170.1, 169.2, 168.2, 167.3, 167.2, 143.6, 141.2, 137.3, 136.3, 136.1, 135.4, 134.4, 
134.2, 132.5, 132.4, 131.1, 131.0, 130.1, 129.3, 129.2, 129.0, 128.9, 128.8, 128.7, 
128.6, 128.2, 127.9, 127.8, 127.1, 127.1, 125.7, 125.4, 125.0, 120.0, 82.1, 82.0, 67.3, 
63.2, 56.4, 54.8, 51.7, 46.9, 44.4, 44.2, 42.7, 42.2, 41.8, 41.3, 38.4, 28.0, 26.7, 24.8, 







































































Rotaxane 23 (74 mg, 46.5 µmol, 1 equiv.) was dissolved in 2 mL piperidine/CHCl3 
(1:3) and was stirred at room temperature for 2 hours. The solvent was removed 
under reduced pressure and the crude material was purified by flash column 
chromatography on silica gel with CHCl3-MeOH (96:4) as eluent to give 24 as a 
white foam (50 mg, 36.6 µmol, 78%); 1H NMR (400 MHz, CDCl3): δ = 8.30 (s, 2H, 
HC and HC’), 8.10(d, 2H, J = 8.6 Hz, HB), 8.07 (d, 2H, J = 8.6 Hz, HB’), 7.69-7.57 (m, 
4H, HD and HD’), 7.56-7.13 (m, 19 H, H4, H5, H6, H7, H9, H16, H17, H18, and HA), 7.09 
(s, 8H, HF and HF’), 6.92 (d, 1H, J = 7.2 Hz, H11 or H13 or H19), 6.85 (bt, 1H, H11 or 
H13 or H19), 6.46 (d, 1H, J = 7.6 Hz, H11 or H13 or H19), 4.60-4.42 (m, 5H, HE and 
H14), 4.41-4.25 (m, 5H, HE and H20), 3.72-3.63 (m, 1H, H1), 3.47-3.37 (m, 2H, H8 or 
H10 or H12), 3.36-3.24 (m, 3H, H15, H21 and H8 or H10 or H12), 3.11 (dd, 1H, J = 3.2 
Hz, J = 16.4 Hz, H14), 3.06-2.98 (m, 2H, H2 and H8 or H10 or H12), 2.97-2.84 (m, 2H, 
H8 or H10 or H12), 1.86-1.65 (m, 2H, NH2), 1.58-1.46 (m, 1H, H22), 1.45-1.33 (m, 
11H, H21 and H24), 1.00 (s, 9H, H3), 0.85 (m, 6H, H23); 13C NMR (100 MHz, 
CDCl3): δ = 172.0, 171.6, 170.3, 170.2, 169.9, 168.8, 167.9, 166.8, 137.4, 137.4, 
136.2, 136.1, 135.4, 135.4, 133.9, 132.8, 131.4, 131.3, 130.1, 130.0, 129.3, 129.1, 
129.0, 128.6, 128.5, 127.8, 127.1, 127.0, 124.6, 124.5, 82.1, 82.0, 65.6, 56.4, 54.5, 
51.7, 44.1, 42.5, 42.4, 41.4, 41.2, 38.8, 38.6, 28.0, 26.8, 24.8, 22.5, 22.1; FAB-





























































To a solution of rotaxane 24 (49 mg, 36.0 µmol, 1 equiv.), Boc-Leu-Phe-Gly-OK 25 
(35 mg, 72.1 µmol, 2 equiv.) and NEt3 (11 µL, 79.2 µmol, 2.2 equiv.) in CHCl3 (10 
mL), was added BOP (17 mg, 38 µmol, 1 equiv.) and the reaction mixture was stirred 
overnight at room temperature. The solvent was removed under reduced pressure and 
the crude material was purified by flash column chromatography on silica gel with 
CH3Cl-MeOH (98:2 to 86:14) as eluent to give 26 as a white foam (54 mg, 84%); 
[α]D -89.1 (c 0.009 in CHCl3); 1H NMR (400 MHz, CDCl3): δ = 8.30 (s, 2H, HC   
and HC’), 8.06 (d, 4H, J = 7.2 Hz, HB and HB’), 7.90 (bt, 2H, HD), 7.85 (bt, 2H, HD’), 
7.60-7.00 (m, 32H, H10, H11, H12, H19, H20, H21, H31, H32, H33, HF, HF’, HA, and HA’), 
6.90 (bt, 1H, H15 or H22 or H24 or H26 or H28), 6.79 (d, 1H, J = 7.2 Hz, H15 or H22 or 
H24 or H26 or H28), 6.63 (bd, 1H, H15 or H22 or H24 or H26 or H28), 6.54 (bs, 1H, H15 
or H22 or H24 or H26 or H28), 6.47 (bs, 1H, H15 or H22 or H24 or H26 or H28), 6.13 (d, 
1H, J = 6.8 Hz, H2), 5.92 (d, 1H, J = 8.0 Hz, H13), 4.92 (bd, 1H, H34) 4.76-4.54 (m, 
4H, HE ), 4.50-4.43 (m, 1H, H8), 4.39-4.14 (m, 8H, HE’, H29, H35, H14’, and H16’), 
3.93-3.86 (m, 1H, H3), 3.83-3.78 (m, 1H, H14), 3.74-3.62 (m, 1H, H27’), 3.51-3.14 
(m, 2H, H25), 3.25 (dd, 1H, J = 6.8 Hz, J = 17.2 Hz, H23), 3.20-3.14 (m, 1H, H23’), 
3.10-2.96 (m, 3H, H9, H17’ and H27), 2.89-2.76 (m, 3H, H9’,H17 and H30), 2.65-2.62 
(m, 1H, H9), 1.57-1.47 (m, 1H, H37), 1.43-1.32 (m, 22H, H1, H4, H36, and H3  9), 1.00 
(s, 9H, H18), 0.86-0.75 (m, 6H, H38); 13C NMR (100 MHz, CDCl3): δ = 173.2, 
172.5, 171.7, 171.4, 170.7, 170.4, 170.1, 169.6, 167.8, 167.3, 167.1, 157.4, 137.3, 
137.2, 136.1, 136.0, 135.5, 134.4, 134.1, 132.8, 132.6, 131.2, 131.0, 129.9, 129.3, 
129.2, 129.0, 128.9, 128.8, 128.6, 127.8, 127.3, 127.3, 127.1, 127.0, 125.6, 81.9, 
81.2, 81.0, 55.1, 54.8, 54.6, 54.4, 51.8, 51.6, 44.6, 44.4, 43.9, 42.7, 42.2, 41.3, 41.0, 
40.3, 38.7, 36.7, 28.2, 28.0, 26.8, 24.8, 22.8, 22.5, 22.0, 21.9, 21.6; FAB-HRMS: 























































































Rotaxane 26 (0.019 g, 0.010 mmol) was dissolved in a H2O:TFA (1:9)  solution (5 
mL). The reaction mixture was stirred overnight at room temperature and then 
concentrated under reduced pressure. A solution of Et2O:CHCl3 (3:1) was added 
(5mL), the solid was sonicated for 10 min, filtered and washed with Et2O:CHCl3 
(3:1) (3 × 5 mL) to give 27 as a white solid (0.014 g, 89%); 1H NMR (400 MHz, 
MeOD-d4): δ = 8.40 (s, 2H, HC), 8.05 (m, 4H, HB), 7.61 (t, 2H, J = 7.5 Hz, HA), 
7.41-7.18 (m, 10H, H8, H9, H10, H19, H25, H26 and H27), 7.16 (s, 8H, HF), 4.59-4.49 
(m, 2H, H6 and H23), 4.47-4.39 (bs, 8H, HE), 4.37-4.35 (m, 1H, H1), 4.22 (t, 1H,  J = 
5.6 Hz, H14), 3.91 (dd, 1H, J = 6.9 Hz, J = 9.0 Hz, H29), 3.60 (dd, 1H, J = 5.6 Hz, J = 
11.3 Hz, H15), 3.57 (dd, 1H, J = 5.5 Hz, J = 11.2 Hz, H15’). 3.56-3.20 (m, 8H, H17, 
H19 and H21), 3.09-2.94 (t, 1H, J = 6.0 Hz, H7 and H24), 2.86 (dd, 1H, J = 9.1 Hz, J = 
14.0 Hz, H7’ or H24’), 2.86-2.67 (m, 2H, H12), 2.67 (dd, 1H, J = 10.3 Hz, J = 14.0 Hz, 
H7’ or H24’), 1.67-1.41 (m, 6H, H2, H3, H30 and H31), 0.86-0.77 (m, 12H, H3, H4, H31 
and H32); 13C NMR (100 MHz, MeOD): δ = 175.6, 173.8, 173.5, 172.6, 172.2, 
171.6, 171.1, 170.4, 170.2, 169.3, 169.1, 138.6, 138.6, 138.4, 138.2, 135.6, 135.6, 
131.8, 131.7, 130.4, 130.3, 130.2, 130.1, 129.9, 129.6, 129.5, 128.9, 128.6, 128.0, 
128.0, 127.9, 62.8, 56.8, 56.1, 56.0, 52.7, 52.2, 45.4, 45.3, 45.3, 43.4, 43.2, 42.4, 
41.6, 41.4, 39.2, 38,1, 26.7, 25.9, 25.2, 23.3, 21.9, 21.5; FAB-HRMS: m/z = 











































































The peptide sequence (LFGSGGGFL) was assembled on Fmoc-Leu-Wang resin 
(0.62 mmol/g) via the Fmoc solid-phase peptide synthesis strategy on a 433A 
Applied Biosciences automated peptide synthesizer using Fmoc/tBu strategy, with 
HBTU/HOBt as coupling reagents, DIPEA as a base and NMP as the reaction 
solvent. The coupling sequence was carried out on a 0.1 mmol scale with the 
“Fastmoc” program supplied by the manufacturer, consisting in a single coupling 
followed by capping with an acetic anhydride solution then a deprotection with 20% 
piperidine in NMP. 10-Fold excess was used for protected amino acids and coupling 
reagents and 20-fold excess for DIPEA. Serine was introduced as its t-butyl ether 
Fmoc-Ser(tBu)-OH. 
Peptidylresin was washed with CH2Cl2 and treated with TFA/H2O/PhOH/iPr3SiH 
(88.5:5:5:2.5) for 2h. The crude product was then precipitated by slow addition of the 
supernatant into ice-cold Et2O and washed twice with the same solvent to afford 28 
as a white solid. [α]D -41.8 (c 0.02 in MeOH); 1H NMR (400 MHz, MeOD-d4): δ = 
7.38-7.11 (m, 10H, H8, H9, H10, H19, H25, H26 and H27), 4.68 (dd, 2H,  1H, J = 4.6 Hz, 
J = 9.4 Hz, H6 or H23), 4.68 (dd, 2H,  1H, J = 6.1 Hz, J = 9.2 Hz, H6 or H23), 4.47-
4.38 (m, 2H, H14 and H1 or H29), 4.09-4.66 (m, 1H, H12, H15, H17, H19, H21 and H1 or 
H29), 3.21 (t, 1H, J = 6.0 Hz, H7 or H24), 3.18 (t, 1H, J = 6.2 Hz, H7 or H24), 3.04 (dd, 
1H, J = 9.2 Hz, J = 13.9 Hz, H7’ or H24’), 2.92 (dd, 1H, J = 9.4 Hz, J = 14.0 Hz, H7’ or 
H24’), 1.57-1.55 (m, 6H, H2, H3, H30 and H31), 1.02-0.86 (m, 12H, H3, H4, H31 and 
H32); 13C NMR (100 MHz, MeOD): δ = 173.7, 173.5, 172.4 (2×), 172.2 (2×), 172.0 
(2×), 171.4, 138.4, 138.3, 130.4, 130.3, 129.6, 129.5, 129.5, 128.0, 127.8, 62.7 (2×), 
57.3, 57.1, 56.0, 52.8, 52.4, 43.9, 43.6, 43.3, 41.6, 38.8, 37.8, 26.0, 25.3, 23.4, 23.3, 
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The rotaxanation of peptides has already shown great potential for protecting 
peptides against the action of endogenous peptidases. The ring component of the 
assembly induces remarkable changes in the peptides’ properties. Solubility and 
lipophilicity can be greatly influenced by this encapsulation method. Importantly, it 
has been shown that the activity of the peptide in question is completely inhibited 
when encapsulated within a rotaxane structure. Although theses structures display 
optimal properties to act as peptide drug carriers, future functional devices able to 








































Herein we describe how, in collaboration with the group of Gesson, we combined his 
prodrug approach with the peptide rotaxanes of Leigh, to synthesize nanodevices 
capable of protecting, transporting and releasing an anti-cancer peptide. This device 
consists of an ADEPT (Antibody directed enzyme prodrug therapy) specific prodrug 
of Met-enkephalin (YGGFM), mechanically encapsulated into a Leigh type rotaxane 
assembly. The mechanism of release of the so-called rotaxane propeptide is dictated 
by the action of a specific β-galactosidase enzyme located around cancer cells (via 
Antibody-enzyme conjugates bound to cancer cells) whose action provokes 
hydrolysis and self-immolation of the stopper with immediate disassembly of the 
architecture.   
The device has been successfully synthesized using the C-elongation methodology 
optimized in Chapter 2. β-Galactosidase triggered release has been studied in vivo, 
as well as resistance against endogenous peptidases. Finally its half-life in human 
plasma was measured.  
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5.1 Introduction and background 
5.1.1 Opioids as anti-cancer agents 
 
Opioid peptides, discovered in the mid-1970’s, belong to a small family of peptides 
derived from three different precursor proteins. They are produced in the brain 
periphery and are involved in several physiological processes such as nociception, 
cognition, release of hormones and neurotransmission. However, a few decades ago, 
opioid peptides were also found in a wide variety of human and animal tumours in 
neural and nonneuronal tissues.1,2 These studies suggested that opioid peptides are 
integral components of most tumour cells. Further studies showed that they are 
located in the cytoplasm of tumour cells suggesting that they are either produced or 
sequestered in malignant cells.2 Met-enkephalin is one of these opioid peptides, 
whose sequence varies from Leu-enkephalin by only the last residue, and has been 
studied extensively regarding its anti-tumour properties. Zagon and co-workers have 
identified it as a negative cell growth regulator and termed it OGF (opioid growth 
factor).3 It has been demonstrated that cell proliferation is inhibited when a specific 
receptor located at the nucleus periphery is blocked. The proteomic nature of this 
receptor is distinctly different from classical opioid receptors and has been named 
OGF receptor (OGFr) by Zagon et al.4 Cell replication is interrupted by OGF at the 
G0-G1 phase of the cell cycle and recent studies proved that OGF uses the p16 and 
p21 pathways to restrict cell proliferation.5 
If these recent results showed the great potential of Met-enkephalin as an anti-tumour 
agent, the very few in vivo tests performed to date, with human tumours-implanted 
mice do not seem to follow the same trend as the in vitro experiments.6 The stability 
of the peptide in biological fluids seems to be the main limiting factor,7,8 along with 
cell penetration.9 Several reports have shown conclusively that both Leu and Met-
enkephalin have very short half-lives in both mouse and human plasma.10 The group 
of Horvat has recently brought valuable evidence to light that suggests that cell 
penetration is also likely to be one of these limiting factors, by synthesizing a 
lipophilic analogue showing higher activity than OGF.9  
In the hope of improving its pharmacokinetics, two examples of OGF prodrugs have 
already been reported. The first one proved to be resistant only to aminopeptidases 
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and was rapidly decomposed by endopeptidases in human plasma11 while the second, 
despite having shown good stability in human plasma, has not found any applications 
to date (probably due to its non specific mode of release).12 
 
5.1.2 Prodrugs and anti-cancer therapy 
 
The prodrug strategy is particularly useful in anti-cancer therapy since it represents 
an efficient way to get around the lack of specificity exhibited by anti-tumour agents 
towards tumour cells. In order to minimize side effects, it is important to design anti-
cancer prodrugs in such a way that the active drug is delivered and activated only at 
the tumour site. Additionally, chemical modification of the drug should be performed 
so as to decrease toxicity in its prodrug version to minimize side effects due to non-
specific cell targeting.  
In anti-cancer therapy using prodrugs, three main approaches are possible. In the 
simplest case the prodrug is selectively activated by endogenous enzymes in tumour 
tissues (tumour-activated prodrugs; TAP) (Scheme 5.1a).13,14 To be efficient, this 
method requires that the level of the chosen enzyme is significantly higher in tumour 
tissues that in tumour-free tissues. Several enzymes fulfill this requirement to various 
extents, the most studied belong to three main classes: oxidoreductases, transferases 
and hydrolysases.  
 
Scheme 5.1. Treatment of a tumour over the course of a) TAP, b) ADEPT 
 
The second alternative to achieve local activation of prodrugs is the use of enzyme 
immunoconjugates. In this, strategy termed Antibody-Directed Enzyme Prodrug 
Therapy (ADEPT),14,15 specific antigens expressed in tumour cells are used to target 
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enzymes to the tumour (Scheme 5.1b). A specific antibody-enzyme conjugate that 
binds exclusively to tumour cells is administered to the patient before treatment. 
After the excess of unbound conjugates has left the blood stream (several days) the 
prodrug is administered and selectively activated by the conjugate extracellularly. 
The main advantage of ADEPT is the potential to use prodrugs activated by non-
human enzymes, which are introduced into the body via the Antibody-enzyme 
conjugate. The third strategy (originally designed to circumvent the immunogenic 
issues of ADEPT) utilizes targeted delivery of genetic material encoding for 
prodrug-activating enzymes to tumour cells. This approach can be divided into two 
subclasses termed Gene-directed Enzyme Prodrug Therapy (GDEPT) and Virus-
directed Enzyme Prodrug Therapy (VDEPT).14,16 In the former, the gene is delivered 
via non-viral vectors whereas in the latter method this task is accomplished by viral 
vectors. These two techniques have the advantage of avoiding the immunogenic side 
effects of ADEPT caused by the injection of animal-produced antibody-enzyme 
conjugates. In further contrast to ADEPT, drug activation is performed intracellularly 
and the prodrug must therefore penetrate the cell before activation. 
 
5.1.3 Gesson’s approach to anti-cancer prodrugs 
 
Over the past few decades, the Gesson group have elaborated prodrugs of various 
known anti-cancer drugs that are selectively activated via ADEPT or PMT (Prodrug 
Mono Therapy). The latter method is of the TAP type and relies on abnormally high 
β-glucuronidase activity in the necrotic tissue of solid tumours.17,18 Thus the Poitiers 
group, in collaboration with Hoechst-Marion-Roussel and the group of Monneret, 
have extensively investigated the β-glucuronidase-mediated release of anti-cancer 
drugs, under PMT.18,19  
The mere functionalization of anti-cancer agents by glucuronic acid does not produce 
fast enough rates of cleavage in vitro to expect the dug to be released in sufficient 
amount around the tumour site in vivo.20 Linking the glucuronic acid (called the 
“trigger”) to the drug via a spacer group, which self-immolates once the β-glucosidic 
linkage is hydrolyzed, gives much faster rates of release (Scheme 5.2).21 The 
glucuronide, now more distant from the anti-cancer drug, is better recognized by the 
Chapter five   Met-enkephalin rotaxane propeptide 
 
 136
enzyme. Scheme 5.2 shows Gesson’s most optimized system, which underwent 



















































Scheme 5.2. Gesson’s HMR 1826 prodrug of doxorubicin and its mechanism of release under PMT 
anti-cancer treatment. 
 
Hydrolysis of the glucuronic bond forms the unstable phenolate ion, whose 
elimination, driven by the production of CO2, produces a highly reactive quinone 
methide intermediate, 5. The surrounding water quenches this intermediate very 
quickly, giving rise to the re-aromatized nitrophenol 6. 
5.1.4 The design of a Met-enkephalin rotaxane propeptide for ADEPT 
strategy 
 
As a first step toward the realization of drug carriers, a few systems made from 
interlocked structures that disassemble in the presence of an enzymatic stimulus have 
already been described. Yui et al. first described rotaxane-based carriers where the 
stopper is made out of two consecutive amino acids.23 Under a proteolytic enzymatic 
stimulus, the stopper is hydrolyzed, triggering the release of the constituents of the 
interlocked architecture. Anderson also utilized a proteolytic enzyme to cleave the 
stopper of a cyclodextrin-based rotaxane, although the design and the function of his 
system are fundamentally different from that of Yui.24,25 In a more applied manner, 
Stoddart and Zink reported an enzyme-responsive molecular silica nanocontainer 
capable of carrying drugs.26 Molecules trapped in the pores of silica nanoparticles by 
means of rotaxane-based stalks covalently bound to the nanoparticles, are released 
upon esterase-triggered disassembly of the rotaxane structure.  
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If these systems bring valuable information on how rotaxane-based drug carriers 
should operate, they are still elementary and the aspect of specificity is omitted in the 
design. Proteolytic enzymes and esterases as used by Yui and Stoddart, are by no 
means specific to only one substrate and since they are found in various places in the 
human body, cannot be used to target a precise location in vivo. 
To achieve specificity, the target has to be well known and well studied, and thus in 
the present chapter we describe how (in collaboration with the group of Gesson, 
whose prodrugs have already been shown to be successful in phase-I clinical trials) 
we applied Leigh-type rotaxanes to the specific delivery of Met-enkephalin.  
The previously described elongation method for the synthesis of peptidorotaxanes 
(Chapter 4) was used to build a Met-enkephalin rotaxane carrier, consisting of a 
Gesson-type prodrug of Met-enkephalin, topologically encapsulated within a 
rotaxane structure (termed a Rotaxane propeptide) (Figure 5.1). 
 
 
Figure 5.1. Chemical structure of a Met-enkephalin rotaxane propeptide 
 
In the same way as the Boc-Leu-enkephalin rotaxane, the assembly was stoppered at 
the C-terminus by two consecutive Phe and Met residues. At the N-terminus though, 
‘stoppering’ was ensured by the trigonal arrangement between the trigger-spacer unit 
and the adjacent Tyrosine residue. The operation of this nanodevice should be simple 
and only requires, in theory, a tumour treated under PMT or ADEPT. The β-
glycosidic linkage is cleaved in the presence of the appropriate enzyme, allowing the 
decarboxylation driven elimination to occur. Once the spacer has undergone 
elimination, the whole assembly dissociates, releasing the active peptide (scheme 
5.3). 

































































































Scheme 5.3. Operation of Met-enkephalinephalin rotaxane propeptide.  
 
5.2 Results and discussion 
5.2.1 Design and synthesis 
 
In order to maximize the chances of success we selected Gesson’s most studied 
trigger-spacer combination (Scheme 5.2). We swapped the glucuronic acid trigger 
for a galactose-based trigger to avoid the tricky final deprotection of the acid group 
of the glucuronide.27 This does not affect the system’s applicability to anti-cancer 
treatment, as galactose is compatible with ADEPT. Given the similarity between 
Met-enkephalin and Leu-enkephalin, it was straightforward to adapt the synthesis of 
the Leu-enkephalin rotaxane to our device. The synthesis was carried out in a 
convergent manner, the key step being a C-elongation of the pre-activated rotaxane 
precursor. 
The synthesis of the self-immolative moiety was carried out according to a know 
procedure (Scheme 5.4).28  
 








































Scheme 5.4. Synthesis of the galactose-based trigger-spacer unit. 
 
Commercial acetylated bromogalactose was coupled to commercially available 
aldehyde 7 under Konigs-Knorr conditions and subsequently reduced and activated. 
The activated trigger-spacer unit 10 was reacted with the three amino acid fragment 

























































Scheme 5.5. Synthesis of the rotaxane-forming template fragment 
 
This three amino acid moiety was synthesized from commercial fragments 11 and 
13, using common peptide coupling chemistry and a Boc protection scheme. The C-
terminus of the peptidic fragment was protected with an allyl ester, orthogonal to the 
Boc and acetyl groups, whereas the phenol moiety of the tyrosine residue was 
protected with an acetyl group. Fragment 15 was obtained in good overall yield, and 
stirring it overnight in MeCN in the presence of 10 and pyridine afforded the trigger-
spacer-peptide precursor 16 (Scheme 5.6).  












































































































































































Scheme 5.6. Synthesis of activated rotaxane building block  
 
Activation using BOP chemistry gave similar yields of 17 to those reported in the 
previous chapter.25 Finally, the rotaxane forming-reaction (using the ‘standard’ 16 
fold excess of macrocycle precursors) proceeded in slightly better yield (26%) than 
for the Leu-enkephalin analogue. This shows that the numerous acetyl groups and 
the nitro group in the molecule do not interfere with template recognition and are 
stable towards the excess of para-xylylenediamine. In fact the less bulky acetyl 
group on the tyrosine residue leads to higher yields of rotaxane than does the benzyl 
group previously used (chapter 4). Purification of rotaxane 18 from the starting 
thread was not possible via silica gel flash chromatography, but size exclusion 
chromatography proved to be a good alternative.  
 
The 1H NMR spectrum of rotaxane-activated ester 18 (Figure 5.2) shows the 
interlocked nature of the molecule unambiguously, with most resonances of the 
thread shifted upfield in the rotaxane. According to the chemical shifts of protons H7, 
H8 and H9 of the spacer, the macrocycle has access to the part of the thread beyond 
the tyrosine residue, showing the importance of the orthogonal arrangement of the 
latter with respect to the spacer, in order to effectively stopper the assembly. 





Figure 5.2. 1H NMR spectra (400 MHz, CDCl3, 300K) of a) thread 17, b) Rotaxane propeptide 
activated building block 18. The assignments and colouring of signals correspond to the lettering 
shown in scheme 5.6. 
 
The downfield shift of the amide proton of the glycine residue (H16) is indicative of a 
hydrogen bond to a carbonyl from the macrocycle, confirmed by the high 
multiplicity of the signal for HE (due to the restricted motion of the ring in the NMR 
timesale) and by the large upfield shift of an signal from a glycine residue, 
supposedly H17, indicating that the macrocycle spends most of its time over that 
residue. The molecule is then likely to adopt the conformation shown in scheme 5.6, 
which predominates on the NMR timescale. 
 

































































































































































Scheme 5.7. C-elongation of rotaxane building block 16 by allyl-protected and non-protected Phe-
Met fragments. Protecting group cleavage leads to the rotaxane propeptide. 
  
C-elongation using the allyl-protected dipeptidic residue 19 was rather slow (using 5 
equivalents of dipeptide), but reached an acceptable yield of 66% if left for an 
extended period of time (48 h) (Scheme 5.7, Route A). Surprisingly, cleavage of the 
C-terminal ally group of 21 could not be accomplished due to the gelation effect 
displayed by the molecule: when dissolved in CH2Cl2, THF, DMF or MeCN, 21 
formed a thick gel preventing the cleavage reaction from occurring. Hence, 
elongation was performed using 5 equivalents of the non-protected Phe-Met residue 
20 (Scheme 5.7, Route B), which displayed comparable kinetics to the allyl-
protected analogue 19. Elongated rotaxane 22 was isolated in 40% yield (59 % of 
unreacted 20 recovered from the reaction). The final cleavage of the acetyl groups 
afforded a quantitative amount of rotaxane propeptide 2. Purification by preparative 
HPLC gave 2 in high purity (> 95%).  
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For the purposes of comparison, the non-rotaxane encapsulated propeptide was also 
synthesized, starting from building block 24, obtained earlier from de-allylation of 
16 (Scheme 5.6).  The coupling step of the last two amino acid fragments proved to 
be troublesome, but was not optimized further as the final product could be isolated 


























































































Scheme 5.8. Synthesis of free the propeptide (27) 
 
The 1H NMR spectra of both thread (27) and rotaxane (2) in CD3OD are shown in 
Figure 5.3. Apart from the signals corresponding to the carbohydrate protons (shown 
in black), most of the resonances in the thread are shifted upfield in the rotaxane 
indicating that the macrocycle is able to (and does) move beyond the original 
template. Although the rotaxane Gly-Gly methylene protons H15 and H16 are the most 
shielded, indicating the macrocycle spends most of its time in this region, various 
peptide protons near the C-terminus (e.g. H24) and protons in the nitrophenol spacer 
near the N-terminus are shielded to some extent by the aromatic rings of the 
macrocycle. 
 




Figure 5.3. 1H NMR spectra (400 MHz, CD3OD, 300K) of a) propeptide 27, b) Rotaxane propetide 2. 
The assignments and colouring of signals correspond to the lettering shown in schemes 5.7 and 5.8. 
Residual solvent peaks are shown in grey. 
 
5.2.2 In vitro β-galactosidase triggered release of Met-enkephalin 
 
In order to assess the efficiency of our system, beta galactosidase assays were 
conducted on both the non-rotaxane-protected propeptide and on the rotaxane 
propeptide. Prior to enzymatic cleavage, some basic solubility tests in water were 
carried out with the thread and the rotaxane. HPLC comparison of saturated solution 
of each compound in water with a solution of the same compound of a known 
concentration in DMSO/water, gave a solubility of 2.2 g/L (2.3⋅10-3 mol/L) for 
propeptide 27 and 670 mg/L for rotaxane propeptide 2 (4.6⋅10-4 mol/L). As expected, 
the lypophilic character of the macrocycle is transmitted to the rotaxane, whose 
solubility in water decreases of a few orders of magnitude, being about 10 times less 
soluble in water than the parent thread 2. Although this value is in the lower limit of 
drug administration standards, it is still higher than several commercial drugs.  
To carry out enzymatic tests with β-galactosidase, however, a solution containing 
2.5% DMSO was used in order to reach higher concentrations, allowing us to 
compare the rate of hydrolysis with reported data.29 Thus mixing a solution of thread 
in phosphate buffer/DMSO with a solution of β-galactosidase at 37 °C gave, almost 
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instantly, an intense yellow coloration characteristic of the nitrophenolate spacer 
adduct 6 (Figure 5.4). Pleased by this preliminary result, the course of the hydrolysis 























Observed by LCMS, stable 












Figure 5.4. HPLC traces of hydrolysis of propeptide 27 (left) and rotaxane propeptide 2 (right), with 
E. coli β-galactosidase in 97.5 % phosphate buffer (0.02 M, pH 7.0), 2.5 % DMSO, at 37 °C using 10 
U/µmol of substrate (substrate concentration 0.33 mM): a) references of individual components 2, 4, 6 
and 27, after b) t = 2min., c) t =5 min., d) t =10 min 
 
Hydrolysis of both compounds was carried out at the same concentration and 
temperature and aliquots were withdrawn from the media at the same time intervals. 
Commercial Met-enkephalin and spacer hydrolysis adduct 6 were used as references. 
Cleavage of either the thread or rotaxane propeptide proceeded at almost the same 
rate with complete release of Met-enkephalin after 10 and 15 minutes30 respectively 
and the amount of Met-enkephalin released proved quantitative for both species (by 
HPLC) (Scheme 5.4).  
Interestingly, the starting propeptides are almost totally consumed within two 
minutes after addition of the enzyme, producing the intermediate species 3 and 28 
(characterized by LCMS) (Scheme 5.1 and Figure 5.4),31 demonstrating that 
elimination of CO2 is the rate limiting step. This also gives strong evidence that the 
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macrocycle does not have any negative effects on substrate recognition, since the 
galactose unit is hydrolyzed equally as fast in both thread and rotaxane. However, the 
rate of CO2 elimination is determined by the ability of the carbamate group to adopt a 
perpendicular conformation with respect to the plane of the phenyl ring (assuming 
that the elimination cascade is of the E2 type). This occurs slightly slower in the 
rotaxane, presumably because of the restricted conformational freedom of the thread 
caused by its encapsulation within the macrocycle. 
 
5.2.3 In vitro stability tests  
5.2.3.1 Stability toward pancreatic enzymes  
 
As the main barrier to peptide drug administration is of a proteolytic nature, we were 
interested in placing our rotaxane in contact with a set of relevant enzymes to 
evaluate its potential to increase the pharmacokinetics of the encapsulated peptide. If 
a drug is to be administered orally, several types of proteases will be encountered 
along the metabolic pathway. Careful analysis of specificity of the most common 
pancreatic enzymes revealed that α-chymotrypsin (an endopeptidase) and 
carboxypeptidase A (a metallo-exopeptidase) readily hydrolyze Met-enkephalin.32 
According to previous reports on the digestion of enkephalins,33,34 α-Chymotrypsin 
shows a strong preference for both aromatic residues whereas carboxypeptidase A, 

















α−chymotripsin prefered cleavage sites
Carboxypeptidase A cleavage site  
Scheme 5.9. Selectivity of α-chymotrypsin and carboxypeptidase A towards Met-enkephalin (4) 
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Accordingly, experiments were set up in which the three compounds, Met-
enkephalin (4), non-rotaxane encapsulated propeptide 27 and rotaxane propeptide 2 
were placed in the presence of α-chymotrypsin and carboxypeptidase A. Rates of 
cleavage were analyzed by HPLC (by plotting the absolute area of the peak displayed 
by the starting material) and the amount of enzyme was adjusted in order to be able 
to compare the rates of cleavage of the three species relative to one another. Under 
these conditions (see Experimental section), complete digestion of Met-enkephalin 
with either α-chymotrypsin or carboxypeptidase A occurred in less than 6 hours. 
Free propeptide 27 exhibited slower kinetics with both enzymes but was completely 
hydrolyzed in less than 24 hours. LCMS data carried out on the non-protected 
propeptide was in accordance with the predicted selectivity of the enzymes (Scheme 
5.10).  
Rotaxane propeptide 2 showed an improvement compared to the non-protected 
propeptide with both enzymes, being completely cleaved in less than 48 hours (about 
8 times slower than Metenkephalin), however this improvement (relative to free 
Metenkephalin) is not high enough to be exploited for oral drug administration.35 The 
rate difference observed for all three species proves that the structural change has an 
impact on substrate recognition, but not to the expected extent. The selectivity of 
both enzymes suggests that only the last peptidic bond of the peptide is vulnerable to 
hydrolysis. It is however impossible to conclude on the ability of the macrocycle to 
protect the adjacent bonds since cleavage by α-chymotrypsin could also occur, in 

























































































Scheme 5.10. Carboxypeptidase A and α-chymotrypsin cleavage of rotaxane propeptide 2 and the 
potential fragments (as deduced from LCMS studies on the cleavage of free propeptide 27). 
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Although rotaxane propeptide 2 was expected to show comparable resistance to α-
chymotrypsin as that observed with the (structurally very similar) Boc-Leu-
enkephalin rotaxane (Chapter 3),36 previous work from Anderson demonstrates that 
little structural or positional changes in the rotaxane can affect the recognition by the 
proteolytic enzyme. In a study, they show, that α-chymotrypsin cleavage of a 
rotaxane stoppered by two consecutive amino acids (Arg-Phe) can be either inhibited 
(as with Boc-Leu-enkephalin rotaxane) or even accelerated (compared to enzymatic 
cleavage of the parent thread) depending on the position of the ring on the thread. In 
this example, when the α-cyclodextrin ring is forced (via isomerization of a double 
bond) to reside close to the terminal Arg-Phe residues, cleavage is not observed 
(even though the ring does not sit over these residues). However, when the 
macrocycle has access to the whole thread, hydrolysis is even faster than for the non-
interlocked thread! (see Chapter 3) This effect is believed to be due to activating 
interactions between the ring and the enzyme, and seems to be in accordance with 
Smithrud’s observations on host-guest rotaxanes (see Chapter 3).37 Hence, when the 
ring is not blocked in one location, a rotaxane structure has the ability to rearrange 
dynamically with the ring shuttling along the thread in order to maximize the binding 
free energy of the substrate-enzyme complex and hydrolysis could be favoured. In 
our case, the macrocycle is believed to have sufficient freedom of movement so that 
the above-mentioned phenomenon applies to our system. 
These preliminary assays confirm the necessity of the macrocycle to sit over the 
residues prone to hydrolysis for as long a period of time as possible (See Chapter 3), 
in order for the rotaxane structure to be as efficient as possible for protecting the 
peptide.  
5.2.3.2 Stability in human plasma 
 
Previous results motivated us to investigate on the stability of propeptides toward 
enzymes present in the systemic circulation. Aminopeptidase M and the Angiotensin 
Converting Enzyme (ACE) have both been identified to be responsible for 
enkephalins hydrolysis in human and animal plasma. Hydrolysis studies on Met-
enkephalin revealed that the peptide is cleaved between theTyr-Gly, Gly-Gly by 
Amino peptidase M, and between the Gly-Phe residues by ACE (Scheme 5.11).7,10,38  


















Aminopeptidase M prefered cleavage sites
ACE cleavage site  
Scheme 5.11. Selectivity of Aminopeptidase M and ACE towards Met-enkephalin 
 
Aminopeptidase M requires, by definition,34 a free terminal amine for substrate 
recognition, and should not hydrolyze 2 or 27; conversely, ACE will provide 
information on the ability of the macrocycle to protect the peptide at the Gly-Phe 
linkage.  
To test these assumptions, all three substrates were incubated with either 
Aminopeptidase M or ACE for 50 hours. The quantity of enzyme used was 
arbitrarily chosen in order to measure a half-life time accurately for all species; their 
rates of hydrolysis were measured by HPLC (Figure 5.5 anf 5.6). In both cases, 
rotaxane 2 exhibited very high stability compared to Met-enkephalin. Measured half-
life times were much greater than 60 hours with both Aminopeptidase M and ACE, 
which represents a greater than a 100-fold increase in stability. 
 
Figure 5.5. Enzymatic digestion of (i) rotaxane propeptide 2 (blue circles), (ii) thread 27 (green 
diamonds) and (iii) Met-enkephalin 4 (orange squares) with porcine kidney aminopeptidase M. 
Reactions were carried out at 25 °C in 95 % phosphate buffer (0.05 M, pH 7.2), 5 % DMSO, using 
0.005 U/µmol of substrate. 0.0025 U/µmol of enzyme was added every 12 hours. 39 
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Free propeptide 27 shows reasonable stability under Aminopeptidase M conditions 
as expected, but slow decomposition can still be observed, however.40 In the presence 
of ACE, the resistance of 27 against proteolysis is only slightly higher than Met-
enkephalin, demonstrating that the macrocycle protects the peptide efficiently up to 
the Gly-Phe linkage. 
 
Figure 5.6. Enzymatic digestion of (i) rotaxane propeptide 2 (blue circles), (ii) thread 27 (green 
diamonds) and (iii) Met-enkephalin 4 (orange squares) with rabbit lung angiotensin converting 
enzyme (ACE). Reactions were carried out at 25 °C in 95 % HEPES buffer (0.05 M, pH 8.3), 5 % 
DMSO, 0.3 M NaCl, using 0.8 U/µmol of substrate. 0.4 U/µmol of enzyme was added every 12 hours.  
 
Improved pharmacokinetics could therefore be expected if the rotaxane propeptide 
was to be administered intravenously, since Aminopeptidase M and ACE are the 
only two enzymes responsible for Met-enkephalin breakdown in human plasma. 
 
Although the galactose-nitrophenol unit is believed to be stable for several hours in 
biological fluids when incorporated to prodrug systems, as an ultimate proof of 
stability, our nanodevice was incubated in human plasma as along with species 27 
and 4. 
Hence, commercial human plasma was reconstituted in phosphate buffer and samples 
were incubated at 37°C for several days. Aliquots were withdrawn periodically and 
(after the proteins had been precipitated) the rate of decomposition was measured in 
the same way as described above. The concentration of incubated substrate was 
based on the dose of Met-enkephalin that has been administered to mice during anti-
tumour assays (10 mg/Kg).34 This dose was adjusted to a hypothetical adult human of 
weight 70 Kg, with a blood volume of roughly 5 L, and this quantity was translated 
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to 100 µL sample experiments. 2 and 27 could be monitored easily under these 
conditions, whereas Met-enkephalin 4 did not show a high enough UV-absorbance 
maximum to be monitored at that concentration. The quantity of Met-enkephalin 4 
was thus increased 20-fold, but its rate of decomposition (supposedly diminished by 
this increase) was still much faster than for rotaxane 2 (Figure 5.7).  
 
 
Figure 5.7. Stability of (i) rotaxane propeptide 2 (blue circles), (ii) thread 27 (green diamonds) and 
Met-enkephalin 4 (orange squares) in human plasma, reconstituted from lyophilized powder with 0.01 
M Tris buffer at pH 7.4, at 37 °C.  
 
The half-life time of rotaxane 2 is in the range of highly stable drugs, showing less 
than 10% decomposition after 4 days incubation in human plasma, whereas the non-




From a practical point of view, the synthesis of the first peptide carrier based on 
topological encapsulation has been achieved. Although not optimized yet, the 
synthesis is based on simple and readily available building blocks and could lead to 
rotaxane propeptides on the gram scale without the need for extended purification 
procedures. Preliminary results on β-galactosidase mediated drug release are very 
encouraging, as the rate of peptide release is of the same order of magnitude as that 
already reported in the literature for anti-cancer prodrugs. β-Galactosidic linkage 
cleavage proceeds in a clean manner, with quantitative release of the peptide (by 
Chapter five   Met-enkephalin rotaxane propeptide 
 
 152
HPLC).  Stability studies of the device in human plasma are very promising 
regarding the potential applications of rotaxane propeptides in ADEPT anti-cancer 
treatment strategies. 
On a purely scientific level, this study has provided valuable insight into the 
applicability of mechanical encapsulation to the specific delivery of bioactive 
peptides. The device presented in this Chapter represents a potential breakthrough in 
the way drugs are designed, and further advanced biological assessment would 
hopefully confirm it. 
The studies on proteolytic cleavage have confirmed the hypothesis of Chapter 3. The 
ring is effective at protecting the amino acids over which it spends the most time, but 
the intermittent presence of the ring in proximity to the last two residues is 
insufficient to avoid the formation of a substrate-enzyme complex that leads to 
hydrolysis of the peptidic bond between these last two residues. This issue highlights 
the limitations of the system and, as stated earlier, the elaboration of a carrier device 
where the peptide can be completely concealed by the ring would be a major 
advance. 
 
Scheme 5.12. Proposed synthesis of future nanodevices by successive C- and N-elongation of 
activated rotaxane precursors 
 
Although the synthesis of the first generation rotaxane-encapsulated propeptides 
expounded above has been carried out in a stepwise fashion, the next generation 
could be synthesized in a convergent manner using the successive N and C-
elongation methods developed in Chapter 4. This would allow for late stage 
diversification, and the synthesis of any combination of trigger, spacer and peptide 
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starting from a single building block would be possible (scheme 5.12). Thus, the 
addition of the last two amino acids of the sequence and the trigger-spacer unit at a 
late stage could lead to a library of close analogues for screening with various 
tumour treatments. Furthermore, by varying the trigger unit, a fluorescent version of 
the chosen trigger-spacer-peptide combination could be synthesized for use in 
biological assays (e.g. in vivo distribution). 
 
5.4 Experimental section 
 
E. coli β-Galactosidase enzymatic cleavage  
Enzymatic hydrolysis was carried out with commercial β-galactosidase from 
Escherichia coli E.C. 3.2.1.23 (1000 units/mg protein (biuret), aqueous glycerol 
suspension (1:1), 10 mM Tris buffer salts and 10 mM magnesium chloride, pH 7.3). 
Substrates were incubated at 37°C with the enzyme (10 Units/µmol of substrate) in 
20 mM Phosphate buffer at pH 7.0 containing 2.5% (v/v) DMSO (concentration of 
substrate 0.1 mmol/L). Aliquots (20 µL) were periodically withdrawn from the 
medium and diluted into a solution of TFA (0.1%) in H2O (40 µL). The rate of 
hydrolysis was monitored by analytical HPLC and LCMS. 
 
Enzymatic stability toward α-Chymotrypsin 
Digestions were carried out with commercial α-Chymotrypsin from bovine pancreas 
(59 units/mg, lyophilised powder). Solution of the enzyme in Tris buffer 50 mM, pH 
7.8, containing 10 mM CaCl2, were freshly prepared before use. Substrates were 
incubated at 25°C with the enzyme (5 Units/µmol of substrate) in Tris buffer 50 mM, 
pH 7.8, containing 10 mM CaCl2 and 10% (v/v) MeCN (concentration of substrate 1 
mmol/L). Aliquots (10 µL) were periodically withdrawn from the medium and 
diluted into a solution of TFA (0.1%) in H2O (20 µL). The rate of decomposition was 
measured by plotting the absolute area of the peak of interest against time. 
 
Enzymatic stability toward Carboxypeptidase A 
 
Digestions were carried out with commercial Carboxypeptidase A from bovine 
pancreas (Type II-PMSF treated, 73 units/mg protein, aqueous suspension with 
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toluene added). Substrates were incubated at 25°C with the enzyme (5 Units/µmol of 
substrate) in 20 mM Phosphate buffer at pH 7.0 containing 5% (v/v) DMSO 
(concentration of substrate 0.25 mmol/L). Aliquots (10 µL) were periodically 
withdrawn from the medium and diluted into a solution of TFA (0.1%) in H2O (20 
µL). The rate of decomposition was measured by plotting the absolute area of the 
peak of interest against time. 
 
Enzymatic stability toward Aminopeptidase M 
Digestions were carried out with commercial microsomal Leucine Aminopeptidase 
(Aminopeptidase M), from porcine kidney, type IV-S, E.C. 3.4.11.2 (24 units/mg 
protein (Bradford), suspension in 3.5 M (NH4)2SO4 solution, pH 7.7, containing 10 
mM MgCl2). Substrates were incubated at 25°C (to minimize loss of activity) with 
the enzyme (5.10-3 Units/µmol of substrate) in 50 mM Phosphate buffer at pH 7.2 
containing 5% (v/v) DMSO (concentration of substrate 0.25 mmol/L). Enzyme was 
added to the medium every 12 hours to compensate for loss of activity (2.5.10-3 
Units/µmol of substrate). Aliquots (5 µL) were periodically withdrawn from the 
medium and directly used for analytical HPLC monitoring. The rate of 
decomposition was measured by plotting the absolute area of the peak of interest 
against time. 
 
Enzymatic stability toward Angiotensin Converting Enzyme 
Digestion were carried out with commercial Angiotensin Converting Enzyme from 
rabbit lung (3.92 units/mg protein (modified Warburg-Christian), lyophilized 
powder). The enzyme was kept in a solution of 10 mM potassium phosphate buffer, 
pH 7.0, containing 0.5 M NaCl (Concentration: 1 mg of enzyme/mL) and stored at -
20°C [Stewart, T. A., et al., Human Peptidyl Dipeptidase (Converting Enzyme, 
Kininase II). Meth. Enzymol., 80, 450-460 (1981).]. Substrates were incubated at 
25°C (to minimize loss of activity) with the enzyme (0.8 Units/µmol of substrate) in 
50 mM HEPES buffer at pH 8.3 containing 0.3 M NaCl and 5% (v/v) DMSO 
(concentration of substrate 0.125 mmol/L). Enzyme was added to the medium every 
12 hours to compensate for loss of activity (0.4 Units/µmol of substrate). Aliquots (5 
µL) were periodically withdrawn from the medium and directly used for analytical 
HPLC monitoring. The rate of decomposition was measured by plotting the absolute 
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area of the peak of interest against time. 
 
Stability in human plasma 
Stability in human plasma was carried out with commercial lyophilized human 
plasma reconstituted by dissolving the solid in the appropriate volume of 0.01 M Tris 
buffer at pH 7.4. Substrates were incubated at 37°C in the freshly prepared solution 
(0.150 µmol of substrate/mL). Aliquots (50 µL) were periodically withdrawn from 
the medium, poured into cold MeOH (50 µL) to precipitate the proteins and cooled 
on ice. After 30 min., the sample was centrifuged (17 000 g, 2 min) and the 
supernatant analyzed by analytical HPLC. The rate of decomposition was measured 
by plotting the absolute area of the peak of interest against time. 
 
 
To a solution of 22 (31 mg, 0.019 mmol) in MeOH (5 mL) at 0°C was added drop-
wise a solution of MeONa (10 mg, 0.19 mmol, 10.0 equiv.) in MeOH (3 mL). The 
mixture was stirred for 1 hour at 0°C, neutralized with Amberlite IR-120 and filtered. 
MeOH was then evaporated to afford 2 (29 mg, 0.019 mmol, quant.) as a pale brown 
solid which was then purified by preparative RP-HPLC using a linear gradient (58 to 
80% in 20 min) of MeCN in H2O at a flow rate of 10 mL/min to give rotaxane 1 as a 
pale yellow solid. Purity (HPLC): >95%. M.p. 172-174°C; 1H NMR (400 MHz, 
CD3OD): δ = 8.46 (s, 2H, HC), 8.06 (d, 4H, J = 8.0 Hz, HB), 7.63-7.59 (m, 3H, H9 
and HA), 7.35 (d, 1H, J = 8.8 Hz, H7), 7.23-7.08 (m, 16H, H8, H25, H26, H27 and HF), 
6.82 (d, 2H, J = 8.4 Hz, H22), 6.61 (d, 2H, J = 8.4 Hz, H23), 5.01 (d, 1H, J = 8.0 Hz, 
H1), 4.95-4.73 (m, 2H, H10), 4.56-4.29(m, 10H, H18, H20 and HE), 4.21 (dd, 1H, J = 
9.6 Hz, J = 4.8 Hz, H12), 3.91 (d, 1H, J = 3.2 Hz, H4), 3.85-3.74 (m, 4H, H2, H5 and 
H6), 3.59 (dd, 1H, J = 9.6 Hz, J = 3.2 Hz, H3), 3.15-3.02 (m, 3H, H16 and H24), 2.86 
(dd, 1H, J = 14.0 Hz, J = 5.2 Hz, H21), 2.78-2.64 (m, 3H, H14 and H24), 2.48 (dd, 1H, 
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3H, H30), 1.83-1.72 (m, 1H, H28); 13C NMR (100 MHz, CD3OD): δ = 174.8, 174.2, 
173.9, 170.7, 170.0, 169.2, 169.1, 157.8, 157.1, 156.7, 151.0, 141.5, 138.6, 138.5, 
138.4, 135.6 (x2), 134.1, 132.4, 132.0, 131.4, 130.4, 130.2 (x2), 130.0, 129.6, 129.2, 
128.0, 127.9, 125.3, 125.2, 118.7, 116.2, 102.9, 77.4, 74.9, 72.0, 70.2, 65.8, 62.5, 
57.6, 56.2, 52.8, 45.4, 45.3, 43.2, 42.4, 39.2, 37.9, 31.9, 31.2, 30.8, 15.2; LRFAB-
MS (3-NOBA matrix): m/z 1463 [M+H]+, 1485 [M+Na]+; LRESI-MS: m/z 1463 
[M+H]+; HRESI-MS: m/z 1463.5122 (calcd. for C73H79N10O21S 1463.5136 [M+H+).  
 
 
To a solution of 26 (54 mg, 0.047 mmol, 1 equiv.) in MeOH (7 mL) at 0°C was 
added a solution of MeONa (26 mg, 0.47 mmol, 10.0 equiv.) in MeOH (4 mL) drop-
wise. The mixture was stirred for one hour at 0°C, neutralized with Amberlite IR-
120, filtered. And concentrated under reduced pressure. Purification by flash column 
chromatography on silica gel with CH2Cl2-MeOH (9:1 to 1:1) to afford 27 (38 mg, 
0.041 mmol, 87%) as a pale brown solid which was then re-purified by preparative 
RP-HPLC using a linear gradient (27 to 45% in 15 min) of MeCN  in H2O at a flow 
rate of 10 mL/min to give rotaxane 27 as a white solid. Purity (HPLC): >98%. M.p. 
158-160°C; 1H NMR (400 MHz, CD3OD): δ = 7.76 (bs, 1H, H9), 7.41 (bs, 2H, H7 
and H8), 7.26-7.24 (m, 4H, H25 and H26), 7.19-7.16 (m, 1H, H27), 7.04 (d, 2H, J = 8.0 
Hz, H22), 6.69 (d, 2H, J = 8.0 Hz, H23), 5.08 (d, 1H, J = 7.6 Hz, H1), 5.09-4.94 (m, 
2H, H10), 4.63 (dd, 1H, J = 9.2 Hz, J = 4.4 Hz, H18), 4.30 (m, 2H, H12 and H20), 3.93 
(d, 1H, J = 3.2 Hz, H4), 3.89-3.75 (m, 8H, H2, H5, H6, H14 and H16), 3.63 (dd, 1H, J = 
9.6 Hz, J = 3.2 Hz, H3), 3.21 (dd, 1H, J = 14.4 Hz, J = 4.4 Hz, H24), 3.07 (dd, 1H, J = 
13.6 Hz, J = 5.6 Hz, H21), 2.98 (dd, 1H, J = 14.0 Hz, J = 9.6 Hz, H24), 2.81 (dd, 1H, J 
= 13.6 Hz, J = 9.2 Hz, H21), 2.46 (t, 2H, J = 8.0 Hz, H29), 2.13-2.10 (m, 1H, H28), 
2.03 (s, 3H, H30), 2.00-1.93 (m, 1H, H28); 13C NMR (100 MHz, CD3OD): δ = 177.6, 
175.2, 172.8, 172.2, 171.6, 170.0, 158.4, 157.3, 151.0, 141.7, 138.7, 134.3, 132.6, 
131.4, 130.4, 129.5, 129.1, 127.8, 125.3, 118.8 , 116.3, 102.9, 77.2, 74.8, 72.0, 70.2, 
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953 [M+Na]+; LRESI-MS (negative mode): m/z 929 [M-H]-; HRESI-MS: m/z 
948.3287 (calcd. for C41H54N7O17S 948.3297 [M+NH4]+)  
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The design, synthesis and operation of a model rotaxane peptide carrier are 
described. This novel device, which operates autonomously, has been adapted to 
anti-cancer treatment. Selective targeting of tumour cells is achieved by 
functionalizing of the macrocycle constituent of the device with targeting ligands. 
Release of the hypothetic drug is achieved via enzymatic cleavage of a self-
immolative stopper. Binding of the targeting ligands to their specific receptors 
should trigger endocytosis-mediated internalization of the whole device and 
metabolism by tumour-specific enzymes will release the active peptide into the 
cytoplasm.  
 
Model rotaxane propeptides in which the hypothetic bioactive peptide consists of a di 
or triglycil fragment were synthesized. The self-immolative stopper is a variation of 
Gesson’s HMR 1826 original trigger-spacer unit used in chapter 5, bearing an allyl 
group on the nitrophenol moiety. The latter group is large enough to avoid slippage 
of the macrocycle without the need for an adjacent side chain amino acid (see 
chapter 5). Carbohydrate groups were attached to the macrocycle constituent as a 
model for targeting ligands and to improve aqueous solubility of the molecule. 
Methodology was developed to isolate the corresponding macrocycles, with the aim 
of subjecting them to biological assays. Solubility of rotaxanes and macrocycles 










6.1.1 Ligand targeted therapy 
 
Selectivity is by far the most important aspect of anti-cancer therapy. Under ADEPT 
this aspect is addressed by the use of antibody-enzyme conjugate targeting combined 
with a specific mode of drug release. Although this method has led to some 
encouraging results, it suffers from highly demanding practical procedures. To tackle 
this issue, conceptually similar approaches have been developed alongside ADEPT, 
where the active drug is directly attached to a monoclonal Antibody (mAb), or where 
mAbs are used as single agents.1,2 Here specific targeting is achieved by binding to 
specific antigens, as with ADEPT. 
A somewhat related but simpler approach has recently become popular. The idea is 
to specifically target cancer cells via the binding of a ligand to tumour-associated 
receptors, rather than antigens. These receptors, which are over expressed in cancer 
cells, are numerous and ligands can vary from high to low molecular weight 
compounds depending on the receptor targeted.2,3 Many receptors that bind relatively 
small molecules have been investigated, such as the epidermal growth factor receptor 
(EGFr),4 the folate receptor,5 glucose uptake receptors (GLUTs),6 galectins7 and the 
asialoglycoprotein receptor.8  
Targeting is then accomplished by designing ligand-prodrug conjugates that display 
high affinity for the targeted receptor. This ligand-functionalized prodrug binds to 
the individual receptor and is subsequently internalized via receptor-mediated 
endocytosis or through passive facilitated transport (e.g. in the case of GLUTs). 
Metabolism in the endosomes or lysosomes releases the active drug directly into the 
cytoplasm (scheme 6.1). 




Scheme 6.1. General principle of ligand targeted therapy. Binding of the ligand to the receptor 
triggers endocytosis-mediated internalization. Metabolism in the endosomes or lysosomes releases the 
active drug inside the cell. 
 
6.1.2 Towards ligand targeting rotaxane propeptides 
 
Ligand targeted therapy has a great advantage over anti-cancer therapies that rely on 
antigen targeting in that the drug can be directed to the tumour site without the need 
for sophisticated bioengineering. Attaching a targeting ligand to a prodrug is 
sufficient to convey the drug directly into the malignant cell.  
Therefore, as opposed to the Met-enkephalin rotaxane propeptide (Chapter 5), 
designed solely for ADEPT, a new device based on ligand targeting would have the 
advantage of carrying the drug into the cytoplasm before release. This aspect is of 
capital importance since passive transport of peptides through the cell membrane is 
usually very poor. This is also an opportunity to fully exploit the interlocked nature 
of the carrier device, since now the macrocycle constituent can serve not only to 
protect the peptide against degradation, but also act to target the drug to the desired 
site. Yui and coworkers have already demonstrated that ligand-functionalized 
rotaxanes bind to various receptors,9 for example polyrotaxanes where the 
macrocycle constituents are functionalized by small peptides10 or carbohydrates11 
showed improved binding strength over non-interlocked analogues.  
According to these results, functionalization of our macrocycle with a ligand with 
affinity for the desired target should in theory convey the peptide directly into cancer 
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cells. The release of the bioactive molecule inside the cell could be realized by 
enzymes specific to cancer cells.12 
A generic device would be designed as in scheme 6.1 where the macrocycle 
constituent is substituted with targeting ligands and the biodegradable stopper would 
be cleaved inside the cell – after receptor mediated-endocytosis – by over-expressed 
enzymes (scheme 6.1).  
 
Figure 6.1. A generic design for an autonomous ligand-targeted peptide carrier. 
 
6.1.3 Design of a model rotaxane carrier for ligand-targeted therapy 
 
The first step toward the development of an autonomous and universal device for 
peptide delivery, as stated in chapter 3, is the creation of a universal type of 
biodegradable stopper. This means that, as opposed to the Met-enkephalin rotaxane 
in Chapter 3, the biodegradable stopper should be able to prevent slipping of the 
macrocycle without the need for an adjacent amino acid side chain. To achieve this 
task, it was a rational choice to build on the already well-established trigger-spacer 
combination of Gesson. While the trigger unit cannot easily be modified without 
interfering with enzyme recognition, the spacer can be decorated with blocking 
groups that will act as stoppers (Figure 6.2).  
As the trigger unit, β-galactosidase was deemed a good choice for an initial model 
compound. Indeed, lysosomal β-galactosidase activity can be exploited for 
intracellular drug release in a ligand-targeted scheme. The enzyme is present in 
several mammalian cells and is over-expressed in a range of tumour cells.13 As with 
ADEPT, the rate of drug release should be as high as possible and this rate will be 
the major parameter which is taken into account when assessing the suitability of 
potential spacers. Such new spacers would allow the use of di- and tri-glycyl 
diphenylethyl stoppered peptides to be used as models (because of their efficient 
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templating ability, see chapter 4) for the assessment of trigger-spacer biodegradation 
properties (Figure 6.2). 
 
Figure 6.2. A model rotaxane peptide carrier. 
 
In the second part of this chapter, a general methodology for the attachment of 
functional groups to the macrocycle constituent of the device will be developed. 
 
To be able to screen the future carrier rotaxanes against a wide range of targets, it is 
desirable to build libraries of devices comprising the same bioactive peptide but 
bearing different sets of targeting ligands. Hence attachment of the functional groups 
has to occur at as late a stage in the synthesis as practically possible. An excellent 
tool to accomplish this task is the so-called ‘click’ concept promulgated by Sharpless 
recently. Compatible with highly functionalized molecules, giving high yields of 
pure product, the ever-popular CuAAC ‘click’ reaction concurrently discovered by 
Meldal and Fokin,14-16 seemed to be the reaction of choice. Already used in the Leigh 
group to attach highly functional groups to the macrocycle constituent of rotaxanes,17 
it seemed straightforward to adapt it to our system (Figure 6.2).  
For a first trial, the groups attached to the rotaxane were chosen in such a way as to 
enhance solubility of the whole device, in addition to providing a model for a 
targeting ligand.  
Knowing that several receptors display high affinity for carbohydrates (Glucose 
uptake transporters (GLUTs), galectins or asialoglycoprotein receptors), and can 
induce endocytosis upon binding (galectins or asialoglycoprotein receptors), it was a 
rational choice to take advantage of their highly hydrophilic character to 
simultaneously ameliorate the solubility of the device in aqueous media. The 
improved binding capacity of carbohydrate-containing polyrotaxanes to lectin 
receptors observed by Yui and co-workers also motivated this choice.9,11 The 
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requirements when designing ligands that bind to these receptors vary considerably 
from one receptor to another. Monosaccharides (for GLUTs),18 high molecular 
weight oligosaccharides19 or saccharide cross-linked polymers.20 could potentially be 
used as ligands. No attempt to design a specific ligand was made here, but emphasis 
was given to enhancing the aqueous solubility of the devices.  
 
6.2 Result and discussion 
6.2.1 Assessment of Gesson’s nitrophenyl-malonaldehyde-based 
system as a self-immolative stopper 
 
In a first attempt to build an autonomus anticancer device, a previously published 
trigger-spacer combination was used, which theoretical models (CPK) showed to be 
bulky enough to stopper a rotaxane assembly (Scheme 6.2).  
 
Scheme 6.2. Design of a nitrophenyl-malonaldehyde-based rotaxane propeptide model and its 
mechanism of drug release. 
 
The trigger consists of the typical carbohydrate unit of Gesson’s systems, whereas 
the spacer consists of a nitrophenyl-malonaldehyde-based unit, whose β-
glucuronidase triggered-elimination is similar to that of the phenol-based spacer used 
in chapter 5. In this case, the trigonal arrangement of the sugar unit and the 
nitrophenyl group (present in the Met-enkephalin rotaxane propeptide via the 
Tyrosine residue) act as a stopper for the structure. Cleavage of the sugar moiety will 
Chapter six   Rotaxane propeptide models  
 
 170
disrupt this arrangement and the macrocycle will slip over that end of the molecule. 
For initial studies, a sample of the imidazole-activated glucuronic acid version of the 
trigger-spacer building block 8 (Scheme 6.4) was provided by the group of Gesson,21 
and was successfully coupled to the glycylglycyl stoppered model peptide 4.  
Synthesis of 4 was carried out using conventional peptide chemistry, under 
‘activated’ (EDCI and DMAP) coupling conditions (Scheme 6.3).  
 
 
Scheme 6.3. Synthesis of model peptide fragment 
 
Although the coupling step did not pose any problem (no risk of epimerization due to 
the presence of exclusively glycines), the final cleavage of the Boc protecting group 
was particularly laborious and 4 was obtained in reasonable purity only after several 
purification steps. Undesired DKP formation, often observed in peptide synthesis 
involving glycylglycine fragments,22 was suspected to dominate the reaction, 
although none of the side products could be indentified. Subsequent coupling of 4 to 
the trigger-spacer group 8 proceeded with good conversion (Scheme 6.4), but 
unfortunately purification of the  product was very difficult. Slow eluting silica gel 
chromatography column afforded thread 9 in sufficient purity to carry out the 
rotaxane formation step under the conditions mentioned previously.  
 
 
Scheme 6.4. Attempted synthesis of model rotaxane propeptide 




The 1H NMR spectrum of the crude mixture revealed good conversion to rotaxane 10 
compared to the thread (~50%), but once again purification was difficult by any 
means attempted (silica gel, alumina or gel permeation chromatography). A 
relatively pure sample of rotaxane was obtained after purification by preparative 
TLC. Even though rotaxane 10 was not fully characterized, 1H NMR analysis 
confirmed its structure. Unfortunately, leaving the sample in CHCl3 over extended 
periods of time (approximatively 24 hours) resulted in high degree of decomposition 
to side products (revealed by 1H NMR), preventing further synthetic steps. 
Qualitative assays later showed that light is the main factor affecting the stability of 
the molecule. Although never observed before (neither in the Met-enkephalin 
rotaxane propeptide nor by Gesson’s research team), this fast rate of decomposition 
was attributed to the highly UV absorbing nitroaromatic unit combined to the 
hydrogen bonding effect of the macrocyclic amides.23 
 
6.2.2 A bis-galactose-based self-immolative stopper 
6.2.2.1 Design and synthesis 
 
Despite synthetic setbacks, this initial trial set up the requirements for the design of 
the next generation propeptide models. Therefore, although the apparently unstable 
nitro group of the spacer could be replaced by a halogen atom,24 substitution with a 
halogen would result in significantly slower elimination of the spacer than with a 
nitro group. However, as the spacer used in the Met-enkephalin rotaxane propeptide 
has proved stable when incorporated into a rotaxane structure, it was jugged sensible 
to develop on that same trigger-spacer core instead, substituting the aromatic ring to 
provide a similar trigonal junction as that in rotaxane 2. A straightforward solution 
provided by the team of Gesson relied on a slightly modified version of this spacer 
where the position para to the nitro group is substituted by a second sugar unit 
(Scheme 6.5). 




Scheme 6.5. Design of a bis-galactose based rotaxane propeptide model and its mechanism of peptide 
release 
 
The advantage of such a system is that only one sugar unit has to be cleaved to allow 
for the quinone methide formation-decarboxylation cascade to occur, and 
dethreading can take place as soon as one sugar unit is cleaved (Scheme 6.5). 
The synthesis of the trigger-spacer group shown, in β-galactose series, in Scheme 6.6 
was based on a similar strategy to the one previously mentioned for Met-enkephalin 
propeptide spacer (Chapter 5). 
 
 
Scheme 6.6. Synthesis of bis-galactose based spacer 
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Starting from commercial aldehyde 15, double Konigs-knorr reaction afforded 
precursor 16 in good yield which, after NaBH4 reduction, furnished the activated 
carbonate 18 ready to be coupled to the peptide fragment.  
Reacting model peptide 4 with the activated trigger-spacer unit 18 in MeCN 
overnight afforded thread 19 in good yield (Scheme 6.7). Rotaxane-forming reaction 
using the standard 16-fold excess of macrocycle precursors gave 21 in 43% yield, 
which was purified from the unreacted thread by gel permeation chromatography. 
Cleavage of the acetyl protecting groups finally afforded model rotaxane propeptide 
11. Precipitation in Et2O gave a sufficiently pure batch of product to attempt 
preliminary enzymatic trials.  
 
Scheme 6.7. Synthesis bis-galactose based rotaxane propeptide model 
 
The 1H NMR spectrum of the acetyl-protected rotaxane 21, together with the 
spectrum of the non-interlocked thread, are shown in Figure 6.3. The spectrum 
shows the characteristic shifts of an interlocked structure. The strong upfield shift of 
the glycine proton signals indicates that the macrocycle predominantly resides over 
the peptide backbone. However, it can readily access the nitrophenyl core of the 
spacer unit, manifested in the upfield shift exhibited by signals of protons H8 and H9. 
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Downfield shift of the signals given by protons H12 and H14 are indicative of 
hydrogen bonding to the macrocycle, which adopts a twisted conformation (Scheme 
6.7). 
 
Figure 6.3. 1H NMR spectra (400 MHz, CDCl3, 300K) of a) propeptide 20, b) Rotaxane propetide 21. 
The assignments and colouring of signals correspond to that shown in Scheme 6.7. Residual solvent 
peaks are shown in grey.  
 
6.2.2.2 In vitro trials 
 
Preliminary enzymatic assessments with β-galactosidase on the rotaxane-
encapsulated model propeptide could, unfortunately, not be carried out in satisfactory 
solubility conditions. Although the presence of two galactose units in the structure 
were expected to greatly enhance solubility in aqueous media, rotaxane 11 showed 
very poor solubility in purely aqueous buffer. This trend was found to be only 
slightly improved in a 1:1 mixture of phosphate buffer/DMSO. In these dilute and 
very high DMSO-content solutions, almost no cleavage could be observed in the 
presence of β-galactosidase, even using a very high enzyme/substrate ratio.  
Nevertheless, hydrolysis studies on the non-rotaxane protected thread 20 has enabled 
the evaluation of the new trigger-spacer group. It, indeed, exhibited higher solubility 
than its interlocked analogue, and β-galactosidase assays could be carried out under 
satisfactory dilution conditions. 
It was therefore surprising to find that when thread 20 is in the presence of the 
enzyme, the cleavage of the galactose trigger was rather messy, although some 
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peptide is released. A chromatogram of the enzymatic hydrolysis of thread 20 after 
45 minutes is shown in Figure 6.4. 
 
 
Figure 6.4. HPLC traces of hydrolysis of propeptide 20, with E. coli β-galactosidase in phosphate 
buffer (0.02 M, pH 7.0), at 37 °C using 80 U/µmol of substrate (substrate concentration 0.5 mM): a) 
references of individual components 4 and 20, after b) t = 45 min., The peaks coloured in green are 
those observed when the chromatogram is recorded at 420 nm.  
 
As well as peaks due to the released peptide and remaining starting material several 
additional peaks were observed, in contrast to the only-expected spacer elimination 
adduct 14 (Scheme 6.5). Identification of 14 failed using several methods. In order to 
produce a reference, synthesis of 14 was attempted by reduction of commercial 
aldehyde 15. The use of either NaBH4 or LiAlH4 as reducing agents led to 
decomposition of starting material, unfortunately.  
Nevertheless, some valuable information could be drawn from the chromatogram 
recorded at 420 nm, the wavelength where the nitrophenol core exhibits a 
characteristic absorption (giving an intense yellow colour). At this wavelength, only 
the compounds containing the nitrophenol core are expected to appear. Surprisingly, 
most of the peaks of the by-products detected at 254 nm appeared in the trace 
recorded at 420 nm (shown in green in the chromatogram recorded at 254 nm, Figure 
6.4b), meaning that these compounds very likely have the nitrophenol group in their 
structure. 
To gain a better understanding of how these by-products are formed, LCMS was 
carried out using the electrospray ionization technique. Unfortunately, both positive 
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and negative ionization mode gave only the ion peak of one species (Figure 6.4b) and 
the expected elimination adduct 14 could not be identified.25 The peak at Rt = 32 min 
([M+H]+ = 478) corresponding to compound 23 (Figure 6.4b), which is the product 
of nucleophilic attack of the released peptide on the quinone methide intermediate 13 























Scheme 6.8. Reaction of quinone methide 13 and its tautomer with nucleophiles. 
 
With these data in hand, it was possible to rationalize the production of side products 
during enzymatic cleavage by the attack of nucleophiles (other than water) on the 
quinone methide intermediate 13. Indeed, a recent study26 shows that quinone 
methides substituted with electron-donating groups are much less reactive than those 
unsubstituted or substituted with electon-withdrawing groups. Thus, the presence of 
the extra donating OH group in intermediate 13 presumably renders it less reactive 
than its analogue 24 (produced in the study of chapter 5, Scheme 6.8). The kinetics 
of the reaction of 13 with the surrounding water to produce 14 will be inherently 
slower. Nucleophilic attack on the Michael acceptor by stronger nucleophiles present 
in solution will then be favourable (confirmed by the presence of 23, figure 6.4). The 
side products observed can thus derive from oligomerization of 13, for example, or 
from attack of some nucleophilic residues of the enzyme.27 Carrying out the 
enzymatic hydrolysis in varying concentrations confirmed this hypothesis as the 
degree of side product produced increased with substrate concentration. Diluting the 
reaction medium led to less side products but extended reaction times, and the 
conditions in Figure 6.4 were found to be optimum, although reaction did not reach 
completion after several hours and many side products were detected. Unfortunately 
even under these optimized conditions the behaviour of this new trigger-spacer 
combination is very far from reaching the minimum standard for targeted drug 
release and had to be abandoned. 
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While looking for new alternatives of self-immolative spacers, an intriguing side 
product was produced from the allyl-protection reaction leading to 25 (Scheme 6.9). 
What was found to be the product of a Claisen rearrangement, 26, showed to our 
surprise that, in combination with a sugar unit would act as suitable stopper (by CPK 
models). Although substitution of the position ortho to the phenoxy group can, in 
some cases, be detrimental to substrate recognition by the enzyme, it is likely that an 
allyl group would have only a minor effect.  
Optimization of the Claisen rearrangement led to a good yield of allyl-substituted 
precursor from allyl-protected nitrophenol 25 (Scheme 6.9). Coupling with 
peracetylated bromogalactose afforded – after NaBH4 reduction, and subsequent 
activation – the trigger-spacer, ready to couple to the model peptide.  
 
 
Scheme 6.9. Synthesis and activation of the Trigger-spacer unit 
 
To be able to produce a large quantity of peptide, the low yielding synthesis of the 
glycylglycyl model 4 was abandoned in favour of synthesis of the tripeptidic 
analogue 34, using a CbZ protecting group scheme. The potential formation of DKP 
adducts is now avoided and final deprotection using H2 over Pd/C afforded pure 34 
in good overall yield (Scheme 6.10).   




Scheme 6.10. Synthesis of model peptide drug 
 
The assembly of the rotaxane propeptide was carried out under previously described 
conditions. Scheme 6.11 shows the synthesis of rotaxane 38, together with its 
corresponding thread, necessary for enzymatic comparative studies. Final rotaxane 
and thread were purified by preparative RP-HPLC.  
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6.2.3.2 In vitro β-galactosidase assays 
 
Preparative HPLC afforded thread 36 and rotaxane 38 in high enough purity to 
subject them to β-galactosidase assays. The mechanism of peptide release is shown 
in Scheme 6.12.  
 
Scheme 6.12. Mechanism of peptide release 
 
Again, rotaxane 38 displayed very poor solubility in purely aqueous media (Table 
6.1) and a high volume of DMSO was necessary to solubilize it in a phosphate buffer 
solution. As expected, under these conditions, the assay did not give any meaningful 
results. 
Nevertheless, thread 36 was sufficiently soluble in a 9:1 mixture of phosphate 
buffer/DMSO and enzymatic hydrolysis was found to reach an acceptable rate using 
a 10 fold excess of enzyme compared to that used with the Met-enkephalin rotaxane 
studied previously. As shown in Figure 6.5, peptide release reached completion after 
1 h 30 min and was achieved in quantitative yield (measured by HPLC).  




Figure 6.5. HPLC traces of hydrolysis of propeptide 36, with E. coli β-galactosidase in 90 % 
phosphate buffer (0.02 M, pH 7.0), 10 % DMSO, at 37 °C using 100 U/µmol of substrate (substrate 
concentration 0.2 mM): a) references of individual components 34, 36 and 41, after b) t = 1 h, c) 1 h 
30 min.28  
 
It is worthy to note that the intermediate arising from hydrolysis of the sugar before 
the spacer undergoes elimination (39, Scheme 6.12) is observed here as well (Figure 
6.5). Interestingly, contrary to the Met-enkephalin rotaxane propeptide, the ratio 
between intermediate 39 and propeptide 36 appears to be much less significant29 and, 
more importantly, as opposed to Met-enkephalin rotaxane propeptide, the starting 
thread 36 is not totally consumed before intermediate 39 is consumed. Hence, in this 
case, the limiting step is not the elimination of the spacer but the hydrolysis of the 
carbohydrate unit by the enzyme (see chapter 5). This is in accordance with the 
expected weaker affinity of β-galactosidase for this new galactose-allylnitrophenol 
unit (due to substitution at the ortho position). Overall, even though it exhibits 
slower hydrolysis kinetics, the allyl-based spacer was jugged to be a good starting 
point for the assessment of the enzymatic cleavage of rotaxane propeptide models 
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6.2.4 Funtionalization of the macrocycle with glucose-based groups 
 
To be able to enhance solubility of the rotaxane propeptide and at the same time 
produce a model for ligand-targeted therapy, it was decided, as a first step, to attach 
two glucose groups to the macrocycle constituent. To assess the effect of this on 
solubility, two different rotaxanes were synthesized in which the glucose groups 
were linked to the structure either directly or via an intercalating tetraethyleneglycol 
(TEG) group. A third rotaxane, functionalized solely by the TEG linker, was also 
synthesized in order to determine the influence of this linker on the solubility of the 
rotaxane (Scheme 6.13).  
To link the glucose groups to the macrocycle, the popular concept of ‘click’ 
chemistry30 was found to be the perfect tool to obtain high yields of pure products. 
The highly tolerant and high yielding ‘click’ CuAAC (Copper-catalyzed Alkyne-
Azide Cycloaddition) reaction – popularized by Meldal and Fokin14,15 – allows for 
very late stage diversification starting from an easy to prepare azide-functionalized 
rotaxane. Following precedent from the Leigh group,17 a rotaxane, 42, bearing a bis-
azide functionalized macrocycle was synthesized from 5-azidoisophthaloyl 
dichloride and para-xylylenediamine (Scheme 6.13). The yield was surprisingly 
high, and, more interestingly, purification by ordinary silica gel flash 
chromatography was possible without the need to carry out an additional gel 
permeation chromatography purification step. The reaction could be easily scaled up, 
and a large batch of rotaxane 42 allowed for CuAAC reaction trials.  
 




Scheme 6.13. Synthesis of functionalized rotaxane propeptide models. 
 
Meanwhile, the three alkyne fragments were prepared. The synthesis was based on 
well-known chemistry, starting from cheap, commercially available starting 
materials (Scheme 6.14). The alkyne functionality was introduced by linking of a 
propargyl unit. Following literature procedures,31 propargyl alcohol was coupled to 
peracetylated β-glucose 44, to yield fragment 45. TEG was desymmetrized using 
propargyl bromide, affording fragment 46,32 which was used to prepare the mixed 
TEG-glucose derivative 47.  The glucose units were left protected for the CuAAC 
reaction and were deprotected, together with the galactose from the thread, at the 
very last step. 
 




Scheme 6.14.  Synthesis of hydrophilic targeting ligand models 
 
The CuAAC reaction trials were primarily performed using procedures described by 
the Leigh group.17,33 Stirring a mixture of rotaxane 42 with alkyne 45, 46 or 47 in the 
presence of a catalytic amount of copper salt and Et3N in dry CH2Cl2 overnight 
afforded the desired product in apparent good conversion (seen by NMR analysis of 
the reaction mixture) (Scheme 6.13). However, upon purification by flash 
chromatography, the yield dropped considerably (<35%, for all three rotaxanes). In 
each case, purification proved very difficult due to a co-eluting spot of very similar 
RF value to that of the product. Reaction conditions were modified in an attempt to 
circumvent this purification issue. Adding TBTA 34,35 to the reaction mixture did not 
show any notable improvement and carrying out the reaction under Fokin’s original 
conditions15 failed to produce any product presumably due to poor solubility of the 
substrates in the aqueous-based solvent mixture.  
Examination of the reaction of rotaxane 42 with fragment 47, after extensive 
purification by preparative TLC, revealed that pure product could be isolated in 70% 
yield. Isolation and 1H NMR analysis of the side product suggested a compound 
similar to 43c, however its exact structure could not be elucidated. A mono-
substituted adduct was, however, ruled out by mass spectrometry. 
According to the latter result, it then appears that the low isolated yields obtained for 
43a and 43b were as well due to purification issues. Side products are presumably 
formed by Cu(II)-promoted side reactions and screening of different Cu(I) stabilizing 
ligands would allow for the reaction conditions to be optimized. However, this work 
is not described here.  
The synthesis of model rotaxane propeptides was completed by the acetyl-
deprotection of the carbohydrate units, which proceeded smoothly in MeONa/MeOH 
(Scheme 6.15).  
 




Scheme 6.15. Final cleavage of the acetyl protecting groups 
 
6.2.5 Isolation of macrocycles via rotaxane synthesis followed by 
controlled dethreading 
 
One issue that arises from the release of the peptide in vivo, is that of the fate of the 
remaining components of the rotaxane, released concomitantly. If the biological 
activity of the peptide is supposed to be known, the toxicity and metabolism of the 
spacer adduct and of the macrocycle would have to be studied additionally. To do so, 
it is necessary to develop a general method to isolate the macrocycle constituent of 
the rotaxanes synthesized. 	  
The release of the macrocycle alongside the peptide could also be exploited for the 
delivery of an additional bioactive compound to the same target. Thus, 
functionalization of the macrocycle with bioactive compounds would give one more 
function to the macrocycle, aside from protecting the peptide, targeting it and 
improving the solubility of the rotaxane.36 This functionalization will not be 
discussed here, but the isolation of the free macrocycles synthesized as part of our 
rotaxane propeptide models will be described. Their solubility in aqueous media will 
be measured. 
As previously reported, the synthesis of benzylic amide macrocycles via the direct 
condensation of the corresponding diacyl chlorides and para-xylylenediamine leads 
predominantly to [2]catenanes.37 The isolation of the macrocycle was, however, 
proved possible by hydrolysis of an ester-stoppered rotaxane.38 Similarly, using the 
more efficient fumaramide template and the commercially available acid 49, thread 
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50 was synthesized (Scheme 6.16), which, after rotaxane formation and attachment 
of the appropriate hydrophilic groups, could be hydrolyzed to release the 
corresponding macrocycles 53a, 53b and 53c (Scheme 6.16).  
 
 
Scheme 6.16. Synthetic pathway for the isolation of functionalized macrocycles. Groups R and R1 
correspond to those depicted in Schemes 6.13 and 6.15 respectively. 
 
The hydrolysis step proved to be capricious and did not give good results using 
similar conditions to that reported in the literature.39 The desired products were 
obtained by carrying the reaction out in a concentrated solution of NaOH in a 
mixture of THF/EtOH/H2O over extended periods of time. Free macrocycles were 
isolated with their carbohydrate residues fully deprotected. 53a precipitated out from 
solution and was pure enough, after several washings. 53b and 53c were further 
purified by preparative RP-HPLC.  
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6.2.6 Solubility of rotaxane propeptides 
 
To assess the effect of the hydrophilic groups on the solubility of the rotaxanes and 
the free macrocycles, quantitative solubility measurements in water were carried out. 
A known quantity of each compound was dissolved in a known volume of 
DMSO/X/H2O (X= MeOH, EtOH or MeCN) and the solution was analyzed by 
HPLC. The absolute area of the peak of interest was then compared with the area of 
the peak produced by a saturated solution of the same compound in pure water at 
20°C. The solubility of some of the propeptides synthesized thus far, together with 
that of the free macrocycles is reported in Table 6.1. 
 
Table 6.1. Solubility of rotaxanes propeptide and free propeptides 
 
Compound  Solubility in water (at 20°C, in mol/L) 
Solubility in water (at 
20°C) 
Propeptide 36 8.6 ·10-4 663mg/L 
Rotaxane propeptide 38 3.8 ·10-7 <500ug/L 
Rotaxane propeptide 48a 3.0 · 10-7 555ug/L 
Rotaxane propeptide 48b 6.0 ·10-6 11mg/L 
Rotaxane propeptide 48c 2.2 · 10-2 49.1g/L 
Macrocycle 53a 4.7 · 10-7 <500ug/L 
Macrocycle 53b 1.7 · 10-5 18mg/L 
Macrocycle 53c 1.7 · 10-4 236mg/L 
Met-enkephalin propeptide 2.3 · 10-3 2.2g/L 
Met-enkephalin rotaxane 
propeptide 
4.6 · 10-4 674mg/L 
 
The solubility of the rotaxanes was seen to increase with the flexibility of the 
structure. Surprisingly, rotaxane 48a was almost completely insoluble in water, 
despite containing two polar hydrophilic glucose groups on the macrocycle and one 
galactose on the thread. The flexibility of the less polar TEG groups on rotaxane 48b, 
accounts for its slightly higher solubility (11mg/L). A combination of both flexibility 
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and hydrophylicity is exhibited by rotaxane 48c, which shows an exceptionally high 
solubility (49g/L), compared to rotaxane 48a and 48b. This clearly demonstrates the 
need for both flexibility and hydrophilicity in the molecule.  
The same trend is followed by the free macrocycles, but to a lesser extent. The 
highest solubility is seen for macrocycle 53c (236 mg/L), as expected. Macrocycle 
53b, although not very soluble in water, shows high solubility in a wide range of 
organic solvents. This is not the case for 53a however; even though it contains two 
carbohydrate hydrophilic groups, it displays a similar solubility to that of the original 
non-substituted macrocycle (<500 mg/L).  
 
6.2.7 1H NMR spectra of Ally-nitrophenol-based rotaxane propeptides 
 
The 1H NMR spectra of rotaxanes 37, 42 and 43a-c are shown in scheme 6.6, 
together with the spectrum of the non-interlocked thread 35. They all show the 
common features of interlocked molecules, with the signals of the thread counterpart 
shifted upfield in the rotaxanes. The Glycine residues’ signals are shifted furthest 
upfield, which is evidence for a slight preference of the macrocycle for the peptidic 
fragment over the rest of the molecule (due to the high number of consecutive 
carbonyl groups). The aromatic protons of the spacer, H7, H8 and H11 are 
considerably shielded showing that the macrocycle is accessing this part of the 
thread. All rotaxanes, without exception, have their terminal amide proton, H19, 
shifted downfield which is characteristic of a hydrogen bonded amide. The high 
multiplicity of the splitting due to HE of the macrocycle, is a sign of slow pirouetting. 
This gives strong evidence that H19 is hydrogen bonded to a carbonyl of the 
macrocycle, through a twisted conformation (Scheme 6.11 and 6.13).  
 




Figure 6.6. 1H NMR spectra (400 MHz, CDCl3, 300K) of a) propeptide 35, b) Rotaxane propeptide 
37, c) Rotaxane propeptide 42, d) Rotaxane propeptide 43a, e) Rotaxane propeptide 43b, f) Rotaxane 
propeptide 43c. The assignments and colouring of signals correspond to that shown in Scheme 6.11 
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6.2.8 In vitro β-galactosidase assays 
 
All three rotaxanes were tested for β-galactosidase hydrolysis. The solubility of 48c 
in neat phosphate buffer was optimum and was then used for preliminary trials. 
Unfortunately it was found that with the same substrate/enzyme ratio used for the 
non-interlocked thread, the reaction was very slow and almost not noticeable. 
Increasing the amount of enzyme ten fold (1000 U enzyme/µmol substrate) showed 
clean cleavage and quantitative release of peptide (by HPLC), but the process was 
complete only after 10 hours (Figure 6.7).   
 
 
Figure 6.7. HPLC traces of hydrolysis of propeptide 48c, with E. coli β-galactosidase in phosphate 
buffer (0.02 M, pH 7.0), at 37 °C using 1000 U/µmol of substrate (substrate concentration 0.2 mM): a) 
references of individual components 34, 41, 48c and 53c, after b) t = 2 h, c) 10 h. 
 
Rotaxanes 48a and 48b were very difficult to solubilize under the assay conditions 
even in a solution containing more than 10% DMSO. Turbid solutions of both 
rotaxanes in a  DMSO/phosphate buffer (1:9) solution were used in the same 
concentration conditions as above but, as expected, did not give great results. 
Cleavage of rotaxane 48b did not reach completion even after 24 hours with the 
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same substrate/enzyme ratio as above (Figure 6.8). This slower rate of hydrolysis is 
most probably related to its poor solubility. 
 
 
Figure 6.8. HPLC traces of hydrolysis of propeptide 48b, with E. coli β-galactosidase in 90 % 
phosphate buffer (0.02 M, pH 7.0) and 10% DMSO, at 37 °C using 1000 U/µmol of substrate 
(substrate concentration 0.2 mM): a) references of individual components 34, 41, 48b and 53b, after 
b) t = 8 h, c) 24 h. 
 
Rotaxanes stoppered with the allyl-based spacer exhibited a rate of hydrolysis greater 
than 100 times inferior to that of Met-enkephalin rotaxane. This decrease in rate 
compared to the free propeptide 36 is mainly due to the fact that the macrocycle can 
reach the spacer end of the thread to a considerable extent, interfering with the 




In conclusion, the development of a model for the construction of autonomous 
rotaxane carriers has been successful. It has been demonstrated that the attachment of 
functional groups on the macrocycle constituent of the device at a late stage in the 
synthesis is possible, and a small library of compounds has been prepared.  Although 
the CuAAC reaction did permit the isolation of functionalized rotaxanes in high 
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yields in all cases, optimization of the reaction conditions by the screening of Cu(I) 
stabilization additives would improve this key step. Once optimized, the attachment 
of dendritic polysaccharides could be studied as a practical example of a targeting 
ligand.  
 
Figure 6.9. A new type of spacer in which blocking of the macrocycle is accomplished further away 
from the carbohydrate unit. 
 
Furthermore, the development of peptide carriers solely stoppered by a self-
immolative spacer has proved feasible. Although the rate of hydrolysis is presumably 
too slow to be practically useful in anti-cancer therapy, it has been demonstrated that 
this is partially due to the ortho substitution of the nitrophenol, and to a larger extent 
the fact that the macrocycle is accessing the spacer end of the molecule, interfering 
with enzyme recognition. To remedy this problem, a spacer with a blocking group 
attached further away from the carbohydrate unit may prevent the macrocycle 
accessing the recognition site. A recent example from Shabat, based on a 
hydroxymandelic acid core, where the blocking group is attached to the carbon α to 
the carbamate group, holds great potential for the development of new self-
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6.4 Experimental section 
6.4.1 General methods 
 
β-galactosidase enzymatic cleavage  
Enzymatic galactose hydrolysis was carried out with commercial β-galactosidase 
from Escherichia coli E.C. 3.2.1.23 (1000 units/mg protein (biuret), aqueous glycerol 
suspension (1:1) in 10 mM Tris buffer salts containing 10 mM magnesium chloride, 
pH 7.3). Prodrugs were incubated at 37oC with the enzyme (10-100 Units/0.1 μmol 
of substrate) in 20 mM Phosphate buffer containing 2.5-10% (v/v) DMSO at pH 7.0 
(concentration of substrate 0.2 mmol/L). Aliquots (20 μL) were periodically 
withdrawn from the medium and diluted into a solution of TFA (0.1%) in H2O (40 
μL). Hydrolysis was monitored by analytical HPLC and LCMS. 
 
General method A: Benzylic amide rotaxane formation 
To a vigourously stirred solution of thread (0.462 mmol, 1 equiv.) and NEt3 (16.2 
mmol, 35 equiv.) in 150 mL of dry CHCl3 under nitrogen, was simultaneously added 
a solution of p-xylylenediamine (7.40 mmol, 16 equiv.) in CHCl3 (50 mL) and a 
solution of isophthaloyl dichloride (7.40 mmol, 16 equiv.) in CHCl3 (50 mL) over a 
period of 3 hours using motor-driven syringe pumps. The reaction mixture was 
stirred for a further 2 hours and  filtered over a Celite® pad. The solid was washed 
with CHCl3/MeOH 2 % (3 x 100mL) and the combined filtrates were concentrated 
under reduced pressure.  
 
General method B: CuAAC coupling of model ligands on azide functionalized 
macrocycles 
To a solution of rotaxane (0.035 mmol, 1.0 equiv.), alkyne (0.070 mmol, 2.0 equiv.), 
and [Cu(CH3CN)4](PF6) (0.017 mmol, 0.5 eq) in dry CH2Cl2 (5 mL) and under N2 at 
room temperature was added NEt3 (0.077 mmol, 2.2 equiv.) and the mixture was 
stirred overnight. Air was bubbled through the mixture for 15 minutes then a 
saturated solution of NH4Cl was added (15 mL). The layers were separated and the 
aqueous layer was extracted with CH2Cl2 (1 × 10 mL). The combined organic 
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fractions were washed with a 1M solution of EDTA/K2CO3 (2 × 10 mL) and brine 
(10 mL), then dried (MgSO4) and concentrated under reduced pressure.  
 
General method C: Acetyl groups cleavage 
To a solution of rotaxane or thread (0.025 mmol, 1 equiv.) in MeOH (5 mL) at 0°C 
was added drop-wise a solution of MeONa (0.25 mmol, 10 equiv.) in MeOH (1.5 
mL) and the mixture was stirred for 1 hour at 0°C. The solution was neutralised with 
IRC-50 resin and filtered and the solvent was evaporated under reduced pressure. 




To a solution of tBoc-glycylglycine (2.63 g, 9.1 mmol, 1.0 equiv.), EDCI.HCl (2.09 
g, 10.9 mmol, 1.2 equiv.) and DMAP (1.32 g, 10.9 mmol, 1.2 equiv.) in CH2Cl2 (100 
mL) at room temperature, was added 2,2-diphenylethanamine (1.70 g, 8.6 mmol, 
0.95 equiv.) and the reaction mixture was stirred overnight. An aqueous solution of 
HCl (1M) (150 mL) was added. The layers were separated and the aqueous layer was 
extracted with CH2Cl2 (3 × 50 mL). The combined organic fractions were washed 
with H2O (50mL), dried (MgSO4) and concentrated under reduced pressure. The 
crude solid was dissolved in CH2Cl2 (10 mL) and Et2O (150 mL) was added. The 
resulting white precipitate was sonicated for 5 minutes and filtered by gravity to give 
7 as a white solid (3.59 g, 8.7 mmol, 96%). M.p. 142-144 °C; 1H-NMR (400 MHz, 
CDCl3, 298 K): δ = 7.35 (m, 1H, H2 or H4), 7.260-7.134 (m, 10H, H9, H10 and H11), 
6.98 (m, 1H, H6 ), 5.71 (m, 1H, H2 or H4), 4.152 (t, J = 8.5 Hz, 1H, H8), 3.80 (d, J = 
8.0 Hz, 2H, H7), 3.691 (s, 2H, H3 or H5), 3.634 (s, 2H, H3 or H5), 1.40 (s, 9H, H1); 
13C-NMR (100 MHz, CDCl3, 298 K): δ = 170.4, 168.9 (× 2), 141.6, 128.4, 127.8, 
126.6, 80.2, 50.2, 43.6, 42.3 (× 2), 28.1; LRESI-MS: m/z = 412 [M+H]+; HRESI-
MS : m/z = 412.2230 [M+H]+ (calc. for C23H30O4N3 412.2231 [M+H]+). 
 




Compound 7 (133 mg, 0.43 mmol) was dissolved in a 15% (v/v) solution of TFA in 
CH2Cl2 (15 mL) and the mixture was stirred overnight at room temperature. Solvents 
were evaporated under reduced pressure. To the crude oil was added Et2O (30 mL) 
and the resulting white precipitate was sonicated for 10 minutes and filtered by 
gravity. The solid was re-dissolved in CH2Cl2 (50mL), an aqueous saturated solution 
of NaHCO3 (20 mL) was added, the layers were separated and the aqueous layer was 
extracted with CH2Cl2 (5 × 50 mL). The combined organic fractions were dried 
(MgSO4) and concentrated under reduced pressure to afford pure 4 as a light yellow 
oil (48%). 1H-NMR (400 MHz, CDCl3/CD3OD (3:1), 298 K): δ = 7.31-7.12 (m, 
10H, H5, H6 and H7), 4.26-4.12 (m, 3H, H3 and H1 or H2 ), 3.83 (d, J = 8.0 Hz, 2H, 
H4), 3.72 (s, 2H, H1 or H2); 13C-NMR (100 MHz, CDCl3/CD3OD (3:1), 298 K): δ = 
173.4, 169.8, 142.1, 128.8, 128.2, 127.0, 50.6, 44.1 (× 2), 42.6; LRESI-MS: m/z = 




To a solution of α-D-galactopyranosyl bromide-2,3,4,6-tetraacetate (3.3 g, 8.38 
mmol, 2.1 equiv.) in CH3CN (30 mL) at 0°C was added 2,4-dihydroxy-5-
nitrobenzaldehyde (730 mg, 3.99 mmol, 1 equiv.) and Ag2O (2.3 g, 9.97 mmol, 2.5 
equiv.). The mixture was stirred at room temperature over night, filtered through 
silica, washed with ethyl acetate and concentrated under reduced pressure. 
Purification by flash column chromatography on silica gel with petrol.-EtOAc (1:1 to 
10:11) as eluent gave 16 as a white solid (2.2 g, 2.61 mmol, 65%). M.p. 192-194°C; 
1H NMR (300 MHz, CDCl3): δ = 10.22 (s, 1H, H9), 8.43 (s, 1H, H8), 6.91 (s, 1H, 
H7), 5.44 (d, 1H, J = 7.9 Hz, H1), 5.65-5.28 (m, 6H, H2, H3 and H4), 5.35 (d, 1H, J = 
8.2 Hz, H1), 4.41-4.26 (m, 4H, H5 and H6), 4.05-3.95 (m, 2H, H6), 2.23-1.99 (m, 
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24H, H-Ac); 13C NMR (75 MHz, CDCl3): δ = 186.1, 171.3, 171.1, 170.3 (x2), 
170.2, 170.1, 169.4, 169.3, 161.2, 154.8, 135.7, 126.9, 120.2, 103.4, 99.1, 97.8, 71.2, 
71.0, 70.5, 70.3, 68.0, 67.5, 67.0, 66.9, 61.3, 61.2, 20.8, 20.6 (x2), 20.5; LRFAB-MS 
(3-NOBA matrix): m/z 866.5 [M+Na]+; HRFAB-MS (3-NOBA matrix): m/z 
866.19582 (calcd. for C35H41NO23Na 866.19616 [M+Na]+).  
 
 
To a solution of 16 (2.0 g, 2.37 mmol, 1 equiv.) in CHCl3/iPrOH (16 mL/11 mL) was 
added silica (1.8 g). The mixture was cooled to 0°C and NaBH4 (1.1 g, 12 equiv.) 
was added portion-wise. After 3h at 0°C, the solution was allowed to warm up to 
room temperature and filtered through Celite®. Solvents were evaporated under 
reduced pressure and purification by flash column chromatography on silica gel with 
petrol.-EtOAc (4:6 to 3:7) as eluent gave 17 as a white solid (1.7 g, 1.97 mmol, 
83%). M.p. 124-126°C; [α]D +44.8 (c 0.07 in CHCl3); 1H NMR (300 MHz, 
CDCl3): δ = 7.95 (s, 1H, H8), 6.91 (s, 1H, H7), 5.61-5.48 (m, 4H, H2 and H4), 5.35-
5.31 (m, 2H, H1 and H3), 5.20-5.19 (m, 2H, H1 and H3), 4.64-4.57 (d, 2H, J = 13.9 
Hz, H9), 4.38-4.27 (m, 3H, H5 and H6), 4.20-4.13 (m, 1H, H5), 4.05-3.98 (m, 2H, H6), 
2.62 (bs, 1H, OH), 2.23-2.02 (m, 24H, H-Ac); 13C NMR (75 MHz, CDCl3): δ = 
171.0, 170.8, 170.4, 170.3, 170.2 (x2), 170.0, 169.5, 157.5, 150.4, 135.3, 126.4, 
126.1, 104.9, 100.0, 98.1, 71.1, 71.0, 70.6, 70.3, 68.5, 67.8, 67.0, 66.8, 61.2, 61.1, 




To a solution of 17 (700 mg, 0.83 mmol, 1 equiv.) in CH2Cl2 (15 mL) was added p-
nitrophenyl chloroformiate (370 mg, 1.82 mmol, 2.2 equiv.) and pyridine (170 µL, 
2.5 equiv.) and the reaction mixture was stirred overnight. Water was added, the 
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layers were separated and the aqueous layer was extracted with CH2Cl2 (3 × 15 mL). 
The combined organic fractions were washed with H2O (50mL), dried (MgSO4) and 
concentrated under reduced pressure. Purification by flash column chromatography 
on silica gel with petrol.-EtOAc (7:3 to 65:35) as eluent gave 18 as a white waxy 
solid (803 mg, 0.80 mmol, 96%). 1H NMR (300 MHz, CDCl3): δ 968.29 (d, 2H, J = 
9.2 Hz, H11), 8.07 (s, 1H, H8), 7.43 (d, 2H, J = 9.2 Hz, H10), 6.94 (s, 1H, H7), 5.63- 
5.50 (m, 4H, H2 and H4), 5.36-5.14 (m, 6H, H1, H3 and H9), 4.38-4.22 (m, 4H, H5 
and H6’), 4.07-3.98 (m, 2H, H6), 2.23-2.02 (m, 24H, H-Ac); 13C NMR (75 MHz, 
CDCl3): δ.2171.1, 170.4, 170.3, 170.2, 170.1, 169.7, 169.5, 158.3, 155.5, 152.4, 
151.8, 145.7, 135.0, 128.5, 125.5, 122.0, 118.8, 104.3, 99.5, 98.1, 71.1, 71.0, 70.5, 
70.4, 68.0, 67.7, 67.0, 66.9, 64.6, 61.2, 61.1, 21.0 (x2), 20.8 (x3), 20.7; LRESI-MS: 
m/z 1033.2, 1034.2, 1035.2 [M+Na]+. 
 
 
To a solution of 18 (780 mg, 0.77 mmol, 1 equiv.) in CH3CN (40 mL) was added 
peptide 4 (286 mg, 0.92 mmol, 1.2 equiv.) and Et3N (0.3 mL, 1.92 mmol, 2.5 equiv.) 
and the reaction mixture was stirred for 19 hours. Water was added, the layers were 
separated and the aqueous layer was extracted with EtOAc (3 × 40 mL). The 
combined organic fractions were washed with H2O (50mL), dried (MgSO4) and 
concentrated under reduced pressure. Purification by flash column chromatography 
on silica gel with petrol.-EtOAc (4:6 to 2:8) then CH2Cl2-MeOH (9:1) as eluent gave 
19 as a white waxy solid (699 mg, 0.59 mmol, 77%). M.p. 128-130°C; [α]D +22.3 (c 
1.7·10-2M  in CHCl3); 1H NMR (400 MHz, CDCl3): δ = 7.89 (s, 1H, H8), 7.31-7.18 
(m, 10H, H17, H18 and H19), 7.07 (bt, 1H, J = 4.8 Hz, H14), 6.94 (s, 1H, H7), 6.32 (bt, 
1H, J = 5.6 Hz, H12), 5.75 (bt, 1H, J = 5.2 Hz, H10), 5.57 (dd, 1H, J = 8.0 Hz, J = 10.4 
Hz, H2), 5.51-5.49 (m, 3H, H2 and H4), 5.32-5.30 (m, 3H, H1 and H3), 5.23 (dd, 1H, J 
= 3.2 Hz, J = 10.4 Hz, H3), 5.19 (d, 1H, J = 8.0 Hz, H1), 5.06-4.98 (d, 2H, J = 13.9 
Hz, H9), 4.37-4.26 (m, 3H, H5 and H6), 4.20-4.16 (m, 2H, H5 and H16), 4.09-4.00 (m, 
2H, H6), 3.88 (t, 2H, J = 6.4 Hz, H15), 3.81-3.78 (m, 4H, H11 and H13), 2.22-2.02 (m, 
24H, H-Ac); 13C NMR (100 MHz, CDCl3): δ = 170.9, 170.7, 170.2, 170.1, 170.0, 
Chapter six   Rotaxane propeptide models  
 
 197 
169.9, 169.7, 169.3 (x2), 168.6, 157.2, 156.1, 150.6 , 141.7, 141.6, 135.0, 128.7, 
127.9, 126.8, 126.3, 121.2, 104.9, 99.6, 98.0, 70.9, 70.4, 70.2, 68.1, 67.5, 66.8, 66.7, 
61.0 (x2), 60.7, 50.3, 44.3, 43.7, 43.0, 20.8 (x2), 20.7 (x3), 20.6; LRFAB-MS (3-
NOBA matrix): m/z 1183.7 [M+H]+, 1205.7 [M+Na]+; HRFAB-MS (3-NOBA 
matrix): m/z 1183.37652 (calcd. for C54H63N4O26 1183.37305 [M+H]+)  
 
Using general method A, thread 19 (200 mg, 0.17 mmol, 1 equiv.), p-
xylylenediamine (377 mg, 16 equiv.), isophthaloyl dichloride (563 mg, 16 equiv.) 
and Et3N (0.9 mL, 35 equiv.) in CHCl3 (100 mL) gave crude 21 as an orange solid. 
Purification by flash column chromatography on silica gel with CHCl3-MeOH (99:1 
to 93:7) as eluent gave a mixture of thread 19 and rotaxane 21. This mixture was 
resolved by size exclusion chromatography using CHCl3/MeOH (50/50: v/v) as 
eluent to give rotaxane 21 as a white solid (93 mg, 0.05 mmol, 31%). M.p. 164-
166°C; [α]D +12.9 (c 0.05 in CHCl3) 1H NMR (400 MHz, CDCl3): δ = 8.15 (s, 2H, 
HC), 7.98 (t, 4H, J = 7.6 Hz, HB), 7.64 (t, 2H, J = 4.4 Hz, HD), 7.55 (bs, 3H, H8 and 
HD), 7.46 (t, 2H, J = 8.0 Hz, HA), 7.32 (ls, 1H, H14), 7.23-7.06 (m, 18H, H17, H18, H19 
and HF), 6.91 (s, 1H, H7), 6.49 (bs, 1H, H12), 5.64 (bs, 1H, H10), 5.56 (dd, 1H, J = 8.0 
Hz, J = 10.4 Hz, H2), 5.49 (d, 2H, J = 3.2 Hz, H4), 5.46 (dd, 1H, J = 8.0 Hz, J = 10.4 
Hz, H2), 5.31 (dd, 1H, J = 3.6 Hz, J = 10.4 Hz, H3), 5.23 (dd, 1H, J = 10.4 Hz, J = 3.2 
Hz, H3), 5.21 (t, 2H, J = 8.0 Hz, H1), 4.64 (bs, 2H, H9), 4.54-4.49 (m, 8H, HE), 4.45-
4.27 (m, 3H, H5 and  H6’), 4.19 (t, 1H, J = 6.4 Hz, H5), 4.10-4.00 (m, 3H, H6 and 
H16), 3.71 (t, 2H, J = 6.0 Hz, H15), 3.34 (d, 2H, J = 5.2 Hz, H11), 2.80 (bdd, 2H, J = 
22.4 Hz, J = 17.2 Hz, H13), 2.14-2.02 (m, 24H, H-Ac); 13C NMR (100 MHz, 
CDCl3): δ 170.9, 170.8, 170.1 (x2), 170.0, 169.9, 169.5, 169.5, 169.4, 168.4, 166.9, 
166.8, 157.2, 156.2, 156.1, 150.6, 141.4, 137.3, 137.2, 134.8, 134.0, 133.9, 131.0, 
130.8, 128.9, 128.7, 127.8, 126.9, 126.3, 124.8, 120.8, 105.6, 99.5, 98.2, 77.2, 70.9, 
70.3, 70.1, 68.1, 67.6, 66.8, 61.0, 60.4, 44.3, 44.1, 41.8, 29.6, 20.8 (x2), 20.7, 20.6, 
Chapter six   Rotaxane propeptide models  
 
 198
20.5; LRFAB-MS (3-NOBA matrix): m/z 1716.8 [M+H]+ HRFAB-MS (3-NOBA 
matrix): m/z 1715.57894 (calcd. for C86H91N8O30 1715.58411 [M+H]+).  
 
 
Using general method C, thread 19 (250 mg, 0.21 mmol, 1 equiv.) and MeONa (228 
mg, 4.2 mmol, 20 equiv.) at 0°C in MeOH (12 mL) gave crude 20 as yellow solid. 
Purification by flash column chromatography on silica gel with CH2Cl2-MeOH (8:2 
to 1:1) as eluent gave 20 as a yellow solid (144 mg, 0.17 mmol, 81%). M.p. 135-
137°C; 1H NMR (400 MHz, CDCl3): δ = 7.98 (s, 1H, H8), 7.30-7.15 (m, 11H, H7, 
H17, H18 and H19), 5.18 (m, 2H, H9), 5.14 (d, 1H, J = 8.0 Hz, H1), 5.09 (d, 1H, J = 8.0 
Hz, H1), 4.27 (t, 1H, J = 8.0 Hz, H16), 4.03 (dd, 2H, J = 4.0 Hz, J = 8.0 Hz, H5), 3.91-
3.72 (m, 16H, H2, H4, H6, H11, H13 and H15); 13C NMR (100 MHz, CD3OD): δ = 
172.8, 171.6, 170.4, 160.7, 153.7, 143.8, 134.7, 129.6, 129.2, 127.7, 127.6 , 120.4, 
104.7, 102.3, 102.1, 77.7, 74.9, 74.8, 71.9 (x2), 70.6, 63.1 (x2), 62.2, 51.7, 49.9, 
45.1, 43.4; LRFAB-MS (3-NOBA matrix): m/z 847.1 [M+H]+; 869.1 [M+Na]+ 




Using general method C, rotaxane 21 (43 mg, 0.025 mmol, 1 equiv.) and MeONa 
(27 mg, 0.5 mmol, 20 equiv.) at 0°C in MeOH (5 mL) gave crude 11 as yellow solid. 
Purification by flash column chromatography on silica gel with CH2Cl2-MeOH (9:1 
to 1:1) as eluent gave 11 as a yellow solid (33 mg, 0.022 mmol, 88%). M.p. 
decomposition; 1H NMR (400 MHz, CD3OD): δ = 8.27 (bs, 2H, HC), 8.01 (dd, 4H, 
J = 7.6 Hz, J = 1.6 Hz, HB), 7.62-7.58 (m, 3H, H8 and HA), 7.21-7.12 (m, 15H, H7, 
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H17, H18, H19 and HF), 6.99-6.97 (m, 4H, HF), 5.10 (d, 1H, J = 7.6 Hz, H1), 4.98 (d, 
1H, J = 8.0 Hz, H1), 4.78-4.68 (d, 2H, J = 13.2 Hz, H9), 4.33 (bs, 8H, HE), 4.06-3.80 
(m, 11H, H2, H4, H5, H6, H15 and H16), 3.63 (dd, 1H, J = 9.6 Hz, J = 3.2 Hz, H3), 3.57 
(dd, 1H, J = 9.6 Hz, J = 3.2 Hz, H3), 3.49-3.38 (m, 4H, H6 and H13), 2.78 and 2.65 (d, 
2H, J = 16.4 Hz, H11); 13C NMR (100 MHz, CD3OD): δ 171.9, 170.3, 169.3, 160.4, 
158.3, 153.6, 143.6, 138.6, 135.6, 135.5, 134.0, 131.8, 131.7, 130.1, 129.9, 129.8, 
129.6, 129.0, 127.8, 127.7, 119.6, 104.3, 102.2, 102.1, 77.7, 77.6, 74.9, 74.8, 71.8, 
71.7, 70.6, 70.5, 63.2, 63.1, 61.8, 49.9, 45.3, 45.2, 44.9, 44.8, 42.3; LRESI-MS: m/z 
1401.8, 1402.8, 1403.8 [M+Na]+; LRFAB-MS (3-NOBA matrix): m/z 1402.9 
[M+Na]+ HRFAB-MS (3-NOBA matrix): m/z 1379.50013 (calcd. for C70H75N8O22 
1379.49959 [M+H]+).  
 




3-nitro-4-(2-propenyloxy)benzaldehyde (5.60 g, 27.05 mmol, 1 equiv.) was heated at 
160-165°C over a period of 17 hours. After allowing the mixture to reach room 
temperature, aqueous HCl (1M) (50 mL) and CH2Cl2 (50 mL) were added. The 
layers were separated and the aqueous layer was extracted with CH2Cl2 (3 × 50 mL). 
The combined organic fractions were dried (MgSO4) and concentrated under reduced 
pressure. Purification by flash column chromatography on silica gel with Petrol.-
EtOAc (8:2 to 6:4) as eluent gave 26 as a yellow solid (3.20 g, 15.46 mmol, 57%). 
M.p. 82-84°C; 1H NMR (400 MHz, CDCl3): δ = 11.41 (bs, 1H, OH), 9.91 (s, 1H, 
H6), 8.51 (d, 1H, J = 2.0 Hz, H1), 8.01 (d, 1H, J = 2.0 Hz, H2), 6.03-5.93 (m, 1H, H4), 
5.20-5.18 (m, 1H, H5), 5.16 (dq, 1H, J = 11.2 Hz, J = 1.6 Hz, H5), 3.53 (d, 2H, J = 
6.8 Hz, H3); 13C NMR (100 MHz, CDCl3): δ 189.0, 157.7, 135.8, 134.1, 133.5, 
133.3, 128.4, 126.9, 118.0, 33.7; LRFAB-MS (3-NOBA matrix): m/z 208 [M+H]+  
 




To a solution of 26 (100 mg, 0.48 mmol) in CHCl3/iPrOH (2.4 mL/1.6 mL) was 
added silica (90 mg). The mixture was cooled 0°C and NaBH4 (320 mg, 12 equiv.) 
was added portion wise. After stirring for 1 hour at 0°C, the solution was allowed to 
reach room temperature and filtered over Celite®. Concentration of the filtrate under 
reduced pressure and purification by flash column chromatography on silica gel with 
Petrol.-EtOAc (9:1 to 8:2) as eluent gave 41 as a yellow solid (40 mg, 0.19 mmol, 
40%). M.p. 40-42°C; 1H NMR (400 MHz, CDCl3): δ = 10.92 (bs, 1H, H7), 7.98 (d, 
1H, J = 2.0 Hz, H1), 7.48 (d, 1H, J = 2.0 Hz, H2), 6.03-5.93 (m, 1H, H4), 5.15 (t, 1H, 
J = 1.2 Hz, H5), 5.12 (dq, 1H, J = 6.4 Hz, J = 1.2 Hz, H5), 4.65 (s, 2H, H6), 3.48 (d, 
2H, J = 6.4 Hz, H3), 1.91 (bs, 1H, H8); 13C NMR (100 MHz, CDCl3): δ 152.8, 
136.4, 135.1, 133.3, 132.5, 131.9, 121.2, 117.2, 64.0, 33.9; LRESI-MS (negative): 
m/z 208 [M-H]-  
 
 
To a solution of 26 (570 mg, 2.75 mmol, 1.1 equiv.) in CH3CN (30 mL) at 0°C was 
added α-D-galactopyranosyl bromide-2,3,4,6-tetraacetate (1.03 g, 2.51 mmol, 1 
equiv.) and Ag2O (872 mg, 4.12 mmol, 1.5 equiv.). The mixture was stirred at room 
temperature over night, filtered through silica, washed with ethyl acetate and 
concentrated under reduced pressure. Purification by flash column chromatography 
on silica gel with petrol.-EtOAc (85:15 to 6:4) as eluent gave 27 as a yellow solid 
(1.16 g, 2.16 mmol, 79%). M.p. 78-80°C; [α]D +32.7 (c 0.04 in CHCl3) 1H NMR 
(400 MHz, CDCl3): δ = 9.97 (s, 1H, H12), 8.11 (d, 1H, J = 2.0 Hz, H7), 7.96 (d, 1H, 
J = 2.0 Hz, H8), 5.96-5.86 (m, 1H, H10), 5.48 (dd, 1H, J = 10.4 Hz, J = 7.6 Hz, H2), 
5.37 (d, 1H, J = 2.8 Hz, H4), 5.22-5.14 (m, 2H, H11), 5.05 (dd, 1H, J = 10.4 Hz, J = 
3.2, H3), 4.95 (d, 1H, J = 8.0 Hz, H1), 4.02 (d, 2H, J = 6.8 Hz, H6), 3.81 (dt, 1H, J = 
6.8 Hz, J = 0.8 Hz, H5), 3.58 (dd, 2H, J = 6.4 Hz, J = 1.2 Hz, H9), 2.18 (s, 3H, H-
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Ac), 2.16 (s, 3H, H-Ac), 1.99 (s, 3H, H-Ac), 1.96 (s, 3H, H-Ac); 13C NMR (100 
MHz, CDCl3): δ 189.1, 170.3, 170.2, 170.1, 169.6, 149.6, 145.5, 139.2, 134.7, 
134.6, 133.1, 124.1, 118.3, 102.3, 71.5, 70.6, 68.7, 66.6, 60.8, 34.1, 20.9, 20.8, 20.7, 
20.6; LRFAB-MS (3-NOBA matrix): m/z 538 [M+H]+, 560 [M+Na]+; HRFAB-
MS (3-NOBA matrix): m/z 538.15524 (calcd. for C24H28NO13 538.15607 [M+H]+).  
 
 
To a solution of 27 (700 mg, 1.30 mmol, 1 equiv.) in CHCl3/iPrOH (20 mL/14 mL) 
was added silica (1.0 g). The mixture was cooled 0°C and NaBH4 (594 mg, 15.6 
mmol, 12 equiv.) was added portion wise. After stirring for 1 hour at 0°C, the 
solution was allowed to reach room temperature and filtered over Celite®. 
Concentration of the filtrate under reduced pressure and purification by flash column 
chromatography on silica gel with Petrol.-EtOAc (6:4 to 3:7) as eluent gave 28 as a 
yellow solid (608 mg, 1.13 mmol, 87%). M.p. 110-112°C; [α]D +39.8 (c 0.01 in 
CHCl3) 1H NMR (400 MHz, CDCl3): δ = 7.60 (d, 1H, J = 2.0 Hz, H9), 7.40 (d, 1H, 
J = 1.6 Hz, H11), 5.93-5.83 (m, 1H, H14), 5.45 (dd, 1H, J = 10.4 Hz, J = 8.0 Hz, H2), 
5.35 (d, 1H, J = 2.8 Hz, H4), 5.14 (bs, 1H, H15), 5.11 (dd, 1H, J = 7.2 Hz, J = 1.2 Hz, 
H15), 5.02 (dd, 1H, J = 10.4 Hz, J = 3.6 Hz, H3), 4.82 (d, 1H, J = 8.0 Hz, H1), 4.69 
(bs, 2H, H16), 4.03 (dd, 2H, J = 6.8 Hz, J = 3.6 Hz, H6), 3.77 (t, 1H, J = 6.4 Hz, H5), 
3.50 (t, 2H, J = 4.8 Hz, H13), 2.37 (bs, 1H, H13), 2.18 (s, 3H, H-Ac), 2.15 (s, 3H, H-
Ac), 1.98 (s, 3H, H-Ac), 1.96 (s, 3H, H-Ac); 13C NMR (100 MHz, CDCl3): δ 170.5, 
170.4, 170.2, 169.7, 145.3, 144.4, 139.0, 137.5, 135.6, 132.2, 121.0, 117.4, 102.7, 
71.2, 70.7, 68.7, 66.7, 63.5, 60.8, 34.1, 21.1, 20.9, 20.7, 20.6; LRFAB-MS (3-
NOBA matrix): m/z 538 [M+H]+, 562 [M+Na]+; HRFAB-MS (3-NOBA matrix): 
m/z 562.15284 (calcd. for C24H29NO13Na 562.15366 [M+Na]+).  
 
 




To a solution of 28 (433 mg, 0.80 mmol, 1 equiv.) in CH2Cl2 (15 mL) was added p-
nitrophenyl chloroformiate (356 mg, 1.76 mmol, 2.2 equiv.) and pyridine (160 µL, 
2.0 mmol 2.5 equiv.) and the reaction mixture was stirred for 24 hours at room 
temperature. Water was added, the layers were separated and the aqueous layer was 
extracted with CH2Cl2 (3 × 15 mL). The combined organic fractions were washed 
with H2O (50mL), dried (MgSO4) and concentrated under reduced pressure. 
Purification by flash column chromatography on silica gel with petrol.-EtOAc (6:4) 
as eluent gave 29 as a white solid (540 mg, 0.77 mmol, 96%). M.p. 66-68°C; 1H 
NMR (400 MHz, CDCl3): δ = 8.29 (d, 2H, J = 9.2 Hz, H14), 7.71 (d, 1H, J = 2.0 Hz, 
H7), 7.50 (d, 1H, J = 2.0 Hz, H8), 7.39 (d, 2H, J = 9.2 Hz, H13), 5.96-5.85 (m, 1H, 
H10), 5.48 (dd, 1H, J = 10.8 Hz, J = 8.0 Hz, H2), 5.38 (d, 1H, J = 2.4 Hz, H4), 5.27 
(bs, 2H, H12), 5.20-5.14 (m, 2H, H11), 5.05 (dd, 1H, J = 10.8 Hz, J = 3.6 Hz, H3), 
4.88 (d, 1H, J = 8.0 Hz, H1), 4.06 (t, 2H, J = 6.8 Hz, H6), 3.80 (t, 1H, J = 7.6 Hz, H5), 
3.56 (t, 2H, J = 6.0 Hz, H9), 2.20 (s, 3H, H-Ac), 2.17 (s, 3H, H-Ac), 2.01 (s, 3H, H-
Ac), 1.97 (s, 3H, H-Ac); 13C NMR (100 MHz, CDCl3): δ = 170.4, 170.3, 170.2, 
169.7, 155.4, 152.4, 145.7, 145.4, 138.5, 135.3, 134.1, 132.1, 125.5, 122.9, 121.8, 
118.0, 102.7, 71.3, 70.7, 69.1, 68.7, 66.7, 60.8, 34.1, 20.9, 20.8, 20.7, 20.6; LRFAB-
MS (3-NOBA matrix): m/z 705 [M+H]+, 727 [M+Na]+.  
 
 
To a solution of Cbz-glycine (3.62 g, 17.3 mmol, 1.0 equiv.), EDCI.HCl (3.31 g, 
17.3 mmol, 1.0 equiv.) and DMAP (2.11 g, 17.3 mmol, 1.0 equiv.) in CH2Cl2 (180 
mL) at room temperature, was added glycylglycine ethylester hydrochloride (3.74 g, 
19.0 mmol, 1.1 equiv.) and the reaction mixture was stirred overnight. An aqueous 
solution of HCl (1M) (100 mL) was added, the layers were separated and the 
aqueous layer was extracted with CH3Cl/iPrOH (3:1) (3 × 50 mL). The combined 
organic fractions were dried (MgSO4) and concentrated under reduced pressure. To 
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the crude solid was added Et2O (50 mL). The resulting white suspension was 
sonicated for 5 minutes and filtered by gravity to give 31 as a white solid (5.42 g, 
15.4 mmol, 90%). M.p. 133-135°C, 1H-NMR (400 MHz, CDCl3/CD3OD (1:1), 298 
K): δ = 7.38-7.20 (m, 5H, H1, H2 and H3), 5.06 (s, 2H, H4), 4.15 (q, J = 7.1 Hz, 2H, 
H8), 3.99-3.74 (m, 6H, H5, H6 and H7), 3.30 (t, J = 7.1 Hz, 3H, H8). 13C-NMR (100 
MHz, CDCl3/CD3OD (3:1), 298 K): δ = 170.8, 170.3, 170.2, 136.2, 128.6, 128.3, 
128.1, 107.0, 67.3, 61.7, 44.3, 42.4, 41.1, 14.0; LRESI-MS: m/z = 374 [M+Na]+; 




To a solution of 31 (2.24 g, 6.37 mmol, 1.0 equiv.) in a 2:3:3 mixture 
H2O/EtOH/THF (320 mL) at 0ºC was added crushed NaOH (395 mg, 9.55 mmol, 1.5 
equiv.) in one portion and the reaction mixture was stirred at that temperature for 20 
min. An aqueous solution (1M) of HCl (40 mL) was added and solvents were 
evaporated under reduced pressure. To the resulting solid was added H2O (30 mL), 
the suspension was sonicated for 5 minutes, filtered under suction and washed with 
H2O (50 mL). The solid was re-suspended in a 1:6 mixture of MeOH/Et2O (50mL), 
sonicated for 5 minutes, filtered by gravity and washed with Et2O (20 mL) to afford 
32 as a white solid (1.70 g, 5.25 mmol, 82%). M.p. 182-184°C; 1H-NMR (400 
MHz, DMSO d6, 298 K): δ = 12.58 (s, 1H, H11), 8.16 (dt, J = 5.6 Hz and J = 5.6 Hz, 
2H, H5 and H4), 7.49 (t, J = 6.0 Hz, 1H, H9), 7.14-7.25 (m, 5H, H1, H2 and H3), 5.03 
(s, 2H, H4), 3.75 (dd, J = 5.5 Hz and J = 5.5 Hz, 4H, H6 and H8), 3.67 (d, J = 6.0 Hz, 
2H, H10); 13C-NMR (100 MHz, DMSO d6, 298 K): δ = 171.0, 169.3, 169.0, 156.4, 
136.9, 128.2, 127.7, 127.6, 65.4, 43.4, 41.6, 40.4; LRESI-MS: m/z = 346 [M+Na]+; 








To a solution of 32 (1.52 g, 4.7 mmol, 1.0 equiv.), EDCI.HCl (991 mg, 5.17 mmol, 
1.1 equiv.) and DMAP (631 mg, 5.17 mmol, 1.1 equiv.) in CH2Cl2 (100 mL) at room 
temperature, was added 2,2-diphenylethanamine (878 mg, 4.4 mmol, 0.95 equiv.) 
and the reaction mixture was stirred overnight. An aqueous solution (1M) of HCl (50 
mL) was added, the layers were separated and the aqueous layer was extracted with 
CH2Cl2 (3 × 50 mL). The combined organic fractions were washed with H2O (40 
mL), dried (MgSO4) and concentrated under reduced pressure to afford 33 as a white 
solid (1.87 g, 3.72 mmol, 80%). M.p. 210-212°C; 1H-NMR (400 MHz, DMSO d6, 
298 K): δ = 8.13, 8.05, 7.49 (3t, J = 5.6 Hz, J = 5.8 Hz and J = 6.0 Hz,  3H, H5, H7 
and H9),  7.86 (t, J = 5.5 Hz, 1H, H11), 7.38-7.09 (m, 15H, H1, H2, H3, H14, H15 and 
H16), 5.03 (s, 2H, H4), 4.18 (t, J = 7.7 Hz, 1H, H13),  3.75-3.67 (m, 4H, H6, H11),  
3.66, 3.58 (2d, J = 6.1 Hz and J = 5.7 Hz, 4H, H8 and H10); 13C-NMR (100 MHz, 
DMSO d6, 298 K): δ = 169.4, 168.9, 168.6, 156.4, 142.7, 136.9, 128.3, 128.2, 127.8, 
127.7, 127.6, 126.3, 65.4, 49.9, 43.4, 43.0, 41.9, 41.7; LRESI-MS: m/z = 525 




A solution of 33 (2.65 g, 5.27 mmol, 1.0 equiv.) in a 3:4:13 mixture 
H2O/MeOH/THF (500 mL) was heated up to 50ºC until 33 had fully dissolved (5 
min). The solution was then allowed to cool to room temperature and palladium 
(10%) on carbon (561 mg) was added in one portion. The reaction vessel was purged 
with H2 by means of three vacuum/H2 cycles and the mixture stirred at room 
temperature for 15 hours. The solid was filtered off with Celite®, MeOH and THF 
were evaporated under reduced pressure and the remaining aqueous layer was 
extracted with CH3Cl/iPrOH (3:1) (3 × 50 mL). The combined organic fractions 
were dried (MgSO4) and concentrated under reduced pressure. The resulting yellow 
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oil was re-dissolved in CH2Cl2 (10 mL) and Et2O (50 mL) was added. The resulting 
white precipitate was sonicated for 5 minutes and filtered by gravity to afford 34 as a 
white solid (1.30 g, 3.52 mmol, 67%). M.p. 50-52°C, 1H-NMR (400 MHz, CDCl3, 
298 K): δ = 8.07-7.81 (m, 1H, H6), 7.42-7.25, 6.75-6.58 (2m, 2H, H2 and H4 ), 7.25-
6.95 (m, 10H, H9, H10 and H11), 4.10 (t, J = 7.8 Hz, 1H, H8),  3.75-3.67 (m, 4H, H6, 
H11),  3.75, 3.64, 3.28 (3s, 4H, H3, H5 and H7); 13C-NMR (100 MHz, CDCl3, 298 
K): δ = 169.7 (× 2), 169.0, 141.7, 128.6, 128.0, 126.7, 50.2, 43.8 (× 2), 42.8, 42.6; 
LRESI-MS: m/z = 391 [M+Na]+; HRESI-MS: m/z = 369.1924 [M+H]+ (calc. for 
C20H25O3N4  369.1921 [M+H]+). 
 
 
To a solution of 29 (529 mg, 0.75 mmol, 1 equiv.) in CH3CN (35 mL) was added 
peptide 34 (332 mg, 0.90 mmol, 1.2 equiv.) and Et3N (260 µL, 1.87 mmol, 2.5 
equiv.) and the reaction mixture was stirred for 24 hours. Water was added, the 
layers were separated and the aqueous layer was extracted with EtOAc (3 × 40 mL). 
The combined organic fractions were washed with H2O (50mL), dried (MgSO4) and 
concentrated under reduced pressure. Purification by flash column chromatography 
on silica gel with petrol.-EtOAc (4:6 to 2:8) then CH2Cl2-MeOH (9:1) as eluent gave 
35 as a light brown solid (599 mg, 0.64 mmol, 85%). M.p. 126-128°C; 1H NMR 
(400 MHz, CDCl3): δ = 7.57 (d, 1H, J = 2.0 Hz, H7), 7.39 (m, 2H, H15 and H17), 
7.37 (d, 1H, J = 2.0 Hz, H8), 7.27-7.16 (m, 10H, H22, H23 and H24), 6.65 (t, 1H, J = 
5.2 Hz, H19), 6.08 (t, 1H, J = 4.8 Hz, H13), 5.93-5.82 (m, 1H, H10), 5.46 (dd, 1H, J = 
10.8 Hz, J = 8.0 Hz, H2), 5.37 (d, 1H, J = 2.8 Hz, H4), 5.15 (d, 1H, J = 1.2 Hz, H11), 
5.12 (dd, 1H, J = 9.2 Hz, J = 1.2 Hz, H11), 5.06 (dd, 1H, J = 10.4 Hz, J = 3.6 Hz, H3), 
5.00 (s, 2H, H12), 4.85 (d, 1H, J = 8.0 Hz, H1), 4.17 (t, 1H, J = 8.0 Hz, H21), 4.03 (d, 
2H, J = 6.4 Hz, H6), 3.91-3.76 (m, 9H, H5, H14, H16, H18 and H20), 3.50 (m, 2H, H9), 
2.19 (s, 3H, H-Ac), 2.15 (s, 3H, H-Ac), 2.00 (s, 3H, H-Ac), 1.95 (s, 3H, H-Ac); 13C 
NMR (100 MHz, CDCl3): δ = 170.5, 170.4, 170.2, 169.8, 169.7, 169.3, 168.9, 
156.4, 145.4, 145.0, 141.9, 137.9, 135.4, 134.4, 133.5, 128.8, 128.1, 126.9, 122.2, 
117.7, 102.7, 71.1, 70.7, 68.8, 66.7, 65.3, 60.7, 50.5, 44.4, 44.0, 43.1, 42.9, 34.0, 
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29.8, 20.9, 20.8, 20.7, 20.6; LRESI-MS: m/z 957 [M+Na]+; LRFAB-MS (3-NOBA 
matrix): m/z 935 [M+H]+; HRFAB-MS (3-NOBA matrix): m/z 934.33837 (calcd. 
for C45H52N5O17 934.33585 [M+H]+). 
 
 
Using general method C, thread 35 (100 mg, 0.11 mmol, 1 equiv.) and MeONa (58 
mg, 1.1 mmol 10 equiv.) at 0°C in MeOH (5 mL) gave crude 36 as a brown solid. 
Purification by flash column chromatography on silica gel with CH2Cl2-MeOH (95:5 
to 8:2) as eluent gave 36 as a light brown solid (57 mg, 0.07 mmol, 64%). For 
enzymatic trials, a fraction was re-purified by preparative RP-HPLC using a linear 
gradient (35 to 55 % in 20 min) of MeCN in H2O  at a flow rate of 10 mL/min to 
give 36 as a white solid. Purity (HPLC): >97%; M.p. 145-147°C; 1H NMR (400 
MHz, CD3OD): δ =7.57 (d, 1H, J = 2.0 Hz, H7), 7.45 (d, 1H, J = 2.0 Hz, H8), 7.24-
7.19 (m, 8H, H22 and H23), 7.14-7.10 (m, 2H, H24), 5.99-5.89 (m, 1H, H10), 5.11-5.04 
(m, 4H, H11 and H12), 4.47 (d, 1H, J = 8.0 Hz, H1), 4.24 (t, 1H, J = 8.0 Hz, H21), 3.80-
3.73 (m, 8H, H14, H16, H18 and H20), 3.70 (m, 2H, H4, and H5), 3.66-3.54 (m, 4H, H6 
and H9), 3.44 (dd, 1H, J = 10.0 Hz, J = 3.6 Hz, H3); 13C NMR (100 MHz, CD3OD): 
δ = 173.1, 172.1, 171.5, 159.0, 147.9, 147.0, 143.8, 138.5, 137.5, 135.5, 134.7, 
129.6, 129.2, 127.7, 122.8, 117.4, 107.1, 77.1, 74.7, 72.5, 69.7, 66.5, 61.6, 51.6, 
49.9, 45.1, 43.8, 43.3, 34.5; LRES+-MS: m/z 766 [M+H]+, 788-789-790 [M+Na]+; 
LRFAB-MS (3-NOBA matrix): m/z 766 [M+H]+; HRFAB-MS (3-NOBA matrix): 








Using general method A, thread 35 (200 mg, 0.21 mmol, 1 equiv.), p-
xylylenediamine (466 mg, 3.36 mmol ,16 equiv.), isophthaloyl dichloride (696 mg, 
3.36 mmol, 16 equiv.) and Et3N (1.0 mL, 7.35 mmol, 35 equiv.) at room temperature 
for 3 hours gave crude 37 as an orange solid. Purification by flash column 
chromatography on silica gel with CHCl3-MeOH (99:1 to 85:15) as eluent gave a 
mixture of thread 35 and rotaxane 37. This mixture was resolved by size exclusion 
chromatography using CHCl3/MeOH (50/50: v/v) as eluent to give rotaxane 37 as a 
light brown solid (161 mg, 0.11 mmol, 51%). M.p. 160-162°C; [α]D +7.8 (c 0.009 in 
CHCl3) 1H NMR (400 MHz, CDCl3): δ 8.19 (s, 2H, HC), 8.00 (d, 4H, J = 7.2 Hz, 
HB), 7.81 (bs, 4H, HD), 7.47 (t, 2H, J = 7.6 Hz, HA), 7.35 (s, 1H, H7), 7.23 (s, 1H, 
H8), 7.21-7.09 (m, 18H, H22, H23, H24 and HF), 6.98 (bs, 3H, H15, H17 and H19), 5.89-
5.79 (m, 1H, H10), 5.73 (bs, 1H, H13), 5.46 (t, 1H, J = 8.8 Hz, H2), 5.37 (bs, 1H, H4), 
5.14-5.05 (m, 3H, H3 and H11), 4.84 (d, 1H, J = 7.6 Hz, H1), 4.74 (bs, 2H, H12), 4.48-
4.39 (m, 8H, HE), 4.05 (t, 1H, J = 8.0 Hz, H21), 4.02 (d, 2H, J = 6.8 Hz, H6), 3.80 (t, 
1H, J = 6.0 Hz, H5), 3.70 (bs, 2H, H20), 3.46-3.42 (m, 4H, H9 and H14), 3.30 (bs, 2H, 
H18), 2.93 (bs, 2H, H16), 2.17 (s, 3H, H-Ac), 2.16 (s, 3H, H-Ac), 2.01 (s, 3H, H-Ac), 
1.94 (s, 3H, H-Ac); 13C NMR (100 MHz, CDCl3): δ 170.5, 170.3, 170.2, 170.1, 
169.7, 169.2, 168.2, 167.2, 156.3, 145.3, 145.0, 141.7, 137.7, 137.4, 135.3, 134.3, 
133.9, 133.7, 131.0, 129.1, 129.0, 128.8, 128.0, 127.0, 125.4, 122.2, 117.7, 102.6, 
71.1, 70.7, 68.8, 66.7, 65.3, 60.7, 50.5, 44.5, 44.2, 42.7, 42.1, 33.9, 20.9, 20.8, 20.7, 
20.6; LRFAB-MS (3-NOBA matrix): m/z 1467 [M+H]+; HRFAB-MS (3-NOBA 
matrix): m/z 1466.54845 (calcd. for C77H80N9O21 1466.54688 [M+H]+). 
 
 




Using general method C, rotaxane 37 (98 mg, 0.067 mmol, 1 equiv.) and MeONa 
(36 mg, 0.67 mmol 10 equiv.) at 0°C in MeOH (10 mL) gave crude 38 as a brown 
solid. Purification by flash column chromatography on silica gel with CH2Cl2-MeOH 
(98:2 to 9:1) as eluent gave 38 as a light brown solid (75 mg, 0.058 mmol, 87%). 
M.p. 178-180°C; 1H NMR (400 MHz, CD3OD): δ = 8.34 (bs, 2H, HC), 8.05-8.03 
(m, 4H, HB), 7.59 (t, 2H, J = 7.6 Hz, HA), 7.23-7.01 (m, 18H, H22, H23, H24 and HF), 
5.97-5.87 (m, 1H, H10), 5.09 (dd, 1H, J = 8.8 Hz, J = 1.6 Hz, H11), 5.05 (bs, 1H, H11), 
4.57 (bs, 2H, H12), 4.48-4.39 (m, 9H, H1 and HE), 3.93 (t, 1H, J = 8.0 Hz, H21), 3.82 
(t, 1H, J = 3.2 Hz), 3.76 (dd, 1H, J = 9.6 Hz, J = 7.6 Hz,), 3.65 (dd, 1H, J = 11.2 Hz, 
J = 6.8 Hz), 3.57-3.44 (m, 10H, H14, H16, H18 and H20); 13C NMR (100 MHz, 
CD3OD): δ 172.4, 171.2, 170.5, 169.0, 158.1, 147.7, 147.0, 143.6, 138.8, 138.3, 
137.5, 135.7, 134.9, 134.7, 131.7, 130.1, 130.0, 129.9, 129.8, 129.6, 129.4, 129.0, 
127.8, 127.7, 122.8, 117.4, 107.1, 77.1, 74.7, 72.5, 69.7, 66.2, 61.7, 51.7, 49.9, 45.2, 
45.0, 44.9, 43.2, 42.6, 34.4; LRFAB-MS (3-NOBA matrix): m/z 1299 [M+H]+; 
HRFAB-MS (3-NOBA matrix): m/z 1299.51035 (calcd. for C69H73N9O17 calcd. 
1299.51244 [M+H]+).  
 
 
Using general method A, thread 35 (400 mg, 0.43 mmol, 1 equiv.), p-
xylylenediamine (933 mg, 6.88 mmol, 16 equiv.), 5-azidoisophthaloyl dichloride 
(1.67 g, 6.88 mmol, 16 equiv.) and Et3N (2.1 mL, 15.05 mmol, 35 equiv.) in CHCl3 
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(200 mL) at room temperature for 3 hours gave crude 42 as an orange solid. 
Purification by flash column chromatography on silica gel with CHCl3-acetone (9:1 
to 4:6) as eluent gave a mixture rotaxane 42 as a light yellow solid (421 mg, 0.27 
mmol, 63%). M.p. dec.; 1H NMR (400 MHz, CDCl3): δ = 7.88 (bs, 2H, HB), 7.62 
(bs, 4H, HC), 7.54 (bs, 4H, HA), 7.34 (s, 1H, H7), 7.18-7.17 (m, 1H, H15), 7.14 (d, 4H, 
J = 7.6 Hz, HE), 7.10 (s, 1H, H8), 7.07 (bs, 10H, H22, H23 and H24), 7.01 (d, 4H, J = 
7.2 Hz, HE), 6.86 (bs, 2H, H17 and H19), 5.83-5.73 (m, 1H, H10), 5.63 (bs, 1H, H13), 
5.39 (dd, 1H, J = 10.4 Hz, J = 8.0 Hz, H2), 5.30 (d, 1H, J = 3.6 Hz, H4), 5.08-4.97 
(m, 3H, H3 and H11), 4.77-4.76 (m, 3H, H1 and H12), 4.50-4.46 (m, 4H, HD), 4.31-
4.27 (m, 4H, HD), 4.00-3.91 (m, 3H, H6 and H21), 3.74 (t, 1H, J = 7.2 Hz, H5), 3.66 
(bs, 2H, H20), 3.45 (bs, 2H, H14), 3.41 (d, 2H, J = 6.4 Hz, H9), 3.25 (bs, 2H, H16 or 
H18), 2.97 (bs, 2H, H16 or H18), 2.10 (s, 3H, H-Ac), 2.08 (s, 3H, H-Ac), 1.93 (s, 3H, 
H-Ac), 1.88 (s, 3H, H-Ac); 13C NMR (100 MHz, CDCl3): δ = 170.6, 170.4, 170.2, 
169.7, 169.4, 168.1, 166.0, 156.5, 145.3, 145.1, 141.6, 141.5, 137.8, 137.2, 135.7, 
135.3, 133.8, 133.5, 129.3, 128.9, 127.9, 127.2, 122.1, 121.6, 121.0, 117.8, 102.7, 
71.1, 70.7, 68.7, 66.7, 65.4, 60.7, 53.9, 50.6, 44.5, 44.4, 42.9, 42.4, 34.0, 31.9, 29.4, 
21.0, 20.8, 20.7 (x2); LRESI-MS: m/z 1550.44 [M+H]+; LRFAB-MS (3-NOBA 
matrix): m/z 1550.5 [M+H]+;  HRFAB-MS (3-NOBA matrix) submitted  
 
 
Using general method B, rotaxane 42 (61 mg, 39.4 µmol, 1.0 equiv.), alkyne 45 (30 
mg, 78.8 μmol, 2.0 equiv.), [Cu(CH3CN)4](PF6) (7 mg, 19.7 μmol, 0.5 equiv.) and 
NEt3 (12 μL, 78 μmol, 2.0 equiv.) in CH2Cl2 (7 mL) at room temperature overnight 
gave crude 43a as an yellow solid. Purification by flash column chromatography on 
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silica gel with CHCl3-acetone (7:3 to 45:55) as eluent gave 43a as a light yellow 
solid (31 mg, 13.4 μmol, 34%). M.p. 166-168°C; 1H NMR (400 MHz, CDCl3): δ 
= 8.27-8.23 (m, 4H, HA and HF), 8.20 (bs, 2H, HB), 8.09 (bs, 2H, HC), 8.01 (bs, 4H), 
7.35 (s, 1H, H7), 7.17 (s, 1H, H8), 7.10-7.08 (m, 8H, HE), 7.04-6.99 (m, 10H, H22, H23 
and H24), 6.93- 6.87 (m, 3H, H15, H17 and H19), 5.79-5.69 (m, 2H, H10 and H13), 5.36 
(dd, 1H, J = 10.4 Hz, J = 8.0 Hz, H2), 5.31 (d, 1H, J = 3.2 Hz, H4), 5.20-5.16 (m, 2H, 
HJ), 5.08-4.99 (m, 7H, H3, H11, HI and HK), 4-99-4.80 (m, 4H, HG and HH), 4.80-4.69 
(m, 3H, H12 and H1), 4.47-4.44 (m, 4H, HD), 4.34-4.31 (m, 4H, HD), 4.22-4.11 (m, 
4H, HM), 4.00-3.90 (m, 3H, H21 and H6), 3.79-3.71 (m, 4H, H5 and HL), 3.62 (bs, 2H, 
H14), 3.51 (bs, 2H, H16), 3.36 (d, 2H, J = 6.8 Hz, H9), 3.24 (bs, 2H, H18), 2.82 (bs, 
2H, H20), 2.11 (s, 3H, H-Ac), 2.07 (s, 3H, H-Ac), 2.01 (s, 6H, H-Ac), 1.97 (s, 6H, H-
Ac), 1.95 (s, 6H, H-Ac), 1.94 (s, 6H, H-Ac), 1.93 (s, 3H, H-Ac), 1.88 (s, 3H, H-Ac); 
13C NMR (100 MHz, CDCl3): δ = 171.1, 170.7, 170.4, 170.2, 170.0, 169.7, 169.6, 
169.2, 165.7, 145.5, 145.3, 145.0, 141.7, 137.8, 137.3, 137.2, 136.3, 136.2, 135.3, 
133.4, 129.2 (x2), 128.8, 127.9, 127.0, 122.1, 121.9, 121.6, 117.8, 102.6, 100.4 (x2), 
72.8, 72.1, 71.3, 71.1, 70.7, 68.8, 68.4, 66.7, 65.3, 63.0, 62.0, 60.7, 44.7, 44.2, 33.9, 
29.8, 21.0 (x3), 20.9 (x2), 20.8 (x 6), 20.7; LRFAB-MS (3-NOBA matrix): m/z 
2322 [M+H]+; HRFAB-MS (3-NOBA matrix): m/z 2321.80494 (calcd. for 
C11013CH122N15O41 calcd. 2321.79562 [M+H]+). 
 
 
Using general method B, rotaxane 42 (100 mg, 64.6 μmol, 1.0 equiv.), alkyne 46 (30 
mg, 129.2 μmol, 2.0 equiv.), [Cu(CH3CN)4](PF6) (12 mg, 32.3 µmol, 0.5 equiv.) and 
NEt3 (20 µL, 142.1 µmol, 2.0 equiv.) in CH2Cl2 (10 mL) at room temperature 
overnight gave crude 43b as yellow solid. Purification by flash column 
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chromatography on silica gel with CHCl3-acetone (7:3 to 45:55) as eluent gave 43b 
as a light yellow waxy solid (31 mg, 13.4 µmol, 24%). 1H NMR (400 MHz, 
CDCl3): δ = 8.31 (bs, 4H, HA and HF), 8.22 (bs, 2H, HB), 8.18 (bs, 2H, HC), 7.35 (s, 
1H, H7), 7.18 (s, 1H, H8), 7.09-6.99 (m, 21H, HE, H15, H17, H19, H22, H23 and H24), 
5.96 (bs, 1H, H13), 5.79-5.69 (m, 1H, H10), 5.36 (dd, 1H, J = 10.4 Hz, J = 8.0 Hz, 
H2), 5.30 (d, 1H, J = 3.2 Hz, H2), 5.03-4.98 (m, 3H, H3 and H11), 4.77-4.74 (m, 3H, 
H1 and H12), 4.68 (bs, 4H, HG), 4.39-4.35 (m, 8H, HD), 3.97-3.94 (m, 3H, H6 and 
H21), 3.77 (t, 1H, J = 6.8 Hz, H5), 3.69-3.47 (m, 34H, HH, HI, HJ, HK, HL, HM, HN, 
HO, and H14), 3.37-3.35 (m, 2H, H9), 2.96-2.79 (m, 6H, H16, H18 and H20), 2.11 (s, 
3H, H-Ac), 2.06 (s, 3H, H-Ac), 1.93 (s, 3H, H-Ac), 1.87 (s, 3H, H-Ac); 13C NMR 
(100 MHz, CDCl3): δ = 170.6, 170.4, 170.2, 170.1, 170.0, 169.7, 169.2, 168.6, 
166.0 (x2), 156.3, 146.2, 145.3, 145.0, 141.9, 137.7, 137.3, 137.2, 136.3, 136.2, 
135.4, 134.2, 133.4, 129.1, 128.7, 128.0, 126.9, 126.2, 122.0, 121.4, 117.7, 102.6, 
72.7, 71.1, 70.7, 70.5 (x2), 70.2, 70.1, 68.8, 66.7, 65.2, 64.6, 61.5, 60.7, 50.5, 44.7, 
44.2, 42.4, 41.8, 34.0, 29.8, 20.9, 20.8, 20.7 (x2); LRFAB-MS (3-NOBA matrix): 
m/z 2014 [M+H]+ 2036 [M+Na]+; HRFAB-MS (3-NOBA matrix): m/z 2013.81525 
(calcd. for C98H11813CN15O31 2013.81517 [M+H]+).  
 
Using general method B, rotaxane 42 (70 mg, 45.2 µmol, 1.0 equiv.), alkyne 47 (51 
mg, 90.4 µmol, 2.0 equiv.), [Cu(CH3CN)4](PF6) (8 mg, 11.3 µmol, 0.5 equiv.) and 
NEt3 (14 µL, 90.4 µmol, 2.0 equiv.) in CH2Cl2 (7 mL) at room temperature overnight 
gave crude 43c a yellow solid. Purification by preparative TLC on silica eluted 4 
times with CHCl3/acetone (1:1) as eluent gave 43c as a white solid (84 mg, 31.6 
µmol, 70%). M.p. 133-135°C; [α]D +51.3 (c 0.008 in CHCl3) 1H NMR (400 MHz, 
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CDCl3): δ 8.38 (m, 2H, HB), 8.24 (bs, 2H, HF), 8.19 (bs, 6H, HA and HC), 7.40 (s, 
1H, H7), 7.22 (s, 1H, H8), 7.18-7.06 (m, 20H, HE, H15, H17, H22, H23 and H24), 6.95 
(bs, 2H, H19), 5.85-5.75 (m, 2H, H10 and H13), 5.43 (dd, 1H, J = 10.4 Hz, J = 8.0 Hz, 
H2), 5.37 (d, 1H, J = 3.6 Hz, H4), 5.20 (t, 2H, J = 9.6 Hz, HR), 5.10-5.04 (m, 5H, H3, 
H11 and HS), 5.97 (dd, 2H, J = 9.6 Hz, J = 8.0 Hz, HQ), 4.82 (m, 2H, H1 and H12), 
4.76 (s, 4H, HG), 4.58 (d, 2H, J = 8.0 Hz, HP), 4.55-4.43 (m, 8H, HD), 4.24 (dd, 2H, J 
= 12.0 Hz, J = 4.4 Hz, HU), 4.11 (dd, 3H, J = 12.0 Hz, J = 2.0 Hz, HU’), 4.07-3.98 
(m, 4H, H6 and H21), 3.93 (dt, 2H, J = 4.0 Hz, J = 4.4 Hz, HT), 3.85 (t, 1H, J = 6.8 
Hz, H5), 3.77-3.56 (m, 36H, HH, HI, HJ, HK, HL, HM, HN, HO, H14 and H16), 3.42 (d, 
2H, J = 6.4 Hz, H9), 3.30-3.22 (m, 2H, H18 ), 2.84 (bs, 2H, H20), 2.17-1.95 (s, 36H, 
H-Ac); 13C NMR (100 MHz, CDCl3): δ 170.9, 170.4 (x2), 170.2, 169.7, 169.6, 
165.8, 146.5, 145.0, 141.8, 137.7, 137.4, 137.3, 136.4, 136.3, 135.3, 134.1, 133.3, 
129.9, 129.1, 128.8, 128.0, 126.9, 126.1, 121.9 (x2), 121.2, 117.7, 102.6, 101.0 (x2), 
72.9, 71.9, 71.4, 71.0, 70.7, 70.6, 70.3, 70.1, 69.3, 68.8, 68.5, 66.8, 65.2, 64.6, 62.1, 
60.7, 50.5, 44.7, 44.3, 44.1, 42.4, 42.3, 41.8, 33.9, 29.8, 29.4, 21.0, 20.9 (x2), 20.8, 
20.7; LRFAB-MS (3-NOBA matrix): m/z 2675 [M+H]+, 2698.9 [M+Na]+; 
HRFAB-MS (3-NOBA matrix): m/z 2695.98021 (calcd. for C12613CH153N15O49Na 




Using general method C, rotaxane 43b (27 mg, 13.4 µmol, 1 equiv.) and MeONa (7 
mg, 0.134 mmol 10 equiv.) at 0°C in MeOH (4 mL) gave crude 48b as a brown 
solid. Purification by preparative RP-HPLC using a linear gradient (37 to 55 % in 20 
min) of MeCN in H2O at a flow rate of 10 mL/min to give rotaxane 48b as a light 
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yellow solid. Purity (HPLC): >94%. M.p. 102-104oC; 1H NMR (400 MHz, 
CD3OD): δ 8.57 (s, 2H, HB), 8.36 (s, 4H, HA), 8.29 (s, 2H, HF), 7.14 (s, 8H, HE), 
7.12-6.89 (m 12H, H7, H8 H22, H23 and H24) , 5.78-5.68 (m, 1H, H10), 4.95-4.90 (m, 
2H, H11), 4.65 (s. 4H, HG),  4.45-4.34 (m, 10H, H12 and HD), 4.21 (d, 1H, J = 7.7 Hz, 
H1), 3.88 (t, 1H, J = 7.7 Hz, H21), 3.69-3.10 (m, 48H, H2, H3, H4, H5, H6, H9, H14, 
H16, H18, H20 HH, HI, HJ, HK, HL HM, HN and HO); 13C NMR (100 MHz, CD3OD): δ 
171.2, 167.5, 167.4, 158.1, 147.4, 143.6, 138.7 (x2), 137.4, 134.4, 130.0, 129.6, 
129.0, 127.8, 127.7, 127.3, 123.5, 123.1, 123.0, 122.6, 117.4, 106.9, 77.1, 74.6, 73.6, 
72.4, 71.6, 71.5, 71.4, 71.0, 69.7, 66.1, 65.0, 62.2, 61.8, 51.7, 45.2, 45.0, 43.1, 42.8, 
34.3, 30.8; LRFAB-MS (3-NOBA matrix): m/z  HRFAB-MS (3-NOBA matrix): 
submitted  
 
Using general method C, rotaxane 43c (24 mg, 9.0 umol, 1 equiv.) and MeONa (16 
mg, 0.270 mmol 30 equiv.) at 0°C in MeOH (3 mL) gave crude 48c as a brownish 
solid. Purification by preparative RP-HPLC using a linear gradient (33 to 45 % in 15 
min) of MeCN in H2O at a flow rate of 10 mL/min to give rotaxane 48c as a pink 
solid. Purity (HPLC): >94%. M.p. 130°C (dec.); 1H-NMR (400 MHz, CD3OD, 300 
K): δ = 8.69 (s, 2H, HB), 8.47 (s, 4H, HA), 8.39 (s, 2H, HF), 7.41-6.92 (m, 20H, H7, 
H8, H22, H23, H24, HE), 5.92-5.77 (m, 8H, H10), 5.07-4.98 (m, 2H, H11), 4.78 (s, 4H, 
HG), 4.56-4.38 (m, 8H, HD), 4.32 (d, J = 7.7 Hz, 2H, H1), 4.29 (d, J = 7.8 Hz, 2H, 
HP), 4.04-3.93 (m, 3H, HO and H21), 3.90-3.10 (m, 52H, HH, HI, HJ, HK, HL, HM, HN, 
HO’, HU, H2, H3, H4, H5, H6, H9, H12, H14, H16, H18 and H20); 13C-NMR (100 MHz, 
CD3OD, 300 K): δ = 172.5, 171.2, 170.6, 167.5, 167.4, 158.1, 147.4, 146.8, 143.6, 
138.8, 138.7, 138.2, 137.4, 134.7, 134.5, 130.0 (× 2), 129.6, 129.5, 129.0 (× 2), 
Chapter six   Rotaxane propeptide models  
 
 214
127.9, 127.7, 123.6, 123.2, 123.1, 122.6, 117.4, 106.9, 104.4, 78.0, 77.9, 77.1, 75.1, 
74.6, 72.4, 71.7, 71.6, 71.6, 71.5, 71.4, 71.0, 69.7, 69.6, 66.1, 65.0, 62.8, 61.8, 51.7, 
45.2, 45.0, 43.1, 42.8, 34.3; LRESI-MS: m/z = 1085.4 (100%) [M+2H]2+; isotopic 
pattern matches that calculated for C103H131Cl6N15O37. 
 
 
To a solution of peracetylated β-D-glucose (1.21 g, 3.1 mmol, 1.0 equiv.) and 
propargyl alcohol (0.27 mL, 4.65 mmol, 1.5 equiv.) in anhydrous CH2Cl2 (8 mL) 
under N2 at 0ºC, was added BF3.Et2O (2 mL, 15.5 mmol, 5 equiv.) drop wise. The 
reaction mixture was allowed to warm up to room temperature and stirred overnight. 
An aqueous saturated solution of NaHCO3 (30 mL) was added, the layers were 
separated and the aqueous layer was extracted with CH2Cl2 (3 × 25 mL). The 
combined organic fractions were dried (Na2SO4) and concentrated under reduced 
pressure. The resulting brown residue was purified by flash column chromatography 
on Silica gel with CH2Cl2-acetone (98:2) as eluent to give pure 45 as a white solid 
(940 mg, 2.43 mmol, 79%). M.p. 100-102°C; [α]D +59.2 (c 0.1  in CHCl3) 1H-NMR 
(400 MHz, CDCl3, 298 K): δ = 5.22 (t, J = 9.5 Hz, 1H, H3), 5.08 (t, J = 9.5 Hz, 1H, 
H4), 4.99 (t, J = 9.5 Hz, 1H, H2), 4.76 (d, J = 7.9 Hz, 1H, H1), 4.35 (d, J = 2.3 Hz, 
2H, H7), 4.26 (dd, J = 4.6 Hz and J = 12.3 Hz, 1H, H6), 4.13 (dd, J = 2.2 Hz and J = 
12.3 Hz, 1H, H6’), 3.71 (ddd, J = 2.4 Hz, J = 4.5 Hz and J = 10.0 Hz, 1H, H5), 2.46 
(t, J = 2.4 Hz, 1H, H8), 2.07, 2.04, 2.10, 1.99 (4s, 12H, OAc); 13C-NMR (100 MHz, 
CDCl3, 298 K): δ = 170.6, 170.2, 169.3, 169.2, 98.0, 78.0, 75.4, 72.6, 71.8, 70.8, 
68.2, 61.6, 55.8, 20.7, 20.6, 20.5, 20.4; LRESI-MS: m/z = 409 [M+Na]+; HRESI-
MS: m/z = 404.1552 [M+NH4]+ (calc. for C17H26O10N  404.1551 [M+H]+). 
 
 
To a solution of peracetylated β-D-glucose (317 mg, 0.81 mmol, 1.0 equiv.) and 46 
(283 mg, 1.22 mmol, 1.5 equiv.) in anhydrous CH2Cl2 (2 mL) under N2 at 0ºC, was 
added BF3.Et2O (0.52 mL, 0.40 mmol, 5 equiv.) drop wise. The reaction mixture was 
allowed to warm up to room temperature and stirred overnight. An aqueous saturated 
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solution of NaHCO3 (10 mL) was added, the layers were separated and the aqueous 
layer was extracted with CH2Cl2 (3×15 mL). The combined organic fractions were 
dried (Na2SO4) and concentrated under reduced pressure. The resulting brown 
residue was purified by flash column chromatography on silica gel with CH2Cl2-
acetone (93:7) as eluent to give pure 47 as a colourless oil (378 mg, 0.67 mmol, 
83%). 1H-NMR (400 MHz, CDCl3, 298 K): δ = 5.13 (t, J = 9.5 Hz, 1H, H3), 5.01 (t, 
J = 9.6 Hz, 1H, H4), 4.91 (dd, J = 8.0 Hz and J = 9.5 Hz, 1H, H2), 4.55 (d, J = 8.0 
Hz, 1H, H1), 4.19 (dd, J = 4.7 Hz and J = 12.3 Hz, 1H, H6), 4.14 (d, J = 2.4 Hz, 2H, 
H15), 4.06 (dd, J = 2.3 Hz and J = 12.3 Hz, 1H, H6’), 3.87 (dt, J = 4.0 Hz and J = 11.0 
Hz, 1H, H7), 3.71-3.52 (m, 16H, H5, H7’, H8, H9, H10, H11, H12, H13, and H14), 2.40 (t, 
J = 2.3 Hz, 1H, H16), 2.01, 1.97, 1.95, 1.93 (4s, 12H, OAc); 13C-NMR (100 MHz, 
CDCl3, 298 K): δ = 170.4, 170.0, 169.2, 169.1, 100.6, 79.5, 74.4, 72.6, 71.5, 71.0, 
70.5, 70.4 (× 2), 70.3, 70.1, 70.0, 68.8 (× 2), 68.2, 61.7, 58.1, 20.6, 20.5, 20.4, 20.3; 
LRESI-MS: m/z = 585 [M+Na]+; HRESI-MS: m/z = 580.2600 [M+NH4]+ (calc. for 
C25H42O14N 580.2600 [M+ NH4]+). 
 
 
To a solution of 5-Amino-pentan-1-ol (3.0 g, 29.10 mmol, 1.0 equiv.) in dry DMF 
(40 mL) at 0 oC was added a solution of fumaroyl dichloride (0.90 g, 5.81 mmol, 2.0 
equiv.)  in DMF (15 mL) over a period of 2 hours using motor-driven syringe pumps. 
The reaction mixture was stirred for a further 2 hours, concentrated under reduced 
pressure. The residue was re-dissolved in CH2Cl2 (300 mL) and a solution of HCl 
(3M) in diethyl ether was added until all of the unreacted 5-Amino-pentan-1-ol had 
precipitated. The solid was filtered through a plug of Celite®, the plug was washed 
with warm DMF (2 × 15 mL) and solvents were removed under reduced pressure to 
afford 22 as a light yellow solid. (1.16 g, 4.05 mmol, 70%). M.p. = 219-222oC; 1H-
NMR (400 MHz, DMSO d6, 300 K): δ = 8.36 (t, 2H, J = 5.6 Hz, H6), 6.80 (s, 2H, 
H7), 3.36 (t, 4H, J = 6.4 Hz, H1), 3.12 (q, 4H, J = 6.0 Hz, H5), 1.47-1.34 (m, 8H, H2 
and H4), 1.32-1.21 (m, 4H, H3); 13C-NMR (100 MHz, DMSO d6, 300 K): δ = 
163.6, 132,6, 60.6, 32.2, 28.8, 28.6, 23.0; FAB-MS: m/z = 286 [M]+. HRESI-MS: 
m/z = 287.1967 [M+H]+ (calcd for C14H27N2O4 287.1965 [M+H]+). 
 




To a solution of 3,3,3-Tris-(4-chloro-phenyl)-propionic acid 49 (1.53 g, 3.77 mmol, 
2.0 equiv.), EDCI.HCl (984 mg, 5.13 mmol) and DMAP (625 mg, 5.12 mmol) in 
CH2Cl2 (30 mL) at room temperature, was added 22 (490 mg, 1.71 mmol) and the 
reaction mixture was stirred overnight. CH2Cl2 (250 mL) and an aqueous solution of 
HCl (1M) (50 mL) were added, the layers were separated and the aqueous layer was 
extracted with CH2Cl2 (2 × 25 mL). The combined organic fractions were washed 
with an aqueous saturated solution of NaHCO3, dried (MgSO4) and concentrated 
under reduced pressure. Purification by flash column chromatography on silica gel 
with CH2Cl2-MeOH (98:2) as eluent gave 50 as a white solid. (1.50 g, 1.41 mmol 
84%). M.p. 132-136 oC; 1H-NMR (400 MHz, CDCl3/CD3OD, 9:1): δ = 8.01 (t, 2H, 
J = 5.6 Hz, H9), 7.23-7.16 (m, 12H, H1), 7.12-7.04 (m, 12H, H2), 6.71 (s, 2H, H10), 
3.75 (t, 4H, J = 6.5 Hz, H4), 3.59 (s, 4H, H3), 3.23-3.17 (m, 4H, H8), 1.51-1.26 (m, 
8H, H5 and H7), 1.19-1.05 (m, 4H, H6); 13C-NMR (400 MHz, CDCl3/CD3OD, 9:1): 
δ = 170.4, 164.2, 144.2, 133.0, 132.6, 130.3, 128.2, 64.3, 54.6, 46.0, 39.6, 29.0, 28.0, 
23.2; FAB-MS: m/z = 1061 [M+H]+; HRFAB-MS (glycerol matrix): m/z = 
1061.20286 [M+H]+ (calcd for C5613CH52D35Cl6N2O6 1061.20053 [M+H]+). 
 
 
To a vigourously stirred solution of thread 50 (525 mg, 4.94 mmol, 1 equiv.) and 
NEt3 (2 mL, 14.8 mmol, 30 equiv.) in 1 L of dry CHCl3 under nitrogen, was 
simultaneously added a solution of p-xylylenediamine (1.00 g, 7.40 mmol, 15 equiv.) 
in CHCl3 (50 mL) and a solution of isophthaloyl dichloride (1.81 g, 7.40 mmol, 15 
equiv.) in CHCl3 (50 mL) over a period of 3 hours using motor-driven syringe 
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pumps. The reaction mixture was stirred for a further 2 hours, filtered over a celite® 
pad and the filtrate was concentrated under reduced pressure. The resulting orange 
solid was purified by flash column chromatography on silica gel with acetone-
CH2Cl2 (10:90) as eluent to give rotaxane 51 as a light orange solid (690 mg, 4.12 
mmol, 83%). M.p. 175oC (dec.); 1H-NMR (400 MHz, CDCl3, 298 K): δ = 8.03 (m, 
2H, HC), 7.81-7.67 (m, 6H, HD and H10), 7.66 (s, 4H, HB), 7.21-7.12 (m, 20H, HF, 
H1), 7.09-7.01 (m, 12H, H2), 5.74 (s, 2H, H10), 4.45 (bs, 8H, HE), 3.72 (t, J = 6.5 Hz, 
4H, H4), 3.14 (m, 2H, H8), 1.45 (bquint, J = 7.2 Hz, 4H, H5),  1.37-1.21 (m, 4H, H7), 
1.17-1.05 (m, 4H, H6); 13C-NMR (100 MHz, CDCl3, 298 K): δ = 170.3, 165.9, 
165.4, 143.8, 141.6, 136.6, 135.3, 132.3, 130.0, 129.5, 128.7, 127.9, 121.4, 120.8, 
64.0, 54.4, 45.7, 43.8, 39.5, 28.4, 27.7, 23.0; LRESI-MS: m/z = 1697.4 [M+Na]+; 
HRESI-MS : m/z = 1694.4408 (100%) [M+NH4]+, isotopic pattern matches that 
calculated for C88H82Cl6N13O10. 
  
 
Using general method B, rotaxane 51 (59 mg, 0.035 mmol, 1.0 equiv.), alkyne 45 (27 
mg, 0.070 mmol, 2.0 equiv.), [Cu(CH3CN)4](PF6) (6.6 mg, 0.017 mmol, 0.5 eq) and 
NEt3 (11 µL, 0.077 mmol, 2.2 equiv.) in CH2Cl2 (5 mL) at room temperature 
overnight gave pure 52a as a light yellow solid (80 mg, 0.032 mmol, 81%). M.p. 
120-124 oC; [α]D +78.2 (c 0.05 in CHCl3) 1H-NMR (400 MHz, CDCl3): δ = 8.50-
8.19 (m, 8H, HA, HB and HF), 8.19-7.95 (m, 2H, H9), 7.95-7.58 (m, 4H, HC), 7.24-
6.87 (m, 32H, H1, H2 and HE), 5.84 (s, 2H, H10), 5.23 (t, 2H, J = 9.4 Hz, HJ), 5.17-
4.99 (m, 6H, HG, HI and HK), 4.93 (d, 2H, J = 12.5 Hz, HH), 4.79, 4.77 (2s, 2H, HG’) 
4.51-402 (m, 12H, HD and HM), 3.69 (bt, 4H, J = 6.3 Hz, H4), 3.57-3.43 (m, 4H, H3), 
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3.26-3.05 (m, 4H, H8), 2.07, 2.03, 1.99, 1.97 (4s, 24H, OAc), 1.55-1.18 (m, 8H, H5 
and H7), 1.18-1.02 (m, 4H, H6); 13C-NMR (100 MHz, CDCl3, 300 K): 170.7, 170.2, 
169.5, 169.4, 165.7, 145.1, 144.0, 137.4, 136.6, 135.5, 132.4, 130.2, 129.1, 128.1, 
122.2, 99.4, 98.0, 72.7, 71.8, 71.1, 70.8, 69.7, 68.3, 68.2, 64.1, 62.2, 61.9, 55.9, 54.5, 
45.8, 39.7, 28.7, 27.8, 23.1, 20.8, 20.7, 20.6, 20.5; LRMALDI-MS: m/z = 2471.5 
(100%) [M+Na]+, isotopic pattern matches that calculated for C122H122Cl6N12O30Na.  
 
Using general method B, rotaxane 51 (97 mg, 0.058 mmol, 1.0 equiv.), alkyne 46 (27 
mg, 0.116 mmol, 2.0 equiv.), [Cu(CH3CN)4](PF6) (11 mg, 0.029 mmol, 0.5 eq) and 
NEt3 (16 µL, 0.127 mmol, 2.2 equiv.) in CH2Cl2 (15 mL) at room temperature 
overnight gave pure 52b as a light yellow solid (115 mg, 0.054 mmol, 93%). M.p. 
100-102oC; 1H-NMR (400 MHz, CDCl3, 300 K): 8.50-8.23 (m, 8H, HA, HB and HF), 
8.23-8.07 (m, 2H, H9), 7.95-7.74 (m, 4H, HC), 7.21-6.92 (m, 32H, H1, H2 and HE), 
5.86 (s, 2H, H10), 4.80 (s, 4H, HG), 4.46-409 (m, 8H, HD), 3.84-3.43 (m, 40H, H3, H4, 
HH, HI, HJ, HK, HL HM, HN and HO), 3.21-3.03 (m, 4H, H8), 1.53-1.19 (m, 8H, H5 and 
H7), 1.18-1.00 (m, 4H, H6); 13C-NMR (100 MHz, CDCl3, 300 K): 170.2, 165.6, 
165.0, 146.1, 144.0, 137.4, 136.6, 135.5, 132.4, 130.2, 129.1 (× 2), 129.0, 128.1, 
124.5, 122.2, 121.8, 72.5, 70.5, 70.4, 70.3, 70.0, 69.9, 64.5, 64.1, 61.4, 54.5, 45.8, 
44.1, 39.7, 29.6, 27.9, 23.2; LRMALDI-MS: m/z = 2163.6 (100%) [M+Na]+, 
isotopic pattern matches that calculated for C110H118Cl6N12O20Na.  
 




Using general method B, rotaxane 51 (250 mg, 0.149 mmol, 1.0 equiv.), alkyne 47 
(168 mg, 0.298 mmol, 2.0 equiv.), [Cu(CH3CN)4](PF6) (28 mg, 0.074 mmol, 0.5 eq) 
and NEt3 (455 µL, 0.077 mmol, 2.2 equiv.) in CH2Cl2 (15 mL) at room temperature 
overnight gave pure 52c as a light yellow solid (296 mg, 0.105 mmol, 78%). M.p. 
95-98oC; [α]D +9.8 (c 0.008 in CHCl3) 1H-NMR (400 MHz, CDCl3): 8.41 (s, 2H, 
HB), 8.36 (s, 4H, HA), 8.26 (s, 2H, HF), 7.98-7.77 (m, 4H, HC), 7.74-7.56 (m, 2H, 
H9), 7.22-7.12 (m, 12H, H1), 7.12-6.97 (m, 20H, H2 and HE), 5.75 (s, 2H, H10) 5.21 
(t, 2H, J = 9.5 Hz, HR), 5.08 (t, 2H, J = 9.6 Hz, HS), 4.98 (t, 2H, J = 8.8 Hz, HQ), 4.80 
(s, 4H, HG), 4.60 (d, 2H, J = 7.9 Hz, HP), 4.47-4.30 (m, 8H, HD), 4.25 (dd, 2H, J = 
4.4 Hz and J = 12.2 Hz, HU), 4.13 (d, 2H, J = 11.5Hz, HU’), 3.93 (dt, 2H, J = 4.3Hz 
and J = 11.1 Hz, HH), 3.81-3.45 (m, 40H, H3, H4, HH’, HI, HJ, HK, HL HM, HN and 
HO), 3.20-297 (m, 4H, H8), 2.07, 2.04, 2.01, 1.99 (4s, 24H, OAc), 1.51-1.17 (m, 8H, 
H5 and H7), 1.17-1.00 (m, 4H, H6); 13C-NMR (100 MHz, CDCl3, 300 K): 170.7, 
170.2, 169.4, 165.6, 165.5, 165.1, 144.0, 132.5, 130.2, 128.9, 128.1, 122.3, 100.8, 
72.8, 71.7, 71.2, 70.6, 70.5, 70.5, 70.2, 70.0, 69.0, 68.3, 64.5, 64.1, 61.9, 55.4, 54.5, 
45.9, 44.2, 44.2, 39.6, 29.6, 28.7, 27.8, 20.7, 20.6, 20.6, 20.5; LRMALDI-MS: m/z = 
2823.8 [M+Na]+, isotopic pattern matches that calculated for C138H154Cl6N12O38Na.  
 




Rotaxane 52a (195 mg, 0.092 mmol) was stirred for 24 hours at room temperature in 
a solution of NaOH (10M) in THF/H2O/EtOH (1:1:1) (10 mL). The resulting 
suspension was filtered by suction and the solid rinsed with water (75 mL), followed 
by MeOH (15 mL) and DCM (15 mL) to give macrocycle 53a as colourless solid (54 
mg, 0.051 mmol, 55%). M.p. 250°C (dec.), 1H-NMR (400 MHz, DMSO d6, 300 
K): δ = 9.35-9.14 (m, 4H, HC), 8.97 (s, 2H, HB), 8.45 (s, 4H, HA), 8.20 (s, 2H, HF), 
7.27 (s, 8H, HE), 5.24-4.88 (m, 6H, -OH), 4.97 (d, J = 12.5 Hz, 2H, HG), 4.76 (d, J = 
12.5 Hz, 2H, HG’), 4.64 (bs, 2H, -OH), 4.44 (bs, 8H, HD), 4.34 (d, J = 12.5 Hz, 2H, 
HH), 3.72 (d, J = 11.5 Hz, 2H, HM), 3.54-3.41 (m, 2H, HM’), 3.24-2.96 (m, 8H, HI, 
HJ, HK and HL); 13C-NMR (100 MHz, DMSO d6, 300 K): δ = 164.6, 145.4, 137.9, 
136.6, 136.4, 127.9, 125.7, 122.7, 121.0, 102.2, 76.9, 76.5, 73.3, 70.0, 61.4, 61.1, 
42.7; LRESI-MS: m/z = 1051 [M+H]+; HRESI-MS: m/z = 1051.3797 [M+H]+ 
(calc. for C50H55N10O16 [M+H]+ 1051.3792); isotopic pattern matches that calculated 
for C50H55N10O16. 
 




Rotaxane 52b (40 mg, 0.018 mmol) was stirred for 4 days at room temperature in a 
solution of NaOH (1M) in THF/H2O/EtOH (3:2:5) (10 mL). An aqueous solution of 
HCl (1M) was added drop wise until pH equalled 7. The whole solution was loaded 
on a preparative Silica TLC plate that was eluted with CH2Cl2/MeOH (15:85) to give 
macrocycle 53b as white waxy solid (18 mg, 0.016 mmol, 90%). 1H-NMR (400 
MHz, CD3OD/CDCl3 (1:1), 300 K): δ = 8.42, 8.41 (2s, 4H, HA), 8.35 (bs, 2H, HB), 
8.11 (t, 2H, J = 1.4 Hz, HF), 7.28 (s, 8H, HE), 4.70 (s, 2H, HG), 4.53 (s, 8H, HD), 
3.72-3.49 (m, 32H, HH, HI, HJ, HK, HL HM, HN and HO). 13C-NMR (100 MHz, 
CD3OD/CDCl3 (1:1), 300 K): δ = 166.4, 137.8, 137.7, 136.9, 128.9, 125.3, 122.7, 
122.1, 72.8, 70.8, 70.7, 70.6, 70.5, 70.3, 70.1, 64.4, 61.4, 44.3 (× 2); LRESI-MS: 
m/z = 1101 [M+Na]+; HRESI-MS: m/z = 1101.4651 [M+Na]+ (calc. for 








Rotaxane 53c (122 mg, 0.050 mmol) was stirred for 48 hours at room temperature in 
a solution of NaOH (10M) in THF/H2O/EtOH (1:1:1) (10 mL). An aqueous solution 
of HCl (1M) was added drop wise until pH equaled 7. Solvents were removed under 
vacuum. The resulting solid was re-dissolved in a 1:1 mixture of MeCN/H2O (10 
mL), filtered by gravity and the filtrate was used for purification by preparative RP-
HPLC using a linear gradient of MeCN (25 to 40 % in 20 min) in H2O to give 
macrocycle 53c as a white solid (18 mg, 0.012 mmol, 25%). M.p. 205-207°C; 1H-
NMR (400 MHz, CD3OD/CDCl3 (1:1), 300 K): δ = 8.41, 8.40 (2s, 6H, HA and HB), 
8.09 (s, 2H, HF), 7.23 (s, 8H, HE), 4.70 (s, 4H, HG), 4.55-4.42 (m, 8H, HD), 4.16 (d, J 
= 7.8 Hz, 2H, HP), 3.95-3.83 (m, 2H, HO), 3.74 (dd, J = 2.7 Hz and J = 12.1 Hz, 2H, 
HU) 3.73-3.49 (m, 32H, HH, HI, HJ, HK, HL, HM, HN, HO’ and HU’) 3.26-3.00 (m, 8H, 
HQ, HR, HS and HT); 13C-NMR (100 MHz, CD3OD/CDCl3 (1:1), 300 K): δ = 166.5, 
146.3, 137.8, 137.7, 136.8, 128.9, 125.4, 122.7, 122.2, 103.1, 76.6, 76.5, 73.8, 70.8 
(× 2), 70.7, 70.6, 70.5, 70.4, 70.3, 70.0, 68.7, 64.4, 61.9, 44.3; LRESI-MS: m/z = 
1425 [M+H]+; HRESI-MS: m/z = 1425.5709 [M+Na]+ (calc. for C66H86N10O24Na 
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Alexandra M. Z. Slawin,‡ Aurélien Viterisi,† and D. Barney Walker†
Contribution from the Schools of Chemistry, UniVersity of Edinburgh, The King’s Buildings,
West Mains Road, Edinburgh EH9 3JJ, and UniVersity of St. Andrews, Purdie Building,
St. Andrews, Fife KY16 9ST, United Kingdom
Received May 17, 2007; E-mail: David.Leigh@ed.ac.uk
Abstract: A synthetic approach to rotaxane architectures is described in which metal atoms catalyze covalent
bond formation while simultaneously acting as the template for the assembly of the mechanically interlocked
structure. This “active-metal” template strategy is exemplified using the Huisgen-Meldal-Fokin Cu(I)-
catalyzed 1,3-cycloaddition of azides with terminal alkynes (the CuAAC “click” reaction). Coordination of
Cu(I) to an endotopic pyridine-containing macrocycle allows the alkyne and azide to bind to metal atoms
in such a way that the metal-mediated bond-forming reaction takes place through the cavity of the
macrocyclesor macrocyclessforming a rotaxane. A variety of mono- and bidentate macrocyclic ligands
are demonstrated to form [2]rotaxanes in this way, and by adding pyridine, the metal can turn over during
the reaction, giving a catalytic active-metal template assembly process. Both the stoichiometric and catalytic
versions of the reaction were also used to synthesize more complex two-station molecular shuttles. The
dynamics of the translocation of the macrocycle by ligand exchange in these two-station shuttles could be
controlled by coordination to different metal ions (rapid shuttling is observed with Cu(I), slow shuttling with
Pd(II)). Under active-metal template reaction conditions that feature a high macrocycle:copper ratio, [3]-
rotaxanes (two macrocycles on a thread containing a single triazole ring) are also produced during the
reaction. The latter observation shows that under these conditions the mechanism of the Cu(I)-catalyzed
terminal alkyne-azide cycloaddition involves a reactive intermediate that features at least two metal ions.
Introduction
Most noncovalent bond directed approaches1 to rotaxanes
developed to date require at least stoichiometric quantities of a
template which often involves pre-established strongly binding
recognition motifs that “live on” 2 in the mechanically inter-
locked molecule that is formed. Besides holding the reactive
fragments in an orientation that directs interlocking, the template
is generally otherwise passive during the reaction. Building on
the principles of transition-metal catalysis, we recently3 began
to explore a strategy in which template ions could also play an
active role in promoting the crucial final covalent bond forming
reaction that captures the interlocked structure (i.e., the metal
has a dual function, acting as a template for entwining the
precursors and catalyzing covalent bond formation between the
reactants). This “active-metal” 4 template process is shown
schematically in Figure 1 in both stoichiometric (1 equiv of
† University of Edinburgh.
‡ University of St. Andrews.
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the active template is required) and catalytic (the active template
turns over during the reaction) forms. There are several
potentially attractive features of such a synthetic approach to
mechanically interlocked architectures, including (i) the inherent
efficiency of a reaction in which the macrocycle-metal complex
performs multiple functions, (ii) the lack of a requirement for
permanent recognition elements in each component of the
interlocked product, which increases the structural diversity
possible in catenanes and rotaxanes and enables their formation
to be “traceless”, (iii) in some cases only substoichiometric
quantities of the active template may be required (i.e., the
catalytic active-metal template variant, Figure 1b), (iv) the
strategy could prove applicable to many different types of well-
known transition-metal-catalyzed (and even organocatalytic)
reactions, (v) reactions that only proceed through a threaded
intermediate would allow access to several currently inaccessible
mechanically linked macromolecular architectures, and, finally,
(vi) the coordination requirements during key stages of the
catalytic cycle of active-template reactions could provide insight
into the mechanisms of the catalyzed reactions.
Since the preliminary report3 appeared on the realization of
this strategy for rotaxane formation utilizing the Cu(I)-
catalyzed5-7 1,3-cycloaddition8 of organic azides and terminal
alkynes (the CuAAC “click” 9,10 reaction), we have been
delighted to see the concept be quickly adopted11 to make
rotaxanes12 with other Cu(I)-catalyzed reactions, including
alkyne-homocoupling and C-S bond forming reactions.13,14
Here we expand on our investigation of the original system,
showing that the active-metal template rotaxane-forming CuAAC
reaction works well for both mono- and bidentate pyridine-
containing macrocyclic ligands and can also be used to
synthesize more complex two-station degenerate molecular
shuttles whose interstation shuttling can be controlled by
coordination to different metal ions. Furthermore, using a high
macrocycle:copper ratio, [3]rotaxanes with two macrocycles on
a single thread are somewhat unexpectedly produced during the
active-metal template reaction. Together with some simple
kinetic studies carried out under various rotaxane- and thread-
forming reaction conditions, these experimental results provide
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(10) A listing of examples of the use of “click” reactions is available at http://
www.scripps.edu/chem/sharpless/click.html.
(11) Indeed, it was predicted3 that, “Chelation to catalytic centers could lead to
rotaxane- and catenane-forming protocols based on other metal-mediated
reactions, including cross-couplings, condensations, and other cycloaddition
reactions”. For a recent example involving Pd(II)-catalyzed alkyne homo-
couplings, see: Berná, J.; Crowley, J. D.; Goldup, S. M.; Hänni, K. D.;
Lee, A.-L.; Leigh, D. A. Angew. Chem., Int. Ed. 2007, 46, 5709-5713.
(12) For the synthesis of rotaxanes and catenanes using the CuAAC reaction in
“passive” template stoppering or macrocyclization protocols, see: (a)
Mobian, P.; Collin, J.-P.; Sauvage, J.-P. Tetrahedron Lett. 2006, 47, 4907-
4909. (b) Dichtel, W. R.; Miljanić, O. Š.; Spruell, J. M.; Heath, J. R.;
Stoddart, J. F. J. Am. Chem. Soc. 2006, 128, 10388-10390. (c) Miljanić,
O. Š.; Dichtel, W. R.; Mortezaei, S.; Stoddart, J. F. Org. Lett. 2006, 8,
4835-4838. (d) Aprahamian, I.; Dichtel, W. R.; Ikeda, T.; Heath, J. R.;
Stoddart, J. F. Org. Lett. 2007, 9, 1287-1290; (e) Braunschweig, A. B.;
Dichtel, W. R.; Miljanić, O. Š.; Olson, M. A.; Spruell, J. M.; Khan, S. I.;
Heath, J. R.; Stoddart, J. F. Chem. Asian J. 2007, 2, 634-647.
(13) Saito, S.; Takahashi, E.; Nakazono, K. Org. Lett. 2006, 8, 5133-5136.
(14) Saito et al. imply13 that the concept of binding of a substrate in a cavity
while simultaneously activating it to catalysis is an extension of Vögtle’s
anion template route to rotaxanes [(a) Seel, C.; Vögtle, F. Chem.sEur. J.
2000, 6, 21-24]. Actually the two strategies are rather fundamentally
different. In the Vögtle reaction the macrocycle does not increase the
reactivity of any of the building blocks for the rotaxane. In fact, the
hydrogen bonding of the macrocycle to the phenoxide anion, combined
with the steric hinderance conferred by the presence of the macrocycle,
greatly decreases its reactivity. The only reason that rotaxane is formed in
the Vögtle system is that the more reactive unthreaded phenoxide anion is
completely insoluble under the reaction conditions. The active-template
strategy described in ref 3 and elaborated upon in this paper has much
more in common with Sauvage’s original (passive) metal template ideas
combined with Mock’s [(b) Mock, W. L.; Irra, T. A.; Wepsiec, J. P.; Adhya,
M. J. Org. Chem. 1989, 54, 5302-5308] and later Steinke’s [(c) Tuncel,
D.; Steinke, J. H. G. Chem. Commun. 1999, 1509-1510. (d) Tuncel, D.;
Steinke, J. H. G. Chem. Commun. 2002, 496-497. (e) Tuncel, D.; Steinke,
J. H. G. Macromolecules 2004, 37, 288-302] use of curcubituril to
accelerate a reaction within a macrocycle cavity to form rotaxanes.
Figure 1. “Active-template” strategy to rotaxane architectures. The
formation of a covalent bond between the green and orange “stoppered”
units to generate the thread is promoted by the catalyst (shown in gray)
and directed through the cavity of the macrocycle (shown in blue) by the
catalyst’s coordination requirements. (a) Stoichiometric active-metal tem-
plate synthesis of a [2]rotaxane: (i) template assembly and covalent bond
forming catalysis, (ii) subsequent demetalation. (b) Catalytic active-metal
template synthesis of a [2]rotaxane.
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Cu(I)-Catalyzed Terminal Alkyne-Azide Cycloaddition
(CuAAC Reaction)
Recently, there has been a tremendous surge of interest in
so-called click9,10 methodologies for functional molecule syn-
thesis, the most popular of which is the Huisgen-Meldal-
Fokin15 Cu(I)-catalyzed 1,3-cycloaddition of organic azides with
terminal alkynes (the CuAAC reaction).5-7 The most common
catalyst systems for this reaction employ water or alcohol
solvents and use a Cu(II) salt in the presence of a reducing agent
(often sodium ascorbate) to generate the required Cu(I) catalyst
in situ.5b,7a Metallic copper5b,7a or copper clusters16 have also
been employed as precatalysts, and in some cases Cu(I) salts
can be used directly. However, in apolar solvents Cu(I) salts
usually require the presence of nitrogen5b,7a,17 or phosphorus18
ligands, or acetonitrile as a cosolvent, to stabilize the Cu(I)
oxidation state, and undesired alkyne-alkyne homocoupling
products are often observed under such reaction conditions.5b,7a
The basic mechanism of the CuAAC reaction is believed to
be that shown in Scheme 1. A [2+3] cycloadditionsthe
mechanism of the thermal (i.e., uncatalyzed) Huisgen reaction8s
is ruled out19 for the Cu(I)-catalyzed reaction on the basis of
DFT calculations which show that reaction via a (formally Cu-
(III)) metallacycle is a more favorable pathway by up to
11.7 kcal mol-1 (Scheme 1).5b,20,21 The same calculations
suggest that the rate-determining step is the formation of the
Cu metallacycle from a reactive intermediate involving copper-
coordinated alkyne and, presumably, azide (organoazido-metal
complexes are likely intermediates in many transition-metal-
mediated reactions of azides, and Cu(I)-N3R complexes have
been characterized by X-ray crystallography22). However, the
exact nature of this reactive intermediate is unclear (Scheme 1,
types A-C).
In the absence of competing ligands,23 copper(I) acetylides
exist as complex multi metal atom aggregates,24 and kinetic
studies17a,25 by Fokin and Finn on the generic ligand-free23 Cu-
(I)-catalyzed alkyne-azide reaction show that in DMSO-water
mixtures the reaction mechanism is second-order with respect
to copper. The same studies found first-order kinetics with
respect to the azide and alkyne (actually slightly higher than
first-order with respect to the alkyne).25 However, relatively little
is known about the ligand-promoted Cu(I)-catalyzed cycload-
dition in organic solvents. Recent experiments by Straub,26 in
which mononuclear copper(I) acetylides ligated to a sterically
demanding N-heterocyclic carbene react efficiently with bulky
organoazides at room temperature, support the notion that a
single copper atom mechanism (A(i), Scheme 1) is viable for
the reaction, at least when the copper is bound to bulky ligands.
Recent DFT calculations7c,21 suggest that !-activation of the
copper acetylide unit by coordination of a second copper atom
(e.g., A(ii) or, more likely under ligand-free conditions or with
small monodentate ligands, bridged27 intermediates such as B(i)
or B(ii), Scheme 1) greatly enhances the reactivity of the copper
"-acetylide, accelerating formation of the metallacycle. Alter-
natively, a pathway25 in which the reacting azide and alkyne
are coordinated to different copper(I) atoms (intermediate C(i)
or C(ii)) would also be consistent with the second-order kinetics
observed in DMSO-water. It may well be that several of these
types of intermediates28 can provide viable pathways for the
CuAAC reaction, with the different characteristics of the
intermediates being relatively favored or inhibited by factors
such as the solvent, bulk and coordination number of an added
ligand, the strength of ligand-copper binding, and the amount
of ligand-free Cu(I) present in solution. Given the tendency of
copper(I) acetylides to aggregate, however, doubly bridged
intermediates such as B or C should be abundant species under
most conditions. Accordingly, if coordination of the azide to
the same copper atom significantly increases the reactivity of
the "-acetylide, type B(ii) intermediates are probably involved
in the dominant pathways in most reported CuAAC reac-
tions.
Despite the uncertainty over the precise nature of the reactive
intermediate, since tertiary amines and pyridines facilitate5b,17
the reaction in organic solvents, we reasoned that a macrocycle,
1, bearing an endotopic ligating nitrogen atom might be able to
direct the CuAAC reaction of a “stoppered” alkyne, 2, and a
“stoppered” azide, 3, through the macrocycle cavity to give a
[2]rotaxane, 4, in an active-metal template synthesis (Scheme
2).
Active-Metal Template CuAAC Rotaxane Synthesis
A 2,6-bis[(alkyloxy)methyl]pyridine macrocycle (1a), previ-
ously used29 as both a mono- and bidentate ligand for various
transition metals in classical “passive” template rotaxane and
catenane syntheses, seemed a suitable candidate for initial
investigations. Pleasingly, stirring of an equimolar mixture of
(15) The Cu(I)-catalyzed terminal alkyne-azide cycloaddition is often referred
to as the “Sharpless copper click reaction” or the “Sharpless-Huisgen
alkyne-azide cycloaddition”. However, Sharpless gives Fokin the credit
for the idea and recognition of the copper catalysis of this reaction at Scripps
[Rouhi, A. M. Chem. Eng. News 2004, 82 (7), 63-65]. The initial work at
Scripps was carried out shortly after, and without knowledge of, the first
paper (ref 5a) describing the Cu(I)-catalyzed alkyne-azide cycloaddition
(on solid-supported resins) had been submitted by Meldal and co-workers.
(16) Pachon, L. D.; van Maarseveen, J. H.; Rothenberg, G. AdV. Synth. Catal.
2005, 347, 811-815.
(17) (a) Chan, T. R.; Hilgraf, R.; Sharpless, K. B.; Fokin, V. V. Org. Lett. 2004,
6, 2853-2855. (b) Lewis, W. G.; Magallon, F. G.; Fokin, V. V.; Finn, M.
G. J. Am. Chem. Soc. 2004, 126, 9152-9153.
(18) Perez-Balderas, F.; Ortega-Munoz, M.; Morales-Sanfrutos, J.; Hernandez-
Mateo, F.; Calvo-Flores, F. G.; Calvo-Asin, J. A.; Isac-Garcia, J.; Santoyo-
Gonzalez, F. Org. Lett. 2003, 5, 1951-1954.
(19) If the [2+3] cycloaddition were the preferred mechanism of the Cu-
catalyzed reaction, the structures A-C shown in Scheme 1 would still be
relevant as reactive intermediates.
(20) Himo, F.; Lovell, T.; Hilgraf, R.; Rostovtsev, V. V.; Noodleman, L.;
Sharpless, K. B.; Fokin, V. V. J. Am. Chem. Soc. 2005, 127, 210-216.
(21) Ahlquist, M.; Fokin, V. V. Organometallics, in press, cited in ref 7c.
(22) Dias, H. V. R.; Polach, S. A.; Goh, S.-K.; Archibong, E. F.; Marynick, D.
S. Inorg. Chem. 2000, 39, 3894-3901.
(23) In this paper we use the phrases “ligandless” and “ligand-free” to describe
copper that is not bound to the macrocyclic pyridine ligands added to the
CuAAC reactions to generate the active-template synthesis. As discussed
in the text and ref 28, any Cu(I) that is not coordinated to pyridine units
will be complexed by molecules of acetonitrile, azide, alkyne, water, or
other donor atoms present.
(24) Mykhalichko, B. M.; Temkin, O. N.; Mys’kiv, M. G. Russ. Chem. ReV.
2000, 69, 957-984.
(25) Rodionov, V. O.; Fokin, V. V.; Finn, M. G. Angew. Chem., Int. Ed. 2005,
44, 2210-2215.
(26) Nolte, C.; Mayer, P.; Straub, B. F. Angew. Chem., Int. Ed. 2007, 46, 2101-
2103.
(27) (a) Bohlmann, F.; Schönowsky, H.; Inhoffen, E.; Grau, G. Chem. Ber. 1964,
97, 794-800. (b) Siemsen, P.; Livingston, R. C.; Diederich, F. Angew.
Chem., Int. Ed. 2000, 39, 2632-2657.
(28) Note: Copper(I) acetylides are generally complex extended multiatom
aggregates, at least in the solid state and in the absence of good nitrogen
ligands (see ref 24). The types of reactive intermediates shown in Scheme
1 are not meant to be precise or definitive structuressindeed, some of them
(e.g., A(ii) and B(ii)) are very closely relatedsbut rather are meant to
illustrate different (possible) features of the putative reactive intermediate:
How many copper atoms are needed to play significant structural or
electronic roles during the catalysis? Is the copper "-acetylide !-activated
by an additional Cu atom? If the intermediate has two or more copper
atoms, is it doubly bridgedsas envisaged for a Glaser coupling, which
can be ruled out with bidentate ligands for Cu if azide is also coordinateds
or singly bridged? Are the reacting azide and alkyne attached to the same
or different Cu atoms?
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the pyridine macrocycle 1a, alkyne 2, azide 3, and [Cu(CH3-
CN)4](PF6) in CH2Cl2 for 24 h affordedsafter demetalation with
KCNsa mixture of [2]rotaxane 4a (57%) and the noninterlocked
triazole thread 5 (41%), together with some of the unconsumed
starting macrocycle (Scheme 2 and Table 1, entry 1).3 By
varying the reaction conditions and reactant stoichiometry (Table
1), yields of up to 94% of [2]rotaxane with respect to the amount
of macrocycle used were achieved (5 equiv of 2 and 3; Table
1, entry 2) for this stoichiometric active-metal template reaction
(Figure 1a). The use of substoichiometric amounts of copper
was investigated to determine whether the metal would turn
over as both a template and a cycloaddition catalyst (i.e., a
Scheme 1. Proposed Mechanism of the Huisgen-Meldal-Fokin Cu(I)-Catalyzed Alkyne-Azide Cycloaddition (CuAAC) Reaction48
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catalytic active-metal template synthesis, Figure 1b). When using
20 mol % (with respect to 1a) [Cu(CH3CN)4](PF6) at room
temperature, the reaction appeared to stop after an amount of
[2]rotaxane equivalent to the amount of copper present had been
formed, suggesting that the multidentate rotaxane sequesters the
transition metal during the reaction, inhibiting further catalytic
activity. Addition of pyridine as a competing ligand enabled
the catalyst to turn over, producing a substoichiometric reaction,
but the reaction was extremely slow at 25 °C (Table 1, entry
3). Elevating the temperature (70 °C, ClCH2CH2Cl) gave an
(29) (a) Fuller, A.-M.; Leigh, D. A.; Lusby, P. J.; Oswald, I. D. H.; Parsons, S.;
Walker, D. B. Angew. Chem., Int. Ed. 2004, 43, 3914-3918. (b) Fuller,
A.-M. L.; Leigh, D. A.; Lusby, P. J.; Slawin, A. M. Z.; Walker, D. B. J.
Am. Chem. Soc. 2005, 127, 12612-12619. (c) Leigh, D. A.; Lusby, P. J.;
Slawin, A. M. Z.; Walker, D. B. Chem. Commun. 2005, 4919-4921. (d)
Leigh, D. A.; Lusby, P. J.; Slawin, A. M. Z.; Walker, D. B. Angew. Chem.,
Int. Ed. 2005, 44, 4557-4564. (e) Fuller, A.-M. L.; Leigh, D. A.; Lusby,
P. J. Angew. Chem., Int. Ed. 2007, 46, 5015-5019.
Scheme 2. Active-Metal Template CuAAC Synthesis of [2]Rotaxanes 4a-o from Alkyne 2, Azide 3, and Macrocycles 1a-oa
a Reagents and conditions: (i) 1a-o (0.01 M), Cu(I) salt (generally [Cu(CH3CN)4](PF6); see the text), poorly coordinating solvent (generally CH2Cl2; see
the text), and, in the catalytic version of the active-metal template reaction (Figure 1b), 3 equiv of pyridine; (ii) KCN, CH2Cl2/CH3OH.3 For the effect of
the reaction conditions and reagent stoichiometry on the yields of 4a and 5, see Table 1. For the relative yields of 4a-o using a standardized set of reaction
conditions see Figure 4
.
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improved yield (82%) of rotaxane 4a in a reasonable time period
(36 h) using only 4 mol % Cu(I) with respect to both 2 and 3
(Table 1, entry 4).
Effect of the Nature of the Cu(I) Source
A number of different Cu(I) salts were screened for the
reaction shown in Scheme 2 using the conditions shown in Table
1, entry 1, but replacing the [Cu(CH3CN)4](PF6) salt with other
Cu(I) complexes. The use of CuOTf‚benzene gave a 78%
conversion of 2 and 3 into triazole products after 24 h but only
a 46% yield of [2]rotaxane 4a. By letting the reaction continue
for a further 2 days (72 h in total), complete conversion of the
starting azide and alkyne to triazole products was achieved (48%
rotaxane). Substituting CuI for [Cu(CH3CN)4](PF6) led to very
little reaction during the first 24 h (8% conversion to triazole),
presumably due to the low solubility of CuI in CH2Cl2, but
interestingly, what little alkyne and azide had reacted formed
rotaxane with high selectivity (7:1 rotaxane:thread). The reaction
proceeded slowly to completion (>98% conversion) over three
weeks. However, at the end point of the reaction the product
ratio (56:44 rotaxane:thread) was no different from that of the
analogous [Cu(CH3CN)4](PF6)-mediated experiment.
We also synthesized and isolated various discrete Cu(I)-1a
complexes and tested their efficacy in the active-metal template
reaction. The macrocycle 1a and the different Cu(I) salts were
mixed in CH3CN solution and the resulting Cu(I)-1a complexes
obtained through precipitation by vapor diffusion with diethyl
ether. The preformed Cu(I)-1a complexes were submitted to
the standard rotaxane-forming reaction conditions (Table 1, entry
1). The preformed [Cu(CH3CN)4](PF6)-1a complex gave 76%
conversion to triazole and a 53% yield of [2]rotaxane; the
preformed CuOTf-1a complex gave 53% conversion to triazole
but only a 5% yield of [2]rotaxane; the preformed CuI-1a
complex gave results identical to those of the CuI-1a complex
formed in situ (i.e., >98% triazole conversion over 3 weeks,
56% rotaxane).
Although there is some variation in the efficacy of the various
Cu(I) salts on the rotaxane-forming reaction and some unex-
plained variation in the rotaxane:thread ratio during the course
of the reaction with some sources of Cu(I), simple addition of
[Cu(CH3CN)4](PF6) is the most convenient way of maximizing
the CuAAC yield of rotaxane.30
Kinetic Studies
Some simple kinetic measurements were made to determine
whether, under these reaction conditions, the Cu(I)-catalyzed
alkyne-azide cycloaddition is actually accelerated by pyridine-
based ligands. The rate of formation of triazole products (i.e.,
thread, plus rotaxane where relevant) was compared for the
ligand-free23 reaction and reactions containing pyridine, 2,6-
dimethylpyridine (lutidine), 2,6-bis[(alkyloxy)methyl]pyridine
macrocycle 1a, and 6, a close but acyclic analogue of 1a.
The results (Figure 2) show that both lutidine and 6, the
acyclic analogue of 1a, significantly accelerate the CuAAC
reaction rate (essentially complete conversion to triazole after
3 h) compared to that of the Cu(I)-catalyzed reaction when no
pyridine-based ligand is added (complete conversion after 6 h).
The presence of pyridine also initially accelerates the reaction,
but the conversion tails off after 2 h, suggesting that using
unsubstituted pyridine as a ligand facilitates the oxidation of
Cu(I) to noncatalytic Cu(II) under the reaction conditions. The
role of the pyridine ligands in the rate acceleration is probably
to break up extended copper(I) acetylide aggregates to form
smaller reactive intermediates of the types shown in Scheme 1,
although we cannot rule out an electronic effect of the ligand
on the metal as well.
Interestingly, the Cu(I)-catalyzed formation of triazole prod-
ucts (both rotaxane and thread) in the presence of macrocycle
1a (with 1 equiv of Cu)swhich also presumably breaks up the
(30) We also examined the effect of different alkyne substrates on the rotaxane
formation. The alkynes (see the Supporting Information) were submitted
to the standard click reaction conditions (Scheme 2). Using a longer, more
flexible, alkylalkyne or an arylalkyne in the place of 2 led to similar yields
of the corresponding [2]rotaxanes (and similar overall conversions of the
substrates into triazole products), indicating the active-metal template
rotaxane-forming reaction is rather insensitive to substrate modifications.












triazole 2 + 3f4a + 5 (%)
yield of
rotaxane 1af4a (%)
1a 1 1 CH2Cl2 25d >95 57
2a 5 1 CH2Cl2 25d 92 94
3b 5 0.2 CH2Cl2 25d 44 59
4b 5 0.2 ClCH2CH2Cl 25f 70e 94 82
5c 1 0 ClCH2CH2Cl 25f 70f <5 0
a All reactions were carried out at 0.01 M concentration with respect to 1a using the procedure shown in Scheme 2. b 3 equiv of pyridine. c Control
experiment with no [Cu(CH3CN)4](PF6) present to demonstrate that the thermal reaction does not occur at these temperatures. d 24 h. e 12 h and then 24 h.
f 12 h and then 72 h.
Figure 2. Conversion to triazole (i.e., thread + rotaxane if applicable) vs
time for different pyridine-based ligands for the CuAAC reaction. Condi-
tions: (i) ligand (1 equiv), alkyne 2 (1 equiv), azide 3 (1 equiv), [Cu(CH3-
CN)4](PF6) (1 equiv, 1 or 2 equiv with 1a), CD2Cl2, rt, 0.01 M. The
conversion of 2 and 3 into the triazole products (thread 5, + rotaxane 4a
where relevant) was monitored by 1H NMR.
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copper acetylide aggregatessis actually slower (24 h compared
to 6 h) than the ligand-free Cu(I)-catalyzed reaction. While it
might seem surprising that the active-metal template reaction
is slower than the ligand-free reaction given that excellent yields
of rotaxane are obtained under both stoichiometric and catalytic
active-metal template conditions (Table 1), the rationale for this
is quite straightforward. First, the alkyne-azide cycloaddition
with the macrocyclic ligand must take place through the
macrocycle cavity, a sterically restricted environment compared
to the ligandless Cu(I)-catalyzed reaction, effecting the solvation
of the reactive species as well as hindering any motion required
to achieve bond formation or changes of geometry at the copper
center. Second, the macrocyclic ligand might disfavor certain
types of reactive intermediates (e.g., B) on steric grounds, so
the reaction may proceed through another type of slower
reacting, but still viable, intermediate (e.g., A or C rather than
B). The reason that the ligandless formation of the triazole thread
does not dominate given the slow rate of rotaxane formation is
that the macrocycle is an excellent ligand for the Cu(I) and
sequesters it, preventing the inherently faster ligand-free reaction
(probably via B(ii)) from occurring. Accordingly, addition of a
second equivalent of Cu(I) to the reaction containing 1a should
accelerate the rate of triazole formation to close to the ligand-
free rate. Indeed, this was found to be the case (Figures 2 and
3). However, while one might expect this increase to be totally
due to thread formation, analysis shows that the rate of rotaxane
formation is also increased by adding an extra equivalent of
Cu(I) to this reaction (Figure 3). In fact, the final yield of [2]-
rotaxane only falls from 57% to 22% even though the triazole-
forming reaction is complete in 6 h instead of 24 h. The
acceleration of the rotaxane-forming reaction by excess Cu(I)
strongly suggests that !-activation of the copper acetylide unit
(see Scheme 1) is the dominant process in the CuAAC reaction
mechanism of 1a.
Effect of the Macrocycle Structure on [2]Rotaxane
Formation
To further investigate both the scope and the mechanism of
the active-template rotaxane-forming reaction shown in Scheme
2, we varied the structure of the pyridine-based macrocycle.
The macrocycles used in the study are shown in Figure 4, and
their syntheses are detailed in the Supporting Information. To
compare the relative yields of rotaxane and thread within the
ligand series, the macrocyclic ligands were screened using a
standard, rather than optimized,31 set of stoichiometric active-
metal template reaction conditions in which the original
macrocycle 1a generates appreciable quantities of both rotaxane
and thread. The conditions used were 1 equiv of macrocycles
1a-o, 1 equiv of alkyne 2, 1 equiv of azide 3, and 1 equiv of
[Cu(CH3CN)4](PF6) at a concentration of 0.01 M in CH2Cl2 at
room temperature for 24 h. In most cases the starting alkyne 2
and azide 3 were completely consumed during the course of
the reaction. After 24 h (72 h for 1n and 1o) each reaction was
treated with KCN to remove the Cu(I), analyzed by 1H NMR
to determine the yield (shown in Figure 4) under the standard
set of conditions, and then purified to give authentic samples
of each [2]rotaxane. The yield (the percentage shown in red in
Figure 4) of each rotaxane is the conversion of the macrocycles
1a-o to the corresponding [2]rotaxanes 4a-o. The conversion
to triazole (the percentage shown in parentheses in Figure 4) is
the overall conversion of the alkyne 2 and azide 3 into both
thread 5 and rotaxanes 4a-o.
Mono- and Tridentate Macrocycles. In addition to the
strongly coordinating pyridine nitrogen, macrocycle 1a has two
ether oxygen atoms that could potentially be involved in (albeit
weak) coordination to the metal atom during the active-template
reaction, making 1a a monodentate or possibly weakly bidentate
or very weakly tridentate ligand.32 Not only is macrocycle 1b
missing the ether oxygen atoms, but the pyridine nitrogen atom
lone pair is tied up in strong intramolecular bifurcated hydrogen
bonds to the adjacent amide groups,33 so it was rather surprising
to find that [2]rotaxane 4b was successfully produced in the
active-metal template reaction, albeit in only 6% yield. Coor-
dination of 1b to the copper occurs at the expense of the
intramolecular hydrogen bonds34,35 so that 1b is able to act as
an effective monodentate ligand. In contrast, the use of 1csa
tridentate macrocyclic ligand with three hard donor atomss
gave a similar overall conversion to triazole but with no rotaxane
(31) The standard reaction conditions use 1 equiv of each reagent and low
temperatures to minimize the background uncatalyzed thermal cycloaddi-
tion. These conditions were chosen to allow the relative efficacy of the
different macrocycles in promoting rotaxane formation to be assessed. No
attempt was made to optimize the reaction conditions to improve the
rotaxane yields reported in Figure 4. For macrocycles 1a, 1i, 1j, 1f, 1l,
1m, and 1nsall of which produce significant rotaxane and are not degraded
under the reaction conditionssvirtually all the macrocyclic ligand can be
converted to rotaxane by using extended reaction times and an excess of
the azide and alkyne building blocks.
(32) For an X-ray structure of 1a as a monodentate ligand in a rotaxane (Pd(II)
as the metal atom) see ref 29b; for X-ray structures of a related pyridine
diether ligand acting as a bidentate ligand in a rotaxane (Cu(II) or Ni(II)
as the metal atom) see ref 29d.
(33) (a) Hunter, C. A.; Purvis, D. H. Angew. Chem., Int. Ed. Engl. 1992, 31,
792-795. (b) Johnston, A. G.; Leigh, D. A.; Nezhat, L.; Smart, J. P.;
Deegan, M. D. Angew. Chem., Int. Ed. Engl. 1995, 34, 1212-1216. (c)
Leigh, D. A.; Moody, K.; Smart, J. P.; Watson, K. J.; Slawin, A. M. Z.
Angew. Chem., Int. Ed. Engl. 1996, 35, 306-310. (d) Leigh, D. A.; Murphy,
A.; Smart, J. P.; Slawin, A. M. Z. Angew. Chem., Int. Ed. Engl. 1997, 36,
728-732. (e) Leigh, D. A.; Murphy, A.; Smart, J. P.; Deleuze, M. S.;
Zerbetto, F. J. Am. Chem. Soc. 1998, 120, 6458-6467. (f) Deleuze, M. S.;
Leigh, D. A.; Zerbetto, F. J. Am. Chem. Soc. 1999, 121, 2364-2379. (g)
Clegg, W.; Gimenez-Saiz, C.; Leigh, D. A.; Murphy, A.; Slawin, A. M.
Z.; Teat, S. J. J. Am. Chem. Soc. 1999, 121, 4124-4129. (h) Biscarini, F.;
Cavallini, M.; Leigh, D. A.; León, S.; Teat, S. J.; Wong, J. K. Y.; Zerbetto,
F. J. Am. Chem. Soc. 2002, 124, 225-233. (i) Bottari, G.; Dehez, F.; Leigh,
D. A.; Nash, P. J.; Pérez, E. M.; Wong, J. K. Y.; Zerbetto, F. Angew. Chem.,
Int. Ed. 2003, 42, 5886-5889. (j) Leigh, D. A.; Venturini, A.; Wilson, A.
J.; Wong, J. K. Y.; Zerbetto, F. Chem.sEur. J. 2004, 10, 4960-4969.
Figure 3. Formation of triazole products (rotaxane 4a, 9; thread 5, b) vs
time for the CuAAC reaction in the presence of macrocycle 1a. Condi-
tions: (i) 1a (1 equiv), 2 (1 equiv), 3 (1 equiv), [Cu(CH3CN)4](PF6) (1 or
2 equiv), CD2Cl2, rt, 0.01 M. The conversion of 2 and 3 into thread 5 and
rotaxane 4a was monitored by 1H NMR.
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formed. Upon addition of 1c to the copper catalyst and other
reagents the solution changed color immediately from colorless
to blue-green. This suggests that most of the Cu(I) is rapidly
oxidized to Cu(II) upon coordination to 1c.36 The resulting Cu-
(II)-1c complex is not catalytically active for the alkyne-azide
cycloaddition, and any tridentate Cu(I)-1c complex lacks the
free coordination sites necessary to bind azide and alkyne in
the same aggregate.37 However, enough of the copper in the
reaction is not tied up as the 1c complex for the ligandless
thread-forming triazole reaction to proceed to completion within
24 h.
Macrocycle 1d has a structure similar to that of 1a except
that the pyridine nitrogen is oxidized. The result, >98%
conversion to triazole but only a trace of rotaxane when using
1d as the macrocycle in the active-template reaction, shows that
the N-oxygen atom greatly affects the ligand’s ability to
coordinate to Cu(I). Macrocycle 1e also has a constitution
(34) Hydrogen bond energies are usually in the range of 1-10 kcal/mol, whereas
coordinate bonds have energies of 20-80 kcal/mol;35 thus, the stabilization
of the copper(I) ion upon coordination should compensate for the loss of
the two hydrogen bond interactions. In fact, all of the pyridine-containing
macrocycles studied exhibit complexation-induced shifts in the 1H NMR
spectra (CDCl3) upon addition of [Cu(CH3CN)4](PF6), indicating that
copper(I) ions interact with the macrocycles in every case.
(35) Goshe, A. J.; Crowley, J. D.; Bosnich, B. HelV. Chim. Acta 2001, 84, 2971-
2985.
(36) This oxidation of Cu(I) to Cu(II) in the presence of 1c occurs even when
great care is taken to exclude both moisture and oxygen from the reaction
mixture. It appears that the macrocycle itself is the oxidant. However, there
is some remaining [Cu(CH3CN)4](PF6) which catalyzes the formation of
the thread 5.
(37) The multidentate ligand tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine
(TBTA) is a highly effective copper ligand for the CuAAC reaction [see
refs 6b and 17a,b and Gupta, S. S.; Kuzelka, J.; Singh, P.; Lewis, W. G.;
Manchester, M.; Finn, M. G. Bioconjugate Chem. 2005, 16, 1572-1579].
However, the individual triazole-functionalized “arms” of TBTA are weakly
coordinating ligands, so TBTA probably functions by the alkyne and azide
displacing two of the triazole groups to form the reactive intermediate.
Figure 4. Influence of the macrocycle structure on the active-metal template CuAAC rotaxane-forming reaction in Scheme 2 under a standardized set of
reaction conditions. Conditions for Scheme 2: (i) 1a-o, 2, 3, [Cu(CH3CN)4](PF6), CH2Cl2, rt, 24 h (72 h for 4n and 4o), 0.01 M concentration with respect
to each of 1a-o, alkyne 2, azide 3, and [Cu(CH3CN)4](PF6); the reactions were not run under an inert atmosphere, nor using distilled or dried solvents; (ii)
KCN, CH2Cl2/CH3OH. The conversion of each macrocycle to [2]rotaxane is given as a percentage yield in red, and the overall conversion of 2 and 3 into
triazole products (rotaxanes 4a-o and thread 5) is shown for each macrocycle in parentheses. The designation “trace” means that the rotaxane was observed
by ESI-MS but could not be detected by 1H NMR. The colors and lettering correspond to the signals and assignments of the 1H NMR spectra shown in
Figure 5.
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similar to that of 1b, but the secondary amides are methylated,
eliminating their ability to form hydrogen bonds. AM1 calcula-
tions38,39 using Spartan (see the Supporting Information) show
that the methyl groups distort and partially fill the macrocycle
cavity. The result is that, like that of 1d, little of the CuAAC
reaction is directed through the macrocycle cavity to form
rotaxane. The same effect is seen for macrocycle 1f, the bis-
N-acetylated analogue of 1c.
Removing the pyridine nitrogen atom, macrocycle 1g,
completely switches off rotaxane formation, confirming the need
for a ligating donor atom. Replacing the benzylic oxygens of
1a by more strongly coordinating sulfur atoms produces another
tridentate macrocycle, 1h. As with 1c, no rotaxane is formeds
consistent with the premise that tridentate ligand complexes of
Cu(I) lack the vacant coordination sites necessary to bind both
azide and alkyne37sand the yield of triazole is also only 30%,
indicating that 1h is particularly effective in sequestering the
copper. Oxidation of the sulfide groups to sulfones, macrocycle
1i, restores the ability of the macrocycle to bind to the Cu(I) as
a monodentate ligand, and despite the increased bulk around
the coordinated metal ion, a significant amount (13%) of [2]-
rotaxane 4i is formed by the stoichiometric active-metal template
reaction. In fact, substitution of the benzylic ether oxygen atoms
by methylene groups confirms that only a monodentate mac-
rocycle with a single strongly coordinating donor atom is
required for an efficient active-template rotaxane-forming reac-
tion; macrocycle 1j generates just as much [2]rotaxane as the
parent macrocycle 1a. Modeling suggests that the cavity of
macrocycle 1j is rather more flexible than that of 1a, yet this is
not detrimental for rotaxane formation.
To test whether other macrocycle geometries would be
tolerated by the active-template reaction, we prepared 1k and
1l in which the substituted benzylic units were replaced by
arylalkynyl and aryl groups, respectively. The 2,6-bisalkynylpy-
ridine unit proved to be unstable40,41 under the reaction
conditions, suppressing the overall yield of the CuAAC reaction,
with no rotaxane being produced. However, the active-metal
template CuAAC reaction proceeded smoothly with 1l, albeit
generating rather less rotaxane (25%) than the most effective
examples of other macrocycle geometries (1a and 1j). AM1
calculations38 using Spartan (see the Supporting Information)
indicate that 1l has a well-defined persistent cavity suitable for
the threading of a molecular chain. However, the phenyl groups
flanking the pyridine sterically encumber the nitrogen donor
atom of the macrocycle, and a combination of steric and
electronic factors probably reduces the binding strength of this
macrocycle for Cu(I) ions. The weaker binding leads to more
ligandless23 Cu(I) in solution, resulting in higher conversion of
the substrates into the noninterlocked thread 5 and the relatively
modest yield of [2]rotaxane 4l. Increasing the steric bulk at the
4-position of the pyridine group while simultaneously increasing
the electron-donating ability of the heterocyclic nitrogen atom,
macrocycle 1m, had little effect on the rotaxane yield.
Bidentate Macrocycles. Having established that monodentate
ligands of several different macrocycle geometries and donor
atom orientations (1a, 1j, 1l, 1m) efficiently promote active-
template rotaxane formation, whereas strongly tridentate mac-
rocycles (1c and 1h) do not, we investigated the efficacy of
bidentate macrocycles 1n and 1o.17,42 The bipyridyl macrocycle
1n directs the CuAAC reaction through its cavity to form
rotaxane almost as efficiently as the best monodentate macro-
cycles (45% for 1n f 4n compared to 57% for 1a f 4a and
60% for 1j f 4j). However, it severely inhibits the rate of the
Cu(I)-catalyzed reaction, and it took 3 days for the active-metal
template reaction 1n f 4n to go to completion, compared to
24 h for 1a f 4a and 6 h for the ligand-free Cu(I)-catalyzed
control reaction (Figure 3). The inhibition of the Cu(I)-catalyzed
cycloaddition is even more dramatic with the other bidentate
ligand investigated, the 2,9-diphenylphenanthroline macrocycle
1o used extensively to assemble rotaxanes and catenanes by
the Sauvage group.1b,i Macrocycle 1o completely inhibits the
CuAAC reaction. Even after 3 days under the standard sto-
ichiometric active-metal reaction conditions in the presence of
1o, no triazole products were observed. This latter result is
particularly interesting given that phenanthroline ligands have
previously been reported17 to promote the CuAAC reaction. The
lack of reactivity is presumably a result of the steric bulk about
the Cu(I) center in the complex preventing the complex from
undergoing the various structural variations required for reaction
to take place (e.g., tolerating the change in geometry from Cu-
(I) to the formal Cu(III) species, Scheme 1), together with the
macrocycle being very effective in sequestering the Cu(I) in
this unreactive form. A related Cu(I)-macrocycle complex has
recently been reported to promote the formation of [2]rotaxanes
via a Glaser alkyne homocoupling.13 However, in that case,
intermediates of type B (Scheme 1) are possible with a bidentate
ligand for copper because no azide need be coordinated to the
metal atom.
1H NMR Spectra of the Metal-Free [2]Rotaxanes
The 1H NMR spectra (400 MHz, 300 K, CDCl3) for each of
the rotaxanes formed in >5% yield are shown in Figure 5. The
1H NMR spectra of the rotaxanes (Figure 5b-g) all show upfield
shifts of several signals with respect to the signals of the
noninterlocked components (thread 5, Figure 5a, and the
macrocycles 1a, 1b, 1i, 1j, 1m, and 1n; see the Supporting
Information). Such shielding is typical of interlocked structures
in which the aromatic rings of one component are positioned
face on to with another component and is observed for all the
nonstopper resonances of the axle (Hf-j), indicating that the
macrocycle accesses the full length of the thread. This is as
expected; there should be no strong intercomponent noncovalent
interactions between the thread and the macrocycle in the metal-
free rotaxanes. The one exception is the amide-containing
rotaxane 4b (Figure 5c), which exhibits a significant downfield
shift of the amide resonance with respect to that of the free
macrocycle (see Supporting Information). This can be attributed
to hydrogen bonding between the amides of the macrocycle and
(38) Minimum energy conformations were calculated for each of the metal-
free macrocycles using the Spartan molecular modeling program (Semi-
Empirical, AM1). The results are provided in the Supporting Information.
(39) In the case of 1e no hydrogen bonds are present, thus allowing the Cu(I)
ion better access to the macrocycle’s pyridine nitrogen atom. However, in
each of macrocycles 1e and 1f the nitrogen atom of the pyridine is more
hindered, which may reduce the binding ability of the ligand.
(40) Internal alkynes have been found to react under CuAAC conditions; see:
Dı́ez-González, S.; Correa, A.; Cavallo, L.; Nolan, S. P. Chem.sEur. J.
2006, 12, 7558-7564.
(41) Macrocycle 1k is also photosensitive and decomposes slowly in ambient
light.
(42) Bidentate bipyridine and phenanthroline ligands have been shown to
significantly enhance the kinetics of the CuAAC reaction; see ref 17b.
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the triazole unit of the thread in an interaction similar to that
previously observed between interlocked amide and pyridine
components in rotaxanes and catenanes.1j,29
Active-Metal Template CuAAC Reaction at High
Macrocycle:Cu(I) Ratios: Unexpected Formation of
[3]Rotaxanes
The picture of the active-metal template CuAAC reaction that
we can build up that is consistent with the experimental
observations so far is that the ligand-free [Cu(CH3CN)4](PF6)
salt and macrocycles 1a-o are in equilibrium with the corre-
sponding copper(I)-macrocycle complex in which, in most
cases, the metal atom directs the cycloaddition of the azide and
alkyne through the macrocycle cavity. Although the ligand-free
reaction is inherently faster than the active-metal template one,
the coordinating ability of the macrocycle means that the
rotaxane-forming reaction can become competitive with, or even
dominate, the thread-forming reaction. In general, a stronger
binding macrocyclic ligand (e.g., 1a compared to 1b) should
move this equilibrium in favor of rotaxane formation. However,
some changes in coordination geometry about the metal are
required for the CuAAC mechanism to operate (Scheme 1), so
the most strongly binding macrocycle (1o), which apparently
does not tolerate such changes, actually inhibits the rotaxane-
forming reaction. In view of this, we decided to investigate other
conditions in which rotaxane formation might be increased at
the expense of the thread.
In an attempt to minimize the amount of ligandless Cu(I)
present in the reaction, we carried out the active-metal template
CuAAC protocol under the standard set of conditions (1 equiv
of 2, 1 equiv of 3, 1 equiv of [Cu(CH3CN)4](PF6), CH2Cl2, rt)
used previously but in the presence of 10 equiv of macrocycle
(Scheme 3). Our initial experiments43 were carried out with
monodentate macrocycle 1l, and we were immediately intrigued
to find that the reaction was much slower with 10 equiv of the
macrocycle than it had been with 1 equiv, the higher macrocycle:
Cu(I) reaction taking more than one week to go to completion.
Upon reaching this end point, the mixture of triazole products
was found to consist of 30% thread 5, 37% [2]rotaxane 4l, and,
to our surprise, 33% [3]rotaxane 7l (yields quoted with respect
to the alkyne and azide reactants). A reaction using macrocycle
1a under the same experimental conditions (1 equiv of 2, 1 equiv
of 3, 1 equiv of [Cu(CH3CN)4](PF6), and 10 equiv of 1a, CH2-
Cl2, rt) was again slower than the same reaction with 1 equiv
of macrocycle (3 days to reach completion compared to 24 h),
generating a product mixture of 5% thread 5, 90% [2]rotaxane
4a, and 5% [3]rotaxane 7a (yields quoted with respect to the
alkyne and azide reactants). A similar but less dramatic trend
was seen with bidentate macrocycle 1n; with 10 equiv of 1n
the reaction took 10 days to complete (cf. 3 days with 1 equiv),
producing 3% thread 5 and 97% [2]rotaxane 4n (in this case
no [3]rotaxane 7n could be detected by 1H NMR spectroscopy).
The remarkable features of these high macrocycle:Cu(I) ratio
active-metal template reactions are the following:
(i) Exceptional combined rotaxane yields: 95% ([2]rotaxane
4a + [3]rotaxane 7a) compared to 57% for 4a with 1 equiv of
1a; 70% ([2]rotaxane 4l + [3]rotaxane 7l) compared to 25%
for 4l with 1 equiv of 1l; 97% ([2]rotaxane 4n) compared to
45% for 4n with 1 equiv of 1n.
(ii) Significant slowing of the reaction rates compared to the
low macrocycle:Cu(I) ratio reactions. The largest effect on the
rate is seen with the weakly copper-binding macrocycle 1l; the
smallest effect on the rate occurs for the strongly copper-binding
macrocycle 1n. Again, this is strongly suggestive experimental
evidence that the dominant mechanism of the CuAAC reaction
under these conditions involves activation of the copper
"-acetylide unit by a second, preferably ligandless for steric
reasons, copper atom (i.e., I or II, Scheme 3).
(iii) Formation of [3]rotaxane (in 33% yield using macrocycle
1l)si.e., two macrocycles being threaded during the formation
of one triazole ring. Molecular models show that this can most
reasonably occur through the sort of bridged two copper atom
intermediate III shown in Scheme 3. Since such a doubly
bridged intermediate cannot occur with bidentate ligands (and
no [3]rotaxane is observed with 1n), it seems likely that
monodentate pyridine ligand-promoted CuAAC reactions pro-
ceed via doubly bridged intermediates such as I (Scheme 3),
the equivalent of intermediate B(ii) in Scheme 1, whereas
bidentate bipyridyl ligand-promoted CuAAC reactions proceed
(43) We chose macrocycle 1l for this study because it is a rather poor ligand
(indeed, we were unable to generate complexes with it using several other
metals) due to the steric crowding around the pyridine nitrogen and the
!-electron density presented to the low-oxidation-state copper from the
adjacent aromatic rings. The rather weak Cu(I) binding affinitysmeaning
there is more ligandless23 Cu(I) present in solution than many of the other
macrocycles shown in Figure 4sis most likely the reason for the modest
yield of rotaxane using 1 equiv of this macrocycle. We reasoned the yield
should be improved by increasing the macrocycle:copper ratio.
Figure 5. 1H NMR spectra (400 MHz, CDCl3, 300 K) of (a) triazole thread
5, (b) [2]rotaxane 4a, (c) [2]rotaxane 4b, (d) [2]rotaxane 4i, (e) [2]rotaxane
4j, (f) [2]rotaxane 4m, and (g) [2]rotaxane 4n. The assignments correspond
to the lettering shown in Scheme 2 and Figure 4.
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via simple !-coordinated complexes such as II (Scheme 3), the
equivalent of intermediate A(ii) in Scheme 1.
The 1H NMR spectra of [2]rotaxane 4l and [3]rotaxane 7l
are shown in parts b and c, respectively, of Figure 6. The
resonances for the axle (Hf-j) of the rotaxanes are shifted upfield
compared to the signal for the free noninterlocked thread 5
(Figure 6a). The effect is more pronounced in the [3]rotaxane
(Figure 6c) than in the [2]rotaxane (Figure 6b). Due to the
asymmetry of the thread, the 1H NMR spectrum of [3]rotaxane
7l (Figure 6c) displays inequivalent but overlapping peaks for
the two macrocycle components, which are double the intensity
of the corresponding macrocycle signals in the [2]rotaxane.
Single crystals of 7l suitable for X-ray crystallography were
grown by slow cooling of a hot saturated solution of 7l in
acetonitrile. The solid-state structure (Figure 7) confirmed the
constitution of 7l as a [3]rotaxane. Although it may superficially
appear that face-to-face !-stacking interactions might aid the
relative orientation of the two macrocycles on the thread, in
the solid state the aromatic rings of adjacent macrocycles are
not coplanar and their separation (>3.8 Å) is somewhat greater
than that typically associated with aromatic stacking interactions.
Stoichiometric and Catalytic Active-Metal Template
Synthesis of Bistriazole [2]Rotaxanes
To see whether the copper(I) would turn over catalytically
during the formation of a single molecule, we investigated
systems which require two cycloaddition reactions to be
catalyzed in the formation of each molecule of [2]rotaxane
(Scheme 4). [2]Rotaxanes 10 and 12 were each obtained in good
yields (81% and 74%, respectively) using the conditions shown
in Scheme 4 (0.5 equiv of Cu(I) for each triazole ring formed
in a rotaxane) with either 1a, 2, and the diazide 8 or 1a, 3, and
the dialkyne 9. Since the rotaxane-Cu(I) complex in 4a is strong
enough to sequester the metal in the absence of pyridine, the
lack of formation of more than trace amounts of [3]rotaxane in
the reaction mixtures from Scheme 4 suggests that one mac-
rocycle-Cu(I) complex may act processively to catalyze the
formation of both triazole rings of an individual rotaxane thread.
Such a hypothesis is consistent with the observation25 by
Rodionov et al. (albeit in a ligand-free Cu(I) system) of a strong
kinetic enhancement in the second cycloaddition reaction when
using diazide reactants. Reducing the amount of the copper salt
to 20 mol % with respect to 1a (10 mol % with respect to each
Scheme 3. Effect of the Macrocycle:Cu(I) Ratio on the Active-Metal Template CuAAC Reactiona,b
a Reagents and conditions: (i) 1a, 1l, or 1n (10 equiv), 2 (1 equiv), 3 (1 equiv), [Cu(CH3CN)4](PF6) (1 equiv), CH2Cl2, rt, 24 h (1a), 7 days (1l), 10 days
(1n); (ii) KCN, CH2Cl2/CH3OH. Product yields starting from macrocycle 1a: thread 5 (5%), [2]rotaxane 4a (90%), [3]rotaxane 7a (5%). Product yields
starting from macrocycle 1a: thread 5 (5%), [2]rotaxane 4i (33%), [3]rotaxane 7l (37%). Product yields starting from macrocycle 1n: thread 5 (3%),
[2]rotaxane 4n (97%), [3]rotaxane 7n (0%). bIn the reactive intermediates shown, the copper azide (orange) reacts with any of the copper alkyne units shown
in green. L can be any nonreacting ligand, including other alkyne and azide groups.
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rotaxane triazole ring formed) and introducing 3 equiv of
pyridine to the reaction of 1a, 2, and 8 to allow the processive
catalyst to turn over intermolecularly still generated [2]rotaxane
10 in 63% yield (Scheme 4).
Transition-Metal-Mediated Control of the Shuttling Rate
in Degenerate Two-Triazole-Station Molecular Shuttles
The shuttling of the ring in the degenerate two-station
bistriazole rotaxane 10 in the presence of different diamagnetic
transition-metal salts was investigated using 1H NMR spectros-
copy. Unlike most previously reported molecular shuttless
where the interactions used to direct the synthesis of the
rotaxanes persist in the interlocked structure, resulting in a well-
defined coconformationsthere are no strong noncovalent in-
teractions between the components of metal-free 10. Comparison
of the 1H NMR spectrum of the free thread 11 (Figure 8a) with
that of the rotaxane 10 (Figure 8b) shows uniform shielding of
the thread signals (Hd, He, Hf, Hg, Hh), indicating that the
macrocycle randomly explores the full length of the thread.
Reintroducing copper(I) into the bistriazole rotaxane44 to form
[Cu10](PF6) (Scheme 5) gave a complex that exhibited fast
shuttling of the macrocycle between the two triazole units in
the room temperature 1H NMR spectra in CD3CN/CD2Cl2
(44) For examples of 1,2,3-triazoles as ligands see refs 3, 6s, and 17a,b and (a)
Liu, D.; Gao, W.; Dai, Q.; Zhang, X. Org. Lett. 2005, 7, 4907-4910. (b)
Dai, Q.; Gao, W.; Liu, D.; Kapes, L. M.; Zhang, X. J. Org. Chem. 2006,
71, 3928-3934. (c) Mindt, T. L.; Struthers, H.; Brans, L.; Anguelov, T.;
Schweinsberg, C.; Maes, V.; Tourwe, D.; Schibli, R. J. Am. Chem. Soc.
2006, 128, 15096-15097. (d) Suijkerbuijk, B. M. J. M.; Aerts, B. N. H.;
Dijkstra, H. P.; Lutz, M.; Spek, A. L.; van Koten, G.; Klein Gebbink, R.
J. M. Dalton Trans. 2007, 1273-1276. (e) Huffman, J. C.; Flood, A. H.;
Li, Y. Chem. Commun. 2007, 2692-2694.
Scheme 4. Active-Metal Template CuAAC Synthesis of Bistriazole
Molecular Shuttles 10 and 12a
a Reagents and conditions: (i) 2, [Cu(CH3CN)4](PF6), CH2Cl2, 25 °C,
72 h; (ii) KCN, CH2Cl2/CH3OH, 81% ([2]rotaxane 10) over two steps with
0.5 equiv of Cu(I), 63% ([2]rotaxane 10) over two steps with 0.1 equiv of
Cu(I) + 3 equiv of pyridine; (iii) 3, [Cu(CH3CN)4](PF6), CH2Cl2, 25 °C,
72 h; (iv) KCN, CH2Cl2/CH3OH, 74% ([2]rotaxane 12) over two steps.
Figure 6. 1H NMR spectra (400 MHz, CDCl3, 300 K) of (a) triazole thread
5, (b) [2]rotaxane 4l, and (c) [3]rotaxane 7l. The assignments correspond
to the lettering shown in Scheme 2 and Figure 4.
Figure 7. X-ray structure of [3]rotaxane 7l, from a single crystal obtained
from a saturated acetonitrile solution: (a) viewed side-on; (b) viewed along
the axis of the thread. For clarity, different shades of purple are used for
the carbon atoms of the two rings.
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(Figure 8c).45 Although fast shuttling between well-defined
macrocycle binding sites is very unusual for metal-coordinated
molecular shuttles,46 Cu(I) complexes can exhibit extremely fast
exchange rates.47 In contrast to this dynamic behavior, the 1H
NMR spectrum (Figure 8d) of rotaxane 10 following coordina-
tion of PdCl2 (Scheme 5, ii) displays two sets of peaks for
protons close to the thread triazole rings (e.g., Hf/fʹ′, Hg/gʹ′). This
observation is indicative of the macrocycle in the Cl2Pd10
complex being unable to shuttle between the triazole stations
on the NMR time scale. This restriction to shuttling also
manifests itself in the geminal splitting of the signals corre-
sponding to HC and HD of the macrocycle, which occurs as a
consequence of the two “faces” of the ring being in different
chemical environments. The chemical shifts of one set of the
duplicated signals (e.g., Hf) correspond closely to those of the
free thread 11 (Figure 8a). The other set of duplicate signals
(e.g., Hfʹ′) correspond closely to a model single-triazole rotax-
ane-PdCl2 complex, Cl2Pd4a (Figure 8e, Scheme 5). Heating
the sample of Cl2Pd10 to 343 K (close to the solvent boiling
point of CD3CN) did not lead to any broadening of the signals
in the 1H NMR spectrum, indicating that the macrocycle
shuttling is very effectively blocked by coordination to Pd.
The notable features of these degenerate two-station bistria-
zole rotaxanes are the following:
(i) To our knowledge these are the first examples of molecular
shuttles containing two degenerate transition-metal-binding
stations.
(ii) The dynamics of the macrocycle exchange between the
two well-defined discrete binding sites can be controlled with
remarkable ease, simply through the judicious choice of different
transition-metal ions.
(iii) An active-metal template strategy is much more amend-
able to the synthesis of such shuttles than traditional (passive)
metal template strategies, because the number of binding sites
in the products is not necessarily related to the number of
template sites used for the shuttle synthesis.
Conclusions
The Cu(I)-catalyzed 1,3-cycloaddition of azides with terminal
alkynes is a highly effective reaction for the active-metal
template synthesis of rotaxanes, as illustrated through both
stoichiometric (up to 97% yields) and catalytic (up to 82%
yields) versions of the strategy. The reaction tolerates a wide
(45) We were unable to slow the macrocycle shuttling dynamics in [Cu(10)]-
(PF6) sufficiently, nor isolate that motion from other conformational
processes at low temperatures, to determine an accurate shuttling rate.
(46) Durola, F.; Sauvage, J.-P. Angew. Chem., Int. Ed. 2007, 46, 3537-3540.
(47) For an evaluation of ligand exchange rates at Cu(I) centers, see: Riesgo,
E.; Hu, Y.-Z.; Bouvier, F.; Thummel, R. P. Inorg. Chem. 2001, 40, 2541-
2546.
Figure 8. 1H NMR spectra (400 MHz, CD3CN/CD2Cl2 (9/1), 300 K) of
(a) bistriazole thread 11, (b) bistriazole [2]rotaxane 10, (c) copper-
bistriazole [2]rotaxane complex [Cu10](PF6), (d) palladium dichloride-
bistriazole [2]rotaxane complex Cl2Pd10, and (e) palladium dichloride-
triazole rotaxane complex Cl2Pd4a. The assignments correspond to the
lettering shown in Scheme 5.
Scheme 5. Controlling the Dynamics of Bistriazole Molecule
Shuttle 10 by Coordination to Cu(I) or Pd(II)a
a Reagents and conditions: (i) [Cu(CH3CN)4](PF6) (1 equiv), CD2Cl2
(90%)/CD3CN (10%), 25 °C, 5 min, >99%; (ii) Pd(CH3CN)2Cl2 (1 equiv),
CD2Cl2 (90%)/CD3CN (10%), 25 °C, 5 min, >99%.
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variety of both monodentate and bidentate macrocyclic ligands
which, although inherently slower in promoting covalent bond
formation than the ligand-free23 Cu(I)-catalyzed reaction, all
work by sequestering the majority of the Cu(I) present so that
the rotaxane-forming CuAAC reaction becomes competitive
withsand under many conditions dominatessthe ligand-free
CuAAC reaction. The addition of pyridine enables the Cu(I)
active-metal template to turn over without significantly com-
promising the rotaxane yield. Among several potentially attrac-
tive features of this type of synthetic strategy is that it offers an
unusual experimental probe of the reaction mechanism. The
increase in rates of rotaxane formation by excess ligand-free
Cu(I) supports the suggestion that in CH2Cl2 the copper
"-acetylide is activated by coordination to a second ligandless
copper atom, and the sluggish reaction rates and remarkable
formation of [3]rotaxanes with monodentate macrocycles at high
macrocycle:Cu(I) ratios suggest that, under these conditions,
the CuAAC reaction proceeds via a doubly bridged two copper
atom intermediate (type B(ii), Scheme 1) when using a
monodentate macrocyclic ligand and a simpler !-coordinated
two copper atom intermediate (type A(ii), Scheme 1) when using
a bidentate macrocyclic ligand.48
The experimental results concerning the active-metal template
CuAAC synthesis of bistriazole rotaxanes suggest that the
macrocycle-Cu(I) complex may act processively to catalyze
the formation of more than one triazole ring per thread molecule.
The resulting two-triazole-station molecular shuttles have
interesting and unusual dynamic properties: coordination of the
rotaxane macrocycle to Cu(I) gives a metal-complexed shuttle
in which the ring still shuttles rapidly between the two triazole
units of the thread, even at low temperatures in noncoordinating
solvents. In contrast, complexation of the same two-triazole-
station shuttle to PdCl2 gives a rotaxane in which shuttling does
not occur even at 343K in the presence of d3-acetonitrile.
The template-directed assembly of otherwise difficult-to-
access molecular architectures and the catalysis of covalent bond
formation are two of the most useful tasks that transition metals
can perform in organic chemistry. The active-template concept
combines these two apparently disparate functions into one,
which can producesas the present work exemplifiesshigh-
yielding, mild and effective synthetic routes to complex mo-
lecular structures requiring only catalytic quanitities of metal.
The development of other active-template systems is in progress.
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Rotaxane-Based Propeptides: Protection and Enzymatic Release of a
Bioactive Pentapeptide**
Anthony Fernandes, Aurlien Viterisi, Frdric Coutrot, Stphanie Potok, David A. Leigh,*
Vincent Aucagne,* and Sbastien Papot*
Rotaxane and pseudorotaxane architectures are starting to
attract interest as a means of molecularly encapsulating
substrates for potential biological applications.[1–5] Nano-
valves that can store and release cargo molecules have been
developed,[1] and the encapsulation of squaraine dyes within
rotaxanes has been shown to enhance dye fluorescence and
stability as well as imparting different cell-localization
propensities on the substrates.[2] A stilbene-based rotaxane
has been used to control the reactivity of a dipeptidic thread
against protease hydrolysis,[3] and functionalized rotaxanes
have also been shown to serve as effective vehicles for the
intracellular delivery[4] of fluorescein-derivatized peptides.
Polyrotaxanes have been studied for their potential as drug-
delivery systems.[5] Herein, we report the synthesis and
properties of a rotaxane in which a macrocycle protects an
extended pentapeptide thread from degradation by different
types of peptidases and the cocktail of enzymes present in
human plasma. The glycosidase-catalyzed cleavage of a
carbohydrate unit in a stopper of the rotaxane triggers the
release of the bioactive parent peptide through a self-
immolative mechanism (Scheme 1). The demonstration that
a macrocycle is able to protect an oligopeptide of significant
length from degradation by peptidases, whilst simultaneously
allowing an orthogonal enzyme-activated release mechanism
to be built into the structure, is an important step toward the
ultimate goal of a molecular sheath peptide delivery system.
Benzylic amide macrocycles can be templated around
dipeptides in which glycine is the N-terminal amino acid
residue, to form [2]rotaxanes in good yields.[6] Unfortunately,
investigation of their efficacy in protecting peptide-based
threads from enzymatic degradation (a common drawback to
the use of oligopeptides in biological applications[7]) has been
hampered because the yield of the rotaxane-forming reaction
decreases rapidly with increasing peptide length.[6c,8] We
envisaged that a solution might lie in employing a bulky
nitrophenol ester[9] as a stopper for an extendable,[10] shorter,
and more efficiently constructed, peptide rotaxane. We used
this synthetic methodology to target a [2]rotaxane 1 based on
Met-enkephalin 2 (H-Tyr-Gly-Gly-Phe-Met-OH), also known
as opioid growth factor (OGF). Met-enkephalin 2 is a
pentapeptide with a range of bioactivities that include
regulation of nociception and also antitumor activity by
control of cell growth.[11] Release of the free pentapeptide was
designed to occur through cleavage of an enzyme-accessible
monosaccharide on one of the stoppers (Scheme 1) using
E. coli b-galactosidase, an enzyme that has been successfully
Scheme 1. Enzyme-triggered release of Met-enkephalin 2 from [2]rotax-
ane propeptide 1.
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targeted[12] to specific cell types in antibody-directed
enzyme prodrug therapy (ADEPT[13]) strategies.
Met-enkephalin 2 possesses the glycine residue neces-
sary for rotaxane assembly and a C-terminal amino acid
sequence (Phe-Met) that is bulky enough to act as a
stopper for a benzylic amide macrocycle. The carbohydrate
trigger[14] intended to release the bioactive peptide is
covalently attached to the rest of the thread by a nitro-
benzyloxycarbonyl linker. Following enzymatic activation
with b-galactosidase, self-immolation of the deglycosylated
stopper should result in the release of 2 along with the
mechanical disassembly of the rotaxane architecture
(Scheme 1).
Glycorotaxane[15] 4 was prepared from galactosylated
thread 3, which bears a bulky 2,6-diphenyl-4-nitrophenyl
stopper, in 26% yield (Scheme 2, step a). The rotaxane
yield is not dissimilar to that found previously[6c] using Phe-
Gly threads (32%), despite the presence of both a
nitrophenyl and tyrosyl ester in 3 that could potentially
react with p-xylylenediamine. We were delighted to find
that although nucleophile access to the activated ester
group was hindered by both the macrocycle (which was
tightly locked on the short peptide portion of the thread)
and the phenyl groups on the stopper, treatment of 4 with
H-Phe-Met-OH in CHCl3 at reflux afforded the elongated
[2]rotaxane 5 in 40 % yield (Scheme 2, step b), with no
evidence of any dethreading of 4 or 5 (59 % of 4 was
recovered from the reaction). Deprotection of the hydroxy
groups (Scheme 2, step c) furnished Met-enkephalin rotax-
ane propeptide 1. The corresponding thread 7 was also
prepared (see the Supporting Information).
The partial 1H NMR spectra of [2]rotaxane 1 and
thread 7 are shown in Figure 1. Apart from the signals that
correspond to the carbohydrate protons (shown in black),
most of the resonances in the thread are shifted upfield in
the rotaxane, thus indicating that the macrocycle is able to
(and does) move beyond the original template. Although
the rotaxane Gly-Gly methylene protons H14 and H16 are the
most shielded, which indicates that the macrocycle spends
most of its time in this region, various peptide protons
(orange) near the C terminus (e.g., H24) and protons in the
nitrobenzyloxycarbonyl spacer (green) near the N terminus
are shielded to some extent by the aromatic rings of the
macrocycle.[6]
The ability of the benzylic amide macrocycle to access
almost the full length of the extended peptide augured well
for its ability to protect the thread from degradation. We first
confirmed that Met-enkephalin rotaxane 1 was stable in
phosphate buffer at 37 8C. After 48 hours, no decomposition
Scheme 2. Synthesis of [2]rotaxane propeptide 1. a) Isophthaloyl chlo-
ride, p-xylylenediamine, Et3N, CHCl3, 26 %; b) H-Phe-Met-OH, N,N-
diisopropylethylamine (DIPEA), CHCl3, reflux, 96 h, 40 %; c) NaOMe,
MeOH, 0 8C, quantitative.
Figure 1. Partial 1H NMR spectra (400 MHz, 298 K, CD3OD) of
a) thread 7 and b) rotaxane propeptide 1. The assignments and color-
ing of signals correspond to that shown in Scheme 2. Residual solvent
peaks are shown in gray.
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was observed by HPLC. The protease resistance of the
rotaxane was then probed by comparing the behavior of Met-
enkephalin 2, rotaxane 1, and the thread 7 under the action of
different types of peptidases, the results of which are shown in
Figures 2–4.
Enzymatic digestion of each of the three substrates with
aminopeptidase M, an exopeptidase that hydrolyses Met-
enkephalin sequentially from the N-terminal amino acid,[16]
was monitored by HPLC (Figure 2). While Met-enkephalin
was rapidly degraded (< 30 minutes) using 0.005 units (U) of
enzyme per mmol of substrate, thread 7 and rotaxane 1 proved
stable for many hours under identical conditions and more
than 70% of 7 and more than 95% of 1 were recovered after
2 days. In this case, the stability of both thread and rotaxane
presumably arises from the fact that the part of Met-
enkephalin that is recognized by the enzyme (the N terminus)
is chemically derivatized in both 1 and 7.
We next explored (Figure 3) the stability of 1, 2, and 7
towards angiotensin converting enzyme (ACE), a peptidase
that hydrolyses Met-enkephalin between the Gly and Phe
residues.[17] HPLC showed that while both pristine Met-
enkephalin 2 and the N-functionalized, but non-interlocked,
derivative 7 were degraded within hours, rotaxane 1 exhibited
exceptional resistance towards the action of ACE (> 90%
remaining after 2 days). The difference in stability between
the rotaxane and thread can be attributed solely to the
mechanical barrier to the enzyme provided by the macro-
cycle.
Finally, the stability of each of 1, 2, and 7 to the cocktail of
peptidases and other enzymes present in human plasma was
evaluated (Figure 4). Met-enkephalin 2 was completely con-
sumed in less than 5 minutes in reconstituted human plasma
at 37 8C. The non-interlocked thread 7 was degraded with a
half-life of approximately 5 hours, whilst 90 % of rotaxane 1
was still present after 5 days incubation in the plasma.
Whilst the resistance to peptidases conferred by the
macrocycle on the extended oligopeptide in the rotaxane is
remarkable, if the parent peptide cannot ultimately be
liberated from the molecular sheath then the structure can
have no utility as a propeptide system. HPLC showed that the
incubation of 1 with E. coli b-galactosidase in phosphate
buffer (0.02m, pH 7.0) at 37 8C resulted in the disappearance
of 1 over 2–3 minutes (traces 2 and 3 in Figure 5b) and the
emergence of a new peak with a retention time of 28 minutes
and m/z 1318, which corresponds to the degalactosylated
rotaxane 9.[18] This peak also quickly disappeared (traces 3
and 4 in Figure 5b) concomitantly with the appearance of
benzylic alcohol 6 (the product formed by spontaneous
reaction with water of the quinone methide intermediate
released by self-immolation of the nitrohydroxybenzyl unit
(Scheme 1)), the dethreaded macrocycle (m/z 532), and free
Met-enkephalin 2. Despite the presence of the macrocycle in
1, and its efficacy in protecting the peptide portion of the
rotaxane axle from enzymes, the remote siting of the b-
galactose trigger results in no significant difference between
Figure 2. Enzymatic digestion of rotaxane propeptide 1 (blue dia-
monds), thread 7 (green squares), and Met-enkephalin 2 (orange
circles) with porcine kidney aminopeptidase M. Reactions were carried
out at 25 8C in 95 % phosphate buffer (0.05m, pH 7.2), 5% DMSO,
using 0.005 U mmol1 of substrate. 0.0025 Ummol1 of enzyme was
added every 12 h.
Figure 3. Enzymatic digestion of rotaxane propeptide 1 (blue dia-
monds), thread 7 (green squares), and Met-enkephalin 2 (orange
circles) with rabbit lung angiotensin converting enzyme (ACE). Reac-
tions were carried out at 25 8C in 95 % HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) buffer (0.05m, pH 8.3), 5% DMSO,
0.3m NaCl, using 0.8 U mmol1 of substrate. 0.4 U mmol1 of enzyme
was added every 12 h.
Figure 4. Stability of rotaxane propeptide 1 (blue diamonds), thread 7
(green squares), and Met-enkephalin 2 (orange circles) in human
plasma reconstituted from lyophilized powder with 0.01m Tris (tris(hy-
droxymethyl)aminomethane) buffer at pH 7.4, at 37 8C.
Angewandte
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the rate of formation of free Met-enkephalin from rotaxane
propeptide 1 and thread 7 (Figure 5).
In conclusion, we have demonstrated a rotaxane-based
molecular device in which an oligopeptide can be protected
from a broad range of peptidases for several days and then
released in bioactive form in a matter of minutes through a
specific glycosidase-mediated controlled-release mechanism.
The concept may prove useful for the development of
practical propeptide delivery methods, derivatizing the mac-
rocycle to further improve the properties and characteristics
of the system.
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